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lab, a pasar horas y horas entre risas y lágrimas, y seguir adelante día 
tras día, año tras año. Aprendí a echar de menos y a escribir emails 
interminables. Gracias por todos esos momentos que forman parte de 
nuestra historia y por esta amistad. Nuestra representante más 
internacional, Gabrielísima, una sonrisa venezolana que aunque se 
caiga el mundo es capaz de luchar en silencio contra todo pronóstico. 
Mi hijita. He aprendido mucho de ti, y sé que al otro lado del charco 
siempre tendré un hogar. Te deseo toda la felicidad del mundo, te la 
mereces más que nadie. Coralie completa el inicial grupo de 
doctorandas. Merci beacoup “chica Desigual” porque no habría 
logrado permanecer sin ti entre tanto ratoncito esas largas horas en 
animalario y durante esta ardua tarea llamada tesis. Entre otras cosas! 
:) Gracias por estar siempre pendiente, por tu constancia y ánimos; y 
sin duda tu tesis demostrará todo el intenso trabajo que has realizado. 
Lo lograremos! Amparísima, ver como lograste tu Cum Laude fue uno 
de los días más emocionantes de mi vida. Sin duda la investigación 
tiene la suerte de tenerte en sus filas. Gracias por tu locura y por tus 
ratos en el i36, espero que me hayas perdonado ya haberte “robado” 
la mesa! Para MH tengo más que palabras, un agradecimiento sincero 
por estar desde el principio en esta andadura. Por haber sufrido y 
celebrado cada una de las cosas que han sucedido entre esas cuatro 
paredes, por toda tu ayuda día a día. Gracias, gracias y gracias! Voy a 
echar muchísimo de menos tus buenos días! Lucile y Fabiana, los 
primeros pilares del i36. Gracias por vuestra paciencia y por ser prueba 
de que se sobrevive a la tesis! Gracias Fabs por el tiempo que 
dedicaste a mis primeros pasos por el i-36. Anita, eres (además de la 
dueña de las pipetas más codiciadas del i-36 ;D) un ejemplo a seguir, 
ojalá y sea capaz de alcanzar el punto de buen hacer, constancia y 
pulcritud que tu atesoras. Mil gracias por tu ayuda y predisposición, 
una “animalario’s girl” a la que debo mucho y de la cual he aprendido 
un buen pellizco de lo presentado en este trabajo. Gracias por tus 
consejos y estar siempre ahí para animarme. Esther, gracias por tu 
sonrisa permanente y tu ayuda sin pedir nada a cambio, siempre y 
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cuando fuera.  Tengo el placer de haberte conocido y sé que nos une 
algo más que el jamón! Muito obrigada menhina. Te admiro, de 
corazón. Y sí, estaremos en contacto :P. El grupo fue creciendo, nuevos 
Postdocs: Ximo, Rut, Rich, Marina. Los vecinos del despacho de al lado 
que daban vidilla a los group meetings y siempre han estado ahí 
cuando había que juntar cabezas para sacar algo adelante o para darte 
ánimos en los días de bajón. Gracias por vuestra comprensión y tantos 
y tantos ratos de fructíferas discusiones, almuerzos y cafés. Amaya, un 
apreciado fichaje que nos ha traído una positividad inocente desde 
“tierras lejanas”. Deseo que tu tesis refleje todo el empeño que pones 
en ella, todo saldrá bien! Ha sido todo un placer contar contigo en esta 
última etapa y sin duda aun quedan muchos ratos por disfrutar juntas. 
En los últimos meses el lab ha recibido mucho género másculino :) 
Juanjo, Vicent, mil gracias por soportarme en este último tramo en el 
que he sido más bien poco sociable. Os deseo toda la suerte del 
mundo en este i-36! Gracias también a Matthias, por detenerse a ver 
mis problemas y sentarse a solucionarlos. Gracias por tus quejas y por 
escuchar las mías. He aprendido mucho de ti y espero seguir 
haciéndolo. Vielen dank chico. Y te dejo para el final Aroa, porque 
acabar esto no habría sido posible sin ti. Has sido el aliento del final de 
la carrera. Un viento fresco que me dio fuerzas para acabar cuando el 
barullo me impedía seguir. Voy a echarte de menos compi, muchísimo! 
He aprendido mucho de ti y contigo, nunca olvidaré nuestras andanzas 
a deshoras por el lab, nuestros skypes y meetings, nuestros momentos 
Máxima… y millones de cosas más. Te debo mucho... Gracias por tu 
ayuda y tu positividad que tanto me encanta. Todo te irá bien 
amiguita, sabes que no lo dudo, y espero no estar muy lejos para verlo 
contigo. 
Mención especial al PGA team, tres personitas que hemos 
empleado tiempo, ánimo y un número indefinido de reuniones para 
sacar el trabajo adelante. ¡Aroa y Rich: somos un equipo! Las lecciones 
han sido aprendidas. Siempre me quedará el buen recuerdo de 
nuestro duro trabajo, lo mucho que nos recompensaban los buenos 
resultados y las risas juntos. Multitone!! 
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solucionar cualquier problema y tener una paciencia infinita con mis 
prisas. 
Gracias al Dr. Vicente Felipo y al Dr. Omar Cauli, por ser parte 
de este trabajo y por su paciencia conmigo. Omar, mil gracias por tu 
disposición con tantos experimentos y pruebas que hemos ido 
tanteando y desarrollando, por tus ideas y estar siempre pendiente de 
mí, profesional y personalmente. Has sido una gran ayuda para mí en 
todos estos años. Siempre lo tendré presente. 
Gracias al equipo de proteómica: Luz, Esther y Virginia.  
Gracias por compartir vuestros conocimientos y siempre tener una 
respuesta para mis atolondradas ideas, por vuestra paciencia infinita 
con mis MALDI exprés y vuestras sonrisas. Sois geniales. 
Gracias también al Dr. M.A. Morcillo y su equipo, por toda la 
ayuda en los experimentos in vivo con radioactividad, por su buen 
trabajo y su ayuda en todo momento.  
Mi estancia en Porto debo agradecérsela a nuestra 
colaboradora la profesora Maria Joao Saraiva. Gracias por acogerme 
esos tres meses en ese lugar perdido a orillas del Atlántico. A todo su 
grupo y muy especialmente a Isabel, por enseñarme todo cuanto 
aprendí allí y por estar siempre al otro lado del email cuando la 
necesitaba. 
En todo este tiempo en el CIPF he conocido personas 
luchadoras con fe en la ciencia y el buen hacer, buenas personas con 
las que cruzarse por el pasillo alegraba el día. Gracias a todos por 
vuestros ratos y por solucionarme tantas dudas. Lucía, Roberto, 
Imelda, Carmen, Laura M., Rosa, Lorena, Rafa, Ana, Ali, Mara, Salva, 
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Fuera de lo profesional, tus amigos siguen ahí sin entender 
porqué pasas semanas y semanas sin dar señales de vida. Permanecen 
pendientes de ti, insistiendo en que debes cambiar el chip, consiguen 
que veas más allá de tu negatividad y reconozcas todo lo que has 
logrado. Se esfuerzan por comprender qué les haces a los ratones, qué 
es eso de que se te mueren las células y en qué consiste eso de 
“sintetizar” vehículos que transportan cosas al cerebro. Debo 
agradecer a todo este elenco de amistades el apoyarme estos años, el 
celebrar conmigo mis triunfos y el hacerme ver todo lo bueno que 
tiene la vida si tienes unos amigos indescriptiblemente perfectos. A 
mis cedrillenses y cedrillensas, gracias por vuestras llamadas, los findes 
de charretas y vuestra contagiosa ilusión. Gracias Maco por siempre 
quitarme la venda que me pongo en los ojos y animarme sí o sí a 
seguir adelante y ver todo de una forma distinta, por tu apoyo y 
consuelo día a día. Gracias Vane por aguantar mis pataletas y 
ayudarme a que ser como soy no me autodestruyese ;), gracias por tu 
aliento y tu sonrisa. Gracias Tere por estar pendiente de cada 
movimiento, de alegrarte por cada pequeño logro y de sentir mi dolor 
como propio. Gracias a todos mis tajadinos por sus besos y abrazos tan 
reconfortantes en los findes por Cedrillas, y a ese adorable grupo 
representativo que vino a visitarme durante mi estancia en Porto, 
muitos beijinhos! A mis turolenses (Montse&Alf, Mapi, Yoli) por 
nuestras quedadas y por estar incondicionalmente dispuestos a todo, 
“en lo bueno y en lo malo”. A los zoqueros, por esos findes de 
desconexión. A mi familia Erasmus, por estar cerca 
independientemente de los kilómetros que nos separaran. Y por 
supuesto a mis kimicolocas, esas chicas que siempre, contra viento y 
marea, siempre: están a mi lado. Soportando mi adicción al trabajo y 
comprendiéndome aun siendo absolutamente incomprensible. Gracias 
por vuestras “llamadas de atención”, por ese amor y amistad tan 
incondicional que nos procesamos. Sé que siempre, estemos donde 
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estemos, estaremos unidas. La Uni me concedió este regalo que son 
vuestras sonrisas perpetuas de por vida. Guille+Pablo, sois dos más ;). 
 
Ya casi por último, y sí por ello más importantes: mi hermana y 
mis padres. Esa comprensión sobrehumana que supera todos los 
límites que alcanza mi razón. Sabéis bien que no me soporto ni yo 
misma, y vosotros sois capaces de respaldarme a fe ciega y sin 
preguntas, de tener un tacto silencioso y darme los abrazos y ánimos 
más curativos que existen. Si llego a ser doctora, es gracias a vosotros. 
Vuestro ejemplo y apoyo me ha traído hasta aquí y nunca os daré las 
gracias las suficientes veces. Os amo y adoro, os debo esto y mucho 
más. Y Tatiuska, siempre serás la más grande, este doctorado es tan 
tuyo como mío. Gracias a todos mis tíos: Fernando, Feli, Laura, Luis,…y 
mis superprimos. Por su paciencia con mi impaciencia, porque todos 
los cafés y cervezas que hemos tomado juntos han sido una subida de 
moral y apoyo impagables. Gracias por creer en mí. A mis abuelos 
Lorenzo, Pilar, Fausto y Adoración, por ser el principio de todo y haber 
impreso su huella en mí, gracias por darme todo cuanto amo y 
necesito en esta vida. A través de vuestros ojos siempre me he sentido 
y me siento tremendamente protegida.  
 
Y si alguien tiene derecho a reclamar cada palabra escrita aquí 
ese eres tú: Felipe. Mi equilibrio y parte de la brújula sin la cual no 
comprendo mi vida. Mi agradecimiento será eterno por todos y cada 
uno de los días que ha durado esta etapa. Espero que toda la vida que 
tengo por delante sea bastante para agradecerte que siempre veas 
más allá de lo que yo puedo soñar. Gracias por existir y hacerme 
existir. Tu simple sonrisa es capaz de curar mi alma. Gracias también a 
Puri y Felipe por su apoyo, y al resto de mi ahora familia política, por 
su interés y el ánimo que me han dado. 
 
Y con todas estas palabras no quiero dejar la impresión de que 
esto haya sido “estar con la cabeza debajo del agua” todo el tiempo. 
No. Con estas palabras sólo quiero dejar constancia de que este 
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trabajo habría sido imposible llevarlo a cabo sin la aportación de cada 
una de estas personas. Gracias por estar en mi vida y compartir hoy 
esto. Igual parece demasiado agradecimiento para tan poca 
página…pero el crecimiento no ha sido solo profesional, en lo personal 
he logrado alcanzar unas cuantas metas que, al empezar el camino no 
parecían plausibles y…se han cumplido. Vero, gracias por tu parte. Por 
tu empeño y valentía, por sostenerme este penúltimo año que daba 
por perdido. Para ti mi “gracias” en mayúsculas. GRACIAS. 
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ABSTRACT  
The design of second generation polymer conjugates is 
directed towards four main research areas: the synthesis of novel 
polymeric carriers with defined architectures, an exhaustive physico-
chemical characterization through leading techniques, the use of 
combination therapy pursuing synergism and improved treatments 
and their application on novel molecular targets other than cancer, 
including the crossing of different biological barriers. These guidelines 
have been addressed in this thesis in which the main purpose was to 
build polymer-drug conjugates (PDCs) for the treatment of 
neurodegenerative disorders. 
Based on the well established properties of the poly-glutamic 
acid (PGA) as polymer carrier, a versatile and simple methodology for 
the preparation of well-defined polyglutamate nanocarriers has been 
described. For the first time non-nucleophilic tetrafluoroborate anions 
were used as NCA initiators allowing a multigram scale polyglutamate 
synthesis with defined molecular weight (up to 1200 units), low 
polydispersity (<1.2) and controlled end-chain functionality. Systems 
obtained encompass homopolymers (PGAn), diblocks (DB, PEGm-PGAn, 
PGAn-PEG-X) and triblock copolymers (TB, PEG-PGAn-PEG-X). The 
reason behind this design is based on: (i) the availability of points for 
site-specific conjugation (group X) ( for peptide, protein, antibody, etc 
binding), (ii) the study of the different cell trafficking and (iii) in vivo 
fate depending on polymer solution conformation and its effect on the 
expected biological output.  In addition, deprotection methodology of 
PBLG (poly-benzyl-L-glutamates) was optimised yielding 100% benzyl 
removal without damaging co-polymers structure as well as 
maintenance of the adequate stereoselectivity. Then, post-
polymerisation modification on the PGA block enabled specific and 
orthogonal conjugation of different bioactive molecules such as 
targeting ligands, labelling probes or drugs. 
Cytotoxicity of the novel nanocarriers was evaluated in HUVEC 
cells to secure their cell viability. Continuing with the in vitro assays, 
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investigation of the precise mechanism of internalisation in the same 
cell model was performed aiming to explore possible differences 
based on the size and shape in solution of the different carriers. In all 
cases endocytosis was the preferred cell uptake mechanism and a 
lysosomotropic drug delivery was observed.   
Historically, many studies with PDCs have been focused on 
cancer treatment. Once the clinical benefits of these systems have 
been demonstrated, their use in other diseases has been also 
encouraged, in particular in the area of tissue regeneration and repair. 
In the present work, neurodegenerative disorders have been faced up. 
When damage in the central nervous system (CNS) is involved, drug 
must surpass a biological obstacle known as blood-brain barrier (BBB). 
Conjugation of a targeting ligand for blood-brain barrier (BBB) crossing 
though receptor-mediated endocytosis was the strategy selected for 
drug delivery into the brain. Ligands towards the transferrin receptor 
(TfR) (e.g. transferring (Tf), monoclonal antibody OX26 (mAbOX26), 
iron-mimicking cyclic peptide (cPEP) or Angiopep-2) were covalently 
linked to our polyglutamates trying to favor the BBB entry by active 
targeting. Molecular probes for fluorescence optical imaging, contrast 
agents for MRI or tracers for positron emission tomography (PET) were 
conjugated to our systems, with and without targeting ligands in order 
to monitor conjugate biodistribution comparing their BBB crossing 
capability. In most of the cases, the polymer platform linkage with the 
ligand was a disulphide bond. The bioreversible union allows the 
ligands to be released following transcytosis.  All of the polyglutamate 
systems proved to have an appropriate biodistribution, where non-
specific accumulation in any organ was observed and body elimination 
followed renal excretion. Regarding the targeted systems, TB-Tf was 
found in rat brain after tissue homogenation although in very low 
percentage. Aiming to increase the percentage, the natural ligand Tf 
which presents receptor saturation under physiologic conditions was 
substituted by an antibody able to selectively target this receptor with 
greater efficiency. mAbOX26 was successfully linked to the carrier but 
issues related to solubility issues limited a proper detection in brain. 
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Consequently, peptide ligands were used instead. cPEP was directed to 
TfR and Angiopep-2 to the lipoprotein receptor-related protein-1 
(LRP1). This last peptide is the most advanced for BBB crossing in 
phase II clinical trials. After the results obtained, PGA homopolymer 
and DB were the carriers selected for further studies.  Monitoring of 
these targeted systems did not show BBB crossing may be due to low 
availability of the peptide motifs for receptor recognition. Currently 
other polyglutamates with different structures are being tested to 
surpass this inconvenience. 
When CNS is not involved but peripheral nervous system 
(PNS), brain entering is not a major problem. FAP (familiar amyloidotic 
polyneuropathy) is a rare amyloidotic disease where PNS is the main 
organ affected. A mutation in the protein transthyretin (TTR) promotes 
its aggregation ending up in fibril formation whose deposits promote 
organ failure. As a first proof of concept, treatment of FAP by means of 
PDCs was proposed. Continuing with the polymeric platforms 
exploited in this work, PGA and PEG were selected for conjugation of 
two bioactive molecules able to disrupt amyloid fibrils (doxycycline) 
and to suppress cytotoxicity promoted for the early aggregates (RAGE 
peptide). Two families of conjugates were synthesised following a 
rational design based on the extracellular target of the compounds 
and the properties and requirements of each drug.  Total drug loading 
was varied as well as the linkage alternating biodegradable 
(disulphide) and non-biodegradable (amide) bonds. After in vitro 
screening in appropriate FAP models, Doxy conjugates showed higher 
activity than the parent drug at same concentration and RAGE peptide 
conjugates maintained the original activity. The best candidate of each 
library (PGA-CONH-Doxy and PEP1-PEG-PEP1) was selected and a full 
physico-chemical characterisation was performed in order to explain 
the activity found. Both conjugates proved by LCMS or HPLC 
techniques to be stable under the in vitro conditions used implying 
non requirement of drug release to achieve activity while the others 
not. Furthermore, the conjugates demonstrated stability in plasma and 
non haemolytic activity confirming their suitability for intravenous 
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administration. Studies on solution conformation by dynamic light 
scattering (DLS) showed marked differences in the RAGE peptide 
conjugates where more stable and smaller conjugates (Rh=0.6-3nm) 
corresponded to the most active ones. Regarding the PGA-Doxy, 
different ωt% loading did not show major differences in conformation 
in SANS (small angle neutron scattering) analysis corroborating the 
similar activity found with the selected conjugates.  
Previous to in vivo activity evaluation, biodistribution of the 
conjugates were performed resulting in non-specific organ 
accumulation and elimination via the kidney.  
Finally, combination therapy was proposed as a helpful tool 
due to the target species of the TTR aggregation cascade coexist in the 
advance stages of the disease. Initially, conjugation of both agents in 
the same polymer matrix (PGA homopolymer, DB or TB) was 
suggested but due to the unknown space among respective targets, 
individual PDCs were first tried and combination of the single 
conjugates was suggested as alternative. Thus, preliminary in vitro and 
in vivo studies with both conjugates (PGA-CONH-Doxy and PEP1-PEG-
PEP1) were performed. Comparing the obtained results of 
immunohistochemistry analysis from single conjugates administration 
and their combination (without control samples) it could be concluded 
that the combination group showed lower deposition of non-fibrillar 
TTR. Histological analysis of the organs evidenced normal patterns in 
morphological tissue structures implying the safety of the 
administered conjugates. In any case, PGA-Doxy effect is planned to be 
evaluated in old FAP mice as well as a dose optimisation study should 
be performed in order to finally proved conjugates effectiveness in 
FAP. 
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CHAPTER I. GENERAL INTRODUCTION 
Nanomedicine has been defined as “the use of nano-sized 
tools for the diagnosis, prevention and treatment of disease and to 
gain increased understanding of the complex underlying patho-
physiology of disease. The ultimate goal is improved quality-of-life”. 
This relatively young field has been expanding significantly thanks to 
science and engineering advances and it is poised to revolutionise how 
medical and pharmaceutical industries approach the 21st century’s 
pharmaceutical care challenges.  Currently, about 40 nano-products 
for health care are in routine clinical use. Among the nanotechnologies 
that this term involves, polymer therapeutics (PT) is underlined as the 
most successful first generation nanomedicines [1]. Initial hallmarks of 
PT started in the 70s when the concept of polymer-drug conjugate was 
coined [2] and the “lysosomotropic drug delivery” described [3]. One 
decade after the development of the first polymer-anticancer 
conjugate entered clinical trials (CT28068, PK1, 2-
hydroxymethacrilamide copolymer-doxorubicin (HPMA-Dox) 
conjugate) [4]. Up to now, a first generation of polymer conjugates has 
resulted in several products in the market (PEGylated proteins and 
polymeric drugs) and a growing number of polymer-drug conjugates in 
clinical development mainly as anticancer agents [5-8]. The acquired 
knowledge has built a solid source of background information from 
which a novel generation of polymer therapeutics is emerging. 
Together with the aim of meeting regulatory demands, this second 
bundle is supported by four main strategies:  (1) the synthesis of novel 
polymeric carriers with defined architectures, (2) the implementation 
of better physico-chemical characterisation methods, (3) the use of 
polymer-based combination therapy to increase specificity and 
efficacy of the treatments always looking for synergysm  and (4) the 
application of PDC to new molecular targets other than cancer, 
including the crossing of different biological barriers [8].  
One of this potential novel targets are the neurodegenerative 
disorders. Aging of population leads to a growing incidence of 
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neurodegeneration [9]. The bottleneck for treating the vast majority of 
these diseases relies on the difficulty for drugs in crossing the 
protective barrier that surrounds the brain: the blood-brain barrier 
(BBB). Within an extensive rational design, polymer conjugates bring 
together all the basic requirements to overcome this barrier and 
become a successful therapy for neurodegeneration treatment.   
 The aim of this thesis covered the four explained lines as it was 
focused in the design, synthesis and characterisation of novel polymer 
carriers based on poly-L-glutamic acid (PGA) to construct polymer-drug 
conjugates (PDCs) for neurodegenerative disorders treatment. In the 
cases were the central nervous system (CNS) is involved, active 
targeting for blood-brain barrier (BBB) crossing entangled ligand 
conjugation to the polymeric platform. When it is the peripheral 
nervous system (PNS) the major organs affected, this requirement is 
not required. As a first application of PDC in the neurodegeneration 
field, herein the treatment of a rare amyloidotic disease FAP (Familial 
Amyloid Polyneuropathy) was proposed by means of novel PDCs as 
simple agents and in combination therapy. 
  
I. 1 NEURODEGENERATIVE DISORDERS 
One of the major challenges for the 21st century medicine is to 
find effective treatments to face the growing incidence of 
neurodegenerative diseases. These are tightly related to aging 
population due to constant and considerable increasing of life 
expectancy, environmental cues and/or disordered immunity and less 
with host genetics [10, 11]. It is predicted than disability and mortality 
caused by central nervous system (CNS) disorders will increase up to 
15% in 2020 [12] and 65-year old population will rise from 
approximately 14% in 2010 to 26% in 2100 [13] (FIGURE I. 1) with the 
consequent growing number of affected individuals. 
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FIGURE I. 1 United Nations prediction for aging in world population. From ref 
[13]. 
 
Renowned examples as Alzheimer’s and Parkinson’s diseases 
(AD and PD), stroke, Huntington’s disease (HD), multiple sclerosis (MS) 
and HIV-1-associated dementia (HAD) are only part of the vast number 
of common neurodegenerative disorders. Most of them have been 
well described in terms of pathology and disease mechanism although 
successful treatment strategies have been at best palliative and 
manage only the symptoms [14-16], receiving no benefit from 
currently available medication. 
In western countries, an epidemic progression of chronic 
diseases such as neurodegenerative disorders (together with 
cardiovascular and metabolic afflictions) is expected to be the main 
cause of death in the next few decades. Moreover, these types of 
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pathologies already poses a heavy economic and social burden and it 
is predicted than in few decades their impact will increase 
considerably. This context establishes the urgent need for developing 
novel therapeutic strategies to face neuropathological diseases. Two 
main objectives in this field comprise specific site-directed drug 
delivery systems and the development of early diagnosis 
methodology. 
Regarding causes of the neurodegenerative disorders, 
abnormal accumulation, aggregation and modification of certain 
proteins, effects of viral infections, disrupted blood flow, alterations in 
tissue homeostasis and immunological damage are the main reasons 
[10]. Scientific efforts have been concentrated in understanding key 
molecules and pathways in physiological processes as well as drug 
discovery for treating the different diseases. In addition, it has been 
recognised that neurological disorders may be multisystemic in nature 
which hinders their treatment, i.e. specific neuron death due to a 
cascade of multiple deleterious molecular and cellular events rather 
than a single pathogenic factor [17].  
However, in spite of the assembled knowledge, many drugs 
remain ineffective in the treatment due to the inability to effectively 
deliver and retain them within the brain. Here is found one of the 
major bottleneck in neurodegeneration treatment: the different 
biological barriers that must be surpassed for successful drug delivery 
and avoidance of peripheral side-effects.  
 
I. 1. 1 NERVOUS SYSTEM 
Neurological disorders involve affection to the nervous system 
in the body, being characterised by the gradual and progressive loss of 
cells from the affected organs. Also the emerging symptoms vary 
depending on the region affected in the CNS or the PNS. CNS is 
composed by the brain and the spinal cord while PNS comprises 
cranial, spinal and autonomic nerves that connect CNS to the rest of 
the body.  
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Nervous system main function is based on communicate the 
whole body with the brain and within the brain through electric 
stimulus. It controls muscles, organs, glands and several basic 
processes such as heartbeat, breathing, digestion, urination, blood 
flow regulation or homeostasis maintenance among others. Higher 
functions such as thinking and memory are also regulated [18].   
Nervous tissue is composed mainly by neurons (FIGURE I. 2), 
which transmit nerve messages and glial cells or neuroglia that 
primarily provides neurons insulation, physical support, metabolic 
assistance and protection.  
 
 
FIGURE I. 2 Neuron is the fundamental structural unit of the nervous system. 
Its structure consists of a spherical central portion (the cell body or soma), 
processes called dendrites are implied in bioelectric impulses reception 
toward the cell body and one axon that transmit impulses away from the cell 
body and reach its destination. Ending portion of the axon presents a 
branched morphology named nerve terminal (boutons), which communicate 
with the next neuron or organ. 
 
Glial cells outnumber neurons by ten to one[19]. Unlike the 
neurons, they do not participate directly in synaptic interactions and 
electrical signalling. There are several types of glial cells: (i) Schwann 
cells are PNS structures that wrap neuronal axons to form a protecting 
cover known as the myelin sheath. Furthermore, they assist in the 
conduction of impulses as myelinated nerves conduct faster that 
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unmyelinated ones, (ii) oligodendrocytes have the same functions than 
Schwann cells (among others) but are allocated in the CNS, (iii) 
astrocytes are present in the capillaries of the brain and constitute 
part of the blood-brain barrier (BBB) (further explanation on BBB 
section I.3.1) and (iv) microglia are smaller scavenger cells found in 
CNS and are in charge of remove cellular waste and protect against 
microorganisms  [19-21]. 
 
I. 1. 2 BARRIERS IN THE PERIPHERAL NERVOUS SYSTEM 
Protection of PNS is not as restrictive as for the CNS. The PNS 
is not protected by spine bone and skull or by a structure like the BBB. 
Peripheral nerves tend to lie deep under the skin except in specific 
sites as the elbow joints. This feature exposes them to physical 
damage causing pain, loss of sensation or muscle control. This damage 
promotes neuronal regeneration with support cells aid. Nerve 
regeneration, for example after a transection, will take place but over 
months. Typical treatments after injury relies on surgery or use of an 
autologous nerve graft to guide restoring of the PNS function [22]. 
Peripheral neuropathy can be also caused by other circumstances such 
genetic, metabolic or inflammatory conditions as well as vitamin 
deficiency, infectious diseases or poisoning.  
 
I. 1. 3 BARRIERS OF THE CENTRAL NERVOUS SYSTEM 
Drug delivery to the CNS by means of a systemic approach is a 
highly challenging prospect in drug development. To achieve CNS 
access, therapeutics must overcome three barrier layers, which control 
molecular exchange between blood and neural tissue or its fluid 
spaces. 
These barriers include: the blood-brain barrier (BBB) formed 
by the cerebrovascular endothelial cells between blood and brain 
interstitial fluid (ISF), next the choroid plexus epithelium between 
blood and ventricular cerebrospinal fluid (CSF) and finally the 
arachnoid epithelium between blood and subarachnoid CSF 
(components localised in FIGURE I. 3). In unison, these barriers govern 
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the passage of substances to the brain [23].  
(A)
 
(B) 
 
FIGURE I. 3 (a) The brain is protected by three membranes: the outermost 
dura mater, the arachnoid membrane and the innermost pia mater. The last 
two ones are known as the leptomeninges. On the right it is zoom insert 
inicating where is located the blood-brain barrier. Adapted from refs [24] and 
[25].(b) Fluid compartments in the CNS. Redrawn from ref. [12]. 
ISF=Interstitial fluid. CSF=Cerebrospinal fluid. BBB=blood brain barrier. 
 
I. 1. 3. 1 Blood-brain barrier (BBB) 
Since its discovery by Paul Ehrlich in 1885 [26], BBB has been 
baptized as the most critic nearly insurmountable cellular barrier in 
the human beings. This natural barrier guards brain and spinal cord, 
separating them from the blood flow by an active and restrictive 
cellular complex [23].  
All organs into the body are connected to the circulatory 
system, which by means of blood is supplying through the capillaries: 
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nutrients and essential components for their sustention. Brain is not 
an exception but it has an extraordinary overprotection compared 
with the rest of the organs.  Human brain posses around 100 billion 
capillaries, achieving approximately a total surface area of 20m2 and 
650km of brain capillary endothelium [27].  Before reaching the brain 
from these capillaries, a densely packed brain capillary endothelial cell 
(BCEC) layer with tight junctions must be surpassed: the BBB. In 
humans, thickness of this barrier is estimated to be around 300 to 
500nm.  It allows the passage of specific nutrients and metabolites 
but effluxes or prevents the entrance of non-desired substances, 
maintaining a stable microenvironment (named brain homeostasis) 
and free of inflammation or attack from harmful endogenous 
compounds or exogenously introduced such as drugs.  
Tight junctions (TJs) in the apical region of brain endothelial 
cells possess a unique intercellular occlusion profile [23] (FIGURE I. 4). 
They are composed by complex network of parallel, interconnected, 
transmembrane and cytoplasmatic strands of proteins (junctional 
adhesion molecule-1, occluding, claudyns and cytoplasmic accessory 
proteins). Furthermore, they provide significant transendothelial 
electrical resistance (TEER) (8000V/cm2) to bone marrow 
microvascular ECs. Below TJs, adherens junctions (AJ) are found, 
completing BBB as a physical barrier. This structure is formed by 
transmembrane glycoproteins (cadherins) bond to the cytoskeleton, 
achieving a higher tightening structure between the adjacent brain 
endothelial cells [20]. 
Together with TJs, brain endothelium is characterised by 
remarkably lower degree of endocytosis activity (see FIGURE I. 11) 
than peripheral endothelium. Free diffusion is allowed for small 
gaseous molecules such O2 and CO2 as well as small lipophilic agents. 
In the case of small hydrophilic molecules (i.e. amino acids, glucose, 
etc) or larger and/or hydrophilic essential molecules (i.e. hormones 
transferring for iron, insulin, etc), it is required a specific transport 
system such GLUT1 glucose carrier, amino acid carrier LAT1, 
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transferrin receptors, insulin receptors, or lipoprotein receptors to 
regulate their transcellular traffic. A family of efflux transporters 
prevent entrance of undesired compounds. Transport mechanisms 
through this barrier are explained in section I.4. Finally, low and 
selective permeability is also attributed to lack of fenestrations and 
great number and volume of mitochondria in endothelial cells, as well 
as the lack of lymphatic drainage [28]. 
Besides the BCECs, extracellular base membrane, pericytes, 
astrocytes, microglia and neurons are been described to be functional 
contributors in the BBB. As a whole, these components form the 
“neurovascular unit” (NVU) (FIGURE I. 4). Research studies on each 
component functions and their relative contribution to the BBB has 
been carried out achieving results detailed below, but still there is 
information largely unknown. 
Pericytes are the next critical components of the BBB that are 
located along the vascular endothelium in an intimate position 
regarding BCECs (approximately in a ratio 1:5-6 BCECs). Both are 
separated by a layer of basal lamina. Among their functions have been 
suggested their role in ECs proliferation, microvascular capillary flow 
control, normal regulation of BBB, efflux transporters expression (i.e. 
ATP- binding cassette (ABC) transporters) and has an important role 
during initiation of angiogenesis both in CNS and non-CNS tissue [29-
31]. Recently, it has been demonstrated that pericytes deficiency 
increases BBB permeability to water and a range of low and high 
molecular mass tracers, as well as they regulate BBB specific gene 
expression patterns in endothelial cells and induce polarisation of 
astrocytes [32]. In addition, it has been recently proved that age-
dependent vascular damage in pericyte-deficient mice precedes 
neuronal degenerative changes, learning and memory impairment 
and neuroinflammatory responses. Thus, pericytes control key NVU 
functions required for BBB maintenance and proper neuronal 
structure and function [33, 34]. 
Astrocytes are a class of macroglial cells in the CNS. Astrocytes 
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project endfeet forms a net, surrounding the endothelial cells (FIGURE 
I. 4). They have been described to significantly influence 
neurovascular structure, maintenance and integrity; participating in 
nutrition and metabolic support of neurons. Furthermore, they 
preserve TJs integrity and induce P-gp expression. Together with 
pericytes and the basement membrane, they have been suggested to 
play a role in TJs formation [28]. Current research remark astrocytes 
as ECs survival support in hypoxic and ischemic conditions, when 
acute hypoxic insult is suffered astrocytes protect the endothelial 
barrier. However, in prolonged stages pericytes are more protective. 
This difference is attributed to their intrinsic modulation of specific 
signalling pathways and subsequent released factors [34]. 
The basement membrane is a specialised extracellular matrix 
which separates BCECs and pericytes from the surrounding 
extracellular space [35]; it engulfs them without acting as a barrier for 
small molecules diffusion. Its main function is anchoring the cells in 
place and regulates cellular functions of the BECs through signalling 
molecules on the abluminal BCECs surface.  
Finally, microglia is the 20% of the total glial cell population in 
the CNS and its activity deals with identifying and neutralising foreign 
objects, responding to minor pathological changes and starting a 
coordinated neuroinflammatory response [12]. This glia sheet, which 
derives from systemic circulating monocytes and macrophages, is 
essential for the barrier integrity and transcellular transport through it 
[30].  
Apart from constituting a morphologic obstacle due to the 
named cell complex, BBB is also a metabolic barrier thanks to a 
combination of intracellular and extracellular enzymes [37].These 
enzymes handle drug and nutrients metabolism. Examples can be 
found in ref. [38]. This elevated enzymatic activity has to be taken into 
account once the drug arrives there, in order to prevent rapid 
degradation or deactivation. 
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FIGURE I. 4 Components of the neurovascular unit (NVU).Redrawn from ref. 
[36]. 
 
I. 1. 3. 2. Blood-cereborspinal fluid barrier (BCSFB) 
Morphologically, BCSF barrier is located in the choroid plexus 
and meninges. It is about 1000 times smaller than BBB. The choroid 
plexus, which is the principal source for the cerebrospinal fluid (CSF), 
is formed by cuboidal epithelial cells that contain apically localised 
tight junctions to prevent paracellular transport. On the contrary as 
BBB endothelial cells, endothelial cells of the choroid plexus capillaries 
posses fenestrations and lack tight junctions, forming a leaky 
endothelium [25]. 
One of the barrier faces is the ventricle, where CSF flows out 
to the subarachnoid space surrounding the brain and the spinal cord. 
Then, it returns to blood by different via (FIGURE I. 3). Although there 
is absence of a cellular barrier preventing diffusion from the 
ventricular surface into the brain tissue, the low diffusion speed and 
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high turnover rate of CSF prevents penetration of large molecules into 
deep tissue layers [30].  As the BBB, BCSFB is also an enzymatic 
barrier. 
 
I. 1. 4 TRANSPORT MECHANISMS ACROSS THE BBB 
 
 As it has been already named, transport systems regulate 
passage from systemic circulation into the brain (influx) when turned 
back to blood circulation (efflux). Both types of solute movements are 
present in this endothelium, defining a unidirectional concentration-
dependent profile. Importantly, net flux is a critical parameter in drugs 
reaching therapeutic concentrations within the CNS [12]. The different 
pathways are pictured in FIGURE I. 5. Basically, transport can be 
subdivided in passive and active processes.  
I. 1. 4. 1 Passive transport 
Solute gradient by simple diffusion proceeds from low to high 
concentrations and includes: 
(a) Paracellular (aqueous) diffusion (FIGURE I. 5(a)). 
Apparently, small water-soluble molecules are uptake 
through the TJs and diffuse through the BBB. However, 
this pathway is remarkably diminished in comparison with 
the rest of the organs due to the high TEER at the TJs. 
 
(b) Transcellular (lipophilic) diffusion (FIGURE I. 5(b)). Among 
the passive diffusion mechanism, transcellular diffusion 
constitutes the most favoured. Lipid-soluble substances 
such as oxygen, carbon dioxide, alcohol or steroid 
hormones penetrate ECs through their plasma membrane. 
Either paracellularly or transcellulary, are non-saturable 
and non-competitive pathways. Most of CNS drugs enter 
via this route [39]. 
 
(c) Saturable (carrier-mediated) transport (CMT) (FIGURE I. 
5(d)). Expression of these carriers is often polarised to 
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optimise substrate transport into the brain, which means 
they are co-localised on both the luminal and abluminal 
membranes of the BCECs and thereby operates in both 
directions.  The process is more selective than those 
named before and it has been suggested to involve 
formation of transient narrow pores induced by binding of 
the respective substrate to the carrier that allows only its 
passage. An example is the glucose transporter 1 (GLUT1), 
in charge of glucose trafficking through BBB [40]. 
 
I . 1. 4. 2 Active transport 
In cases where transport requires energy, the passage is 
carried out by means of an electrochemical gradient. Mainly, active 
transport task relies on vesicle formation. As it has been previously 
cited, endocytosis is remarkably diminished in the brain. However, 
more specific subtypes of this mechanism may take place. The general 
term is transcytosis, a group of phenomena which allows passage of a 
molecule through the cellular cytoplasm from blood capillary to brain 
parenchyma. It implies a double process across the BBB layer: 
endocytosis and exocytosis, and can be divided into specific (receptor-
mediated transcytosis) or nonspecific (adsorptive-mediated 
transcytosis) processes. Implicated transporters are commonly named 
ATP-binding cassette (ABC) transporters.  
 
(d) Receptor-mediated transcytosis (RMT) (FIGURE I. 5(e)). 
Essential molecules with high size required for normal 
function in the brain are delivered through specific 
receptors. RMT uses vesicular trafficking mechanism of 
the endothelium to transport nutrients into the 
parenchyma. Process could be divided into three steps: (i) 
Ligand binds its specific receptor localised at the luminal 
membrane of the BCECs, inducing a modification of the 
receptor either through cross-linking or conformational 
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change. This binding induces an endocytic event which 
produces aggregation of both components within pits, (ii) 
then the coated pits trigger the formation of bigger 
vesicles (aprox. 100nm diameter) and cross the cytoplasm 
while they transform into endosomes (acidic pH), where 
dissociation occurs. Afterwards, free receptor is recycled 
to cell surface or degraded through lysosomes. (iii) Finally, 
the ligand containing vesicles can be packed into export 
vesicles to be exocytosed on abluminal face, achieving 
BBB crossing. Complete crossing could be not achieve due 
to some of the vesicles could fuse with a lysosome and be 
degraded and others could bind a second intracellular 
receptor system.  
Therapeutic compounds are able to cross the BBB after 
association or conjugation to the ligands of these 
receptors forming molecular “Trojan horses” [41].  
 
Sometimes RMT is preferred as drug delivery route for 
BBB crossing possibly due to CMT involves molecular 
movement through a small pore while RMT use 
transcytosis [29] and macromolecules could be 
transported. 
 
The three best-studied receptors are (i) the insulin 
receptor (IR), where insulin binds changing its shape to 
form a tunnel for the entry of molecules such as glucose, 
(ii) the transferrin receptor (TfR) which mediates cellular 
uptake of iron by means of its natural ligand: the protein 
transferrin (Tf), which acts as carrier.  TfR is expressed in 
BCECs, choroid plexus epithelial cells and neurons among 
other tissues. Iron-TfR complex is transcytosed across 
BCECs without intraendothelial degradation [42] and (iii) 
the low-density lipoprotein receptor related proteins 1 and 
2 (LDP-1 and 2). These multifunctional endocytic receptors 
mediate internalisation and degradation of several ligands 
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in different metabolic pathways. LRP receptor interacts 
with apoliprotein E (apoE), APP (amyloid precursor 
protein) and lactoferrin among others.  
 
(e) Adsorptive endocytosis (AE or adsorptive-mediated 
transcytosis AMT) (FIGURE I. 5(f)). Molecules as peptides 
or proteins with basic isoelectric point (called “cationic”) 
can be uptake by the brain trough AE, such as protamine, 
histone or albumin [30, 43]. Binding process is mediated 
by electrostatic interactions between positive charged 
moieties of the molecule and the negative charged region 
of the plasma membrane surface region, which initiates 
endocytosis [44]. Main difference from RME is that AE do 
not involve specific plasma membrane receptors. 
Furthermore, AE presents lower affinity but higher 
capacity than RMT. 
 
(f) Efflux transport systems (FIGURE I. 5(c)). Localised at the 
BBB as well as in the BCSFB, efflux systems reinforce 
barrier properties by extruding undesired substances from 
the brain or the CSF pulling them in the blood circulation, 
maintaining homeostasis. ATP family of efflux transporters 
include P-glycoprotein (P-gp), breast cancer resistance 
protein (BCRP) and multidrug resistance related proteins 
(MRPs). P-gp can actively transport many hydrophobic 
amphipathic drugs out of the brain, i.e. loperamide [28, 
45].  
 
There are examples of transporters driving a non-energy 
dependent mechanism such as the organic anion transporter 
(OAT) and organic anion transporter poly-peptide (OATP), that 
have dual function as efflux and influx transporters [46]. 
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FIGURE I. 5 Transport mechanisms in the BBB (redrawn from ref. [23]). (a) 
Paracellular pathway for diffusion of small amounts of water-soluble 
compounds. (b) Transcellular lipophilic pathway for diffusion of lipid soluble 
agents. (c) Efflux transport systems restrict the penetration of many 
substances into the brain turning them to blood stream. (d) Saturable 
transport responsible for the transfer of essential polar solutes. (e) Receptor-
mediated endocytosis is the mechanism used for transport essential proteins. 
(f) Adsorptive endocytosis. Cationisation increases the uptake of poorly 
transportable local plasma proteins. 
 
I. 1. 5 BBB UNDER PATHOLOGICAL CONDITIONS 
BBB role during degenerative development is unknown. 
Scientists discuss if BBB is the starting cause, participates in the 
process or if BBB is damaged as a final result of degeneration. Relying 
on the specific disease it could be a different answer but it is referred 
to display a significant causal part or involvement in the initial 
degenerative process. However, all neurological diseases studied up 
to date have suggested, at least, that BBB dysfunction results from the 
pathogenic process. Nevertheless it has been proposed that barrier 
dysfunction results from the own pathological process. It is 
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noteworthy to remark the existence of a common neuropathological 
condition inflammation and inflammatory mediators are involved in 
BBB disruption. Their mediators have been suggested to be targeted 
or controlled for opening or closing the BBB [28, 47]. BBB cohesion 
along all the disease states is a relevant parameter for understanding 
the disease as well as for therapeutic strategy design.  
Experts remark the importance of using different targeting 
strategies depending on what to treat, only BBB or the brain plus the 
BBB [48]. 
During neurodegenerative processes BBB disruption is a 
common feature in infections, tumours and acute or chronic 
neurodegenerative disorders [47]. Its permeability and protective 
mechanisms such as TJs opening, P-gp up or down-regulation among 
others, are usually diminished in disease state. This impact can be 
defined as an advantage for providing a window of opportunity for 
drugs unable to cross the BBB to reach their target inside the brain by 
means of paracellular route. Several studies on this field have prove 
this affirmation [47]. However, researchers highlight that although 
this aspect may benefit drug efficacy, increasing of BBB impairment 
could lead to higher rates of neurodegeneration. For example, in AD 
restoring BBB integrity will confer better output than increase drug 
transport due to the BBB leakage. BBB disruption allows pathogens 
entrance to in the brain, aggravating or accelerating the disease. On 
the other hand, brain tumours can increase also BBB permeability, 
possibly caused by TJ complex disturbance, growth factors 
accumulation and proinflammatory cytokines [49]. 
It has been already tested in animal models and cell studies 
that transport processes in disease state such AMT and RMT are 
enhanced but it has to be still confirmed for CNS human disorders 
[48].  
 
I. 1. 6 MIMICKING THE BLOOD BRAIN BARRIER 
As important as the development of novel materials and BBB 
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targeting vectors is their biocompatibility and efficient investigation 
towards a successful therapeutic output. In vitro testing is considered 
a powerful tool for the screening of drug and materials and also 
comparing their performance and evaluating their ability for 
controlled drug release depending on the pursued objective. 
However, a step further must be done and studies on animal models 
complete the experimental panel to determine the effectiveness of 
the proposed treatment. Due to the inherent BBB complexity, in vitro 
methodologies for mimicking BBB remain sub-optimal.  
 
I. 1. 6. 1 In vitro methodologies 
By mimicking BBB in vitro, it is possible to pursue two 
different objectives: (i) to gain knowledge about how to cross this 
barrier enhancing drug transport into the brain and (ii) to discover 
how to reduce or prevent its disruption during injury. Then, the main 
objective combining both statements is how to maintain the barrier 
during injury but also facilitate selective opening to enable drug 
access. 
Since contribution of individual cell types is crucial, 
identification and targeting of cell-specific mechanisms may gain 
better results than have been currently obtained using more global 
approaches. In vitro model systems are decisive in this respect. In vitro 
methodologies simplify experimental work, allowing investigation and 
interpretation of experiments that are impossible or complicated to 
perform in vivo. Additionally they are versatile, easy to be 
implemented and inexpensive although unable to fully recreate all 
aspects of a real situation and limited by the type of brain cells used. 
An in vitro BBB model should include: (i) a restricted 
paracellular pathway, (ii) brain capillary endothelial cell 
characteristics, (iii) functional expression of BBB specific transport 
mechanisms, and  (iv) in vivo-like BBB modulation and reproducibility 
[50].  
Lately, co-culture of several cell types makes these systems 
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more relevant. Presence of astrocytes in BCECs vicinity is crucial for 
BBB development, upregulating Pg-p expression, enhance cell-cell 
tight junctions and inducing specific enzymes or transporters [29]. 
Triple culture systems has been also studied adding pericytes to the 
co-cultures named [51]. 
Next step on BBB modelling through in vitro assays considers 
the dimensional feature: 2D and 3D models and blood flow 
properties. 
The strength of 2D model lies on the ability to directly asses 
barrier function within an endothelial monolayer. Experimental 
setting up consists of ECs cultured on one side of a cell-culture insert 
with porous filter membrane (transwell system), allowing formation of 
a monolayer and induction of cell polarity (FIGURE I. 6). Correct 
function is assessed by means of TEER measurements or permeability 
assays that evaluate the diffusion/extravasation of labelled proteins 
and/or cells through the monolayer. As results with endothelial 
monocultures revealed poor TEER values (10-100Ω, compare to real 
situation where TEER>1000Ω)) and higher permeability, co-cultured 
was studied allowing a closer recreation. Even though higher TEER 
values were obtained, the degree of induction remains significantly 
lower than the in vivo situation [33]. 
Microfluidic-systems to simulate the real environment have 
been also tested in 2D systems by applying flow-induced shear stress 
across the monolayer [52-54]. 
2D models have facilitated studies on cell-cell interaction and 
external influences by pharmacological compounds to barrier function 
but they do not take into account the 3D dimensional structure of 
blood vessels and real complex cellular interactions in BBB are also 
missed. 
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FIGURE I. 6 In vitro assembly of the 2D transwell system within a multiple-
well plate. Several co-culture models are also used for this system, even with 
three cell lines. Closer recreation of cell interaction is achieved by growing 
astrocytes on the opposite face of the porous membrane (contact model), on 
the bottom of the well (non-contact model) or used astrocyte-conditioned 
media harvested from growing astrocyte cultures. Redrawn from ref. [33]. 
 
A step further towards in vivo recreation is the use of 3D 
models, in which cellular movement and organisation of dynamic cell-
cell interactions is included. Within this system there are two different 
approaches. On one hand, 3D collagen matrix models grow 
endothelial cells in type I collagen matrix promoting their organisation 
into tube-like structures [55]. Co-culture with other two cell lines 
suggested again to confer better analogy to BBB, allowing them to 
display their unique morphology [33, 56]. Main drawback lies in the 
difficulty of assessing tightness of the formed tubes as well as the TJs 
formation and the absence of flow. On the other hand, there are 3D 
flow systems trying to simulate the shear stress triggered by blood 
flow across the apical surface of the cells. In these models 
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microvascular ECs grown in three dimensions are exposed to flow 
[57]. Its influence has been demonstrated to be important for 
endothelial cell differentiation and metabolism. These advanced 
systems allowed to achieve enhanced TEER values, lower permeability 
output and longer lifetimes. Nevertheless, due to their technical 
demand and high cost they have not been adopted in researcher 
laboratories. Also, doubts on the percentage of correlation with 
cellular organisation in vivo have been reported [33]. 
 
I. 1. 6. 2 In vivo studies 
In vitro models avoid the current exhaustive examination of 
animal experiments and the difficult data translation but it is 
becoming clear that BBB complexity need to be addressed directly by 
in vivo studies, in particular when active transport mechanisms are 
evaluated. 
Concerning RMT methodology, antibodies or peptide 
targeting moieties have presented a vast variety of different results 
between in vitro and in vivo [58], which often do not agree. Studies 
differ either on the carrier exploited, complicating the selection of the 
best targeting residue, or the methodology used to detect BBB 
passage by biodistribution (optical imaging with near-infrared (NIR) 
dyes, radioactivity emission with different isotopes (PET, SPECT), 
magnetic resonance imaging (MRI),…)  and activity studies [59-70].  
Recently, zebrafish has emerged as a premier vertebrate 
organism to model and analyze complex BBB cellular interactions in 
vivo, thus, providing a profitable tool to complement drug discovery 
development studies [71, 72]. Furthermore it has demonstrated to 
express mutated disease-associated human proteins in specific 
neurons to rapidly model aspects of neurological disorders [73]. 
 
I. 1. 7 DELIVERY STRATEGIES TO THE BRAIN. DRUG TARGETING 
 
Although important research efforts have been devoted in 
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targeting and targeted drug delivery to the brain, Markets are still 
waiting to find the Holy Grail in CNS-related diseases: BBB crossing. 
Until now, drug delivery to the brain has been partly accomplished 
through several methods, including invasive or systemic approaches 
(pharmacological or physiological). Most of them combine biology, 
nanotechnology and even biophysics to achieve this common goal. As 
this thesis deals with nanomedicine, an extensive number of examples 
are described in section III related to this strategy. 
Route of administration is a key choice to make when 
designing pharmacological approaches to cross BBB and is highly 
influenced by the selected active principle. Delivery pathway can be 
driven by patient acceptability, important properties of the drug (i.e. 
solubility, stability), and ability to target the disease location or 
effectiveness in dealing with the specific disease. Fortunately, the use 
of drug delivery carriers can diminish the drawbacks of free agents, 
enhancing therefore its possible therapeutic value in the preferred 
route of administration [74]. 
 
I. 1. 7. 1 Invasive approach 
Invasive approaches are based on mechanical breaching the 
BBB and posses the advantage of delivering higher concentration of 
the therapeutic compound due to a direct injection into CSF or 
parenchymal space [75]. Subsequently, this reduces drug 
concentration in peripheral environment and undesired effects. 
Several animal studies by means of this type of drug administration 
have demonstrated its efficiency and efficacy, either by using a mini-
osmotic pump or acute injections through a cannula permanently 
implanted in the skull. However, for human use  alternative methods 
are required as the use of these inventions for extensive periods 
compromise BBB, resulting in patients susceptible to injury and 
infection [76]. Invasive techniques include cerebral 
(intraparenchymal), intraventricular (transcranial), intrathecal (intra-
CSF) delivery and BBB disruption. 
Intracerebral delivery means drug delivery into parenchymal 
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space of the brain, by direct injection (bolus or infusion) via 
intrathecal catheters, controlled release matrices, microencapsulated 
chemicals or recombinant cells [39]. Main limitation of bolus relies on 
low drug diffusion characteristic of this tissue and large dose is 
required. On the other hand, infusion (also named convection 
enhanced diffusion (CED)) phenomena drive drugs to a larger tissue 
region and provides higher drug amount as well as its distribution and 
maintenance over time. Delivery of nanoparticles (NPs) through CED 
has been already demonstrated [69, 77-80]. However, some brain 
areas are difficult to fully saturate with infusate and delivery also 
depends on catheters placement [81]. It must not be forgotten that 
invasive neurosurgery needed give rise the usual risks associated such 
as stroke, infection, edema or temporary loss of neuronal functions. 
Long-term risks could be neurological scars and displacement of 
functional brain leading to permanent deficits. 
Another method which implies brain surgery is the placement 
of intracerebral implants, biodegradable/non-biodegradable drug 
impregnated wafers placed for controlled drug delivery at the brain 
target site. Made of polymeric materials, drugs are encapsulated 
inside it and released by diffusion which present the same limitations 
named before[39]. Invasive neurosurgery drawbacks already detailed 
justify the desirable reduction of frequency for implant placing, which 
always will depend on the individual patient and the specific 
neurological disease. Small implant sizes as well as longer and better 
controlled drug release (i.e. by means of drug conjugation to the 
polymers) will confer important advantages to this system. Most 
successful implants reported to date have only been able to alleviate 
disease symptoms in animal models of neurological disease from two 
to eight months [76] and investigators highlight the challenging issue 
of their translation to human studies and their commercialisation.  An 
example of a polymer implant depot with these characteristics is 
already in the market: Gliadel® (MGI Pharma, Bloomington, USA) [82]. 
As a local delivery system, anticancer drug only reaches adjacent 
areas of the implant [78] (more details in section III). 
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Disruption of the BBB is based on producing leakages in the 
TJs between the endothelial cells. It has been studied different 
techniques such as physical stimuli (ultrasound, microwave or 
electromagnetic fields) and through a chemical substance for 
promoting hyperosmolar nature, i.e. have higher hypertonicity or 
osmotic pressure [83], i.e. mannitol, bradykinin or alkylglicerols. Apart 
from undesired effects for affecting other tissues in the body, these 
alternatives are relatively costly and unwanted blood components can 
enter in the brain causing irreversible damage [84]. 
 
I. 1. 7. 2 Systemic drug administration approach 
By systemic administration BBB becomes the obstacle to be 
circumvented by the drug. Great number of CNS drugs and polymer-
based drug delivery systems containing biomacromolecules are 
administered systemically, mostly via intravenous (IV) injection. In 
comparison to other administration types, IV is a non-invasive method 
that does not disrupt BBB that prevents from a possible brain damage. 
Taking profit of the vast capillary brain surface where each neuron is 
perfused by its own capillary, the drug delivery approach through a 
transvascular route encourages brain drug targeting [85]. However, 
BBB together with rapid clearance from the extracellular fluid, 
decrease drug accumulation. Furthermore, brain availability of drug 
through IV route is directly influenced by the half-life of a drug in 
plasma, the rate of metabolism, non-specific binding to plasma 
proteins and the restriction of permeability of the compound across 
the BBB and into peripheral tissues [78]. Pathological states like 
gliomas reduce or suppress this endothelial barrier, thus enabling 
higher drug concentration to enter the brain. However, diseases such 
as AD or PD do not.[86] 
 Apart from IV, intra-arterial delivery or transnasal route are 
other alternatives of systemic drug administration. For example, 
intranasal delivery of drugs proteins by cationic liposomes has been 
demonstrated [87, 88]. 
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Depending on the main strategy followed, two main 
tendencies have been defined to achieve BBB crossing. 
 
I. 1. 7. 3 Pharmacological approach 
Molecules such alcohol, nicotine or benzodiazepine enter 
passively in the brain crossing the BBB. This ability could be achieved 
for small molecules (<500g/mol) with low hydrogen bonding capability 
and lipophilic profile[89]. Thus, mimicking these characteristics and by 
means of chemical modification of a known active CNS bioactive drug 
this could end up in its passage to the brain. Alternatives as 
methylation, halogenation or blockage of C or N-terminal have been 
successfully exploited [30]. Unfortunately, some of these drug 
variations affect the activity and also lipophilicity increasing could 
promote P-gp exclusion among other disadvantages. Use of colloidal 
drug carriers such as liposomes, nanoparticles or nanogels are also 
included in this category [30]. 
 
I. 1. 7. 4 Physiological approach 
As previously stated, transport systems offer the possibility of 
being used as a large molecule entry to the brain (FIGURE I. 7). This 
includes receptor-, carrier- or adsorptive-mediated endocytosis. See 
explanation of each transport foundation in section I.4 Drugs can be 
derived, encapsulated or conjugated to carrier systems together with 
a targeting moiety. Numerous advantages such as drug protection 
against plasma degradation support this strategy.  
Carrier mediated transcytosis (CMT) is used for molecules 
mimicking nutrient structures and essential compounds. As an 
example, dopamine transformation to levodopa can cross BBB by 
LNAT (large neutral amino acid transporter), used for four decades in 
Parkinson’s treatment [90].  
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FIGURE I. 7 Differential PDC targeting to the BBB/brain. For conjugate design  
it is important to ensure where the target is located. (1) Intracellular targets 
in the brain capillary endothelial cells. 2. Extracellular target in the brain’s 
extracellular space and /or neuron/glial cell surface. 3. Intracellular targets in 
brain cells (neurons, astrocyte, dendritic cells and pericytes). Adapted from 
ref. [48]. 
 
Recent appearance of cell-penetration peptides (CPPs) and 
also several proteins take profit of their positive charge and its 
amphipathic characteristics to cross BBB through AMT [43]. CPPs have 
been conjugated either covalently or non-covalently to poorly 
penetrating drugs (i.e. doxorubicin [91]), nanoparticles (i.e. 
cholesterol NPs [92]) or liposomes (i.e. cholesterol-poly(ethylene 
glycol) (PEG) [61]) have achieved activity once in the brain. SynB 
vectors, penetratin and TAT are some examples of effective CPPs. 
Proteins like albumin conjugated to PEG-PLA nanoparticles have 
demonstrated brain delivery in mice by the same mechanism [93]. 
However, AMT is a non-specific process: the adsorptive process can 
occur in blood vessels in other organs. Furthermore, toxicity and 
immunogenicity due to cationic profiles has to be defined for these 
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systems.  
On the other hand, RMT provides a supported opportunity for 
active targeting of BBB, especially when the target receptor is over-
expressed in the diseased condition or in the affected tissue as brain 
capillary endothelium in this case. In addition, many drug delivery 
strategies have been built up around RMT and AMT, although the 
RMT pathway has been preferred due to its higher specificity, 
especially for toxic agent delivery such as anticancer drugs. In RMT, 
cargo molecules associated with targeting ligands can be transported 
across the BBB, receiving for it the name of “Trojan horse approach” 
[94, 95]. A special remark is done with transferrin receptor in next 
paragraphs due to its importance in the present work. 
Insulin receptor is an extensively characterised RMT system 
used for transporting drugs and genes into the brain. Pardridge et al. 
have successfully constructed a radiolabelled amyloid-beta-peptide 
conjugated to monoclonal antibody (mAb) that binds the human 
insulin receptor as a diagnostic prove for AD, and lately a chimeric 
form of the human insulin receptor mAb on adult monkeys showing 
rapid transport into the primate brain after i.v. achieving 
approximately 4% of the injected dose [96-100]. Despite its efficiency, 
this approach is considered risky because its involvement in glucose 
brain homeostasis. As for transferrin, the in vivo application of insulin 
is limited due to the high concentrations needed that could result in 
lethal overdosing [101]. 
Other receptors exploited are the low-density lipoprotein 
receptor related proteins 1 and 2 (LRP1 and LRP2 receptors) due to 
their diverse range of molecules and mediators such as ApoE, HIV-1 
TAT protein, lactoferrin among others; diphtheria toxin receptor (DTR), 
acetylcholine receptors,….  
More recently, glutathione (GSH) has been also investigated 
as targeting moiety. GSH is and endogenous tripeptide in charges of 
detoxification of intracellular metabolites. BBB express transporters 
for this molecule [102]. Gaillard et al. started in June 2011 a clinical 
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trial to evaluate GSH PEGylated liposomal doxorubicin (2B3-101, to-
BBB technologies, The Netherlands) as a novel option for brain cancer 
treatment administered i.v. [103]. Currently, this approach is in phase 
I/II clinical trial, in patients with primary and metastatic brain 
tumours. Within the same technology, a brain-targeted liposomal 
methylprednisolone is being developed for neuroinflammation [104].  
Additionally, drug must block efflux pumps to remain into the 
brain [105, 106].  Transport influx systems in the cerebral endothelial 
play a key role in the delivery of essential substances to the brain and 
are usually overexpressed in tumours. 
 
I. 1. 8 TRANSFERRIN RECEPTOR AS TARGET 
 Transferrin receptor is by far the most widely portrayed RMT 
system for drug targeting to the brain.  It is a transmembrane 
glycoprotein consisting of two 90kDa subunits linked by a disulfide 
bridge. Each subunit binds one molecule of transferring (Tf). TfR 
mediates cellular uptake of iron bound to Tf (FIGURE I. 8). Mainly, it is 
expressed in hepatocytes, erythrocytes, intestinal cells, monocytes as 
well as in endothelial cells of the BBB, choroid plexus epithelial cells 
and neurons [107]. TfR presence is not studied in all brain diseases but 
remains clear that iron availability in the brain plays a fundamental 
role in their progression [108]. Therefore, iron metabolism may 
influence the efficacy and safety of TfR-mediated targeting to the 
brain. Furthermore, it is over-expressed in malignant cells [109].  
Transferrin is the natural ligand of this receptor. Member of 
Fe-binding glycoproteins (such as lactoferrin, melanotransferrin and 
ovotransferrin), it is mainly synthesised in the liver [110]. It is a single 
chain 80kDa protein folded in two lobes. Each lobe can bind one iron 
ion, virtually irreversible at physiological pH [110]. After binding TfR, 
the receptor-ligand complex is endocytosed via clathrin-coated 
vesicles forming endosomes. In these structures pH reaches 
approximately 5.5, where Fe3+ is released from the protein and 
transported to the cytosol. The remaining apo-Tf (Tf without iron) has 
[CHAPTER I.] 
[66] 
higher affinity for the TfR at low pH and is recycled back to the luminal 
side of the endothelial cell. Apo-Tf is released from the receptor at 
physiological pH and binds iron again. It has been demonstrated that 
Tf has a bi-directional transport [111, 112]. 
 
FIGURE I. 8 Cellular uptake of iron by the transferrin system via receptor 
mediated endocytosis. Redrawn from ref. [113] 
 
Brain drug targeting by TfR strategy can be achieved either by 
using its endogenous ligand Tf or by using an antibody directed 
against the TfR. Each of these vectors has its advantages and 
disadvantages. Tf has been already reported as targeting moiety 
although in vivo its endogenous concentration in serum is already 
significant to compete for the TfR. Not only in brain but also in 
tumours, Tf has been used for the delivery of anti-tumour agents or 
gene therapeutics using polycation-based drug carriers [101, 114]. 
Monoclonal antibodies (mAbs) constitute other targeting 
motif option. Intensive research has been performed with a mAb 
against the rat TfR, the OX26 as a targeting vector [112, 115]. It binds 
to a different region than Tf, diminishing interferences with 
endogenous Tf. Several studies have demonstrated drug delivery 
across BBB with similar or higher efficiency than Tf, i.e. other mAb as 
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RI7217 or 8D3 [116]. Functionalised carriers used include liposomes, 
lipoplexes or cationic amphiphilic systems among others [117-122].  
The mechanism of transcytosis for these ligands is not yet fully 
elucidated but in any case brain drug delivery via for TfR has been 
shown as a promising strategy . By this approach, vasoactive intestinal 
peptide (VIP), brain-derived neurotrophic factor or epidermal growth 
factor (EGF) among others have been transported into the brain 
parenchyma [101]. In addition, Pardridge et al. concluded that 
repetitive administration of cell surface specific mAbs did not result in 
down-regulation of BBB receptors [123]. This fact is relevant due to 
inherent chronic treatment necessary in neurodegenerative disorders. 
However, mAb OX26 targets rat TfR and does not bind human TfR, 
making difficult its translation to clinical setting. Apart from 
immunogenic reactions, humanised or chimeric antibodies 
preparation is a tedious task which could end up in loss of affinity and 
risks on iron homeostasis affection.  
Recently, Atwal et al. and Yu et al. engineered a low-affinity 
bispecific monoclonal antibody with double targeting profile: the 
enzyme β-secretase (BACE1) and the TfR, reaching therapeutic 
concentrations in mouse brain and inhibiting BACE1 activity [64, 124]. 
This interesting therapy was proposed for AD in order to reduce 
production of the aggregation-prone amyloid peptides, thus 
decreasing amyloid plaque formation and slow disease progression. 
Again, this achievement stimulates attempts RMT use to increase 
brain uptake of therapeutic antibodies for brain disorders.   
Making the most of all resources for TfR, novel targeting 
vectors to this receptor are already under study. Small and non-
immunogenic peptide ligands for the human TfR are in the pipeline of 
development [101].  
Despite the difficulties encountered so far and the low 
percentage of BBB crossing (unusually higher than 4% of the 
administered dose [96-100]), it could be said that, the potential for 
receptor-mediated targeting to the brain is very high. Not only the 
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selected targeting ligand is a key parameter for specific drug delivery 
but also other parameters could clearly influence the fate of the 
systems i.e. particle size, material, surface properties, density and 
conformation of targeting ligand. Improvement of drug selectivity is a 
critic parameter in all diseases. Concerning this issue, targeting offers 
an elegant approach to increase not only patient survival but also their 
quality of life [125]. Among the different types of targeting, benefit of 
their employment relies on the disease and its tissue characteristics, 
the chemical and biological properties of the bioactive agent used and 
the rate and time-course of administration.  
I. 2 POLYMER THERAPEUTICS 
 
I. 2. 1 DEFINITION AND CLASSIFICATION 
 
‘Polymer Therapeutics’ (PT) was coined by Prof. Ruth Duncan 
to define a family of new chemical entities (NCEs) considered the first 
polymeric nanomedicines [126]. Polymer therapeutics encompasses a 
variety of complex macromolecular systems, their common feature 
being the presence of a rationally designed covalent chemical bond 
between a water-soluble polymeric carrier (with or without inherent 
activity) and the bioactive molecule(s).  Although a tripartite design 
has been typically described for these systems, inclusion of targeting 
moieties and/or imaging agents has modified this concept [7]. 
 
Polymer therapeutics includes five compound families: 
polymeric drugs, polymers with inherent activity [127, 128]; polymer-
protein conjugates [2, 6, 126];  polyplexes which are multi-component 
systems developed as non-viral vectors for gene/small interfering 
ribonucleic acid (siRNA) delivery [129, 130] , polymeric micelles where 
the bioactive agent is covalently bound [131, 132] and polymer-drug 
conjugates [126] (FIGURE I. 9). These nanosystems hold features such 
as a tailored drug loading, an incorporation of drug combinations or 
intelligent linker design tailored for specific biological conditions 
within the target organ or cell. Furthermore, the versatility of synthetic 
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chemistry and the inclusion of bioresponsive elements and biomimetic 
features provide scope for polymer therapeutics in comparison with 
other nanopharmaceutics [126].   
 
 
FIGURE I. 9 Schematic representation of polymer therapeutics families. 
Redrawn from ref. [126]. 
 
As any other delivery system, central objective of PT is (i) to 
release therapeutics at the desired body site (targeting) and (ii) to 
maintain the drug concentration within a therapeutic window for a 
desired duration (controlled drug release) [133].  
 
Relying on the delivery route, bioavailability in the 
bloodstream allows for distribution to virtually all tissues.  IV is the 
preferred route of administration when using polymer therapeutics as 
profits of the fastest drug distribution in comparison to other 
parenteral routes explored (i.e. subcutaneous (SC), intramuscular (IM) 
or intraperitoneal (IP)) and therefore, could enhance the benefits of 
intrinsic targeting mechanisms such as the EPR effect. Major obstacles 
to overcome after IV injection include tissue-specific issues, 
particularly BBB, tumour microenvironment, cell 
protein
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compartmentalisation, hepatic clearance or renal filtration.  
 
After more than two decades, development of these novel 
entities have result in several products in the market (PEGylated 
proteins and polymeric drugs) (TABLE I. 1) and a growing number of 
polymer-drug conjugates in clinical development (TABLE I. 2), mainly 
as anticancer agents via parenteral administration [5-7]. Knowledge 
acquired on biodistribution, clearance, mechanism of action and 
stability of these conjugates in vivo has helped to design an improved 
second generation of polymer therapeutics.  
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Product name Technology Indication 
Route of 
admin. 
Information source 
Polymer-protein conjugates 
   Zinostatin stimalmer®  Styrene maleic anhydride-
neocarzinostatin, 
(SMANCS) 
Cancer- hepatocellular carcinoma Local admin. 
via hepatic 
artery infusion 
Yamanouchia Japan 
Oncaspar®  PEG-asparaginase Cancer -acute lymphocytic 
leukaemia (ALL) 
IV/IM Enzon 
Peg-intron® PEG-Interferon alpha 2b Hepatitis C SC Schering-Plough 
Pegasys® PEG-Interferon alpha 2a Hepatitis C SC Roche 
Neulasta
TM
 PEG-hrGCSF Chemotherapy-induced neutropenia SC Amgen 
Adagen®  PEG-adenosine deaminase Severe combined immune deficiency syndrome IM Enzon 
Somavert® PEG-HGH antagonist Acromegalia SC Pfizer 
Mircera® PEG-EPO (polyethylene 
glycol-epoetin beta) 
Treatment of anemia associated 
with chronic kidney disease  IV/SC Roche 
Krystexxa
TM 
(pegloticase) 
PEG-uricase Chronic gout IV Savient farmaceuticals 
Cimzia (certolizumab 
pegol) 
PEG-anti-TNF Fab  
Rheumatoid arthritis, Crohn’s 
disease 
SC UCB 
Polymer-aptamer 
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conjugate 
MacugenTM PEG-aptamer (apatanib) AMD Intravitreous OSI-Eyetech 
Polymeric drugs 
    Copaxone®  Glu,Ala,Tyr copolymer  Multiple sclerosis SC Teva 
Renagel® 
Phosphate binding polymer End stage renal failure Oral 
Genzyme (Daiichi) 
licensed) 
Welchol® Cholesterol binding 
polymer Type 2 diabetes Oral Genzyme 
TABLE I. 1 First generation marketed polymer therapeutics. From refs. [1, 134] IV=intravenous, IM=intramuscular, SC=subcutaneous.
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Product name Technology Indication Adm. Stage Information source 
Polymer-protein conjugates 
ADI-PEG 20 PEG-arginine deaminase Cancer-hepatocellular 
carcinoma, melanoma 
IV Phase I/II Phoenix Pharmalogics-Polaris 
Group 
Hemospan® 
MP4OX 
PEG–haemoglobin  Delivery of O2 in post 
surgery and trauma patients 
IV Phase I/II Sangart  
CDP 791 PEG-anti VEGFR-2 Fab  Cancer-NSCLC IV Phase II UCB Pharma 
      
Polymer-aptamer conjugates  
ARC1779 PEG-anti-platelet-binding 
function of von Willebrand 
Factor 
Thrombotic 
microangiopathies 
IV Phase II Archemix 
E10030 PEG-anti-PDGF aptamer AMD Local Phase II Ophthotech 
 combination with Lucentis®  intravitreal   
Polymeric Drugs 
AMG 223 Phosphate binding polymer Hyperphosphatemia in CKD 
patients on hemodialysis 
Oral Phase II Amgen 
VivaGel® Lysine-based dendrimer Microbicide Topical Phase III Starpharma 
Polymer drug-conjugates 
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Opaxio® (CT-
2103; Xyotax)  
 
Poly-L-glutamic acid (PGA)-
paclitaxel 
Cancer-NSCLC, ovarian, 
glioblastoma, various other 
cancers and combinations 
IV Phase III Cell Therapeutics Inc  
Prolindac® HPMA-copolymer-DACH 
platinate 
Cancer-melanoma, ovarian IV Phase III Access Pharmaceuticals  
FCE 28068 (PK1) HPMA copolymer-Dox Breast, lung and colon 
cancer 
IV Phase II Pfizer 
FCE 28069 (PK2) HPMA copolymer-Dox Hepatocellular carcinoma IV Phase I/II Pfizer 
PEG-SN38 Multiarm PEG-camptothecan 
derivative 
Cancer-several IV Phase II Enzon Inc 
IT-101  
(Cyclosert® 
technology 
assembled into 
a NP) 
Polymer-cyclodextrin-
camptothecin 
Solid tumours IV Phase II/III Cerulean Pharma 
NKTR-118 PEG-naloxone Opioid-induced constipation Oral Phase II Nektar 
NKTR-102 PEG-irinotecan Cancer-metastatic breast IV Phase II Nektar 
NKTR-105 PEG-docetaxel Cancer-various IV Phase I Nektar 
XMT-1001 Polyacetal-camptothecin Cancer-various IV Phase I/II Mersana 
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TABLE I. 2 Polymer therapeutics in clinical development. From refs. [1, 134] IV=intravenous, IM=intramuscular, SC=subcutaneous, 
Adm=administration route, dox=doxorubicin.
(Fleximer® 
technology) 
conjugate 
Polyplexes      
CALAA-01 Polymer-cyclodextrin 
nanoparticle-siRNA 
Solid tumours IV Phase I/II Cerulean Pharma 
Polymeric Micelles 
SP1049C  
BiotransportTM 
Pluronic® based formulation of 
Dox  
Cancer-upper GI, NSCLC 
colorectal 
IV Phase III Supratek Pharma Inc  
NK 105  
(Nanocarrier® 
technology) 
Paclitaxel block copolymer 
micelle 
Cancer-stomach IV Phase II NanoCarrier Co.-Nippon Kayaku 
Co  
NK-6004, 
NanoplatinTM 
(Nanocarrier® 
technology) 
Cisplatin block copolymer 
micelle 
Cancer IV Phase I/II NanoCarrier Co.-TOUDAI TLO 
Ltd/   
NC-4016  Oxaliplatin block copolymer 
micelle 
Cancer IV Phase I NanoCarrier Co. TOUDAI TLO 
Ltd/   
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I. 2. 2 PASSIVE TARGETING: EPR EFFECT  
 
Many of the advantages of nanotherapeutics derive from their 
controlled sizes and size-dependent properties like the “enhance 
permeability and retention (EPR) effect”. Described by Maeda et al. 
[135, 136], this phenomenon is based on the unique 
phatophysiological characteristics of most solid tumours, such as 
extensive angiogenesis (hypervasculature), defective vascular 
architecture and an impaired lymphatic drainage. Basically, once the 
macromolecule is in the bloodstream is extravasated to tumour tissue 
due to the “leakiness” of the angiogenic tumour vasculature and 
retained there, promoting their accumulation in the tumour 
interstitium more than in normal tissues (FIGURE I. 10). Systems in the 
range of nanometre size take profit of this passive targeting which 
considerably increases the therapeutic effect. This phenomenon is also 
operative in inflammation areas, which justifies the development and 
use of this class of nanovectors in infectious and inflammatory 
conditions [137]. The EPR effect is ultimately driven by the circulating 
plasma concentration of the polymer conjugate [138]. 
 
FIGURE I. 10 Schematic representation of the EPR effect. Adapted from ref. 
[139]. 
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It has to be considered that the EPR effect has been described 
to be a highly heterogeneous phenomenon, it may change between 
different tumour regions, from tumour models as well as from patient 
to patient [140]. Typically, peripheral area is well-vascularised, there is 
a seminecrotic core and finally an avascular necrotic central region. All 
polymer therapeutics except one (FCE 28069, known as PK2) in the 
clinics relay on the EPR effect (TABLE I. 2) and now, the newer and 
more advanced systems are still mostly designed to fit this description 
[5, 141]. Simply utilising the hyperpermeability of this vasculature 
alone may not be possible to treat the entire tumour [142]. For this 
reason and others in the rest of scenarios, use of active targeting of 
polymer therapeutics will improve disease-to-normal tissue ratios. 
 
I. 2. 3 BARRIERS AT THE CELLULAR LEVEL: ENDOCYTOSIS 
 
Once the macromolecule is accumulated in the damage tissue 
drug release is seek either intracelullarly or in the extracellular matrix 
depending the location of the selected molecular target.  
If an intracellular delivery is required, the first barrier of a 
therapeutic is breeching of the cell membrane, the fluid phospholipid 
bilayer sheet that excludes structures such as proteins from the cell 
interior, whilst retaining nanostructures such as ribosomes within. 
Normal uptake of nanoconjugates is achieved by endocytosis (FIGURE 
I. 11), governed by interactions with proteins and receptors on the cell 
membrane surface. However, there are exceptions to this with some 
PT that use electrostatic interactions to disrupt the cell membrane and 
gain entrance, i.e. polypropylenimine (PPI) [143]. The pH of the 
endosomal compartment drops during maturation to values of ≤ 5.5 
because of the action of ATP-dependent proton pumps located in the 
membrane of the compartment [144]. As discussed, this drop in pH 
can be used for the breakdown of acid cleavable linkers, triggering the 
bioactive compound release within the cell. 
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FIGURE I. 11 Mechanisms of extracellular uptake by endocytosis in a typical 
eukaryotic cell. Endocytosis defines the internalisation of the cell’s plasma 
membrane to form vesicles that capture macromolecules and particles 
present in the extracellular fluid and/or bound to membrane-associated 
receptors. These vesicles undergo to a complex series of fusion events 
directing the internalised substances to an appropriate intracellular 
compartment. The endocytic pathways include clathrin-mediated, 
caveolae/lipid raft mediated, clathrin-, and caveolae-independent 
endocytosis, fluid-phase endocytosis, and phagocytosis. Phagocytosis involves 
the processing of large foreign particles by specialised cells such as 
macrophages, which form part of the reticuloendothelial system (RES). 
However, clathrin-dependent endocytosis consists first in the formation of 
endocytic vesicles (early endosomes) to trap the macromolecule. Depending 
on surface signals of membrane proteins to which nanostructures may be 
non-covalently linked, some may be trafficked along retrograde transport 
pathways for example via the Golgi apparatus and endoplasmic reticulum. 
Others may be carried through late endosomes to lysosomes where they may 
be degraded. Redrawn from [145] and [146]. 
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 Other pathways for release are possible within lysosomes as 
they contain a host of enzymes that are present for the breakdown of 
complex molecules such as lipids and proteins (known as 
lysosomotropic drug delivery usually used for small drugs or enzyme 
replacement therapies) (FIGURE I. 15). For example, the clinical 
performance of OpaxioTM, a poly-L-glutamic acid(PGA)-paclitaxel (PTX) 
conjugate in Phase III trials as anticancer agent highly depend on the 
levels of the lysosomal enzyme cathepsin B. In fact, after finding a 
relation between oestrogen levels and cathepsin B expression in 
cancer patients, the latest clinical trials with OpaxioTM have been 
design only to enrol women with oestrogen levels above 25pg/ml to 
ensure PTX release and therefore antitumor efficacy [147, 148]. 
Summarising, the performance of a PT is usually dependent 
on: efficient endosomal escape, retrograde trafficking and/or late 
endocytic/lysosomal activation for pharmacological activity [149]. 
 
On the other hand, it is important to recognise that the 
combination of hydrolytic enzymes and an acidic pH makes the 
intravesicle environment a hostile place for the therapeutic and can 
result in the inactivation of low Mw drugs as well as degradation of 
proteins, peptides and oligonucleotides that arrive there unless they 
are able to quickly escape to the cytosol. Escape from endosomal 
compartments can be achieved by disrupting the membrane bilayer 
(FIGURE I. 12, endosomotropic delivery). The use of pH-responsive 
endosomolytic systems is one of the preferred approaches to enhance 
cytosolic delivery for bioactives such as proteins, peptides or siRNA 
sequences. To date, the most successful example of this approach is 
CALAA-01, a transferrin targeted siRNA conjugate that consist on a 
self-assembling cyclodextrin containing polycation and anti-EWS-FLI1 
siRNA-based nanoparticle (30-40 nm) pioneered by Davis et al. and 
developed by Cerulean Pharma in Phase I/II clinical trials (TABLE I. 2) 
[150, 151]. Similar strategy has been also followed by Kataoka et al. by 
means of polymeric micelles in order to enhance cytosolic delivery of 
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siRNA sequences [152]. Vesicle membrane disruptive properties can 
relay on the polymeric structure [153] or in protonable linked residues 
[154]. 
Beyond escaping the endosomal membrane barrier, the 
ultimate barrier is to deliver a therapeutic into the nucleus of the cell, 
particularly in gene therapy. It was reported in 1982 that 
anthracyclines can pass into the nucleus by passive diffusion from the 
cytoplasm through the nuclear pore complex (NPC) [155]. Polycations 
such as polyethylenimine (PEI), chitosan and polylysine (PLL) have 
shown initial success in interacting and facilitating the entry of genetic 
material into the nucleus [134]. Use of polymers as gene carriers has 
sparked a lot of interest in the field. Mainly due to the associated risks 
of using viral vectors, such as a reactivation of the virus, toxicity, gene 
control and targeting, which are either not present with polymers or 
can be controlled through the modification of the polymer properties 
such as Mw and architecture and also through conjugation of site 
specific markers or receptors. 
 
In cases where endocytosis is diminished in the cell, polymer-
directed enzyme prodrug therapy (PDEPT) is a useful tool for drug 
delivery [156] (detailed in section II.5.2 below). This system 
encompasses the combination of a polymer-drug conjugate carrying a 
single bioactive agent with a polymer-enzyme conjugate. The aim of 
the combination relies on appropriate and selective drug release from 
the polymer-drug conjugate at the desired site and is independent 
from endocytosis and the intracellular trafficking mechanisms. 
Another approach when these conditions are present is the use of 
plasma membrane disruptors such as melittin or cell penetrating 
peptides [134]. 
 
I. 2. 4 POLYMER CONJUGATION DESIGN THROUGH RATIONAL BASES  
 
As mentioned, polymer conjugation of a protein or a drug is 
classified in two different families of PT. Biological purpose or rational 
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pursued in each case differs although both share a common structural 
composition: a polymer carrier, a linker or spacer and the bioactive 
agent.  
I. 2. 4. 1 Polymer-protein conjugates (PPC) 
 
Most therapies based on peptides, proteins or antibodies 
present as main limitation the short half-life time in blood, low 
stability, modest therapeutic effects and possible immunogenic 
responses. Conjugation of these bioactive molecules to polymeric 
platforms solves named drawbacks considerably enhancing their 
therapeutic output [126, 157]. From a historical perspective, PPC were 
among the earliest nano-therapeutic platforms explored for drug 
delivery which manage a successful clinical translation (TABLE I. 1). 
History started in the early 90s. SMANCS, a conjugate of 
neocarzinostatin (NCS) and poly-(styrene-co-maleic acid) (SMA) for 
hepatocellular carcinoma treatment, was approved for clinical use in 
Japan [158]. Patients showed an extended blood half-life of NCS and 
markedly accumulation at tumour sites. Then followed the first 
enzyme conjugated to poly(ethylene glycol) (PEG) approved for clinical 
use in severe combined immune deficiency (SCID) syndrome: PEG-
adenosine deaminase (Adagen®) [159].  Next advances on PPC were 
chased by an extensive use of this potential and well-stabilised 
technique: PEGylation, originally described in the 70s [160, 161], 
explained in detail in next section II.4.1.1. 
 
For protein conjugation, the synthetic approach must offer 
reproducible site-specific protein modification. Semi-telechelic1 
polymers are required together with a linker that should not produce 
toxic or immunogenic by-products [126]. Bonds between the polymer 
                                                          
1
 SEMI-TELECHELIC: single group at one terminal end which avoiding crosslinked 
reactions and providing a specific point of linkage. 
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and the bio-agent have been adapted to specific release conditions 
[162]. Usually protein release is not desired as the main aim, mostly 
focus on enhancing its residence in blood stream, decrease its 
immunogenicity and avoid its proteolysis. Therefore, non-
biodegradable bonds are utilised (i.e. Oncaspar®). When intracellular 
transport is needed, endosomotropic transport will require 
biodegradable linkers to release the protein through the endosome, 
impeding its lysosomal degradation (FIGURE I. 12). 
 
FIGURE I. 12 Intracellular transport mechanisms for polymer-protein 
conjugates (PPC). Endosomotropic transport (release trough endosomes): 
convenient pathway for intracellular trafficking of proteins or peptides. 
Redrawn from ref. [163]. 
 
 PEGylation 
 
PEGylation is a well-establish technology approved by the 
regulatory FDA (Food and Drug Administration) organism [164] with 
several examples in the market (TABLE I. 1).  PEG has become one of 
the best defined polymer platform for biomedical applications [165]. 
H+
Endosome
H+
Endosomotropic transport
PPC endocytosis
pH 6.5
pH 7.4
nucleous
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PEG is a synthetic non-biodegradable polymer with semi-
telechelic and low polydispersity (Mw/Mn varies from 1.01 for 5000Da 
to 1.1 in 50kDa PEG) [166]. Conjugation techniques have been 
developed since the first generation PPCs mostly based on linear 
monomethoxyPEGs or reaction conditions which could denaturise the 
protein. Currently, sophisticated methodology permits site-specific 
modification following protein mutagenesis or design of degradable 
PEG-protein linkages [126]. This non-ionic, hydrophilic polymer 
provides a steric shield to the conjugate avoiding recognition by 
immune system as well as increases molecule size, thereby reducing 
clearance from the bloodstream impeding rapid excretion through the 
reticulum endothelium system (RES) [167].  In addition, PEGylated 
products show less haemolysis2 and could also diminish aggregation of 
erythrocytes. As mentioned for PPC, PEG augments duration of 
pharmacological activity, quality of life due to controlled release of the 
biomolecule and reduces toxic side effects. Thus, PEG conjugation has 
been defined as an effective strategy to alter the pharmacokinetic3 
(PK) profiles of a variety of biomolecules improving their therapeutic 
output and reaching a balance with their pharmacodynamics4 (PD) 
properties to achieve novel therapies [168]. Considering all these 
advantages, dose frequency is reduced together with the drug amount 
required, improving patient compliance and reducing clinical cost. 
Veronese et al. reported that the PEG conjugates have a favourable 
biodistribution, with preferred accumulation in the damage tissue (e.g. 
tumour, due to the EPR effect), and liver uptake values similar to other 
polymer–drug conjugates, such as (N-(2-
                                                          
2
 HAEMOLYTIC: compounds that promote breakage of the red blood cell (RBC) 
membrane, releasing haemoglobin (Hb). 
3
 PHARMACOKINETICS (PK): body processing of the drug/conjugate. It includes 
absortion, distribution, metabolism and excretion.  
4
 PHARMACODYNAMICS (PD): drug action in the body. It includes the desired 
consequences of the treatment, i.e. therapeutic effect and the non-desired such as the 
side effects. 
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hydroxypropyl)methacrylamide)(HPMA) .  
 
Final activity of the parent compound has to be reliable, thus 
site-specific chain location is critical. Shape and number of PEG chains, 
location next to an active site or a determinant region for active 
conformation could affect the expected activity. PEGylated proteins 
currently in the market used to follow non-specific site attachment 
strategies and were built with PEG sizes ranging from 5 to 40kDa and 
mainly trough amide bonding [169]. Only Cimzia® has a disulphide link 
by using a C-terminal cysteine reaction with maleimide [170].  Free 
cysteines as well as recombinantly placed ones are alternatives for 
site-specific conjugation with PEG derivates (i.e. disulfide, maleimide, 
vinylsulfone end groups). In parallel, to accomplish Mw limitation for 
safe renal elimination branched short PEG chains are proposed as 
alternative. Technical advances in controlled radical polymerisation 
(CRP) are able to form bioconjugates directly by polymerisation from 
modified proteins [171-173].  
PEGylation has had lower impact for small drug conjugation 
because the limited drug loading capacity. However, use of PEG chains 
adsorbed or covalently attached to the surface of nanoparticles is a 
well established methodology [162, 174, 175] (FIGURE I. 13). PEG has 
demonstrated to be the perfect candidate to be grafted, conjugated or 
absorbed to the surface of nanocarriers or to be part of block-
copolymers. Dye to its hydrophilic character PEG provides steric 
stability to the whole and allows bioactive ligands attachment, which 
remain at the outer part of the system (e.g. motifs for BBB crossing 
[47]). 
Although PEG is in the market since the 90s, concerns about 
the fate of PEG and potential toxic effects have been started to be 
recently reported [176]. Among PEGylation drawbacks, adverse side 
effects in the body can be provoked by the progressive accumulation 
of the polymer upon repeated administration or the side products 
formed that lead to hypersensitivity reactions[162]. 
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FIGURE I. 13 Examples of drug delivery systems where PEG is involved. From 
ref. [162]. 
 
Furthermore, its non biodegradability limits the usable Mw  
because for example, oligomers with <400Da have been found to be 
toxic in humans as a result of sequential oxidation into diacid and 
hydroxyl acid metabolites by alcohol and aldehyde dehydrogenase 
[177]. Not only for these reasons, PEG use in biomedical applications is 
being investigated as well as many alternatives for PEG are appearing 
[165]. 
 
I. 2. 4. 2 Polymer-drug conjugates (PDC) 
 
Polymer drug conjugates are nano-sized systems where a small 
MW drug is covalently linked to a polymer [8, 178, 179]. PDC concept 
was born with polymer chemistry adaptation for drug conjugation 
developed by H. Ringsdorf on 1975, together with DeDuve’s 
description of “lysosomotropic drug delivery” [2, 3].  
Drug conjugation to a polymer not only enhances its aqueous 
poor solubility and protects it against degradation; it also changes its 
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PK at the whole organism and even subcellular level with the 
possibility to clearly enhance drug therapeutic value [5, 126, 141].  
With a careful selection of the carrier, conjugation can yield long-
circulating macromolecular systems that display passive targeting 
based on the EPR effect (detailed in section II.2) [180] and therefore 
lower systemic toxicity.  It also limits uptake to the endocytic route, 
favouring lysosomotropic delivery with subsequent transfer of drug 
out of the endosomal/lysosomal compartment providing the 
opportunity to bypass mechanisms of drug resistance associated with 
membrane efflux pumps [126, 181]. This goal is directly related with 
the selection of the appropriate linker or spacer, which has to be 
stable during circulation and able to release the drug under certain 
environment.  
Among the most used polymer carriers for suitable drug 
conjugation (FIGURE I. 14) the following examples are in the pipeline in 
PDCs design. These structures often provide a huge number of 
pendant groups (multivalent carrier) where apart from drug(s) 
conjugation, several molecules could be inserted, e.g. ligands for 
active targeting, stabilising moieties (like PEG), labelling motifs 
(fluorescent dyes, contrast agents,…), etc. 
- HPMA: Initially developed as plasma expander, currently 
HPMA copolymers constitute one of the most studied polymer 
backbone for PDCs [126]. Its conjugates are mainly focused on 
cancer treatment with a special focus on the site-specific 
delivery of anti-cancer drugs. This neutral polymer is 
characterised by its water-solubility, biocompatibility and non-
immunogenicity. Mayor drawback is the non-biodegradability 
which limits the Mw threshold for its safe body clearance. 
CFE28068 (PK1, HPMA-Dox, TABLE I. 2) was the first synthetic 
polymer entering in clinical trials. 
 
- PGA (poly-glutamic acid): PGA is a polypeptide base on 
glutamic acid repeated units, each of them carrying a pendant 
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carboxyl group able for motif conjugation. It is water-soluble, 
non-toxic, biocompatible and biodegradable. In the body, such 
degradability is claimed by the cysteine proteases (particularly 
cathepsin B) which play the key role in the lysosomal 
degradation of this polymer. PGA has been conjugated to 
different class of drugs, e.g. anthracyclines, antimetabolites, 
DNA-binding drugs, taxol or camptothecin. Among these 
polymer-drug conjugates OpaxioTM (formerly Xyotax, PPX, CT-
2103, TABLE I. 2) is in phase III for the treatment of non-small 
cell lung, ovarian carcinoma and has been recently designated 
as orphan drug in combination with radiotherapy for the 
treatment of glioblastoma. As mentioned in section I.2.1, 
OpaxioTM combines PTX covalently linked to PGA. PTX release 
is directly related to polymer degradation. Therefore, 
cathepsin B presence is a prerequisite in patients. 
 
- Dextran: This polymer is a natural polysaccharide which 
monomer is sugar glucose, characterised by α-1,6 linkages 
with hydroxylated cyclohexyl units. It is water-soluble, 
biocompatible and biodegradable in blood and in the gastro-
intestinal tract, although poorly degradable by mammalian 
enzymes, like other biopolymers such as alginates or chitosans 
[1]. Its hydroxyl groups are the linkage point for conjugation, 
via spacers. 
 
- Dextrin, cyclodextrin and polyacetals : these novel polymeric 
carriers are on the second generation of PDCs and their mainly 
reliable due to their biodegradability [182]. PEG-polyacetals 
show pH dependent degradation [183-185] and dextrins are 
degraded by amylase [186]. These carriers have recently 
entered in clinical development (TABLE I. 2). 
 
Within the PDCs design, selection of the linker may fulfil 
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several requisites. Connexion between drug and polymer backbone 
must remain stable during blood circulation and able to trigger drug 
release under specific conditions. Main reason is to achieve an 
effective intracellular drug release by lysosomotropic delivery (FIGURE 
I. 15). Once PDC is endocytosed, conjugate travels through endosomal 
pathway ending in lysosome vesicles. It is in this compartment where 
presence of proteolytic enzymes and/or acidic pH could promote 
carrier and/or linker degradation. Most drugs used in this 
macromolecular constructs are hydrophobic/lipophilic, therefore after 
the release they diffuse out to the cytosol, achieving the desired 
molecular target. 
 
[CHAPTER I.] 
[89] 
 
FIGURE I. 14 Examples of polymer used in the design of polymer therapeutics. 
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PGA=poly-L-glutamic acid, DXT=dextran, HPMA=N-(2-
hydroxypropyl)methacrilamide, pDMAEMA=poly(dimethylamino)ethyl 
methacrylate, PEG=poly(ethylene glycol), PLA=polylactic acid, 
SMA=poly(styrene-maleic acid), PEI=polyethylenimine, 
PAMAM=polyaminoamines, PMLA=Poly(maleic acid), HPMA=N-(2-
hydroxypropyl)methacrylamide, PL=Poly-L-lysine. 
  
 
FIGURE I. 15 Intracellular transport mechanisms for polymer-drug conjugates 
(PDC).  Lysosomotropic transport (release through lysosomes): optimal 
pathway for bioactive agents non susceptible to proteolytic degradation. 
Redrawn from ref. [163] 
 More than 16 polymer-drug conjugates are into clinical trials 
(TABLE I. 2) and as mentioned, possibly OPAXIOTM will be the first PDC 
into the market. PDCs initial field of application was focused on cancer 
therapy, bearing classical chemotherapeutic agents. Currently, future 
of PDCs for cancer treatment is centred in more specific targets and 
combination therapy, to increase efficacy and selectivity. Moreover, 
relationship between polymer architecture and conjugate PK at whole 
organism as well as at cellular level is a challenge area for PDC. As for 
PT in general, PDC also exploited lessons learned to search success in 
PDC endocytosis
endosome
lysosome
Lysosomotropic transport
pH 7.4
pH 6.5
pH 5
nucleous
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the treatment of other human pathologies. Treatment of diabetes, 
hypertension, infections, digestive tract diseases or inflammation, as 
well as regenerative medicine applications or age-related diseases are 
already under study.  FIGURE I. 16 briefly summarises the current 
state-of the art for PDCs [8]. 
 
 
FIGURE I. 16 Current state-of-the-art technology with PDCs relies on 
established foundations from three decades of interdisciplinary research and 
is moved towards four accepted strategies: novel molecular targets in cancer 
as well as other disease, polymer-based combination therapy, new 
architectures and polymeric systems, and an exhaustive physico-chemical 
characterisation essential to clinical translation following regulatory 
indications. Deeper understanding on polymer conjugate features that govern 
clinical risk-benefit is leading to an appreciation of clinical biomarkers that will 
open new possibilities for personalised therapy. Redrawn from ref. [8]. 
I. 2. 5 CHALLENGES AND FUTURE OPORTUNITES FOR POLYMER 
CONJUGATES 
 
First generation of polymer conjugates built a solid source of 
background information including optimisation of structures together 
with methodology development for characterisation, efficacy profiles 
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or pitfalls observed, clinical toxicities and side effect, setting up the 
different novel approaches that can take profit of all the experience 
obtained and improve it [140]. Practical and cost-effective design to 
use them as medicines for specific target indications, safe and 
effective in the context of the administration route, dose and 
frequency are guidelines in the current research [1]. 
For that purpose, four main strategies are followed: (i) the 
synthesis of novel polymeric carriers with defined architectures, (2) 
the search for better physico-chemical characterisation methods, (3) 
the use of polymer-based combination therapy to increase specificity 
and efficacy of the treatments  and (4) their application for new 
molecular targets other than cancer, including the crossing of different 
biological barriers [8]. Besides, initial conjugates were developed for 
parenteral administration and after its successful proof-of-concept, 
rest of administration routes had been tested relying on each specific 
disease scenario.   
 Polymer conjugates also spans the field of diagnostic. Through 
a variety of imaging agents, several have been proposed as 
nanoprobes for monitoring. By means of tracer probe labelling, it is 
possible to build a single targeted conjugate to simultaneously report 
PK, targeting and clearance data in vivo and could also be used to 
report cellular and perhaps subcellular location of a biopsied sample 
ex vivo. Radiolabelled polymer based patient gamma camera imaging 
agents were already tested in vivo by Duncan et al more than one 
decade ago [126]. Other techniques as MRI, PET or optical imaging 
using near infra-red (NIR) fluorescent and luminescent probes are 
approaches under study in the area [1, 187-194]. For instance, an 
intravascular contrast agent, Gadomer-17 (SH L 643 A, Schering, Berlin, 
Germany) is a large dendrimer (Mw about 30-35kDa) containing 24 
gadolinium ions transferred to the clinics although recently retired due 
to a non-adequate PK profile [195] . A step further in this direction 
encompasses the combination of therapeutic and diagnostic abilities 
into the same polymeric platform. This concept (“theranostics”) is 
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based on the “find, fight and follow approach” and offers the 
possibility of early detection, targeting and treatment of several 
diseases [1]. Relevant scientific studies meeting this new concept have 
been already reported [196-198]. 
In parallel, there is a growing effort to better understand the 
structure-activity relationships for defining safety and efficacy of these 
new therapeutics to meet with regulatory demand[1, 199]. First 
examples with polymer conjugates show that the panacea of enabling 
specific and individualised therapy through nanomedicine is becoming 
a feasible approach [200]. 
 
I. 2. 5. 1 Novel polymeric systems with well-defined architectures 
and exhaustive characterisation through physico-chemical 
methodologies 
 
Addressing the necessity of more sophisticated biodegradable 
polymeric carriers with lower PDI and higher drug loading capacity, 
advances on polymer chemistry and physico-chemical characterisation 
techniques are ongoing implementations in the field.   
Although well-tolerated in clinics, non-biodegradable polymers 
limit their use to certain Mw range for save renal elimination and 
possible risk of lysosomal accumulation has to be considered. 
Tendency on biodegradable polymers research is justified by their final 
use in applications as chronic or infectious diseases, for CNS disorders 
or tissue regeneration. Ideally, their hydrolytically or proteolytically 
backbone bonds would be cleaved ending up into small nontoxic 
metabolites eliminated through natural mechanisms. They are suitable 
for repeated parenteral administration and allow the use of higher Mw 
carriers to optimise PK as well as high polymer doses [7, 126]. Several 
examples are already under study, i.e. the lysosomal thiol-dependant 
proteases degradable polyglutamates [201], dextrins degradable by 
amylase and polyacetals which display pH-dependent degradation. In 
this thesis PGA-based carriers have been selected.  
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Concerning polymer manufacturing, several challenges must 
be faced to obtain reproducible and controlled systems. Polymers are 
inherently heterogeneous, and like macromolecules, their 
characterisation is hindered. In order to achieve the desired 
biodistribution, appropriate fate, biological activity and minimize side 
effects; crucial parameters must be exhaustively controlled along the 
polymer synthesis. Those parameters include chain length, Mw 
distribution, polydispersity, microstructure, charge localisation or 
hydrophilic-hydrophobic equilibrium and final conformation in 
solution [8, 138, 202, 203].  Depending on the polymerisation strategy 
followed, synthetic polymers get narrower dispersities than natural 
routes. Regarding microstructure of the polymeric chain, the relative 
stereochemistry (tacticity) [204] obtained after synthesis can directly 
influence on polymer degradation profile.  Moreover, final 
conformational behaviour of the polymer is modulated by the nature 
and net charge of the macromolecular chain where microstructure 
plays a key role[205]. External stimulus could also undergo physical or 
chemical changes in responsive polymers depending on their tailored-
composition (i.e. temperature-responsive micellisation or pH micelle 
dissociation) [133]. Surface charge or zeta potential (the electrical 
potential at the hydrodynamic slipping plane of a particle) is a 
determinant factor in the biological behaviour. It has been observed 
that negative or neutral surfaces significantly avoid nonspecific cellular 
uptake. Charge plays a key role in tubular reabsorption with positive 
charge leading to high retention in the renal cortex [197]. Thus, 
controlling these parameters over polymer sequences is an effective 
strategy for tuning macromolecular properties [185, 202, 204, 205]. 
Simultaneously to optimisation of polymerisation and bioconjugation 
processes, ease and scale up to pilot plant techniques have to been 
kept in mind for facilitate industry translation [206]. 
First generation of conjugates is based on few natural and 
synthetic polymers with linear, random-coil structures such PEG, 
HPMA copolymers or PGA (TABLE I. 1).  Beyond linear polymers, the 
number of possible architectures is countless.  To date, organic 
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synthesis and advanced polymerisation techniques can give birth 
multifaceted polymer carriers able to be engineered around the 
biological processes involved, rather than the current more 
opportunistic use as “carriers”.  Modern synthetic approaches such as 
click chemistry [207] and/or controlled polymerisation methods (like 
RAFT, ATRP or ROP among others [165, 208-211]) have already yielded 
novel and well-defined polymer structure, i.e. multivalent polymers, 
graft and block copolymers, hyperbranched and star polymers, 
dendrimers and dendrons [66, 212-222] (FIGURE I. 17). These novel 
structures provide multivalent surfaces for the immobilisation of drugs 
and/or tracing agents, higher load capacity and the opportunity to 
exploit multiple pathways in cellular trafficking. 
On the other hand, linker chemistry between the bioactive 
part and the polymer has evolved to be considered a key point in the 
conjugate rational design. Apart from enzymatic susceptible, non-
enzymatic or pH-labile linkers, bioresponsive spacers are being 
developed to achieve more sophisticated and controlled constructs 
(i.e. self-immolative linkers) [7].  Linker selection will rely on the 
specific molecular target environment to trigger drug release.  
 
 
FIGURE I. 17  Example of several polymeric structures for PT applications. 
Adapted from ref. [126] . 
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All these evolved chemistry technologies increase the 
complexity of the final structures, therefore requiring exhaustive 
methodologies of characterisation. Clear understanding of physico-
chemical behaviour makes a significant input toward a better 
understanding of its biological analysis which undoubtedly will smooth 
its acceptance in regulatory evaluation on the way to clinical 
development [199]. Sophisticated techniques have emerge in this 
concern, such as small-angle neutron scattering (SANS) for determine 
structure-activity relationships within conjugates [185, 223, 224], 
novel experiments trough NMR in solution such as pulse-field gradient 
spin-echo NMR (PGSE-NMR) to elucidate size, morphology and 
dynamics [182], and several imaging techniques for in vivo or in vitro 
monitoring of the conjugates [225-227].  
Regardless, it has to be ensured that the chemistry used in 
conjugate synthesis will not cause toxicity or immunogenicity in 
biological systems as well as will not modify inherent properties of the 
bioactive compound.  At last, it should be stressed that once drug is 
conjugated, characteristics of the polymer such conformation in 
solution or degradation profiles will vary. Final Mw, size and shape (in 
general solution conformation) of the entire system could end up in 
different biological behaviour, both at whole body and cellular level 
[74, 126].   
 
I. 2. 5. 2 Polymer-based combination therapy  
 
Disease progression underlies multiple molecular mechanisms. 
Unlike single agent therapy, multi-agent therapy can modulate 
different signalling pathways in diseased cells, thus maximising the 
therapeutic output and possibly overcoming mechanisms of 
resistance. Is becoming frequent the use of more than one drug or 
type of treatment in several human pathologies, e.g. cancer, malaria 
or HIV/AIDS. Polymer conjugates offer the advantage of carry multiple 
drugs in a unique platform obtaining the combination therapy 
approach [228]. 
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There have been described four distinct types of polymer-
based combination therapy. This includes (I) polymer-drug conjugate 
plus free drug(s), (II) polymer-drug conjugate plus polymer-drug 
conjugate, (III) single polymeric carrier carrying a combination of drugs 
and (IV) polymer-directed enzyme prodrug therapy (PDEPT) and 
polymer-enzyme liposome therapy (PELT) (FIGURE I. 18) [228]. 
 
 
FIGURE I. 18 Schematic representation of the polymer-based combination 
therapy families: (I) combination of a polymer-drug conjugate carrying a 
single drug administered with a low molecular weight drug or a different type 
of therapy (e.g. radiotherapy), (II) combination of two different polymer-drug 
conjugates each containing a single therapeutic agent,(III) only one polymer 
main chain in which two or more drugs are conjugated and (IV) PDEPT relies 
on the combination of polymer-drug conjugate with a polymer-enzyme 
conjugate capable of the selective release of the drug at the targeted site. 
PELT is a comparable strategy where a polymer-enzyme conjugate is given in 
combination with the liposome to induce its degradation allowing release of 
the encapsulated drug. Redrawn from ref.[228]. 
 
Combination therapy approach is a growing area of research 
which started on cancer treatment, e. g. HPMA copolymer conjugate 
has been studied with different drug cocktails obtaining synergistic 
effects in tumour treatment (i.e. combining chemotherapy 
(doxorubicin (Dox)) and endocrine therapy (aminogluthemide); with 
conjugation of the antiangiogenic agent TNP-470 through an 
enzymatic cleavable linker and amino-bis-phosphonate alendronate; 
or the two drugs gemcitabine and Dox [7]). Nowadays, application of 
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this technology has created high expectancy on other diseases due to 
this first successful proof-of-concept. As first nanosystems in 
combination therapy, CPX-351 has been granted orphan drug status by 
the U.S. Food & Drug administration for the treatment of acute 
myeloid leukemia (AML) and is in two other clinical trials. This prodrug 
is a liposomal formulation of a synergistic 5:1 molar ratio of cytarabine 
and daunorubicin, two drugs used in hematologic malignancies [229].  
 
It should be stressed that there are still many questions to 
address in order to optimise this polymer-based combinations. 
Rationale behind the design must consider the appropriate selection 
of drugs, best activity ratio and adequate polymer loading capacity for 
the desired drug cargo. Release kinetics will also play a key role 
depending on the selected linker for each drug. Again, complexity of 
the final system will require suitable techniques for characterisation 
and further in vivo investigations are required in each individual study 
to confirm that these systems are significantly synergistic, providing a 
more robust therapeutic effect than simple administration of the free 
drugs combined. 
 
I. 2. 5. 3 Novel molecular targets  
 
Recent anti-cancer approaches 
First generation conjugate research was focused on anticancer 
agents. Conjugation of orthodox chemotherapeutic agents, i.e. Dox, to 
water-soluble carriers was developed and lead candidates raised the 
clinical arena [6]. Novel and sophisticated strategies for treating cancer 
are currently ongoing thanks to genomics and proteomics investigations 
on tumour molecular mechanisms. Recent studies have already 
reported the use of polymer conjugation techniques with drugs for 
specific inhibition of kinases and heat-shock proteins [230, 231], 
angiogenesis [232-234], chemoradiotherapy (combination of a 
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photosensitiser agent and a chemotherapeutic drug) [235, 236] and 
apoptotic5 pathways [237-242]. In the last case, proapoptotic approach 
is related with cancer therapy but antiapoptotic has also applications in 
regenerative medicine [243]. Innovative tumour environment targeting 
has been achieved by PEG-rHuPH20 conjugate, able to reduce 
interstitial tumour pressure and enhance therapeutics passage by 
degrading hyaluronan (HA), a glycosaminoglycan polymer often 
accumulated in malignancy [244, 245]. 
 
Targeting diseases other than cancer 
PT approaches towards novel molecular targets for other major 
human diseases than cancer is already a reality. High versatility and the 
favourable risk/benefit balance of these systems allow the design of 
effective treatments for novel molecular targets. 
Initial studies up to date cover a broad spectrum of pathologies, 
trying to seek treatments for chronic and debilitating diseases of our 
aging increasing population. At present, Cimzia® (rheumatoid arthritis), 
Macugen® (age-related macular degeneration (AMD)) and Krystexxa® 
(chronic gout) are in routine clinical use (TABLE I. 1). Examples of 
ongoing studies are extensive review in reference [179] and summarised 
in TABLE I. 3. Attractive research is being carried out for tissue 
regeneration, i.e.  by means of PGA-peptidil conjugate which acts as 
antiapoptotic inhibitor preventing inflammation-induced tissue damage 
[246, 247]; for corneal re-epithelialisation after injury through dextrin-
rhEGF conjugates [248] or the anti-inflammatory therapy provided by 
multivalent dendritic polyglycerolsulfates designed to inhibit leucocyte 
trafficking [249].  Other pioneering approaches include a polymer 
conjugate for sepsis treatment based on PEG linked to a 
lipopolysaccharid (LPS)-neutralising small molecule which neutralise 
bacterial endotoxins [250] or bone targeting conjugates for 
                                                          
5
 APOPTOSIS: Programmed cell death pathway. 
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musculoskeletal diseases such osteoporosis and bone metastasis 
through [251].  
Neurodegenerative disorders have been also targeted by 
polymer therapeutics and are reviewed in deep in next section due to 
the scope of this thesis. 
 
DISEASE POLYMER  DRUG REF. 
DIABETES PGA Phloridzin [252] 
HYPERTENSION SMA AHPP [253] 
HIV PEG Saquinavir [254] 
 
SALP Azidovudine [255] 
 
Carregeenan Azidovudine [256] 
 
Dextrin Azidovudine [257] 
 
PHEA Azidovudine [258] 
HEPATITIS Dextran Lamivudine [259] 
FUNGAL INFECTION PEG Amphotericin B [260] 
LEISHMANIASIS Arabino-galactan Amphotericin B [261, 262] 
 
HPMA copolymer Amphotericin B [263] 
 
HPMA copolymer NPC1161 [264] 
SEPSIS PEG Peptoid 7 [250] 
BOWEL 
CONSTIPATION PEG Naloxol [265] 
ULCERATIVE 
COLITIS Dextran Budesonide [266, 267] 
INFLAMMATORY 
BOWEL DISEASES pDMAEMA Dexamethasone [268] 
INFLAMMATION Poyglycerol sulfates - [249] 
RHEUMATOID 
ARTHRITIS HPMA copolymer Dexamethasone [269] 
 
CDP α-methylprednisolone [270] 
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WOUND HEALING PAMAM Glucosamine [271] 
 
Glucosamine-6-sulphate 
 
 
Dextrin rhEGF [186, 248] 
ISCHEMIA/injury 
reperfusion PGA APAF-1-inhibitors 
[246, 272, 
273] 
 
SMA AHPP [274] 
 
Modified dextran 17β-estradiol [275] 
 
PEG NO [276] 
OSTEOPOROSIS HPMA copolymer PGE1 [269] 
 
HPMA copolymer Alendronate 
 
 
HPMA copolymer D-Asp8 
 TABLE I. 3 Polymer-drug conjugates under study targeting disease other than 
cancer. Updated from ref. [179]. 
SMA=copoly(styrene-maleic acid), AHPP=4-amino-6-hydroxypyrazolo[3,4-
d]pyrimidine, PHEA=poly[α,β -(N-2-hydroxyethyl-DL-aspartamide)], 
PEG=poly(ethylene glycol), PGA=polyglutamic acid, HPMA=N-(2-
hydroxypropyl)methacrylamide, GFLG=Glycin-Phenylalanin-Leucin-Glycin, 
AZT=Zidovudine, pDMAEMA=poly(dimethylamino)ethyl methacrylate, 
PAMAM=poly(amidoamine), CDP=linear cyclodextrin polymer (α-cyclodextrin 
+ PEG), PGE1=prostaglandin E1, GGPNle=Glycin-Glycin-Prolin-NorLeucin, 
mPEG-PLA=methoxy-poly(ethylene glycol)-b-poly(lactic acid). 
 
I. 3 POLYMER THERAPEUTICS FOR THE TREATMENT OF 
NEURODEGENERATIVE DISEASES. 
 
Nanotechnology houses a helpful toolbox able to propose 
solutions to CNS drug delivery problems, such as controlled size and 
optimal delivery in defined conditions as well as specificity to site of 
action, generating drug targeting strategies precise enough to avoid 
damage to the delicate nervous system structures.   
Development of strategies to reach central or peripheral 
nervous systems injured tissues and treat them is an objective pursued 
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by PT. Features conferred to the PT design will influence on the 
percentage of BBB crossing as well as on its pharmacokinetics and 
excretion inside the brain, which are key points that demand an 
exhaustive research. As mentioned, once achieved the site-specific 
area, polymer drug linkage can be tailored to be responsive against a 
particular enzymatic, pH or reductive environmental conditions. 
Administration routes existing for CNS drug delivery have been 
detailed in section I.7 and in each one it is possible to find examples of 
polymer therapeutics research. As explained, surpassing BBB by one or 
the other pathway displays a major issue for brain treatment. 
Although each alternative depends on the final application and the 
effectiveness of the given drug, undoubtedly a direct drug 
administration to the brain region, painless and safe provides an 
improved scenario.  
 
PT possess all the requirements necessary for diagnosis and 
treatment of CNS disorders and brain tumours and therefore, 
constitute a promising field as BBB targeted drug delivery systems. 
Characteristics such as (i) specific strategies for active targeting by 
covalent binding of ligands or monoclonal antibodies of brain 
receptors, (ii) availability of different regions in the polymer backbone 
which serve for specific purpose, and (iii) sustained or controlled 
release of conjugated drugs through cleavable linkers in specific 
environmental situations, can be tailored to achieve this goal. It is 
noteworthy to emphasise that the PT studies described below are still 
at an early stage of development but the results are encouraging for 
future possibilities in achieving successful delivery of therapeutics to 
the CNS. Unlike other nanosystems, nanoconjugates are smaller in size 
so allow better penetration than the liposomes or non-conjugated 
micelles, less immunogenic and chemically more stable in plasma 
[277]. Proofs of nanosized particles translocation across BBB have 
been already achieved for several years [278, 279] but attaining 
inefficient percentage of total administered dose in vivo, typically less 
than 1% [1]. Potential of polymer structures usage for brain diseases 
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treatment was set by Gliadel® wafer (MGI Pharma, Bloomington, USA) 
[82]. This polymer depot was approved by FDA for brain therapy in 
high-grade malignant gliomas [101, 280]. This implantable polymeric 
system is made of a copolymer matrix based on 1,3-bis(p-
carboxyphenoxy)propane and sebacic acid, loaded with carmustine. As 
a local delivery system, anticancer drug only reaches adjacent areas of 
the implant [78]. Unfortunately, this type of monolithic devices are 
beginning to lose popularity because researchers are developing 
materials to be implanted into deep brain regions that can disturb 
superficial brain tissue. Need of less invasive treatments through 
injectable formulations is already a reality [76]. 
 
 Some of the main strategies adopted for crossing the BBB 
include innovative polymer-based therapeutics with covalently bound 
targeting ligands to mimic endogenous molecules (commonly named 
“Trojan Horses”) [281], able to cross to brain parenchyma through 
receptors. PT systems used in this area include: polymeric drugs, 
polymeric micelles, polyplexes and polymer conjugates with linear or 
branch structures. Regarding polymer structures adopted by these 
compounds, few linear examples manage to cross BBB; most of them 
have vesicular conformation which favours the passage. Polymers in 
use for these purposes are shown in FIGURE I. 14. The most used 
polymers in this field are PEG, α-PGA, HPMA, poly-(L-malic acid), 
polyamidoamines (PAMAM) dendrimers, Pluronics®, poyethylenimine 
(PEI) and polylysine (PLL).  Several examples of these formulations are 
given below; it must be highlighted that although goal of BBB crossing 
has been achieved, process has been very inefficient in terms of 
percentage of dose transferred. Usually maximum transfer in vivo is 
typically lower than 4% of the total administered dose  [1]. 
 
Nanosized polymeric micelles are created when individual 
polymer chains (unimers) aggregate above a threshold concentration 
and temperature when dissolved in aqueous solution (known as the 
critical micelle concentration, CMC, and critical micelle temperature, 
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CMT, respectively). Hydrophobic drugs can be solubilised within its 
core, [282, 283] or covalently conjugated [284]. Studies involving 
polymeric micelles of Pluronic® block copolymers consisting of 
hydrophilic poly(ethylene oxide) (PEO) and hydrophobic 
poly(propylene oxide) (PPO) blocks (PEO-b-PPO-b-PEO) have been 
established as promising carriers for CNS drug delivery. The inherent 
amphiphilic character of this polymer gives surfactant-like properties 
and therefore interacts with hydrophobic surfaces and biological 
membranes [285]. In addition to the advantages conferred to the drug 
by micellisation, it has been discovered that Pluronic® unimers exhibit 
biological response modifying activities in drug formulations, therefore 
acting as a polymeric drug [286]. Depending on the aggregation state 
(unimer or micelle), this copolymer was shown to utilise multiple 
pathways to enter cells.[287] Pluronic® unimers are able to 
incorporate into membranes by changing their microviscosity and 
subsequently the translocation into cells is possible through caveolae-
mediated endocytosis [287]. Once there, they can alter multiple 
cellular functions which includes inhibition of mitochondrial 
respiration, ATP depletion, inhibition of drug-efflux transporters (e.g. 
P-glycoprotein, multidrug resistance proteins and breast cancer 
resistance proteins), apoptotic signal transduction and gene 
expression [285]. Individual results from this make it possible to 
elucidate their activity within the brain.  
 
Successful studies have shown brain accumulation through 
conjugation of targeting moieties i.e. polyclonal antibodies against 
brain α2-glycoprotein or insulin, which allowed BBB crossing through 
RMT of Pluronics®, either carrying a drug or a fluorescent probe [282]. 
They have also managed to increased analgesic effects with several 
opioid peptides [288] or polypeptide delivery to the brain via 
degradable disulfide linker (horseradish peroxidise, HRP as a model 
protein [289] and more recently leptin [290, 291]). In addition, 
Pluronics® are able to stimulate transcriptional activation of gene 
expression in vitro and in vivo.[285] Finally, to confirm that this system 
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has future promise in CNS drug delivery it must be remarked that a 
Pluronics®-based formulation of doxorubicin (SP1049C, Supratek 
Pharma) has advanced to Phase III in clinical trials to treat highly 
resistant tumours and could be the first FDA-approved polymeric 
micelle (see TABLE I. 2) [292]. 
 
Ljubimova et al. have designed a novel biodegradable 
nanoplatform based on poly-(β-L-malic acid) (PLMA) for IV treatment 
of gliomas [293, 294]. This polymer conjugate uses a tandem 
combination of monoclonal antibodies (mAbs) to enhance drug 
targeting across: (i) the BBB, thanks to an anti-mouse Tf antibody and 
(ii) the blood-tumour barrier (BTB) where antibody 2C5 targets tumour 
cell surface antigen. Through hierarchical addition, different molecules 
can be covalently attached at the same time to the polymer, e.g. with 
endosomal disrupting units, fluorescent dyes, drugs and PEG chains (as 
spacers and also as protection modules). Recent studies have shown 
that antisense oligonucleotides for tumour-specific protein inhibition 
(laminin-411) and the introduction of a trileucine endosome escape 
moiety have achieved specific accumulation in brain tumours and 
suppression of intracranial glioma growth [295]. PMLA-based delivery 
systems constitute an auspicious tool to treat brain tumours and for 
tumour imaging. However, this system entails drawbacks regarding 
the difficulties of chemical modification and the resulting technical 
limitations for high scale production [296].  
 
PEGylation has also been explored as an alternative approach 
for enhancing brain entrance to non-penetrating peptide/proteins by 
reducing the interaction and/or specificity of the efflux transporters 
and enhance its stability and circulation. PEG conjugation to the opioid 
peptide DPDPE ((2,6-dimethyl-Tyr1,D-Pen2,D-Pen5)enkephalin) 
improved analgesic effect although therapeutic output has to be 
enhanced  [297]. Several trials had been performed like PEGylation of 
growth factors for developing neurotherapeutic/neuroprotective 
conjugates (i.e. NGF (nerve growth factor) [298, 299], recombinant 
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human epidermal growth factor (rhEGF) [300], brain derived 
neurotrophic factor (BDNF) [299, 301-303]) or conjugation to OX26 
antibody by avidin/biotin technology [304, 305]. As well in the 
neuroprotection field, Frank et al. achieved promised pre-clinical 
studies through PEGylation of the granulocyte colony-stimulating 
factor [306]. In a rodent model of Parkinson’s disease, subcutaneous 
administration of a unique dose of the conjugate improved the PK 
profile in comparison with the non-modified counterpart together 
with improved motor performance. While current studies on 
PEGylation for BBB crossing are being carried out, PEG has became 
more popular as an extra complement (sterical stability shell, 
hydrophilic enhancing part, linker, etc) for the same final objective but 
not as the single carrier.    
 
Regarding dendrimers, most research has been focused on 
glioma treatment. Polyamidoamines (PAMAM) have been evaluated 
for brain drug delivery. Sarin et al. have studied how PAMAM size 
influences its accumulation within malignant glioma cells by magnetic 
resonance and fluorescence imaging after IV administration, 
concluding that sizes of 11.1 to 11.9 nm in diameter were able to 
transverse BTB of malignant gliomas [307]. PAMAM-G5 dendrimer 
covalently linked to methotrexate (MTX) was constructed for targeting 
epidermal growth factor receptor-positive brain tumours by means of 
the antibody cetuximab (ICM-C225). By convection-enhanced delivery 
(CED) administration, the bioconjugate was selectively retained in rat 
gliomas [308]. More recently, successful in vitro experiments were 
performed with PAMAM-G4 dendrimers. By means of Tf conjugation, 
pH-bonded combination of Dox and tamoxifen demonstrated brain 
accumulation [309]. 
 
PAMAM dendrimers have also recently been tested in vitro for 
neuroinflammation treatment by its conjugation through a disulfide 
bond to N-acetyl-cystein (NAC), an anti-inflammatory agent [310]. 
Glutathione present in cell cytoplasm triggers drug release. Wu et al. 
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developed a vehicle for boron neutron capture therapy (BNCT) with a 
heavily boronated PAMAM dendrimer chemically linked to C225. In 
vivo studies by CED administration showed higher survival compared 
with control group [311]. Kannan et al. proved dendrimer conjugate 
localisation in astrocytes and activated microglia, cells responsible for 
neuroinflammation, after aubarachnoid injection in preliminary in vivo 
studies in cerebral palsy (CP) rabbit model [312, 313]. No targeting 
ligands were exploited. Same group already demonstrated that this 
conjugate improved myelination organisation, neuronal branching and 
neuronal injury after intrauterine administration in postnatal day 1 to 
5 in the rabbit model, suggesting phenotype reversal [314].  
 
An enhanced rate of transfer across biological barriers has 
been seen for dendrimers and hybrid dendritic architectures. Neutral 
and cationic systems have been demonstrated to have greater 
diffusivity in brain parenchyma after CED administration [312, 314]]. 
BBB crossing with non targeted dendrimers have been attributed to 
mixed cellular entry mechanisms, combining passive and others. 
However, as yet no dendrimers have been transferred into clinical trial 
for parenteral use other than the imaging agent Gadomer-17, 
mentioned above, which did not progress. The chemical simplification 
and systematic studies of dendrimer PK is enabling the optimisation of 
dendrimer structures with greater potential for parenteral use as 
therapeutics or imaging agents [315].  
 
An increasingly popular field in the treatment of brain 
disorders is gene therapy using polyplexes as non-viral vectors. It 
should be remarked that cellular trafficking of these nanomaterials 
strongly depends on their composition, size, shape and surface 
characteristics as well as the cell line used for in vitro studies [287]. 
The surfaces of polyplexes are typically modified with hydrophilic and 
biocompatible polymers such as PEG or 
poly(hydroxypropylmethacrylate) (pHPMA) for in vivo applications, 
with the aim of increasing colloidal stability and solubility after its 
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systemic delivery by preventing aggregation and interaction with 
plasma proteins due to steric repulsions [316]. To improve the activity, 
acid-labile linkers between PEG and a polycationic block have been 
tested to expose the positively charged polyplex (after endosome 
hydrolysis) to enhance membrane disruption and cytosolic escape 
[317]. The design of polyplexes is often complemented by addition of 
brain-specific ligands for targeting neurodegenerative disorders. It has 
been shown that targeting moieties should be linked in distal ends of 
PEG to avoid masking receptor-ligand interaction [318]. Introduction 
of Nuclear Localisation Signal peptides (NLS) into polyplexes has been 
also attempted to achieve DNA delivery [316]. For example, recent 
studies pre-mixing NLS-PEG-trisacridine conjugate with DNA and 
biodegradable polyamines demonstrated significantly enhanced 
transfection into brain capillary endothelial cells [319]. Due to the 
cationic character of PAMAM, its use as non-viral vectors has been 
highly exploited. As a recent example, radio-labelled siRNA-PAMAM 
G7 dendriplexes incorporated in poloxamer 407 (Pluronic ®F127) and 
chitosan gels were proved to achieve BBB crossing after intranasal 
administration by radioactivity measurement [320].  
 
Numerous targeting ligands have been conjugated to them to 
examine their potential for BBB passage. Angiopep-2 is an amino acid 
sequence endocytosed by the low-density lipoprotein (LDL) receptor-
related protein (LRP-1) and to date is the most advanced technology in 
brain drug delivery. Its conjugation to three molecules of Paclitaxel 
(ANG1005, Angiochem Inc., Canada) is in two Phase I clinical trials for 
recurrent malignant gliomas and brain metastases of advanced cancer 
[280]. This peptide-drug conjugate is not a substrate for the P-gp efflux 
transporter and is therefore not pumped out of the brain as it happens 
with the free drug. Once in the brain, ANG1005 gains entry into 
tumour cells via LRP-1 mediated endocytosis and becomes activated in 
the tumour cell after the conjugated PTX is cleaved by esterases from 
the Angiopep-2 backbone, to release the active drug which leads to 
G2/M cell cycle point arrest and eventual tumour cell death (FIGURE I. 
[CHAPTER I.] 
[109] 
19). Angiopep-2 conjugated PEG-PAMAM dendrimer nanoparticles 
were observed to be internalised through clathrin- and caveolae-
mediated endocytosis and partially by macropinocytosis. In vivo assays 
confirmed its passage through BBB and subsequent accumulation, 
showing higher efficiency in gene expression than non-modified 
dendrimers [321]. Transferrin-conjugated PEG-PAMAM dendrimer 
promoted gene expression in mouse brain after IV administration 
[322]. However, PAMAM safety has been always compromised its 
clinical development for systemic applications. 
 
 
FIGURE I. 19 Mechanism of internalisation of Angiopep-2 as GRN1005. From 
ref. [323]. 
 
Number of targeting ligands tested to prove BBB crossing 
through RMT not involving polymer therapeutics is countless. For 
example, Zhan and colleges made up a micelle system with PLA-PEG 
encapsulating PTX, already functionalised with a 16-residue peptide 
named CDX, candid candoxin [60]. This peptide derived from the snake 
neurotoxin candoxin, which binds nAChrs with high affinity. They 
ensured BBB crossing by achieving higher survival in glioblastoma 
treatment and fluorescence detection of the system thanks to 
encapsulated infrared fluorescent dye (DiR). Another investigators 
anchored polysorbate 80 (P80) to dendritic poly(propyleneimine) (PPI) 
system encapsulating the anti-cancer drug docetaxel (DTX) [59]. RMT 
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through LDL receptors were targeted and demonstrated with in vivo 
experiments such as anti-tumour activity and biodistribution studies 
under a gamma camera. 99mTcO4
- was exploited for last purpose.  
 Arap-Pasqualini laboratory has designed, after a screening 
evaluation of small peptides library attached to viral particles, one 
peptide (CRTIGPSVC) that belongs to transferrin protein portion and it 
is currently being developed towards phase I human clinical trials. 
They confirmed that this peptide mimics the ligand of the Tf protein 
(iron), being able to bind, forcing the close conformation of the 
protein: “like if it were carrying iron”. This closed form is the one 
binding to the receptors. Published work demonstrated BBB crossing 
with peptide-targeted phage particles in a mouse model of human 
glioblastoma [324].  
 
Involving polymer therapeutics but not as the main actors, 
entails cell-based therapy transport. Batrakova et. all have developed 
a PEI-PEG complexed nanozyme loaded into bone marrow derived 
monocytes  for Parkinson’s disease treatment [325]. This system was 
able to attenuate oxidative stress due to sustained release of the 
antioxidant enzyme. Recent work based on similar electrostatic 
coupled enzymes (superoxide dismutase 1 (SOD1) and catalase) with 
cationic block copolymers (PEI-PEG or PLL-PEG) followed by covalent 
cross-linking to stabilise the nanoparticles, were radiolabelled and 
studied in vivo [326]. Results showed increased stability in blood and 
brain and increased accumulation in brain tissues, thus potentiating 
this formulation as antioxidant enzyme deliver system to CNS for 
oxidative stress reduction in neurodegenerative diseases. 
 
Future possibilities with polymer therapeutics for brain 
delivery include the need of smart vector development and critical 
evaluation of currently existing ones. Also required its active targeting 
through novel ligands development in order to make the most of 
surface-mediated transcytosis as it is believed it constitutes a 
promising non-invasive strategy. 
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I. 1 4 FAMILIAL AMILOYD POLYNEUROPATHY (FAP): PROPOSAL 
FOR TREATMENT WITH POLYMER-DRUG CONJUGATES 
 
 Amyloidosis is the general term given to neurological diseases 
where an abnormal protein, known as amyloid, is misfolded and 
accumulated as deposits in organs and tissues disrupting their normal 
function. Some examples are given in TABLE I. 4. This large group of 
pathologies leads to cell damage, organ dysfunction and death. 
Amyloid proteins present difficulties to be removed by the body 
promoting their inherent accumulation. Amongst the different types of 
amyloidosis, where Alzheimer’s and Parkinson’s diseases are 
renowned examples, Familial Amyloid Polyneuropathies (FAP) 
constitute a group of inherited amyloidosis that affect mainly 
peripheral nerves [327]. One of the most common FAP is caused by 
transthyretin (TTR) misfolding and deposition in the peripheral 
nervous system, leading to neuronal toxicity and death[328]. 
 
Clinical syndrome 
 
Precursor protein 
  
Alzheimer´s disease 
 
Aβ-protein 
   
Primary Systemic Amyloidosis  Ig Light Chain 
  
Secondary Systemic Amyloidosis  Serum Amyloid A 
  
Senile Systemic Amyloidosis (SSA)  Transthyretin 
  
Familial Amyloid Polyneuropathy (FAP)  Transthyretin 
  
Finnish Hereditary Systemic Amyloidosis  Gelsolin 
   
Type II Diabetes 
 
Islet Amyloid Peptide 
  
Non-Neuropathic Systemic Amyloidosis  Lysozyme 
   
Cerebral Amyloid Angiopathy  Cystatin C 
   
Atrial Amyloidosis 
 
Atrial Natriuretic Factor 
  
Familial Amyloidosis Type III  Apolipoprotein A-1 
  
Hereditary Renal Amyloidosis  Fibrinogen 
   
TABLE I. 4 A selection of diseases coupled to protein misfolding and 
amyloidosis and their precursor proteins. 
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TTR-related FAP has been selected herein as disease to be 
treated for the first time by means of rationally designed polymer-drug 
conjugates. 
 
I. 4. 1 FAP CONCEPT 
 
TTR-related FAP is catalogued as a rare disease, affecting 
around 8.000 patients around the world.  Discovered in 1952 by the 
Dr. Corino de Andrade,[329] it is defined as a late-onset hereditary 
dominant neurodegenerative disorder. Its main characteristics are an 
ascending sensorimotor polyneuropathy and progressive autonomic 
dysfunction. The rate of evolution varies considerably depending on 
the protein mutation but usually manifesting itself upon the 40 decade 
of life and often becoming fatal 10 to 15 years after its onset. Initial 
symptoms are usually loss of sensibility and pain sensation in fingers 
and toes together with walking disability, but mainly dependent on the 
organ(s) involved. Furthermore, it leads to paresis, malabsorption and 
emaciation [330]. All of these symptoms critically disturb the quality 
and activities of patients’ daily lives. As disease progresses, motor 
involvement comes out and ulcers or osteomyelitis may also occur. 
Later symptoms are cardiac dysfunction and renal failure.  
The amyloidogenic mutated protein transthyretin (TTR) is the 
responsible of trigger the formation of extracellular deposits in several 
organs [331]. Prediction of the greatest extent and therefore the cause 
disease symptoms is difficult and peculiar of each individual. Although 
amyloid deposits may occur in any organ, peripheral nervous system is 
the most commonly affected, including nerve trunks, plexus and 
sensory and autonomic ganglia. In the peripheral nerves, tissues such 
as epineurium, perineurium and specially endoneurium are affected 
(FIGURE I. 20). 
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FIGURE I. 20 Structure of a nerve. Connective tissue wrapping. Adapted from 
ref. [332]. 
In the last one, deposits are usually closely opposed to 
Schwann cells or collagen fibrils [333]. Other organs involved are 
heart, intestine and kidney (FIGURE I. 21). 
 
FIGURE I. 21 Amyloid-associated tissues in TTR related FAP patients. Redrawn 
from ref [328]. 
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When heart is remarkably affected, the disease is 
denominated Familial Amyloid Cardiomyopathy (FAC).  TTR amyloid 
fibrils infiltrate the myocardium leading to diastolic dysfunction 
progressing to restrictive cardiomyopathy and heart failure. Several 
specific mutations in TTR have been primarily associated. Heart 
involvement often causes congestive heart failure with tiredness, 
weakness and swelling of the feet due to water retention. Regarding 
intestine, it may cause diarrhea, constipation or both. Deposits can 
also occur in the eye, obstructing vision, and in minor frequency 
deposits may be found in the linings around the brain causing 
headache and stroke-like symptoms [334]. In some cases, there is 
reported direct involvement of the central nervous system (CNS) [335]. 
Amyloid deposition is localised in the leptomeninges in patients 
promoting cerebral infarction, haemorrhage, ataxia or even dementia. 
The mechanism by which the deposits lead to those symptoms 
remains unclear, but TTR synthesised by the choroid plexus could 
contribute to form them as it has been observed in patients following 
orthotopic liver transplantation [336].    
 
I. 4. 2 ONSET OF THE DISEASE 
  
FAP is found worldwide but there are endemic areas with higher 
frequency of patients found in Portugal, Japan and northern Sweden. 
Over 100 point mutations have been identified in TTR and associated 
with FAP; being the most common mutation the replacement of valine 
(V) with methionine (M) at position 30 in the protein sequence: V30M. 
Another common one is the replacement of V with an isoleucine at 
position 122: V122I where 3 to 4 percent of the African-Americans and 
5 percent of some West African populations have this mutation. Most 
of the TTR gene mutations are thought to alter its natural structure 
impairing its ability to bind to other transthyretin proteins and altering 
its normal function.  
 
In elderly people, TTR deposits may cause a condition named 
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senile systemic amyloidosis in which TTR does not have a mutation in 
its gene. Due to unknown reasons that remain unclear, TTR protein 
abnormally begins to form deposits. Heart is the common organ where 
this occurs, promoting slow progressive heart failure. Lungs, blood 
vessels and kidneys could be also affected. It has been estimated that 
10 to 25 percent of population older than 80 suffer this disorder. For a 
patient with FAP, the age at which symptoms develop depends on the 
genetic mutation, ethnic background, and the penetrance of the 
disease [337]. The “penetrance” of a disease-causing mutation is the 
proportion of individuals with the mutation who exhibit clinical 
symptoms.  
 
 Systemic variant of TTR circulates in the blood stream of 
asymptomatic patients; meanwhile it is deposited in several tissues in 
patients. Depending on which TTR mutation causes the disease, rate of 
progression varies. Reason for this difference is not known. The most 
abundant data pertain to the most aggressive variant with early 
disease onset: TTR V30M; from which following observations have 
been made: 
- Variation in age of onset: The usual age of disease onset 
among TTR V30M gene carriers in Portugal, Brazil, and Japan 
is in the third to fourth decade of life. However, there are 
late-onset cases (as seen in Sweden) in which disease onset 
is in the fifth to sixth decade of life. 
- Disease penetrance: In Portugal and Japan, more than 90 
percent of TTR V30M gene carriers develop symptoms by 
middle age. However, in Sweden, disease penetrance is only 
2 percent, and some V30M homozygous individuals remain 
asymptomatic. 
- Some atypical Portuguese and Japanese kindred follow the 
late-onset, low-penetrance Swedish pattern. 
100*
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- Some patients with no family history of amyloidosis and 
asymptomatic relatives with the variant gene carry the V30M 
variant. 
- Disease onset is earlier in males than in females.  
- Age of symptom onset is progressively earlier in successive 
generations. This feature is referred to as anticipation.  
The explanation for the above observations is not well 
understood. Other genetic and/or environmental variables are 
thought to be at play. Anticipation, incomplete penetrance, and 
clinically sporadic cases in kindred’s with unaffected allele carriers also 
have been observed with other TTR variants. 
 
I. 4. 3 TTTR AND AMYLOID FORMATION PATHWAY  
 
TTR gene is located on the long arm of the chromosome 18, at 
position 12.1 and codifies for 55kDa homotetrameric protein with four 
identical, monomeric subunits composed of 127 amino acids [338]. 
Each subunit has a molecular weight of 14kDa. 98 percent of this 
protein is synthesised in the liver and the other 2 percent in the 
choroid plexus of the brain and the retinal pigment in the eye [339] 
(FIGURE I. 22). TTR half life is 2 days. Main function of this protein is to 
act as carrier. TTR is the third transporter of thyroxine in plasma, 
carrying less than TBG (thyroxine-binding globulin) (70%) and albumin 
(15-20%). In the presence of normal levels of TBG, wide fluctuations in 
concentration of TTR or its removal from serum has little influence on 
the concentration of T4. Only 0.5% of circulating TTR in plasma is 
occupied by T4, which when is bond is not active. In the cerebrospinal 
fluid, TTR is the primary carrier of T4 as albumin is not present. This 
protein also acts as a carrier of retinol (vitamin A) through an 
association with RBP (retinol-binding protein). It takes part as a 
positive regulator in the delivery of RBP-bound retinol from plasma, 
preventing kidney filtration and enhancing RBP t1/2 up to 16h. It enters 
by receptor-mediated endocytosis (RBP binds the receptor, retinol 
enters and TTR remains in plasma). 
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FIGURE I. 22 Synthesis, circulation and uptake of TTR pathways. From ref. 
[340]. 
 
It is a sensitive nutritional indicator with high impact in 
prognosis of oncologic patients. It is sensitive to proteins deficiency. 
Furthermore, it has been described that TTR binds A-beta protein, 
which plays the major role in the Alzheimer Disease (AD). It can act like 
a “chaperone” by preventing formation of A-beta amyloid aggregates 
and thereby it may halt progression of AD [341]. This disorder, also an 
amyloidotic disease, affects 5% of the population over the age of 65 
years and 20% over 80 years of age.  
Amyloid deposits are mainly composed by the precursor 
protein transthyretin, but there are several components associated 
such as serum amyloid P component (SAP), sulphonated 
glycosaminoglycans (GAGs), apoliproteins E and J, α1- 
antichymiotrypsin, several basement membrane components such as 
fibronectin, laminin and collagen type IV, complement proteins and 
metal ions. [342] Reasons for amyloid formation are not yet fully 
established. It is believed that several factors take part in the process 
that ends up in fibril formation. For example the inherent 
amyloidogenic potential of the protein that can be influenced or not 
by mutations, tissue and/or circulating factors as well as environment 
and genetic background. A singular characteristic involved in fibril 
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formation is the high content in β-content, present in most 
amyloidogenic proteins.  
Regarding the specific mechanism by which TTR deposits and 
becomes pathological is not fully understood but it is currently 
accepted that the protein undergoes a series of events that lead to 
tetramer dissociation where the partially unfolded monomers self-
assemble originating non-fibrillar aggregates, protofibrils and ending 
up in mature amyloid [343-345] (FIGURE I. 23). Structural studies in 
vitro concluded that fibrillar structures formed by TTR are 
polymorphic, exhibiting fibrils and oligomers of different diameters. 
The assembly dynamics evolves from oligomers of 5-8nm wide to short 
and thin fibrils with 4nm of diameter that twist over each other to end 
up in mature long fibrils of 8nm wide [346] .  
 
 
FIGURE I. 23 TTR amyloid cascade. In order for TTR to form amyloid, the 
tetramer must first dissociate (the rate-limiting step), and then the natively 
folded monomer must undergo partial denaturation to become competent to 
misassemble into a variety of aggregate morphologies, including oligomers 
and amyloid fibrils. Ligands (such as T4; gray and red) stabilise the tetramer 
and thus prevent amyloidogenesis. 
 
Existence of the different species has been proved “in vivo” 
from nerve biopsy samples of asymptomatic patients were small non-
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fibrillar TTR aggregates were coexisting with amyloid deposits in later 
stages of the disease [347] . 
Toxicity of the intermediate species has been studied by nerve 
and salivary glands analysis of FAP patients [348, 349]. Indeed, 
cytotoxicity of early TTR prefibrillar aggregates and not mature fibrils 
have shown oxidative and inflammatory responses in neuronal cells, 
induction of the NF-κB pathway and caspase-3 activation before 
amyloid fibrillar deposition, promoting cell dysfunction and death in 
the last stage [347]. Our collaborators, Saraiva et al., have previously 
contributed for the characterization of the dynamics of TTR fibril 
formation, including the characterization of the different TTR species 
generated along the process of fibril formation ([344]which allowed 
the screening of different drugs in vitro, acting at different stages of 
the amyloidogenic cascade [350, 351], and in vivo  [346]. 
 
I. 4. 4 FAP DIAGNOSTIC 
 
First step for amyloidosis diagnose is to detect amyloid. This 
can be shown in a tissue biopsy with the azodye Congo red (CR) [352] 
with the characteristic apple-green birefringence in polarised light. 
Next steps rely on determining if amyloid deposition is local or 
systemic and the type of amyloid as well as identify the responsible 
precursor protein. Ultrastructural analysis by electron microscopy 
[353], immunohistochemical staining for TTR, protein identification by 
mass spectrometry and genetic testing [354] are require for amyloid-
associated TTR mutation. However, identification of disease-causing 
mutation is not considered as a final diagnostic because penetrance is 
variable [336, 337, 355]. Nevertheless, TTR amyloidosis is a predictable 
disease because gene mutations are detectable from birth in a genetic 
study. Early detection of the disease thanks to biomarkers may help in 
correct clinical treatment of the patients and delay the possible 
morbidity [356]. In the cases of non-hereditary ATTR, cardiac biopsy 
demonstrating amyloid deposits positive for TTR combined with lack of 
identifiable mutation in the TTR gene is necessary. Finally, a helpful 
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tool for ATTR diagnosis is the deposits found in the vitreous body with 
typical cotton wool inclusions due to approximately 20% of the protein 
is expressed in the retinal pigment epithelium of the eye [357]. 
CR method is commonly used in experimental studies of FAP. 
With polarised light, it is obtained a positive green birefringence due 
to amyloid-dye binding. In the early phases of FAP, TTR is already 
deposited in an aggregated non-fibrillar form negative by CR staining 
whereas in advanced stages these aggregates coexist with mature 
amyloid fibrils [356]. With age, short fibrils are easily observed by 
transmission electron microscopy (TEM), which are CR-positive. 
Furthermore, TTR initial aggregates are cytotoxic, both in vivo and in 
vitro, as evidenced by the presence of increased amounts of 
proinflammatory cytokines and oxidative stress markers such as 
nitrotyrosine, in tissues of FAP patients [349]and by apoptotic assays 
using a Schwannoma cell line [347]. 
 
I. 4. 5 FAP TREATMENT 
 
Currently, there is not a specific pharmacologic therapy for 
ATTR. Available therapy is symptomatic. Effective FAP treatment 
alternatives are reduced to orthotropic liver transplantation (OLT), 
thus, suppressing the main source of mutant TTR [328, 358, 359]. 
Ideally, the transplantation should be performed as early in the 
disease course as possible. This therapy usually halts the illness 
progression resulting in amyloid clearance over time, but often with 
evolution of the cardiac amyloid affection. Besides, this strategy is 
extremely invasive, 100% of patients do not show clinical 
improvement and some of them have progression of their disease 
after transplantation. 
 This situation supports the urgent need to encourage medical 
research on new strategies for treating or preventing this disease. 
Together with this effort, complementary studies are carried out in 
identification and characterisation of the species formed along the 
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amyloid cascade process as well as biomarkers of each disease stage.  
Less aggressive therapies for TTR amyloidosis treatment such 
as reduction of amyloidogenic TTR supply by other vias, stabilisation of 
the soluble circulating amyloid precursor, inhibition of aggregation of 
amyloidogenic intermediates and disruption of insoluble deposits have 
been proposed [340]. 
 
I. 4. 5. 1 Reduction of the supply of the amyloidogenic protein 
 
Apart from OLT, another option is gene repair. Nakamura et al. 
reported that single-strand oligonucleotides (SSOs), induce targeted 
single-nucleotide exchanges in the TTR genes in both HepG2 cells 
secreting human wild-type TTR and liver from murine Val30Met TTR 
transgenic mice [360]. However, the level of gene conversion by SSOs 
was very low, with 11.1% and 7.9% conversion rate obtained, 
respectively. Inhibition of TTR synthesis has been also tested by 
Benson and co-workers [361]. They employed antisense 
oligonucleotides (ASOs) to inhibit hepatic expression of TTR. A 
transgenic mouse model carrying the human TTR Ile84Ser mutation 
was created and shown to express high levels of human mutant 
transthyretin. TTR ASOs suppressed hepatic TTR mRNA levels and 
serum TTR levels by as much as 80%. Finally, Kurosawa et al. had used 
small interfering RNAs (siRNAs) for the selective silencing of mutant 
Val30Met TTR in cell culture systems, identifying a siRNA that 
specifically inhibits mutant but not wild-type TTR expression even in 
cells expressing both alleles [362]. 
A gene-therapy study exploiting siRNA has been recently 
initiated by the company Alnylam [363]. ALN-TTR01 is a systemically 
delivered RNAi therapeutic formulated in a first generation lipid 
nanoparticles (LNP) for the treatment of ATTR, including FAP and FAC. 
This vehicle is composed of cationic and fusogenic lipids, PEG and 
cholesterol. ALN targets a conserved region of the TTR gene in wild 
type and all known mutant forms; therefore it has the potential as a 
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therapeutic for all type of patients. Pre-clinical data demonstrated, for 
the first time, that treatment with an RNAi therapeutic could result in 
regression of pre-existing pathogenic TTR deposits in peripheral 
tissues. Additional data demonstrated its potential application for the 
treatment of ocular disease in ATTR. This therapeutic system is being 
improved using second generation LNP delivery technology developed 
in collaboration with Tekmira Pharmaceuticals Corporation, named 
ALN-TTR02.[176] 
I. 4. 5. 2 Stabilisation of amyloidogenic protein precursor 
 
Stabilisation of the TTR-tetramer to prevent formation of the 
destabilised monomer and its misfolding is another promising 
treatment option that under exploration [364] . Some nonsteroidal 
anti-inflammatory drugs such as diflunisal have been shown to 
stabilise TTR in serum [365]. Although this effect has not yet been 
demonstrated in patients with systemic amyloidosis, it may be 
represent great effect at the beginning of the disease, before clinical 
symptoms appear or in patients for whom re-transplantation is 
contraindicated. 
Recently, Vindaquel® (tafamidis; previously named Fx-1006A 
developed by FoldRx Pharmaceuticals now property of Pfizer Inc.) has 
been approved by the EMEA and is in phase III in USA for TTR-FAP 
treatment in patients with stage 1 symptomatic polyneuropathy. It is a 
novel, selective and potent TTR stabiliser first described by Kelly and 
co-workers (FIGURE I. 24) [366]. Administrated by oral route, it 
reduces the burden of disease after 18 months compared to placebo, 
and appears to be safe and well-tolerated. This new chemical entity is 
able to stabilise wild type and variant TTR. It maintains neurologic 
function, reduces burden of the disease enhancing quality of live and 
improving nutritional state with similar side effects than the placebo 
group [367]. 
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FIGURE I. 24 Tafamidis chemical structure. 
 
As TTR crystal structure is well-known, there are other studies 
on protein stabilisers. They are able to fit in avoiding tetrameric 
structure destabilisation that ends up in fibril formation. For example, 
two palindromic ligands have been recently described to prevent TTR 
amyloid formation [368]. After the palindromic ligand is in place, the 
large number of ligand-protein contacts stabilises the complex with 
binding, which is irreversible under physiological conditions. These 
ligands are preferentially bound by and stabilise amyloidogenic 
variants, perhaps by virtue of improved access to the ligand site in 
these molecules, which bind T4 less avidly and are less stable than the 
WT. Furthermore, they have shown good oral bioavailability and a 
favourable PK profile. 
 
I. 4. 5. 3 Disruption of amyloid fibrils 
 
Within this therapeutic approach, the tetracycline doxycycline 
(doxy) is the most advanced compound in study. This drug 
demonstrated to be the most effective compound at disaggregating 
TTR mature fibrils [351]. Doxy was able to disrupt amyloid fibrils in 
vitro, in the treated animals and also achieved other improvements 
regarding amyloid markers [346].  The neuroprotector effect of this 
class of compounds, in addition to its own anti-microbacterial 
properties, was described in several other disease models including 
cerebral ischemia, spinal cord injury, Parkinson´s disease (PD), 
Huntington´s disease (HD), Amyotrophic lateral sclerosis (ALS), 
Multiple Sclerosis (MS), and AD.  
Combination of Doxy with Tauroursodeoxycholic Acid (TUDCA) 
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is already in phase II of clinical trials. TUDCA is a biliary acid with 
antiapoptotic and antioxidant activity. In recent studies combined 
doxycycline and TUDCA administration to mice with amyloid 
deposition using two different concentrations of both drugs, was more 
effective when compared with either parent drugs. Significantly 
lowering of TTR deposition and associated tissue markers was 
observed. The observed synergistic effect of doxy/TUDCA in the range 
of human tolerable quantities, in the transgenic TTR mice models 
prompts their application in FAP, particularly in the early stages of 
disease. During this study, it was suggested that a possible mechanism 
for TTR extracellular aggregation is the influence of secreted 
metabolites generated by oxidative stress and apoptosis on TTR [330].  
 
I. 4. 6 NOVEL TARGET FOR FAP TREATMENT AND POLYMER-DRUG 
CONJUGATES APPROACH  
 
TTR has been proposed to trigger neurodegeneration through 
its engagement to the Receptor for Advanced Glycation End products 
(RAGE). This receptor is a member of the immunoglobulin superfamily 
of cell surface molecules and has been described as a receptor for 
advanced glycation end products (AGEs). RAGE is expressed at low 
basal levels in most adult tissues, except in lungs where is present in 
higher ratio in healthy and elderly adults. At cellular level, RAGE is 
expressed in most of cell types: endothelial, monocytes-macrophages, 
epithelial or neurons [369]. Between its functions, it represents an 
important factor in innate immunity against pathogens, but it also 
interacts with endogenous ligands resulting in chronic inflammation. 
Recent therapeutic strategies highlights RAGE as an important target 
to treat RAGE activation-associated diseases [370].  
RAGE signalling has been implicated in multiple human 
illnesses such as AD, diabetes or aging associated diseases among 
others.  This receptor is also up-regulated in tissues from FAP patients 
[349]. The secreted RAGE form, named soluble RAGE (sRAGE), acts as a 
decoy to trap ligands and prevent interaction with cell surface 
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receptors. sRAGE was shown to have important inhibitory effects in 
several cell culture and transgenic mouse models, in which it 
prevented or reversed full-length RAGE signalling. Following these 
results, the possibility of using a RAGE peptide to prevent toxicity 
triggered by TTR toxic aggregates was investigated. Saraiva et al. 
showed that a human RAGE peptide, corresponding to the 102–118 
amino acid region of the RAGE V-domain, was able to bind TTR and 
abolish TTR-induced toxicity in cell culture [371] and transgenic mouse 
models (unpublished data), in which it prevented or reversed full-
length RAGE signalling. As it has been previously referred, TTR-
aggregate species appear in early disease development stages and 
coexist with fibril deposits in later phases; therefore, RAGE peptide 
constitutes a versatile tool for FAP treatment. 
Because the major drawback that hinders peptides/proteins 
application in therapies is their variable solubility, low bioavailability 
and limited stability, one purpose of the present thesis is to move a 
step further this therapy enhancing the activity already found with 
doxy and RAGE peptide in FAP with polymer-drug conjugates, 
increasing their specificity and diminishing their systemic toxicity. 
These vehicles present advantages not just for peptides but also for 
small chemical compounds, allowing a controlled drug release at the 
desired site.  
Moreover, the property of polymer multivalency allows the 
conjugation of several active compounds within the same polymeric 
carrier, the combination of doxy and RAGE peptide could 
synergistically enhance the therapeutic value of these prodrugs [228]. 
This concept has been already detailed in section II.5.2. Due to the 
molecular complexity of FAP it is expected to achieve better 
therapeutic output if more than one molecular pathway of disease is 
targeted.  
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AIMS OF THE RESEARCH 
 
The present thesis aims at developing novel polymer 
conjugates for the treatment of neurodegenerative diseases. This 
principal objective is divided in specific tasks: 
 
- Development of novel polymer carriers based on poly-L-glutamic 
acid (PGA): a biodegradable, multifunctional and versatile 
polymer. 
Chapter II covers the synthesis of novel polyglutamates by means 
of ring-opening polymerisation (ROP) of α-N-carboxyanhydrides 
(NCA) making use of tetrafluoroborate ammonium salts, a novel 
approach with this type of polymerisation. Deprotection 
optimisation and post-polymerisation processes are included in this 
chapter. 
 
- Exhaustive physico-chemical characterisation of these novel 
entities for a better understanding of their biological behaviour as 
well as in vitro and in vivo evaluation to validate them as 
adequate drug delivery systems. 
In Chapters II, III and IV all the characterisation of the synthesised 
polyglutamates is described. Chapters II and III contain the routine 
characterisation for polymers as well as the synthetic routes for 
their conjugation with different labelling moieties and targeting 
ligands. Chapter IV is focused on the experimentation in cellular 
models in order to evaluate conjugate cytotoxicity and cellular 
internalisation pathways. In this chapter also conjugate 
biodistribution is studied in animal models where special attention 
is taken on brain accumulation and secretion routes.   
 
- Their application to novel therapeutic targets in the polymer 
therapeutics area, such as neurodegenerative disorders. Within 
this topic, two aims were pursued:  
1. To cross Blood-Brain Barrier (BBB) by means of 
receptor-mediated endocytosis through covalent 
binding of targeting ligands,  
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Chapter III comprises polyglutamate labelling with 
targeting moieties such as transferrin, mAbOX26, 
Angiopep-2 and cPEP. The in vivo evaluation of their 
efficacy as brain homing vectors is described in 
Chapter IV. 
 
2. To build novel polymer-drug conjugates (PDCs) for 
the treatment of an amyloidotic disease where the 
peripheral nervous system (PNS) is mainly involved 
and therefore BBB passage was not a prerequisite. 
In Chapter V, Familial Amyloidotic Polyneuropathy 
(FAP) constituted the therapeutical approach for novel 
PDCs in the present thesis. Two bioactive molecules: a 
low MW drug (doxycycline) and a peptidic sequence 
(RAGEpep), were conjugated to PGA and PEG used as 
carriers building a family of conjugates which were 
rationally designed, characterised and evaluated in 
vitro. A preliminary study in vivo has been also 
performed in a FAP animal model. 
 
- The use of combination therapy as a useful tool able to design 
conjugates with enhanced therapeutic value. 
Due to the different targets and the possible synergism in the 
treatment, doxy and RAGEpep conjugates were proposed for 
combination therapy in FAP treatment. A preliminary study in vivo 
utilising this concept is described in Chapter V 
. 
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CHAPTER II. SYNTHESIS AND CHARACTERISATION OF NOVEL 
POLY-L-GLUTAMIC ACID-BASED BLOCK COPOLYMERS AS 
POLYMERIC CARRIERS  
 
As stated in the introduction, the pursuit for novel drug 
delivery carriers more defined and better characterised is currently on 
first line of investigation in the polymer therapeutics field. On the 
other hand, routine clinical use of copaxone [7, 372] and the promising 
phase III clinical results including the recent designation as orphan 
drug of the polymer drug conjugate Opaxio® (polyglutamic acid (PGA) 
paclitaxel conjugate, formerly Xyotax, PPX, CT-2103) [201, 373] have 
underlined the high potential of synthetic polypeptides within 
nanomedicine, in particular polyglutamates (PGA) [374]. Following 
these guidelines, in the present work a family of controlled and 
versatile polyglutamates has been developed by means of an 
improved methodology of ring-opening polymerisation of α-N-
carboxyanhydrides (ROP-NCA).  
 
II. 1 ANTECEDENTS: Ring-Opening Polymerisation (ROP) of α-Amino 
acid N-Carboxyanhydrides (NCAs) 
 
The vast group of polypeptide copolymers include countless 
classes of different materials. They are composed by one of the main 
building blocks used in nature- the amino acids (AAs) constitutive of 
natural proteins. Precisely controlled AA sequences and compositions 
confer unique protein properties. Their versatility allows different 
roles, such as the possibility to catalyse chemical reactions in 
organisms, trigger specific physiological processes or determine cell 
and tissue structural features; evolving with a complete array of useful 
properties for life processes. Since many decades ago, there is a 
growing interest in developing synthetic routes for the preparation of 
these natural polymers in biotechnology applications. To reproduce 
self-assembling of these precise and well-defined structures is 
considered one of the main requirements to this respect [375]. 
Chemical synthesis has made possible the access to complex 
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polypeptide sequences of controlled molecular weight (MW) whose 
regular secondary structures obtainable by introducing different 
blocks provides a wide panel of opportunities. Among all synthetic 
procedures, the Ring Opening Polymerisation (ROP) of α-amino acid-N-
carboxyanhydrides (NCAs) is the most accepted technique to obtain 
polypeptides and polypeptide-based block copolymers with 
remarkable good yields and on multigram scale, with no detectable 
racemisation at the chiral centers. These synthetic systems had been 
already applied in a wide variety of fields including drug delivery, 
molecular imaging or surface coating materials [211, 376-378]. 
 
Historically, first NCA polymerisation data was reported in the 
very beginning of the 20th century by Leuchs [379-381] and almost 50 
years later, synthesis reproducibility remained nearly unfeasible, as 
well as the construction of more complex architectures or defined 
polymers. Apart from the typical difficulties in monomer stability, 
excessive purification requirements or the need of fractionation 
techniques to reach pure well-defined copolymers, the main problem 
relied on the co-existence of alternative reaction mechanisms during 
polymerisation: several interchangeable pathways can occur giving rise 
to broad dispersities6 unpredictable molecular weights, and poor 
controlled chain termini and length [165].  
Every NCA can be polymerised by a nucleophile or a base. Both 
initiation steps lead to a different propagation mechanism. Therefore, 
the ROP of NCAs can follow the nucleophile initiated “normal amine” 
(NA), as well as the base initiated “activated monomer” (AM) 
mechanism. The NA mechanism (NAM) is based on the nucleophilic 
attack of the initiator, therefore, the use of primary amines (more 
nucleophilic than basic character) will mainly lead to this pathway. This 
                                                          
6
 Dispersity or polidispersity index (Ɖ): Dispersity is an inherent property of polymers. 
It is calculated with the expression: 
Ɖ=
)/M(n
n
Mn,
n
Mn
Mw,
Mn
Mw
ii
ii
i
ii





, 
where Mw is the mass-average molar mass and Mn is the number-average molar 
mass.  
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mechanism promotes a linear correlation among ring-opening chain 
growth process with monomer conversion. Furthermore, the 
incorporation of the initiator fragment in the final polymer is expected 
if side-initiating reactions are absent (FIGURE II. 1). This mechanism 
was proved independently by Peggion et al [382] and Goodman et al. 
[383]. 
 
(1)
 
(2) 
 
FIGURE II. 1. ROP-NCA polymerisation schemes of (1) Normal Amine 
Mechanism (NAM) and (2) Activated Monomer Mechanism (AMM). 
 
In contrast, the AMM is triggered by the deprotonation of an 
NCA due to the basicity of the initiator. For that reason this latter 
mechanism is attributed to tertiary amines or metal alkoxide, with 
stronger basicity than nucleophilicity[384]. In the cases of tertiary and 
secondary amine, as well as the alkali halide-initiated polymerisations, 
it is believe that AMM and NAM coexist. Thus, in the AMM, it is the 
deprotonated NCA that becomes the nucleophile initiating chain 
growth (FIGURE II. 1). In the NAM, the initiation rate is faster than the 
propagation. A fast initiation is one of the key requirements to achieve 
a controlled polymerisation, leading to polypeptides with controlled 
Mw and low Mw/Mn as every initiator starts a polymer chain. 
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As AMM mechanism proceeds via anion, it is expected a faster 
propagation rate than the NAM ending in higher Mws, although, since 
AMM initiation is slower than the propagation stage polypeptides with 
high polydispersity indexes are obtained. This justifies the tendency to 
diminish the AM mechanism trying to overcome uncontrolled 
polymerisations. It should be emphasised that since amines can act as 
nucleophiles as well as bases, a given system can switch back and forth 
between the NA and AM mechanisms many times during a 
polymerisation: a propagation step for one pathway is a side reaction 
for the other, and viceversa. Hence, this is the reason why preparation 
of block co-polypeptides and hybrid block copolymers synthesised 
from amine initiators may have homopolymer contamination. 
Moreover, the existence of these interchangeable mechanisms leads 
to the lost of the control of the chain-end functionality which is crucial 
for the synthesis of hybrid copolymers starting from the polypeptide 
block. Apart from that, undesired termination processes, such as NCA 
anion rearranging into an α-isocyanatocarboxylate and carbamate 
mechanisms, could also exists (futher details in ref. [165]). 
 
Not only due to the initiators but also because of a number of 
factors, polymerisation process could end in uncontrolled reactions 
ruining the living nature of NCA-ROPs. For instance, factors which must 
be taken seriously into account are NCA monomers and solvent purity, 
presence of water moisture, CO2 pressure, temperature, presence of 
salts or cleavability of the protecting groups, undesired terminating 
processes, etc [211, 385, 386]. 
 
In order to solve all the associated problems to NCA 
polymerisation, many researchers have developed new techniques 
and mechanisms for NCA-ROP [211, 385-388]. So far the most 
promising approaches rendering well defined polypeptides are based 
on initiation of highly purified NCAs with primary amines through high 
vacuum techniques (HTV) [389], amine hydrochloride salts [390], 
heavy metal catalysts [391], hexamethyldisilazanes (HMDS) [392] as 
well as optimisation of reaction conditions (pressure, temperature 
etc.) [378, 388]. Limitations of these techniques are found for example 
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in the complex equipment needed for HVT set up and do not touch the 
chemical reactivity of the initiating amine, the sensitiveness of the 
HMDS amines to hydrolytic reactions or the side effects of the heavy 
metal catalysts in biomedical applications if exhaustive purification is 
not performed.  
 
Deming et al developed a new class of NCA-initiators based in 
zero valence nickel and cobalt complexes [391], achieving living 
polymerisation of NCAs with high Mw polypeptides via an 
unprecedented activation of the NCAs into covalent propagating 
species. They managed to obtain homo and block co-polypeptides with 
narrow Mw distributions (<1.2), controlled molecular weight (500-
500.000Da), preserving the original chirality of the NCA monomer. This 
protocol was found useful for a wide range of NCAs [375]. Main 
drawbacks rely on complete removal of the metal from the final 
product, the initiating complex synthesis and the requirement of a 
hydrogen atom at the 3-N of the NCA.  
 
Schlaad et al. reported the use of primary amine hydrochloride 
salts as macroinitiators in order to avoid the AMM mechanism [390]. 
Similar to controlled radical polymerisation techniques, the 
nucleophilic amine terminus is transferred into a dormant (i.e. 
protonated) state. The reactivity of primary amine hydrochlorides 
toward NCAs was first investigated by Knobler et al.[393, 394]. In 
particular, interesting about this method is the researcher efforts on 
emphasising for decades that removal of HCl, the most common 
impurity from Fuchs–Farthing NCA synthesis, is crucial for successful 
NCA polymerisation, also because chloride has been described as an 
initiator of NCA polymerisation [395, 396]. The main drawbacks are 
that the polymerisation time increases due to the reduced reactivity of 
the active sites leading to incomplete monomer conversion. Therefore, 
remaining monomer has to be removed before a second block can be 
synthesised. In their work Schlaad and co-workers reported 
polydispersities below 1.1 and Mn not higher than 22 KDa. For the 
normal initiation with a primary amine methodology, control over 
polymerisation process is often lost and consequently, to achieve high 
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degree of polymerisation (DP) or more complex architectures (graft, 
dendritic, stars, branched,..) turns to be complicated due to 
interference of side reactions.  
 
In general polyglutamates synthesised in a controlled manner 
(NAM mechanism) and in the absence of heavy metals having a 
molecular weight average ranging from some thousands up to 80 kg 
mol-1 and polydispersity (Ɖ) of 1.2 to 1.5 are reported in literature. 
However the products described are synthesised either at small scale 
or with low Ɖ, both characteristics have never been reported together 
[378, 385, 388, 389, 397]. This fact emphasises the necessity of 
obtaining well-defined synthetic polypeptides and highlights the 
interest in finding methodologies to enhance polymer Mw giving birth 
to biodegradable and versatile systems to be implemented in the 
different clinical needs.  
  
In this context, a synthetic pathway to a plethora of functional 
polyglutamates (homopolymers, diblock and triblock co-polymers) 
with well-defined structures, tuneable Mws and low dispersities 
(Ɖ=Mw/Mn <1.2) by means of NCA-ROP has been developed and 
optimised within this thesis.   
 
II. 2 RESULTS AND DISCUSSIONS 
 
II. 2. 1 NCA MONOMER SYNTHESIS. SYNTHESIS OF α-BENZYL L-
GLUTAMATE N-CARBOXYANHYDRIDE (NCA) (2). 
The synthesis of N-α-carboxyanhydrides (NCAs) constitutes a 
key stage for the later polypeptide synthesis. For this reason, 
acceptable yields and the use of monomers of extremely high purity 
are required in this first step. Historically, there are two methods 
described in literature for the NCA synthesis: Leuchs methodology 
[379], based on the cyclation of the N-alkoxycarbonyl amino acid 
halides forming the α-amino acid NCA (FIGURE II. 2(A)) and the 
modified method so called Fuchs-Farthing (FIGURE II. 2(B)) when 
process involves the direct phosgenation of unprotected α-amino 
acids  [395, 398].  
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FIGURE II. 2 Scheme of N-α-carboxyanhydrides synthesis described by (1) 
Leuchs and (2) Fuchs. 
 
Phosgene was the initial reagent in this latter protocol, which 
is a highly toxic gas. Triphosgene was suggested as alternative [399], it 
is economically viable, robust, and as a solid material easier to 
manipulate. Importantly, one of the main problems linked to the use 
of phosgene is the fact that by-products can be formed due to an 
excess of the starting reagent and HCl (FIGURE II. 3) leading to broad 
or multimodal molecular weight distribution of the final polypeptide. 
 
FIGURE II. 3 Byproduct formation in presence of HCl and phosgene in excess. 
 
NCA formation mechanism is depicted in FIGURE II.4. In this 
thesis, the synthesis of NCA monomer has been significantly improved. 
The starting protocol chosen from Fuchs-Farthing method was carried 
out with triphosgene, which is transformed to diphosgene that 
decomposes by temperature giving phosgene thus, the stoichiometric 
control is achieved. Once that was solved, the main objective was to 
ensure the complete removal of any HCl traces due to their capability 
to promote NCA self-degradation (FIGURE II. 4).  
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FIGURE II. 4 y-Benzyl-L-glutamate N-Carboxyanhydride synthesis. The 
mechanism involving the direct phosgenation of the unprotected α-amino 
acid. Cyclation proceeds through the formation of N-chloroformyl amino acid 
intermediates and the loss of a second HCl molecule completes the NCA. 
 
In order to remove HCl, herein basification was not possible as 
amines or other commonly used strong bases would attack the formed 
NCA decomposing it. For this reason, different changes were included 
into the former protocol: (i) limonene was added due to its non-
nucleophilic/-basic HCl-scavenger ability ( 
FIGURE II. 5 II. 5) and (ii) bubbling an inert gas into the reaction 
solution pushing HCl out. As an additional step, the solid obtained was 
precipitated and recrystallised several times to remove last traces of 
HCl and any possible remaining impurities.  
 
 
FIGURE II. 5 HCl capture mechanism by limonene. 
 
Monomer identity was achieved by NMR analysis as well as 
with the melting point. Examples of the results obtained are 
summarised In TABLE II. 1 and FIGURE II. 6. The NMR spectra in CDCl3 
showed the correspondent signals of the compound. Both synthetic 
methodologies drove to similar results. The only difference was the 
larger monomer storability achieved with the second method due to a 
better purification procedure. In all cases, once the NCA monomer was 
obtained its usage was immediate. Even though, storability of the pure 
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product was feasible, the monomer was recrystallysed before use to 
avoid any possible impurities derived from auto-polymerisation 
processes. The melting points were in good agreement with the values 
reported in literature [385], the light deviation corresponds to the 
difference in solvent for the recrystalisation.  
 
(A) 
 
(B) 
 
FIGURE II. 6 
1
H-NMR (A) and 
13
C-NMR (B) spectrums of the γ-benzyl-L-
glutamate N-carboxyanhydride (2). 
 
 
 
Yield (%) Melting point (˚C) Melting point lit. (˚C) 
Method 1 87 92.5-94 97 
Method 2 90 93-94 97 
TABLE II. 1. γ-Benzyl-L-Glutamate N-Carboxyanhydride (2) synthesis. 
[CHAPTER II.] 
[180] 
II. 2. 2 GENERAL PROCEDURE FOR NCA POLYMERISATION. SYNTHESIS 
OF POLY-ɤ-BENZYL L-GLUTAMATE. 
 
II. 2. 2. 1 Initiators  
Initiators not only trigger the polymerisation process but also 
they can be used to (i) introduce an ending group into the polypeptide 
either as a specific linkage point for further conjugation or (ii) as a 
reference group to determine the degree of polymerisation (DP) 
and/or (iii) to introduce other polymeric block. In this work, initiators 
fulfil some of the previously described roles acting as a reference to 
quantify the glutamic acid (GA) units via NMR and more importantly as 
a linear polymer block in specific cases.  
 
Initially, n-butylamine was used but it was substituted by neo-
pentylamine to obtain a better signal-to-noise ratio in 1H NMR 
measurements. This amine has 9 instead of the 3 terminal protons, 
which facilitates DP determination by 1H-NMR.  
Moreover, in the present work the polymer polyethylene 
glycol (PEG) was used as a macroinitiator aiming to built diblock co-
polymers. The mixture of polymers with different hydrophilic 
character may result in conferred amphiphilic properties to the final 
system. Therefore, PEG was employed as macroinitiator constituting 
the most polar unit in the block copolymer system. Tailoring the 
number of PEG blocks as well as the length of the polypeptide chain, 
our aim was to obtain a family of polypeptides with a variety of 
conformation in solution and consequently with different biological 
properties regarding cellular membrane transport. 
 
Using the previously described initiators, ROP of-NCAs 
provided two different polymer platforms: the homopolymer 
polybenzyl-L-glutamate (PBLG) by means of n-butylamine (3) or 
neopentyl amine (4), and the diblock copolymer PEG-b-PBLG (6) 
thanks to the PEG initiator. General schemes of their synthesis are 
shown in FIGURE II. 7, (A) and (B), respectively. 
 
 
[CHAPTER II.] 
[181] 
 
(A) 
 
(B) 
 
FIGURE II. 7 PGA homopolymer synthesis. General scheme for polymerisation 
(A) using n-butylamine (nBu) or its ammonium tetrafluoroborate salt. (B) 
utilising neopentyl amine (npt) or its ammonium tetrafluoroborate salt. 
 
II. 2. 2. 2. Optimisation of NCA polymerisation conditions 
The wide range of reaction pathways available make the 
controlled polymerisation of NCAs a challenging task. The first method 
used in this work (section II.4.1) consisted on Glu(Bz)-NCA 
polymerisation in a low polar solvent under less controlled conditions. 
In the second method (section II.4.2) the process was improved by the 
implementation of more sophisticated equipment and strict inert 
conditions, well-dried reagents and solvents. Studies carried out in our 
group pointed DMF as the most appropriate solvent for the 
polymerisations leading to acceptable yields, controlled Mw with 
narrow polydispersities. In DMF it is possible to avoid the formation of 
the salt between the intermediate of the carbamic acid and the amino 
groups of the propagating chains,  restoring the normal first order 
kinetic of the polymerisation [211, 400, 401]. The conditions used in 
each method are summarised in TABLE II. 1.  
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 Material and reagents 
Reaction conditions 
 
T (°C) 
Reaction 
time NCA initiator 
Method 1 
Inert atmosphere, 
anhydrous solvent 
(CH2Cl2, CHCl3) 
25°C 3d normal amine 
Method 2 
Inert atmosphere, 
CO2 exit, 
anhydrous solvent (DMF), 
well-dried reagents, 
Schlenk tubes 
0, 25, 40°C Optimal 
normal amine/ 
BF4 salt 
TABLE II. 2 Conditions used for ROP-NCA polymerisation. 
 
In the table below (TABLE II. 3) characteristics of the diblock 
(DB) co-polymers synthesised through the first and the second 
methods using primary amine as initiator are described. FIGURE II. 8 
shows the general scheme for this polymerisation. The initiator and 
the ratio [monomer]/[initiator] ([M]/[I]) was varied in order to 
synthesise a polyglutamate family with wide ranges of Mw (TABLE II. 
3). 
FIGURE II. 8 Diblock co-polymer synthesis. General scheme for polymerisation 
using methyl-PEG-amine or its ammonium tetrafluoroborate salt as initiator. 
 
The first methodology did not allow achieving high Mw 
polymers due to the lack of a controlled environment that yielded to a 
poor performance when polymers with DP 400 or 800 were seek. 
Polymer polydispersities obtained were also broader than expected 
(TABLE II. 3). Second methodology gave rise to more homogeneous 
systems with lower dispersities (1.05-1.20), reproducibility batch-to-
batch and scalability (from 100mg to 10g synthesis). In any case, DB 
with more than 200 units was not obtained with the conditions tested 
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GPC (DMF 0,1%LiBr) 
Method Initiator [M]/[I] 
tR Yield 
DP 
Mn Ɖ 
 (d) (%) (g/mol)   
1 N-Butyl-NH2 200 3 82 184 40296 1.391 
 
  
400 3 87 154 33726 1.388 * 
 
  800 3 87 110 24090 1.312   
 
mPEG-NH2 200 3 95 208 47501 1.333 
 
  
400 3 66 149 34578 1.247 * 
 
  800 3 59 92 22152 1.295 * 
2 mPEG-NH2 200 14 48 134 31175 1.146 
 
    400 14 54 207 47298 1.051   
TABLE II. 3 NCA polymerisation through method 1 (at 25°C) and 2 (at 4°C) 
using amine initiators. Ɖ=polydispersity index, (*)=bimodal distribution. 
 
In addition, method 1 showed bimodal distributions in the GPC 
analysis which confirmed the co-existence of other chains apart from 
the expected PEG-b-PBLG. As already explained, any impurity or the 
non-removed humidity (H2O) could have started the polymerisation 
ending in mixtures of homopolymers with diblocks. Thus, conditions of 
method 2 were selected for NCA-ROP and were established as the 
starting point in the next studies. 
 
Exploring of NCA polymerisation using tetrafuoroborate ammonium 
salts 
 
To circumvent the mentioned challenges regarding NCA 
polymerisation, in this work novel initiators are proposed to enable 
controlled multigram synthesis of well-defined polyglutamates 
covering a wide Mw range. This novel synthetic approach involves the 
use of ammonium salts such as the non-nucleophilic anion 
tetrafluoroborate (BF4
-) [401, 402]. These salts combine (i) the 
advantages of the primary amine hydrochloride salts avoiding the 
AMM mechanism and reducing the reactivity of the amine (lower 
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nucleophilicity but much lower basic character); and (ii) a counter ion 
lacked of nucleophilic character, overcoming the main drawback of the 
Schlaad methodology. Its inert character is based on the symmetry of 
the ion leading to an equal charge distribution and its composition of 
high electronegative fluorine atoms, which diminish the basicity of the 
anion. Thus, side reactions based on the nucleophilic character of the 
counter ion have been effectively suppressed. Based on these 
advantages, a more controlled polymerisation was expected with 
these initiators.  
 
a)  Methodology for BF4
- ammonium salts preparation. 
These salts were easily prepared by the reaction of the 
corresponding amine with the HBF4 diethylether complex [403] and 
purified by recrystallisation. Schemes of the synthesis are depicted in 
FIGURE II. 9. Although BF4 salts have been reported to be safe[404], it 
is important to note that, salt traces have never been detected in 19F 
NMR after removal of the protection groups and workup (FIGURE II. 
10). 
 
 
FIGURE II. 9 Synthetic route for BF4 salts obtaining. 
 
In order to prove all mentioned assumptions and to 
demonstrate the versatility of the presented method, BF4 salts of 
neopentyl amine, butylamine as well as polyethylene glycol mono-
methylether amine were prepared. The three salt conversions were 
quantitative and NMR analysis (FIGURE II. 11, FIGURE II. 12 and FIGURE 
II. 13) confirmed their identity 
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(A) 
 
(B) 
 
FIGURE II. 10 (A) 
19
F–NMR of PBLG before benzyl deprotection. (B)
19
F–NMR 
of PGA, after benzyl deprotection
7
 (see ref.[405]). 
 
 
 
                                                          
7
 Explanation of chemical shifts: B has two isotopes with spin > ½ and because 
the ion is symmetric one can observed quadrupole splitting rather than 
quadrupole broadening. For [(
10
B)F4]- 
10
B (19.58% abundance) has spin (I) 3 so 
(2nI +1), n =1 the resonance will be split into seven lines of equal intensity 
(19.58/7). On top of this (chemical shift probably but not necessarily the 
same) [(
11
B)F4] 
11
B (80.42% abundant) has spin 3/2 so (2nI +1) the resonance 
will be split into 4 lines of equal intensity so about 20% (80/4) with a different 
B-F coupling. 
A (dd)
-148.71ppm
0.65
f1 (ppm) -148.755-148.625
f1 (ppm) -148.755-148.625
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(A) 
 
(B) 
 
FIGURE II. 11 NMR spectra of nBu-NH3BF4 (14) (A) 
1
H and (b) 
19
F. 
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(A) 
 
 
 
 
(B) 
 
FIGURE II. 12 NMR spectra of npt-NH3BF4 (15) (A) 
1
H and (b) 
19
F. 
 
(A) 
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(B) 
 
FIGURE II. 13 NMR spectra of mPEG-NH3BF4 (16) (A) 
1
H and (B) 
19
F. 
 
b)  NCA polymerisation studies with BF4 salts 
 
Firstly, PGA homopolymer synthesis was carried out. A 
comparison study among the BF4 salts and the normal amine 
initiators was performed with the neopentyl initiator. Reaction 
conditions and polymer characteristics determined are 
displayed in  
TABLE II. 4. GPC analysis as well as IR were used to monitor 
reaction progression. FIGURE II. 14 shows an example of these 
analyses.  
 
The ratio [M]/[I] was previously investigated [401] as clearly 
influenced NCA polymerisations. The study showed that a higher 
dilution leads to less defined polymers that may be attributed to 
secondary structure formation, which is dependent on polypeptide 
concentration in solution. For a ratio [M]/[I]=200, the best yield and 
DP was reach with 0.1g/mL monomer concentration. Therefore, 
polymerisations presented in this work maintained this value. 
 
Temperature was varied from 4°C to 40°C in all cases. As 
expected, due to the equilibrium among the ammonium salt/dormant 
amine, it was confirmed that the reaction rate was slower for BF4 salts 
and for high Mw PGAs, longer time or higher temperature was 
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required. Therefore, 4°C was discharge for BF4 salts initiation. In the 
same way, reactions carried out at 40°C showed higher dispersity 
indexes and lower DPs than expected. These facts could be attributed 
to DMF decomposition to dimethylamine (DMA) at high temperature. 
DMA could also initiate NCA polymerisation, leading to more 
polydisperse systems and consequently smaller chain length due to 
the monomer consumption. 
 
In all synthesis, final products identity was done by 1H-NMR 
(CDCl3) and GPC analysis. Some examples of the results obtained are 
shown in FIGURE II. 16 and FIGURE II. 15. 
 
 
(A) 
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(B) 
 
FIGURE II. 14 Polymerisation reaction monitored through: (A) FTIR technique: 
IR spectra of poly(L-Glu(Bzl)) in DMF solution over time reaction
8
. (B) GPC 
analysis: GPC traces of the polymerisation reaction to obtain PBLG DP=100 
(DMF). 
 
FIGURE II. 15 GPC traces in DMF of the npt-PBLG with DP=50, 100, 200, 400. 
                                                          
8
 NCA monomer related peaks are found at 1785 and 920cm-1 (red line). They 
were used to monitor the reaction (peak at 1857 cm
-1
 also belongs to the NCA 
monomer but can be hidden by DMF absorption). 
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As a conclusion of the study with NH2 and BF4 neopentyl 
initiators it could be said that, polymer MW was precisely controlled 
up to a DP of 200 with NH2 at low temperature or BF4 at 25°C. When 
higher Mw were required, only BF4 salt initiators achieved the desired 
DP (FIGURE II. 17). Even DP=800 was achieved without the need of 
complex initiators or demanding experimental setup [401]. The 
polymers had low dispersities indexes (1.05-1.20) indicating living 
character of the polymerisation itself (see TABLE II. 4). Our novel 
initiators provided reproducibility batch-to-batch as well as enabled 
the scalability of the synthesis, from 100mg to 10g of starting NCA 
monomer. 
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(A) 
 (B) 
 
FIGURE II. 16 
1
H-NMR spectra of
 
npt-PBLGn (10; n=50, 100, 200). (A) Overlay 
spectra where differences among the different DP polyglutamates can be 
observe having the initiator peak as reference. (B) Individual integration of 
each PBLG specie. 
3
4
1
2
5
7
6
3
4
1
5
7
6
200
100
50
reference
n=50
n=100
n=200
[CHAPTER II.] 
[193] 
 
 
    
 GPC data 
(DMF 0,1%LiBr) 
GPC data 
(HFIP) 
NMR 
data 
Initiator DPth 
T 
(°C) 
tR 
(d) 
Yield 
(%) 
Mn Ɖ 
GA 
units 
Mn Ɖ 
GA 
units 
npt-NH2 50 4 5 74 9365 1.134 43 9275 1.16 57 
 
100 
 
8 64 27806 1.064 127 22169 1.113 144 
 
200 
 
11 68 28675 1.100 131 23609 1.138 202 
 
400 
 
16 90 15675 1.140 72 29499 1.108 190 
npt-NH2 50 25 5 74 9581 1.210 44 9316 1.11 47 
 
100 
 
7 80 11876 1.170 54 10984 1.140 78 
 
200 
 
10 79 13914 1.138 64 12084 1.158 114 
 
400 
 
15 78 16365 1.160 75 12475 1.155 121 
npt-BF4 50 25 5 73 10612 1.151 48 7891 1.221 40 
 
100 
 
8 62 16390 1.104 75 15108 1.17 73 
 
200 
 
11 75 22545 1.133 103 20399 1.150 197 
 
400 
 
16 85 44182 1.079 202 35806 1.160 405 
npt-BF4 50 40 3 64 6700 1.100 32 - - - 
 
100 
 
10 76 23186 1.203 106 - - - 
 
200 
 
11 83 26024 1.226 119 - - - 
 
400 
 
11 84 17103 1.26 78 - - - 
DP=degree of polymerisation, npt=neopentylamine, GA=glutamic acid, 
Ɖ=polydispersity, -=measurement not performed 
 
TABLE II. 4 PBLG synthesis through ROP-NCA polymerisation by means of 
different initiators and reaction conditions. Number of glutamic acid (GA) 
units was calculated in two solvents (N,N’ -dimethylformamide (DMF) and 
1,1,1,3,3,3- Hexafluoro-2-propanol (HFIP) and by 1H-NMR (CDCl3) . 
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FIGURE II. 17 Representation of the theoretical DP ([M]/[I]) vs. Mn (kg/mol) 
from GPC (HFIP) data. Legend: ( ) npt-BF4 at 25°C, (  ) npt-NH2 at 25°C, (
) npt-NH2 at 4°C. 
 
As it is specified in TABLE II. 4, the final polymers were 
analysed by GPC in two different solvents: DMF and HFIP (FIGURE II. 
15). GPC measurements should be carried out in the absence of 
secondary structures for a proper Mw, and Ɖ data determination. Even 
DMF, which is usually effective enough in disrupting hydrogen bonds, 
is not able to completely disrupt polypeptide secondary structures. 
HFIP was used as alternative solvent to DMF to ratify an adequate Mw, 
and Ɖ data determination [401]. Comparison of the polymer Mw 
obtained showed not significant differences for both solvents (TABLE 
II. 4). Looking at the GPC traces, slight tailing can be observed for 50 
and 100 unit PGAs since in this range a small amount of polymers are 
too short to form helical structures and therefore a mixture of random 
coils and helical structures is present within the same polymer sample 
(FIGURE II. 15). This can be confirmed by CD spectroscopy (FIGURE II. 
18) and NMR (4.8 ppm). This means that secondary structures cannot 
be neglected in GPC measurements. As in nature, low MW PGAs 
R² = -0,393
R² = 0,2077
R² = 0,9529
0
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30000
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display a more pronounced contribution of random coil structures. 
However, those effects are absent for higher MW PGAs and therefore 
are not attributed to undefined polypeptides but to the nature of the 
polypeptide itself (FIGURE II. 15 and FIGURE II. 18) [406].  
 
 
FIGURE II. 18 CD spectra in HFIP at 20°C. 
 
Using amino terminated PEG initiators, PEG-PGA block 
copolymers (6) were synthesised with the two versions of initiator: 
mPEG2000-NH2 and mPEG2000-NH3BF4. The study included temperature 
modulation (4, 25 and 40°C) (see TABLE II. 1). Diblock copolymers with 
the expected Mw (DP100 or 200) and low Ɖs (1.1-1.2) were obtained 
at low temperatures, using either the NH2 or the BF4 form of the 
mPEG2000 as initiator. Hence, T=4°C with or without BF4 salts as 
initiator were selected for diblock copolymers. When high Mw DB 
would be desired, BF4 salts would be probably required. 
 
In the next figure (FIGURE II. 19), it is exemplified the 
characterisation guidelines used for DB. 
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GPC (DMF 0,1%LiBr) 
Initiator DPth T (°C) t(d) 
Yield 
(%) Mn Ɖ GA units 
PEG-NH3BF4 200 4 21 91 27005 1.27 115 
 
200 25 21 86 21264 1.35 88 
 
200 40 21 79 17856 1.32 73 
PEG-NH2 200 4 15 90 25882 1.23 109 
 
200 25 12 68 12208 1.13 47 
 
200 40 21 74 11456 1.32 44 
TABLE II. 5 DB200 copolymer synthesis. NCA polymerisation in DMF with 
methyl-PEG-amine and its tetrafluoroborate salt at different temperatures (4, 
25 and 40°C). 
 
 
FIGURE II. 19 Diblock copolymer characterisation through GPC (left) and NMR 
(
1
H, CDCl3) (right) techniques. 
 
The results showed up to now demonstrate that, using our 
optimised NCA approach, the control over polymer end groups could 
be enhanced enabling the synthesis of well-defined homo and diblock 
polypeptides of a variety of MW [401]. As an example of the versatility 
of our novel technique, the polymers obtained are summarised in the 
TABLE II. 6, specifying the DP variation and all the BF4 initiators tested. 
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Initiator DPth 
Yield 
(%) 
Mn 
(Da)
A
 
Ɖ
A 
DP
A 
DP
B 
Neopentyl- 
NH3BF4 
50 73 10512 1.1 48 40 
 100 70 16425 1.1 75 73 
 200 75 22557 1.1 103 197 
 400 85 44238 1.1 202 405 
 1200 80 156585 1.2 715 - 
n-Butyl- 
NH3BF4 
50 64 6789 1.1 31 29 
 100 64 13797 1.1 63 60 
 200 63 16206 1.1 74 107 
 400 72 31536 1.2 144 212 
 800 53 48399 1.2 221 - 
 1200 51 94389 1.2 431 - 
PEG(2000)- 
NH3BF4 
50 73 6947 1.2 23 38 
 100 81 13955 1.2 55 79 
 200 80 17678 1.2 72 149 
A=Data obtained by SEC in DMF, B=Data obtained by 
1
H-NMR, DP=degree of polymerisation, Ɖ=polydispersity, 
-=Values below the detection limit. 
TABLE II. 6 NCA polymerisation in DMF with BF4 salts as initiators. 
 
II. 2. 2. 3 Synthesis of the diblock PGAn-PEG through N-terminus 
conjugation to the synthesised polypeptides 
 Another pathway to obtain diblock copolymers could be 
achieved by conjugation of end-chain amino group of the PGA to a PEG 
block with the adequate terminal group. This reaction was carried out 
from two different starting points: PEG conjugation on (i) protected 
PBLG and (ii) deprotected PGA. Both synthetic schemes are depicted in 
FIGURE II. 20. The main drawbacks encountered with this strategy 
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were the availability/exposure of the end-chain amino group for 
reaction and the complete removal of unreacted PEG chains. Aqueous 
conditions were used for the deprotected PGA and organic solvent for 
the protected one. HFIP was selected in order to avoid secondary 
structure formation and therefore, to enhance NH2- group availability 
for further reaction.  
 
(A) Method 1 
 
 
 
(B) Method 2 
 
 
FIGURE II. 20 Alternative synthesis schemes for the obtention of DBs (5). 
 
Yields of HFIP reactions were markedly higher (90%) than 
those obtained from the aqueous one (40-60%). This methodology was 
selected as the best alternative. Both explained methodologies 
provide a novel pathway for DB synthesis. However, comparing this 
approach with the use of NCA polymerisation through PEG initiator, 
the latest one offers more homogeneous final diblocks, whereas PEG 
posterior linkage could give mixtures of PGA and PEG-b-PGA as well as 
lower yields. On the other side, the proposed post-polymerisation PEG 
linkage endows the system with a specific semitelechelic point of 
conjugation. 
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FIGURE II. 21 Alternative diblock copolymer synthesis through method 1. 
NMR characterisation, before and after the reaction. 
 
II. 2. 2. 4 Poly-benzyl-L-glutamate (PBLG) deprotection  
 
 
FIGURE II. 22 General scheme for PBLG deprotection. Benzyl group removal. 
 
The final PGA polymers must be obtained using a deprotection 
method that ensures full removal of protecting groups without 
racemisation; an issue, which is often not considered carefully and 
could induce important changes in nanomedicine behaviour in a 
clinical setting. Changes in secondary structure due to polypeptide 
racemisation will alter immunological properties, degradation profile, 
and secondary structure. Consequently drug release, the PK profile 
and biodistribution maybe unpredictable upon polypeptide-drug 
conjugation.  
 
Deprotection using TFA/HBr or acetic acid/HBr is known to 
lead to deprotection in the absence of racemisation [407, 408], but 
may lead to chain cleavage from protonation of side-chain ester 
groups which react with the amide backbone basic environment avoid 
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it but racemisation can occur unless base equivalents are controlled 
and hydrogenation is ineffective for Mw superior to 10kDa (larger 
chains keep helical conformation impeding access to the catalyst) 
[409]. However, these conditions are not suitable for sensitive 
functional end groups derived from functional initiators, e.g. alkyne or 
biotin moieties as well as PEG based block copolymers (i.e. PEG is 
rapidly degraded under those conditions, see FIGURE II. 25). In respect 
to those needs we have developed a basic deprotection protocol 
avoiding racemisation. Importantly, longer reaction times (up to 16 h) 
are required when undertaking large scale deprotection at acidic as 
well as basic conditions to ensure full benzyl group removal and 
polypeptide stability including secondary structure conformation.  
 
Deprotection under acid conditions: HBr/TFA 
 
The use of the mixture of HBr/TFA leaded to complete removal 
of the benzyl group through simple reaction conditions. Along the 
optimisation procedure, it was proposed to diminish the harsh 
conditions were PBLG was exposed.  Initially, 4eq of HBr per benzyl 
group were used and reaction was carried out for 16h, yielding 100% 
of deprotection (calculated by proton NMR analysis in DMSO-d6). 
Then, equivalents were decreased to 2 with good results. Final 
reaction time to achieve full deprotection was also reduced from 16h 
to 5h. For big scale deprotection of PBLG (>600mg), 16h were still 
requierd to accomplish complete deprotection. Yields were considered 
quantitative under the named optimal conditions. The polymers were 
characterised by 1H-NMR analysis (CDCl3 or DMSO-d6).  
 
In the next figure (FIGURE II. 24) it is shown the characteristic 
spectra PGA before and after DB deprotection. 
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(A) 
 
(B) 
 
FIGURE II. 23 
1
H-NMR spectra of
 
nBu-PGA200 (A) protected (3) and (B) 
deprotected (4). 
 
Regarding the PEG-b-PGA copolymer (FIGURE II. 24), more 
careful set up was sorely required. Acid deprotection led to complete 
removal of the benzyl groups. However, when protected and 
deprotected block-copolymers were evaluated for size in solution 
measurement by DLS technique it was observed a pronounced size 
reduction after deprotection (data not shown). Therefore, integrity of 
PEG blocks was considered to be damaged within the deprotection 
process. 
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FIGURE II. 24 General scheme for DB deprotection (7). Benzyl group removal. 
 
HBr is a common reagent used for ethers cleavage and further 
studies confirmed that PEG was being degraded under the 
deprotection conditions used. PEG stability studies under acidic and 
basic conditions were performed obtaining the GPC profiles overlaid in 
FIGURE II. 25. This confirmed that HBr/TFA deprotection was not 
suitable for PEG block copolymers. 
 
FIGURE II. 25 PEG exposure to deprotection conditions: 
(black: non-treated, red: HBr/TFA treatment, blue: Pd/C, green: LiOH) 
 
Deprotection by catalytic hydrogenation 
Hydrogenation process was suggested as an alternative for 
HBr/TFA deprotection. Bz removal was completely achieved for both 
species (homo- and diblock), however it presented the handicap of 
charcoal removal afterwards, which ended up with marked low yields 
(10-30%) and non-pure final products. Several methods were exploited 
trying to (i) remove the carbon without success (e.g. filtration 
through celite, centrifugation, ultrafiltration, size exclusion 
chromatography, etc.) or (ii) revert the probably adsorption of the 
polymer to the charcoal, that could not be reversed even with 
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repeated washing steps with AcOH and DMSO. Then, this deprotection 
method was rejected. 
 
Deprotection under basic conditions: NaOH aq./THF 
Hence, we were aiming for a dual purpose with the use of this 
alternative methodology: to find the suitable mildest basic conditions 
of benzyl removal that at the same time could maintain PEG integrity. 
Basic deprotections using LiOH and NaOH were evaluated by 
subjecting PEG to the selected conditions (see TABLE II. 7). NMR and 
GPC analysis of the PEG after the exposition were carried out. PEG 
signals and size were not altered after 5h in NaOH solution (with the 
theoretical 2 equivalents per Bz group). Under the same conditions, 
PEG-b-PBLG was fully deprotected. From this preliminary study, it was 
concluded that basic deprotection was an adequate candidate because 
deprotection was reached and PEG did not resulted damaged. 
 
Searching for the mildest conditions, Kataoka’s protocol for 
PEG-poly(b-benzylaspartate) deprotection [131] was proposed as a 
model in which the benzyl groups are easily removed by using a 
solution of NaOH at 0°C during ten minutes. The protocol needs a 
mixture of organic/aqueous solvents to solubilise either the polymer 
or the NaOH. For our systems, a ratio of THF/H2O 8:1 was able to 
solubilise the reagents. Ten minutes of reaction gave an insoluble 
product whose 1H-NMR analysis concluded that the deprotection did 
not occur. For that reason, longer reaction times were evaluated.  
 
In our previous studies (TABLE II. 7), 2eq of NaOH and 5h at 
25°C raised to full deprotection in DBs, therefore same parameters 
were tested decreasing temperature to 4°C. The product was left to 
react for 5h, the reaction was acidified with acetic acid (glacial) and 
purified by ultracentrifugation. 
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Compound Method 
eq. per 
Bz 
group 
tR 
(h) 
Bz 
removal 
PEG 
Integrity
A
 
PEG 
integrity
B
 
PEG2000-
PGA71 
LiOH 4 24 yes 
Lower PEG 
signal 
- 
PEG2000-
PGA71 
NaOH 4 24 yes 
Lower PEG 
signal 
- 
mPEG2000 LiOH 4 24 - New signals - 
mPEG2000 NaOH 4 24 - New signals - 
mPEG2000 LiOH 2 7 - 
Lower 
intensity of 
the new 
signals 
 
mPEG2000 NaOH 2 7 - 
Almost no 
new signals 
- 
mPEG20000 NaOH 2 5 - - 
Comparable 
to non 
treated 
PEG2000-
PGA71 
NaOH 2 5 yes 
Comparable 
PEG signal 
- 
A=
1
H-NMR data, B=GPC data 
TABLE II. 7 Conditions evaluated for studying PEG integrity under PBLG 
deprotection. 
 
The product obtained was completely deprotected according 
to its 1H-NMR. In addition, after comparison of PEG signal before and 
after deprotection (see FIGURE II. 26), differences were considered no 
significant. Then, it was concluded that PEG may be not damage under 
this conditions. 
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FIGURE II. 26 Evaluation by 1H-NMR of DB deprotection under basic 
conditions. 
 
a ) Optimisation of the basic conditions for Bz removal 
 
(i) Use of homopolymers as starting point 
 
The effectiveness of the basic deprotection was preliminary 
studied with PGA homopolymers to optimise conditions for Bz 
removal.  
 
After the studies enumerated in TABLE II. 7, the protocol was 
modified to find milder conditions. Equivalents of NaOH were 
decreased and consequently reaction time enhanced (TABLE II. 8). In 
parallel, this study tried to reveal if under these novel conditions the 
stereochemistry of the Cα of the polypeptides by 
deprotonation/protonation equilibrium and isomerisation processes 
was affected in the final product. It is well reported that the strong 
basic conditions can influence in the stereochemistry [375, 408]. For 
that purpose, each deprotected polymer was evaluated to determine 
its specific rotation ([α]Tλ) value, that was calculated according to the 
literature with the formula in FIGURE II. 27. 
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FIGURE II. 27 Formula for determining the specific rotation [α] of the 
polypeptide chain. α=observed rotation, L=polarimeter cell length (dm), 
c=concentration (g/100mL), T=temperature. 
 
Amino acids α-carbon is chiral which confers optical activity. 
All natural amino acids have an L configuration, which is related to the 
rotation of the plane of polarised light to the left giving negative alpha 
values. The rotation degree of polarised light depends on the number 
of chiral molecules that it encounters through the polarimeter cell. For 
biocompatibility of our systems, L configuration is desired. 
 
 
eq. 
GA 
units 
eq. 
NaOH 
THF:H20 
ratio 
(v/v) 
t 
(h) 
α 
(average) 
SD 
%s
2
 
coeff 
[α]
25
λ 
PBLG 
(45units) 
 
1 1.2 4:1 24 -0.146 0.001 -0.727 -1.46 
1 1.2 5.3:1 24 -0.283 0.001 -0.473 -2.83 
1 1.2 8:1 24 -0.311 0.001 -0.428 -3.11 
TABLE II. 8 Optimisation of the THF:H2O ratio and concentration with 1.2 eq, 
24h. SD=standard deviation, coeff=coefficient. 
 
Negative values were assigned to L conformation. In this 
preliminary study, the most negative value was considered as the best 
result taking into account the previous statement. Therefore, the ratio 
8:1 THF:H20  was selected for the next study. 
 
Aiming to reduce the reaction time, 16h was evaluated 
repeating the same conditions than TABLE II. 9. However deprotection 
was not achieved with 1.2eq of NaOH. For that reason, the equivalents 
were increased to 1.5 and 16h was maintained this time. The 
experiments done let us to conclude that deprotection depended on 
the THF:H2O ratio, being optimal under 8:1 ratio. 
 
cL
T



100
 
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eq. 
GA 
units 
eq. 
NaOH 
THF:H20 
ratio (v/v) 
t 
(h) 
α 
(average) 
SD 
%s
2
 
coeff 
[α]
25
λ 
PBLG 
(45units) 
1 1.5 64:1 16 * 
   1 1.5 32:1 16 * 
   1 1.5 16:1 16 -0.466 0.002 -0.330 -4.66 
1 1.5 8:1 16 -0.479 0.002 -0.345 -4.79 
1 1.5 4:1 16 -0.237 0.001 -0.598 -2.37 
 
*deprotection not achieved. 
    TABLE II. 9 Optimisation of the THF:H2O ratio and concentration with 1.5 eq, 
16h. 
 
The next study was focused on diminishing the reaction time 
with 1.5eq of NaOH, once THF:H2O ratio was fixed. Results are 
summarised in TABLE II. 10 and 8h were at least needed to achieve 
PBLG deprotection. However, a more negative alpha value was 
obtained for 16h reaction.  
 
 
eq. 
GA 
units 
eq. 
NaOH 
THF:H20 
ratio 
(v/v) 
t 
(h) 
α 
(average) 
SD 
%s
2
 
coeff 
[α]
25
λ 
PBLG 
(45 
units) 
1 1.5 8:1 2 * 
   
1 1.5 8:1 4 * 
   
1 1.5 8:1 6 * 
   
1 1.5 8:1 8 -0.484 0.003 -0.7586 -4.84 
1 1.5 8:1 16 -0.615 0.002 -0.2877 -6.15 
 
*deprotection not achieved. 
   
TABLE II. 10 Time optimising using 8:1 THF:H2O ratio and 1.5 eq. NaOH. 
 
Therefore, this first study using the homopolymer, let us to 
conclude that 1.5eq, 16h and the THF:H20 ratio 8:1 parameters were 
able to deprotect the polybenzylglutamate, with the highest negative 
alpha value that we could obtained being around -0,6. 
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With the purpose of proving that the found conditions were 
correct regarding non-stereochemical changes along the deprotection, 
α values of comparable polymers were studied. The selected species 
were:  
(i) A commercial deprotected PGAn with different GA units 
(n=100, 200 and 300). 
(ii) L-polyglutamates obtained by solid phase peptide synthesis 
(SPPS). SPPS provide a defined stereochemistry in the 
polypeptide chain, e.g. L-peptide. Our comparison with these 
polymers was centered on proving that racemisation did not 
occur either during polymerisation. The number of linked 
glutamic acid units obtained through this technique is limited, 
overall if protected side chains are necessary in the final 
polypeptide.  
(iii) HBr deprotected polyglutamates. As named before, acid 
deprotection has been demonstrated not to affect to 
stereochemistry of the initial polymer. This procedure was 
carried out with our polyglutamates as well as with the SPPS 
commercial one. 
 
The collected data from each species is compiled in the table 
below (TABLE II. 11). [α] values from commercial PGA (-5.67, -5.45, 
-4.85), SPPS PGA (-5.12) and HBr deprotection (-5.55, -5.50 ) are in  
the same range that those achieved with our optimised basic 
deprotection  products (-6.15).  In addition, it was demonstrated 
that strong basic conditions affect optical activity as PGA15 after 
treatment with concentrated NaOH gave positive [α] value (0.07).  
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α 
coefficient SD 
%s2 
coeff. [α]
25
λ 
Other commercial PGAn (n=100units) -0.567 0.001 -0.2242 -5.67 
Other commercial PGAn (n=200units) -0.545 0.001 -0.243 -5.45 
Other commercial PGAn (n=300units) -0.485 0.002 -0.315 -4.85 
PGA20 HBr deprotected -0.555 0.001 -0.210 -5.55 
PGA15 (SPPS) -0.512 0.002 -0.357 -5.12 
PGA15 (SPPS) treated with NaOH 2M, 
16h 0.007 0.001 18.470 0.07 
TABLE II. 11 Observed rotation for several commercial PGAs in comparison 
with ROP-NCA synthesised PGA. 
 
As a final corroboration of the basic deprotection versatility, 
the influence outcome of the polyglutamate Mw was studied. TABLE II. 
12 shows the rotation angle coefficient values obtained which confirm 
that under these conditions polypeptide is fully deprotected 
independently of the chain length and optical activity remains 
untouched. 
 
PBLGn 
α 
(average) 
SD %s
2
 coeff. [α]
25
λ 
n=100 -0.6545 0.0022 -0.3314 -6.55 
n=200 -0.6594 0.0019 -0.2868 -6.59 
n=400 -0.6643 0.0019 -0.285 -6.64 
TABLE II. 12 Comparison of the observed rotation from PGAs with different 
DP after deprotection with the optimal basic protocol. 
 
Summarising, in all cases yields were quantitative under the 
named optimal conditions (1.5eq NaOH in 8:1 THF/H2O ratio,  16h) 
with complete deprotection without deviations in the specific rotation 
([α]Tλ) value of deprotected PGA (TABLE II. 12). Moreover, the [α]
T
λ 
values were identical to PGA 15mers prepared by SPPS independent 
from the optimised acidic or basic methodology (FIGURE II. 29). 
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(ii) Protocol adaptation to diblock copolymers 
After establishing deprotection conditions with 
homopolymers, diblock systems were evaluated with the same 
protocol. However, the use of 1.5eq of NaOH lead to uncomplete 
deprotections forcing to start a novel optimisation process.  
 
Using 16h and the ratio 8:1 THF:H2O settle parameters from 
homopolymer studies, the equivalents of NaOH were varied. TABLE II. 
13 shows how 2, 3 or 4 equivalents managed to deprotect the PGA 
block giving acceptable [α] values. Therefore, following with the 
minimal harsh path the lowest value was chosen: 2 eq, even if 
deprotection yield had to be forfeit.  
 
 
eq. 
NaOH 
[NaOH] 
α 
(average) 
SD %s
2
 coeff. [α]
25
λ 
PEG-b-PGAn 
(n=45units) 
2 0.02 -0.551 0.002 -0.29 -5.51 
3 0.031 -0.51 0.001 -0.292 -5.10 
4 0.041 -0.44 0.005 -0.325 -4.40 
TABLE II. 13 Optimisation of the NaOH equivalents for DB deprotection using 
the same conditions of time and THF/H2O ratio (16h, 8:1). 
 
In addition when reaction time was increased, the same trend 
on [α] values was observed (TABLE II. 14). 
 
 
eq. 
NaOH 
t (h) 
α 
(average) 
SD %s
2
 coeff. [α]
25
λ 
PEG-b-PGAn 
(n=45units) 
2 16 -0.535 0.003 -0.468 -5.35 
2 21 -0.517 0.001 -0.283 -5.17 
2 24 -0.494 0.003 -0.648 -4.94 
TABLE II. 14 Optimisation of the reaction time for DB deprotection. 
 
Summarising, 2 equivalents of NaOH per carboxyl group, 8:1 
THF/H2O ratio and 16h handled PEG integrity whereas deprotection 
was successful. As an example, in FIGURE II. 28 the NMR spectrum of 
DB100 deprotected it is shown. 
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HBr/TFA was selected as simple and effective methodology for 
homopolymers deprotection, adjustable to the starting amount of 
polymer. With the procedure described above it was demonstrated 
that basic deprotection is also affordable with same successful results: 
avoiding racemisation (FIGURE II. 29(A)), full benzyl group removal 
(FIGURE II. 29(B)) with quantitative yields and polypeptide stability 
including secondary structure conformation (FIGURE II. 29(C)). 
Concerning the diblock co-polymer systems, basic deprotection solved 
the substantial drawbacks observed in the HBr/TFA protocol enabling 
to address jointly PEG integrity and benzyl removal.  
 
 
FIGURE II. 28 
1
H-NMR (D2O) spectra of DB100 deprotected. 
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(B) 
 
(C) 
 
FIGURE II. 29 Deprotection methodology optimised for homopolymers and 
diblock co-polymers for complete benzyl group removal. (A) Schematic 
conditions of acidic (1) and basic (2) deprotection methodologies. R 
represents Neopentyl-, nButyl- or PEG- initiators, n is the number of repeating 
units of the glutamic block. The deprotection methodology was optimised for 
homopolymers and diblock co-polymers for complete benzyl group removal 
and non-stereochemical changes. For this last purpose, comparison between 
the observed rotation [α] was performed analysing a PGA
15
 synthesised by 
SPPS, PGA
50
 after acidic and basic deprotection and PEG-b-PGA
50
 after basic 
deprotection as it is reflected in the diagram. The formula used for 
determining the specific rotation of the polypeptide chain was [α]
T
λ
 = (α)·100 
/ L·c where L is the polarimeter cell length (dm), c the sample concentration 
(g/100 mL) and T the temperature, which was 25 °C. (B) 
1
H-NMR (D
2
O) 
analysis after deprotection of PBLG with different DP (50, 100, 200 and 400). 
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In red is pointed out the signal of the initiator used, neopentyl, indicating 
polymer integrity after deprotection. (C) Circular dichroism (CD) spectra in 
ddH
2
O at 20 °C. 
 
II. 2. 2. 4 Synthesis of the triblock copolymer PEG1-b-PGAn-PEG2 (TB) 
With the purpose to synthesise a versatile polymer carrier able 
to allow a site-specific conjugation for peptide/protein (semitelechelic 
PGA) together with a multifunctional part for drug linkage to be 
transported to the brain, a novel system was proposed: an amphiphilic 
block-copolymer based on PGA and PEG.  
 
The designed versatility and multifunctionality of the proposed 
polymeric platform could allow the conjugation in the same polymer 
carrier of (i) a targeting residue (e.g. transferring, monoclonal 
antibodies, peptides) which habilitates receptor-mediated transport to 
the brain, (ii) bioactive agent(s) for the selected disease and/or (iii) 
imaging probes to monitor the in vitro or in vivo studies. 
 
Following with the chemical part, for the synthesis of this 
carrier ROP-NCA polymerisation was applied through a PEG initiator as 
detailed in section II.2.2.1. Once the diblock copolymer was obtained 
(PEG2000-b-PGAn), a third block consisting on a bifunctional PEG was 
bound to the amino terminal group of the polypeptide block. 
 
FIGURE II. 30 Derivatisation of the bi-functionalised PEG: SH-PEG-COOH. 
Scheme of sulfhydryl activation of the followed by NHS activation of the 
carboxyl group. 
 
PEG derivatisation is shown in FIGURE II. 30.  Firstly, PEG 
vector was deactivated in the present work. On one side, the carboxyl 
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group was activated with N-hydroxisuccinimide (NHS). This group will 
favoured amide bond formation with the PGA block. On the other side, 
PEG presented a sulfhydryl group aiming to confer specificity and 
selectivity required for the linkage with the targeting 
ligand/biomolecule through a disulphide bond. To avoid crosslinking 
and enhance triblock reactivity, 4-thiopyridine (4TP) group was used. 
Scheme of both activations are pictured in FIGURE II. 30. 
 
COOH-PEG-S-S-4TP was successfully obtained and its identity 
was confirmed by 1H NMR- signals characteristics from the introduced 
4TP group, although Ellman assay (indirect calculation of the existent 
free SH- groups) and the 4TP test (direct quantification of the released 
4TP) were the most appropriated methodologies to verify the 
activation of the sulfhydryl group. Both assays determined an 85-96% 
of activation in the final product. 
 
To accomplish the amide bond, reactivity of the PEG carboxyl 
group was enhanced. This step involved carboxyl group activation with 
a well established protocol. NHS activation was effectively achieved 
and the Snyder test gave the percentage of activation which ranged 
from 80-90%. Once NHS-PEG-S-S-4TP (13) was synthesised and 
characterised, the next step was its conjugation to the PEG-b-PGA 
copolymer (7). The methodology used started with the deprotected 
DBs with different polypeptide block lengths aiming to construct a 
family of amphiphilic block-copolymers. The general synthetic scheme 
for triblock (9) obtaining is shown in FIGURE II. 31.  
 
FIGURE II. 31  General scheme for triblock (TB, 9) copolymer synthesis. 
 
Coupling reaction was carried out in DMF at basic pH as any of 
the described amide bond formation carried out within this work. For 
purification, un-reacted PEG was removed by ultrafiltration after 
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converting the TB to its sodium salt form. Then, the resulting product 
was passed through a size exclusion column (Sephadex G25) using 
ddH2O as eluent. After lyophilising the fractions, identity of each of 
them was verified by NMR analysis. To determine the degree of PEG 
introduced, 4TP assay was also performed. 
 
In FIGURE II. 32, 1H-NMR (D2O) examples of the different TBs 
synthesised and the percentage of 4TP activation achieved are shown. 
When comparison among the starting deprotected DB and the 
obtained TB was done, PEG signal was found out to increase and 4TP 
presence confirmed the coupling among both polymers. Therefore, 
TBs (PEG200-PGAn-PEG3400, 9) were successfully synthesised and a 
family of amphiphilic block copolymers (n=100, 150,200) based on PEG 
and PGA was achieved. 
 
FIGURE II. 32 
1
H NMR characterisation of TBs. 1H-NMR comparison of db dep 
(7) and TB (9). 
 
Purification steps and unreacted PEG-b-PGA lead to low yields 
(30-40%). After the DB synthesis through alternative methods (section 
II.2.2.3), it was concluded that reaction between protected PGA and 
PEG in the organic solvent HFIP allowed the coupling of both polymers 
with high yields. Hence this methodology was proposed as a viable 
option to increase the yield of the reaction.  
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II. 2. 2. 5 Other post-polymerisation approaches: incorporation of 
alkyne and amide functionalities  
 
Polypeptide block allows further functionalisation of the 
polymer offering multiple options for a unique system. This process is 
called post-polymerisation and constitutes a useful approach for the 
synthesis of functional polymers overcoming the limited functional 
group tolerance of most of the controlled polymerisation techniques 
[410, 411]. Due to all the advantages of the above described 
methodology of NCA polymerisation, the post-polymerisation 
modification of well-defined polyglutamates was only explored 
focused on the incorporation of functionalities for site-specific 
conjugation. 
 
With the synthesised homo- and block-copolymers, several 
modifications have been successfully performed as its reflected in 
reference [401]. In this process, the carboxyl groups are point of 
linkage to different molecules which offers a novel pendant group like 
e.g. alkyne, amino, azide, sulfhydryl group or even act as a spacer 
among the polymer and the selected moiety, e.g. PEG, a biological 
responsive peptidic sequence, etc.  
 
In the present thesis, only incorporation of alkyne and amine 
groups into the PGA chain are described due to their use for 
fluorescence probe (section III.1.1.1), tracing agent (section III.1.1.2)  
or peptide ligand (section III.3.2.3) conjugation (note: sulfhydryl 
groups have been also introduced in this work although from a 
different starting compound, see section III.3.2.3). Both modifications 
were chosen to have suitable moieties for a click-chemistry 
attachment or amide bonding of the corresponding compound with all 
the benefits that this kind of reactions lead as pointed out in the 
introduction. 
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Alkyne modification: Post-polymerisation modification with 
propargylamine.  
PGA post-polymerisation modification with propargylamine 
was performed as reported by Thompson et al.[412] (FIGURE II. 33). 
The activation of the carboxylic acids within the polymer backbone of 
PGA was carried out by using 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methyl morpholinium chloride (DMTMM·Cl-).  
 
 
FIGURE II. 33 General scheme of PGA block post-polymerisation modification 
with propargylamine (21). 
 
Afterwards, propargylamine was added into the reaction 
mixture leading to the corresponding alkyne modified polymer. The 
mechanism of action of DMTMM·Cl- is shown in section III.1.1.1, and 
consists in the formation of the corresponding activated ester with the 
release of 4-methylmorpholine in a first step. This activated ester 
reacts with the corresponding amine compound by adjusting the pH of 
the reacting mixture to 8 in order to favour the amine form of the 
compound instead of the protonated one that coexist in equilibrium, 
with non nucleophilic character (FIGURE III. 37, Chapter III). Alkyne 
content was determined by 1H-NMR analysis. Specifically, the peak at 
3.81 ppm corresponds with the two protons of the CH2 of the 
propargyl residue, and the signal at 2.48 ppm corresponds with the 
acetylenic proton of the propargyl residue. Thus, in comparison with 
the protons of PGA, the % of substitution of each polymer was 
calculated. The usual yield of this reaction gave approximately half of 
desired percentage. This was taken into account in order obtain the 
desired percentage in the final polymer. Results are summarised in 
TABLE II. 15. The resulting Mw of the polymer was calculated taking 
into account the percentage of modified GA units. 
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PGAn Alkyne Content (calc.) 
Alkyne Content 
(
1
H-NMR) 
n=100 50 % 31 % 
n=100 20% 11% 
TABLE II. 15 Alkyne modified polyglutamates (21). 
 
Amine modification: Post-polymerisation modification with a 
monoprotected diamine.  
 
 
FIGURE II. 34 General scheme of PGA block post-polymerisation modification 
with amine groups. 
 
The interchange of a carboxylic pendant group by an amine 
was with a monoprotected diamine: 2-(2(Fmoc-
amino)ethoxy)ethylamine. First, COOH groups were preactivated by 
DIC/HOBt to later coupling of the non protected amine of the diamine. 
The mechanism of DIC/HOBt coupling is shown in section III.1.1.1. 
After the reaction time, solvent was evaporated and the residue was 
washed in a mixture of acetone:chroloform were the polymer 
remained insoluble but the non-reacted monoprotected diamine was 
able to be recovered. From this solution, Fmoc absorbance (290nm) 
was measured and therefore, indirectly calculation of the coupled 
diamine. An additional estimation was performed after Fmoc 
deprotection, repeating the operation after the deprotection time. 
Free Fmoc was again dissolved in the same solvent mixture and 
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quantified, giving a direct percentage of the inserted amines.  TABLE II. 
16 shows a compilation of results obtained for TB200 (9) amine 
modification.  
 
 %free Fmoc-diamine %Fmoc  (=diamine grafted) 
TB200 94 6 
TB200 70 30 
TABLE II. 16 Amine modified polyglutamates (24). 
 
An alternative of amine modification is detailed in chapter III 
section III.3.2.3 (using Boc-diamine) due to the required labelling of 
the polymer carrier to be used in PET experiments. 
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II. 3 CONCLUSIONS 
 
The main aim of this first chapter was to develop a robust 
methodology for synthesising a family of polymers to be used as 
carriers in the form of polymer-drug conjugates. The biodegradable 
and biocompatible poly-glutamic acid was the polymeric platform 
chosen and the ring-opening polymerisation of α-amino acid N-
carboxyanhydrides (ROP-NCA) the methodology selected. 
 
This family was constituted by three systems depending on the 
polymerisation initiator used and the subsequent post-polymerisation 
process performed: homopolymers (PGAn), diblock copolymers (PEG--
b-PGAn), and triblock copolymers (PEG-PGAn-PEG). Then within each 
system the length of the polypeptide block was varied from n=100 to 
n=800. The reason for this variation was to either observe differences 
concerning the hydrophilic/hydrophobic ratio among PEG and PGA 
blocks directly related with conformation in solution and in vitro/in 
vivo properties and/or exploiting the major or minor capacity of 
loading for drugs/probes.  
 
First, NCA monomer synthesis of y-benzylglutamic acid by 
means of Fuchs-Farthing method resulted in the obtention of highly 
pure monomers. Like any impurity as humidity, acid or basic traces 
could start undesired side reactions, special emphasis was done in 
their avoidance or removal either in the synthesis or in the 
purification. Specifically, limonene was used as scavenger agent for the 
removal of the HCl produced in the monomer system in combination 
with a bubbling process using an inert gas. Precipitation as well as 
repeated recrystallisation steps were performed and finally several 
test (e.g. THF solubility, the melting point and 1H-NMR analysis) were 
done to identify possible polymerisation. The obtained monomer was 
well dried and stored under inert atmosphere. In any case, monomer 
was either freshly synthesised or recrystallised before use to finally 
ensure a controlled NCA ring opening polymerisation. 
 
Initial polymerisation methodology involved the use of amine 
initiators and fixed reaction conditions (anh. CHCl3, 25°C, tR=3days) 
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while the degree of polymerisation (DP) was varied (200, 400, 800). As 
result from this, final n=200 was the higher DP achieved and 
polydispersities ranged between 1.2-1.4. Thus, a new strategy was 
developed. On one hand, improvement of the technique was 
optimised by polymerisation under Schlenk conditions, including 
exhaustively dried reagents, solvents and material together with 
optimal settings with respect to temperature and reaction time.  In 
order to monitor the NCA conversion, FTIR spectroscopy and GPC were 
used. With these conditions, control over the reaction was achieved 
and narrow Mw distribution (Ɖ=1.01-1.2) were obtained. On the other 
hand, novel initiators based on ammonium tetrafluoroborates were 
synthesised and for the first time investigated for polyglutamates 
obtaining [401]. The comparison study between NH2 and BF4 neopentyl 
initiators concluded that, Mw of polymers were precisely controlled up 
to a DP of 200 with NH2 at low temperature or BF4 at 25°C. When 
higher Mw was required, only tetrafluoroborate salt initiators 
achieved the desired DP. Summarising, with BF4 initiators 
homopolymers with DP800 and with low dispersity were able to be 
achieved [401].  
 
The results had shown clearly the benefits of this new 
developed strategy, consolidated as a very simple methodology. Our 
novel synthetic approach overcame most of the inherent drawbacks of 
ROP of NCAs leading to a controlled polymerisation with living nature: 
control over Mw was achieved as well as over the amino terminal 
group, like demonstrated latter conjugations with high yields on this 
site. Additionally, the synthesis was scaled up from milligrams to gram, 
conserving the control on the Mw and the low polydispersities [401]. 
As an extra advantage, these novel initiators as nBuBF4 and nptBF4 
are obtained as solids (in contrast to their amine form which is liquid) 
and it facilitates their precise use and consequently a more controlled 
and predictable degree of polymerisation.  
 
Using PEG as macroinitiator for diblock synthesis: PEG-b-PGAn, 
low temperatures for the diblock polymers were the best option, with 
or without BF4 salts for DP 100 or 200. Probably, when high Mw 
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diblocks are desired BF4 salts will be required. 
 
The next step involved the deprotection of the y-
benzylpolyglutamates leading to PGA. In the case of homopolymers, 
acidic deprotection in HBr/TFA as well as basic conditions with the 
mixture NaOH aq. /THF resulted in successful benzyl group removal 
without compromising the chiral properties of the chain 
independently of the length. For simplicity in the protocol and the 
almost quantitative yields obtained with the HBr/TFA method, it was 
finally chosen for the deprotection of the homopolymers. Concerning 
the diblocks, optimisation was successful finding out the most 
adequate reaction conditions. Acidic deprotection compromised PEG 
integrity and basic conditions solved this problem achieving full 
deprotection with acceptable yields. Parameters were optimised with 
caution and with the main aim of determining the less dangerous 
conditions for the polymers in terms of sodium hydroxide equivalents 
and reaction times. Thus, diblocks were safely deprotected without 
PEG degradation. Along the deprotections, the specific rotation value 
([α]Tλ) of each polymer was calculated by means of the observed 
rotation measurement (α). The study pursued the obtaining of the 
highest negative alpha values, which should correspond to the L 
conformation of the amino acids. To use them as a reference, several 
commercial PGAs and acidic PBLG deprotections gave similar values 
and therefore this parameter was considered as a control and served 
us to claim the L conformation maintenance after deprotection.  
 
After diblock synthesis and deprotection, a third block was 
coupled through an amide bond in the N-terminal extreme of the PGA 
building block giving rise to the triblock copolymer PEG-b-PGA-b-PEG-
S-S-4TP. This PEG played a double function. First and more importantly 
providing to the whole system a specific point of linkage for 
probe/targeting ligand conjugation through a disulphide bond. The 
main problems of the synthesis were the purification steps where 
diblock, unreacted PEG and final triblock had to be separated. Thus, 
reaction yields where very low. Secondly these type of polymer 
structures featuring two PEG blocks with the biodegradable PGA 
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segment could offer different morphologies and alternative structures 
respect to the homopolymer or the diblock. Their study may reveal 
new avenues for drug delivery and different or combined cellular 
pathway mechanisms.  
 
In parallel, it has been investigated an alternative strategy for 
the synthesis of DB copolymers based on the incorporation of the PEG 
block on the already synthesised peptidic block. In this case, the 
terminal amino group of PGA was used for coupling a PEG block via 
amide bond, giving the construct PBLG-b-PEG-S-S-4TP. The synthesis 
was performed in aqueous and organic media, achieving higher yields 
in the latter one. The diblock was successfully deprotected using the 
optimised basic methodology. The main purpose of the synthesis of 
these hybrid diblock copolymers was to compare them in terms of in 
vitro and in vivo behaviour with the TB (PEG-b-PGA-b-PEG-S-S-4TP), 
given that both have the same capacity for conjugation in the 
polypeptide block and a specific point of linkage in the chain end of 
the PEG block. The main differences expected from these systems 
belonged to the conformational point of view, regarding conformation 
in solution as well as spatial distribution of the linked ligands/probes 
to the PEG chain-end. These structural characteristics should be 
reflected in the general in vitro/in vivo behaviour of the final 
compounds.  
 
Finally as it was demonstrated that the use of organic media 
for DB synthesis succeeded, it is proposed that the TB synthesis from 
protected DB and using HFIP in order to couple the other PEG chain, 
could enhance the reaction yield and efficiency, therefore improving 
the methodology for its obtaining.  
 
After deprotection, post-polymerisation modification 
approaches with carboxyl pendant groups of the PGA backbone can be 
performed. This strategy enables to build polymers with different 
functional groups for specific and orthogonal conjugations. Alkyne, 
amine and sulfhydryl groups had been easily introduced through 
carboxyl group activation either with DIC/HOBt or DMTMM coupling 
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methodologies. These groups were latter used for labeling or targeting 
ligand specific conjugation (CHAPTER III).  
 
In summary, a novel NCA-ROP methodology through ammonium 
tetrafluoroborate salts and an optimised deprotection procedure had 
leaded to the development of a versatile polymeric platform based on 
the clinically approved PGA, enabling the synthesis of future polymer 
conjugates.  
 
 
[CHAPTER II.] 
[225] 
II. 4 MATERIALS AND METHODS 
 
II. 4. 1 RING-OPENING POLYMERISATION (ROP) OF α-AMINO ACID N-
CARBOXYANHYDRIDES (NCAS). FIRST METHODOLOGY. 
 
II. 4. 1. 1 NCA monomer synthesis. Synthesis of ɤ-Benzyl L-Glutamate 
N-Carboxyanhydride (NCA) (2). 
Monomer synthesis protocol was reproduced from reference [399] 
and reproduced with some modifications detailed below. The general 
synthesis of NCA monomer (2) is depicted in 
 
FIGURE II. 4FIGURE II. 4.  
 
H-L-Glu(OBzl)-OH (1) (8.43mmol, 1eq, 237.26 g/mol) was 
placed in a 2-neck 25mL round bottom flask and anhydrous THF freshly 
distilled was added (25mL). A reflux column was placed and the 
mixture was stirred and heated up to 50°C under a N2 atm. Then, 
0.5eq of trisphosgene (4.2mmol, 296.75 g/mol) was weighted and 
dissolved in anh. THF freshly distilled (3mL). Once dissolved, it was 
added under a N2 atm with a glassware syringe. The reaction was left 
stirring for 3 h at 50°C under a N2 atm. (completed solution was 
observed after 1 h of reaction). Afterwards, reaction solvent was 
evaporated under vacuum to the fourth of its initial volume and 
obtained residue was diluted with anhydrous ethyl acetate (16mL). 
The filtrate was then precipitated from THF/ ethyl acetate into fresh 
hexane (120mL) and filtered under vacuum. The white solid was 
precipitated following the described protocol twice more. Finally, the 
white solid obtained was dried under N2 flow and used immediately. 
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Yield: 87%, m.p.: 92.5-94°C,1H-NMR (DMSO-d6):δ (ppm) 2.01 (2H, m), 
3.31 (2H, s), 4.48 (1H, t), 5.10 (2H, s), 7.37 (5H, s) 9.10 (1H, s). 
II. 4. 1. 2 General procedure for NCA polymerisation. Synthesis of 
poly-ɤ-Benzyl L-Glutamate. 
HOMOPOLYMER (nBuPBLGn) 
The general synthesis of nBu-PGA homopolymer (3) is depicted 
in FIGURE II. 7.  
2g of NCA monomer (2) (7.5 mmol, 264 g/mol) were placed in 
a 100mL round bottom flask. After purging with N2 flow, monomer 
was dissolved under agitation with anh. CH2Cl2 (30mL). Then, a stock 
solution of the initiator in anh. CH2Cl2 (n-butylamine (0.738g/cm
3, 
73.14g/mol) was prepared and calculated equivalents were added into 
the monomer solution. Reaction was maintained in an inert 
atmosphere with an outlet for CO2 escape. After 3days in agitation at 
25°C, the content was poured into fresh diethyl ether (400mL) and 
white solid obtained was collected after centrifugation ((2600rpm, 4°C, 
10min). Product was dried at 40°C under vacuum for 16h. The product 
obtained was analysed by GPC (DMF, 0.1%LiBr) (FIGURE II. 15) and by 
1H-NMR (CDCl3) (FIGURE II. 16). 
 
Yield: 85-92 %, 1H-NMR (300 MHz, CDCl3) δ 7.19 (d, J=3.3 Hz, 5H), 4.98 
(s, 2H), 3.88 (s, 1H), 2.95 – 1.38 (m, 4H), 0.81 (d, J=7.3 Hz).  
e.g. nBu initiated PBLG100: 
1H NMR (300 MHz, CDCl3), δ 7.19 (d, J=3.3 
Hz, 5H), 4.98 (s, 2H), 3.88 (s, 1H), 2.95 – 1.38 (m, 4H), 0.81 (d, J=7.3 Hz, 
0.03H). 
 
DIBLOCK (DBn, PEG-b-PGAn) 
The general synthesis of DB (6) is depicted in FIGURE II. 8.  
1g of NCA monomer (2) (3.8 mmol, 264 g/mol) were placed in 
a 25mL round bottom  flask. After purging with N2 flow, monomer was 
dissolved under agitation with anh. CHCl3 (20mL).  Then, a stock 
solution of the initiator in anh. CHCl3 (MeO-PEG-NH2, 1892g/mol) was 
prepared and calculated equivalents were added into the monomer 
solution. Then contents were preserved in an inert atmosphere with 
an outlet for CO2 escape. After 3days in agitation at 25°C, solution was 
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precipitated into fresh diethyl ether (200mL) and white solid obtained 
was collected after centrifugation ((2600rpm, 4°C, 10min). Solid was 
washed several times with ddH2O and afterwards dried at 40°C under 
vacuum for 16h. The product obtained was analysed by GPC (DMF, 
0.1%LiBr) and by 1H-NMR (CDCl3). 
 
Yield: 53-91%, 1H-NMR (300 MHz, DMF) δ 8.62 (s, 1H), 7.47 (s, 5H), 
5.23 (dd, J=21.8, 12.5 Hz, 2H), 4.24 (s, 1H), 3.56 (s, xH), 2.43 (d, J=52.9 
Hz, 4H).  
 
II. 4. 1. 3 Deprotection of poly(ɤ-benzyl-L-glutamate). Hydrogen 
bromide in TFA. 
HOMOPOYMER (nBuPGAn) 
The general deprotection of PBLG is depicted in FIGURE II. 22.  
In a round bottom flask, poly(γ-benzyl-L-glutamate (1.25g, 
5.69mmol Glu units, average MW unit=219g/mol)  was dissolved in 
TFA under agitation at 25°C. After product dissolving, 4eq (per benzyl 
group) of HBr (33%v/v, 1.49g/mol,81g/mol) were added drop by drop. 
Once glass stopper was placed, yellow mixture was left stirring for 16h. 
Afterwards, solution was precipitated in a large excess of diethyl ether 
and white solid in suspension was recovered by centrifugation 
(2600rpm, 4°C, 10min). Solid was washed per triplicate with fresh 
diethyl ether. Finally, the product was dried under high vacuum and 
deprotection success was checked by 1H-NMR (CDCl3, DMSO-d
6). 
If product was needed in its sodium salt, ddH2O was added 
together with NaHCO3 and vortexed until complete solution was 
observed. For salt excess removal, product was purified by dialysis or 
ultrafiltration (MWCO=1000-3000Da) with ddH2O. 
1H-NMR (D2O) 
analysis was performed.  Finally, to get again the acid form if needed, 
the product was then precipitated by dropwise addition of HCl 6M up 
to a final pH equal to 3.  
Yield: 80-90%, 1H-NMR (300 MHz, D2O) δ: 4.31-4.26 (m, 1H), 2.38-2.14 
(m, 2H) 2.10-1.80 (m, 2H) 2.10-1.80 (m, 2H). 
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DIBLOCK (PEG- b-PGAn) 
 
The general deprotection of DB is depicted in FIGURE II. 24, 
obtaining the PEG-b-PGAn copolymer (7). Diblock deprotection was 
carried out as homopolymer described protocol.  
Yield: 40-65%, 1H NMR (300 MHz, D2O) δ (ppm) 4.16 (1H, t), 1.76-1.89 
(2H, m), 2.13 (2H, m), 3.45 (xH, s), i.e. DB100 δ (ppm) 1.76-1.89 (200H, 
m), 2.13 (200H, m), 3.45 (172H, s), 4.16 (100H, t). 
 
II. 4. 1. 4 Synthesis of the diblock PGAn-PEG  
 
The alternative diblock PGAn-PEG (5) synthesis is depicted in 
FIGURE II. 20.  
Method A 
 
In a round bottom flask, 100 mg of PGA as its carboxylic form 
(14.6mmol, 1eq, 13674g/mol) were dissolved in anh. DMF under 
agitation and N2 flow. In a vial, NHS-PEG-SS-4TP (13) (11mmol, 1.5eq, 
3357g/mol) was dissolved in minimum amount of anh DMF under N2 
flow and added to main solution. pH was adjusted to 8 with DIEA. 
Reaction was allowed to proceed stirring for 72h under inert 
atmosphere at 25°C. Solvent was removed under vacuum and the 
obtained residue was dissolved in NaHCO3 for purification. Firstly, 
crude was ultrafiltrated (Vivaspin®, MWCO=3000Da, 60mL ddH2O), 
and after concentrate the upper part, this was purified through a size 
exclusion column (Sephadex G25). 50 fractions of 2mL were collected 
and lyophilised. For product identification, 4TP assay and 1H-NMR 
analysis of the resultant products was performed. For complete 
unreacted PEG removal, ultrafiltration was carried out with the 
appropriate MW cut off.  
 
Yield: 40-60%, 4TP activation: 94%, 1H-NMR (300 MHz, D2O): δ (ppm) 
1.76-1.89 (2H, m), 2.13 (2H, m), 3.45 (xH, s), 4.16 (1H, t), 7.60 (zH, d) 
8.40 (zH, s). 
(PEG proton signals (x and z) depended on DP of the PGA block and the 
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yield of the coupling reaction, i.e. DB100 (PGA100-PEG-S-S-4TP) with 60% 
third block coupling: δ (ppm) 1.76-1.89 (2H, m), 2.13 (2H, m), 3.45 
(1.69H, s), 4.16 (1H, t), 7.60 (0.012H, d) 8.40 (0.012H, s). 
Method B 
 
In a round bottom flask, 100 mg of PBLG (92 GA units, 
0.005mmol, 1eq, 20200g/mol) were dissolved in hexafluoro-2-
propanol HFIP (10mL) under agitation. In a vial, NHS-PEG-SS-4TP 
(0.006mmol, 1.3eq, 3219g/mol) was dissolved in 2mL of HFIP and 
added to main solution. Reaction was left to proceed for 72h under 
inert atmosphere at 40°C (oil bath). Then, volume of reaction was 
precipitated into cold diethylether and washed twice. For product 
identification, 1H-NMR analysis of the resultant products was 
performed. 
 
Yield: 90%, 1H-NMR (300 MHz, DMF) δ 8.62 (s, 1H), 7.47 (s, 5H), 5.23 
(dd, J=21.8, 12.5 Hz, 2H), 4.24 (s, 1H), 3.56 (s, xH), 2.43 (d, J=52.9 Hz, 
4H).  
 
Note: This protocol required further deprotection of the PBLG block. 
The process was carried out under the optimised NaOH aq/THF 
conditions explained in section II.4.2.5. Yield: 85% 
II. 4. 1. 5 Synthesis of the copolymer PEG1-b-PGAn-PEG2 (TB) 
 
The general synthesis of TB (7) is depicted in FIGURE II. 31.  
After obtaining the amphiphilic diblock-co-polymers 
constituted by polyethylenglycol (PEG) and polyglutamic acid (PGA), N-
terminal end of the polypeptide block allows the conjugation of a third 
block. In this project, this opportunity has been used by coupling a 
third PEG block with a specific terminal group: an activated sulfhydryl, 
4TP. It confers the system a determined linking point for antibody, 
protein or peptide as targeting moiety through a disulfide bound.   
 
 Methodology for derivation of the third PEG block. 
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The general procedure of PEG derivation is depicted in FIGURE 
II. 30. 
a) Sulfhydryl group activation of SH-PEG-COOH: 4TP-PEG-COOH 
(12) 
In a 25mL round bottom flask, COOH-PEG-SH (0.158mol, 1eq, 
3163g/mol) was dissolved in 2mL of ddH2O. 4,4’-dipyridyl-disulfide 
(3.16mol, 20eq, 222.73g/mol) was also dissolved in 2mL of MeOH and 
added dropwised into the main solution. Then, 3mL of TRIS buffer 
0.1M / NaCl 0.3M (pH=10) were added and the reaction was stirred at 
65°C for 30min under a reflux column. The product was purified 
through a Sephadex G-25 column using acetic acid 0.1N as eluent. 50 
aliquots of 2mL each were collected and freeze-dried. Product identity 
was confirmed by 1H-NMR, by an indirect Ellman’s assay looking at 
unreacted SH groups and a direct test through 4TP release. 
Yield: 57%, 4TP activation: 85-96% 
 
b) Characterisation of the activated SH group: 4TP 
 
Ellman’s assay 
Ellman test determines the number or concentration of free 
thiols in a sample. Ellman’s reagent, 5,5´-dithiobis(2-nitrobenzoic acid) 
(DTNB), rapidly reacts by means of a estequiometric interchange thiol-
disulphide in presence of free thiol in media. Thiols react with DTNB by 
cleaving its disulphide bond and releasing 2-nitro-5-thiobenzoate (NTB-
), which ionizes to the NTB2- dianion in water at neutral and alkaline 
pH. This NTB2- ion has a yellow color (λ=412nm). Reaction is highly 
sensitive to pH conditions, oxygen and temperature. Consequently, 
this test is performed with an excess of DTNB at neutral pH and fixed 
T. To carry the experiment, two stock solutions were prepared and 
placed on ice: (i) DTNB solution: 3mM DTNB, 50mM in sodium acetate 
(ddH2O) and (ii) TRIS solution 1M pH=8. 
Firstly, a calibration curve was done using as standard 2-
aminoethanethiol (FIGURE II. 35), ranging concentrations from 10 to 
100μM. 
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FIGURE II. 35 Calibration curve for the Ellman test. 
 
In a quartz cuvette, 50μL DTNB stock, 100μL TRIS stock, 840μL 
ddH2O and 10μL of the sample in solution were well homogenised. 
After 30min incubation, absorbance at 412nm was acquired. 
Concentration of thiol groups was calculated by means of the 
calibration curve of the standard and the stechiometry of the reaction. 
 
4TP release content measurement 
The 4TP group was found to react readily in the presence of 
free thiols [413] under mild conditions at neutral pH. The reaction can 
be monitored by the absorbance at 323nm, corresponding to the 4-
thiopyridone leaving group.  
For carrying out the test, a sample stock 2mM in ddH2O was 
prepared. As –SH reagent, 2-aminoethanethiol was selected and a 
stock 91mM in ddH2O was set. 
 In a quartz cuvette it was added: 200µL of sample stock, 200µL 
of the –SH reagent sock and 1.2mL of potassium phosphate buffer 
0.1M pH=7. Absorbance at 323nm was measured. Ɛ4TP=1.98x10
4M-1cm-
1  [414] . 
 
c) NHS activation of the carboxyl group. Obtaining of 4TP-PEG-
NHS (13) 
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In a 25mL round bottom flask, COOH-PEG-SS-4TP (13) 
(0.086mol, 1eq, 3273g/mol) was added and purged under N2 flow. 
Then, it was dissolved in 6mL of anh. CH2Cl2 under inert atmosphere at 
25°C. DCC (0.18mol, 2eq, 203.33g/mol) was added under N2 flow. The 
reaction was left to proceed for 10min. After that time, NHS 
(0.179mol, 2eq, 115.09g/mol) was dissolved in 4mL of anh. CH2Cl2 in a 
purged vial. When NHS solution was incorporated into the main 
reaction, turbidity appeared due to the formation of the urea 
derivative. The reaction was left stirring for 5h at rt. Afterwards, the 
solution was filtered out and poured in cold diethyl ether to remove 
DCC excess. A pale yellow product was obtained and dried under high 
vacuum. TNBS assay was used to determine activation degree of the 
desired NHS-PEG-SS-4TP. 
Yield: 84%, activation: 87%. 
 
d) Quantification of carboxyl group activation by TNBS assay 
 
TNBS test according to the Snyder and Sabocinsky assay [415] 
was performed to measured the degree of activation of the carboxyl 
end groups of PEG. 
As amine-bearing regent, a solution 10X of the dipeptide Gly-
Gly in borate buffer 0.1M pH=8 (0.0216mmol/mL, 132.12g/mol) was 
prepared. Solution 1X was obtained by a dilution 1:10 in borate buffer, 
achieving the 0.00215mmol/mL desired solution. An equimolar mass 
of the sample (NHS-PEG-SS-4TP, 3357g/mol) was prepared. For that, 
7.2mg of bifunctionalised PEG were dissolved in 1m of the Gly-Gly 
stock. The reaction was left to proceed for 30min (reaction solution). 
TNBS (5% m/v, 293.17g/mol) solution was also prepared in a 
concentration of 7.34mg/mL in ddH2O. 
In plastic cuvettes, the following solutions (TABLE II. 17) were 
prepared per duplicate. After homogenisation, they were left 30min 
protected from light. Finally, absorbance in UV at 420nm was 
measured. The degree of activation was calculated as: 
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
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100
100%
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absactivation
 
where abs(SAMPLE) is the absorbance of the reaction mixture and abs(REF) is the 
absorbance of the Gly-Gly stock solution. 
 
 
Buffer 
(μL) 
TNBS 
solution (μL) 
Gly-Gly 
solution 1X (μL) 
Reaction 
Solution(μL) 
Blank 975 25 0 0 
Sample 950 25 0 25 
Reference 950 25 25 0 
TABLE II. 17 Reagent and buffer amounts for each sample in the TNBS test. 
 
Third PEG block conjugation. Methodology for triblock (TB) synthesis.  
 
The general synthesis of TB (9) is depicted in FIGURE II. 31.  
In a 50mL round bottom flask is placed 1eq of diblock 
previously deprotected (6) (0.031mmol, mPEG-PGAn, e.g. n=109 GA 
units, 15953g/mol), dissolved in anh. DMF (10 mL) and purged with N2. 
In parallel, 1.3eq of NHS-PEG-SS-4TP (13) (0.041mmol, 3357g/mol) was 
dissolved in anh. DMF and under N2 flow before being added to the 
reaction mixture. The pH was adjusted to 8 with DIEA. The reaction 
was allowed to proceed under inert atmosphere at 25°C for 3 days. 
Thereafter, the flask was placed under high vacuum to remove the 
solvent. The solid residue was dissolved with the minimum amount of 
NaHCO3 1M and ultrafiltered (Vivaspin®, MWCO=5000Dal) with ddH2O 
for PEG excess removal and purified with a G-25 SephadexTM column 
(eluent: ddH2O). The fractions were freeze-dried and product identity 
was performed by NMR analysis as well as the 4TP release assay. 
 
Yield: 35%, 1H-NMR (300 MHz, D2O): δ (ppm) 1.76-1.89 (2H, m), 2.13 
(2H, m), 3.45 (xH, s), 4.16 (1H, t), 7.60 (zH, d) 8.40 (zH, s). 
(PEG proton signals (x and z) were related to the each single specie, i.e. 
TB200 with 100% third block coupling: δ (ppm) 1.76-1.89 (400H, m), 
2.13 (400H, m), 3.45 (455H, s), 4.16 (200H, t), 7.60 (2H, d) 8.40 (2H, s), 
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activation: 85-96%. 
 
II. 4. 2 RING-OPENING POLYMERISATION (ROP) OF α-AMINO ACID N-
CARBOXYANHYDRIDES (NCAs). SECOND METHODOLOGY 
 
II. 4. 2. 1 NCA monomer synthesis. Synthesis of ɤ-Benzyl L-Glutamate 
N-Carboxyanhydride (NCA). 
 
The general synthesis of NCA monomer (2) is depicted in 
FIGURE II. 4.  
Protocol from N.M.B Smeets et al. [416] was used as template, 
although several modifications were performed with the aim of 
increasing the purity and stability of the monomer, critical parameter 
for NCA polymerisation. The product was analysed by 1H-NMR, IR and 
melting point which confirms its identity and purity.  
 
H-L-Glu(OBzl)-OH (1)(71.7mmol, 1eq, 237.26g/mol) was added 
to a 2-neck 500mL round bottom flask fitted with a reflux column and 
a dropping funnel under nitrogen flow. System was purged and then 
freshly distilled anh. THF (150mL) was added and the contents were 
heated to 50oC under constant agitation. Limonene (71.5mmol, 1eq, 
0.84g/cm3,136.24g/mol) was added to the stirring suspension. 
Afterwards, diphosgene (0.043mmol, 0.6eq, 1.6525g/cm3, 
197.83g/mol) diluted in anh. THF (10mL) was added dropwise via an 
addition funnel. The reaction was left stirring for 2h at 50oC whilst 
purging with nitrogen. Afterwards, reaction mixture was bubbled with 
nitrogen to aid the removal of HCl for 2h whilst the nitrogen outlet 
was directed through a NaOH 1M solution to neutralise the gas. Then, 
solvent was evaporated under vacuum to the fourth of its initial 
volume and then ethyl acetate (16mL) was added. Mixture was 
precipitated into cold hexane (500mL) giving a white precipitate, which 
was isolated by vacuum filtration and washed with cold hexane. Solid 
was recrystallised from anh. toluene (60mL) and THF (30mL, 
anhydrous) where crystallisation was induced by the dropwise 
addition of hexane. When precipitation was observed the product was 
left overnight in an inert atmosphere at -20oC. The crystals were 
filtered and washed with cold hexane and then dried under vacuum. 
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Recrystallisation was repeated twice. Absence of HCl traces was 
ensured by dissolving the obtained product (2-4mg) in minimum 
amount of THF and added dropwise to a 0.1mmol silver nitrate 
solution (1mL). No precipitation was observed when pure. 1H-NMR 
and melting point analysis confirmed product identity and purity. 
 
Note: synthesis scalable up to 34g of starting material. 
 
Yield: 87%, m.p. 93-94oC, 1H-NMR: (CDCl3, 300MHz, 235et): δ=2.00-
2.30 (m, 2H, CH2CH2), 2.52-2.60 (m, 2H, CHCH2), 4.30-4.34 (m, 1H, CH), 
5.09 (s, 2H, OCH2), 6.40 (s, 1H, NH), 7.30 (m, 5H, Ph), 
13C-NMR: (CDCl3, 
ppm):δ=27.5, 30.6, 57.6, 67.8, 129.2, 129.4, 129.5, 135.9, 152.4, 170.2, 
173.3. 
 
II. 4. 2. 2 Methodology for BF4
- ammonium salts preparation. 
 
 Synthesis of tetrafluoroborate n-butylammonium salt 
Synthesis scheme of nBuBF4 salt (14) is drawn in  
FIGURE II. 9. 
Butylamine (2.7mmol, 73.14g/mol) was dissolved in diethyl 
ether (1mL), and tetrafluoroboric acid diethyl ether complex HBF4.Et2O 
(2.7mmol, 1.18g/cm3, 161.93g/mol) was added dropwise to the 
solution leading to the formation of a white solid salt. Product was 
dried under vacuum and recrystallised from ethylacetate.  
 
Yield: 60%, 1H-NMR (300 MHz, DMSO) δ 7.58 (s, 3H), 2.84 – 2.71 (m, 
2H), 1.56 – 1.43 (m, 2H), 1.39 – 1.25 (m, 2H), 0.89 (t, J=7.3 Hz, 3H). 13C-
NMR (300 MHz, DMSO-d6 ) δ = 38.64, 29.09, 19.08, 13.49. 
 
 Synthesis of tetrafluoroborate neopentylammonium salt 
Synthesis scheme of nptBF4 salt (15) is drawn in FIGURE II. 9.In 
a 15mL vial, neopentylamine (36.74mmol, 0.745g/cm3, 87.16g/mol) 
was dropwise added over 5mL of HBF4·Et2O (34.5mmol, 1.18g/cm
3, 
161.93g/mol), resulting in a white solid formation. Solvent was 
evaporated and solid was recrystallised twice from ethyl acetate and 
washed with cold hexane after filtration. Final product was dried 
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under vacuum. 
 
Yield: 42%, 1H-NMR (300 MHz, DMSO-d6) δ=7.53 (s, 3H), 3.25 (s, 2H), 
0.87 (s, 9H). 13C NMR (300 MHz, DMSO) δ=49.94, 30.21, 26.78. 
 Synthesis of tetrafluoroborate PEG ammonium salt 
 
Synthesis scheme of mPEGBF4 salt (16) is drawn in FIGURE II. 
9. In a 5mL round bottom flask, MeO-PEG(2000)-amine (0.3mmol, 
1910g/mol) was dissolved in THF (3mL), and HBF4.Et2O (0.3mmol, 
1.18g/cm3, 161.93g/mol) was added to the solution leading to the 
formation of a pale yellow salt. Solvent was evaporated and the solid 
residue was washed three times with hexane (washes were repeated 
until pH was not acidic). The obtained solid was dried under high 
vacuum and NMR analysis (1H and 19F) were performed to achieve 
identify. 
Yield: quantitative, 1H-NMR (300 MHz, DMSO-d6):δ (ppm): 7.69 (s, 3H), 
3.78 – 3.70 (m, 2H), 3.52 (d, J=5.4 Hz, 139H), 3.47 – 3.39 (m, 6H), 3.24 
(s, 3H), 3.06 – 2.91 (m, 2H). 
 
II. 4. 2. 3 General procedure for NCA polymerisation. Synthesis of 
poly-ɤ-Benzyl L-Glutamate. 
 
Material used for polymerisation was exhaustively cleaned 
before use. All devices (Schlenk tube, stirring bar, stopper) were 
placed first in DMF (rinsed with acetone), then in diluted H2O2 and 
finally rinsed with ddH2O. Afterwards, material was dried 24h at 80°C. 
All solvents used were recently distilled and over molecular sieve and 
inert atmosphere (Ar). Initiators were dried under vacuum before use 
and monomer was freshly distilled and well dried. 
 
Synthesis scheme of x-PBLG (3 and 10) is drawn in FIGURE II. 7. 
1g of NCA monomer (2) (3.8mmol, 264 g/mol) was added to a 
Schlenk tube and purged with cycles of vacuum/Ar. Then, under Ar 
flow, anh. DMF (freshly purified) was added (concentration: 0.1g/mL). 
Once dissolved, initiator was added and reaction was left stirring 
under Ar/N2 atmosphere with constant pressure. Reaction was 
monitored with GPC by MW and with FTIR by monomer signals 
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disappearance.  When reaction stopped, solution was precipitated in 
cold diethyl ether (50mL) and the obtained mixture was centrifuged 
(2600rpm, 4°C, 10min). Supernatant was removed and the white solid 
was then suspended in ddH2O and freeze-dried. The product obtained 
was analysed by GPC (DMF, 0.1%LiBr) and by 1H-NMR.  
  
PBLG homopolymer: 1H-NMR (300 MHz, DMF) δ 8.58 (s, 1H), 7.42 (s, 
5H), 5.19 (s, 2H), 4.21 (s, 1H), 2.81 (s, 2H), 2.45 (s, 2H). 13C-NMR (101 
MHz, DMF) δ 175.94 (s), 172.26 (s), 162.77– 162.18 (m), 161.98 (s), 
136.76 (s), 128.87 – 127.75 (m), 66.05 (s), 57.13 (s), 35.41 - 34.17 (m), 
32.48 (s) , 30.84, 30.30 – 29.04 (m), 27.28 (s), 25.99 (s). Npt initiated 
PBLG100: 
1H NMR (400 MHz, CDCl3) δ 7.27 (s, 208H), 4.93 (t, J=65.8 Hz, 
65H), 3.94 (s, 13H), 3.14 – 1.44 (m, 82H), 0.89 (s, 2H). 
PEG-b-PBLGn: 
1H-NMR (300 MHz, DMF) δ 8.62 (s, 1H), 7.47 (s, 5H), 5.23 
(dd, J=21.8, 12.5 Hz, 2H), 4.24 (s, 1H), 3.56 (s, xH), 2.43 (d, J=52.9 Hz, 
4H).  
II. 4. 2. 4 Optimisation study for diblock PEG-b-PGAn synthesis. 
Comparison between NH2- and BF4-. 
 
In order to establish the best conditions for the synthesis of 
PEG-b-PGA diblock, an optimisation study was performed. TABLE II. 5 
describes the variety of conditions tested, which included: initiators, 
temperature and solvent. The synthetic steps followed have been 
already described in section II.4.2.3. 
 
II. 4. 2. 5 Deprotection of poly(ɤ-benzyl-L-glutamate). 
 
The general deprotection of x-PBLG is depicted in FIGURE II. 
22.  
Deprotection of poly(ɤ-benzyl-L-glutamate) with HBr in 
trifluoroacetic acid. Optimal conditions 
 
100mg of poly-ɤ-benzyl-L-glutamate (3, 10) were dissolved in 
3mL TFA (TFA volume should be enough to dissolve the polymer and 
not precipitate after HBr addition) in a round bottom flask. Once 
dissolved, 2eq of HBr (48%v/v, 1.49g/cm3, 81g/mol) per carboxylic 
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group were added dropwise. Then, a glass stopper was placed and 
yellow mixture was left stirring for 5h.  Note: For large scale 
deprotection of PBLG (>600mg), 16h were needed to achieve full 
deprotection.  Then, the solution was poured into a large excess of 
cold diethyl ether leading to a white solid that was recovered after 
centrifugation (2600rpm, 4°C, 10min). The product (4 or 11) was 
washed (3x) with diethyl ether and dried over high vacuum. After that, 
the product was then purified by acid-base precipitation (NaHCO3 /HCl 
6M). Dialysis or ultrafiltration was done leading to the sodium salt 
form.  
 
Yield: 75-86%, 1H-NMR (300 MHz, D2O) δ: 4.31-4.26 (m, 1H), 2.38-2.14 
(m, 2H) 2.10-1.80 (m, 2H) 2.10-1.80 (m, 2H). 
 
Deprotection by reduction with Palladium/charcoal 
 Poly(γ-benzyl-L-glutamate) or DB (100-200mg) was dissolved in 
DMF dist. (6mg/mL) under inert conditions (N2 flow). The, catalytic 
amount of palladium on charcoal was added and the flask was again 
purged. The solution was placed in a hydrogen atmosphere and left 
under agitation for 24h at 25°C. The charcoal was removed by 
filtration through Celite®. Solution obtained was concentrated under 
high vacuum and after ddH2O addition freeze-dried.  
Yield: 10-30%, PGA homopolymer: 1H-NMR (300 MHz, D2O) δ: 4.31-
4.26 (m, 1H), 2.38-2.14 (m, 2H) 2.10-1.80 (m, 2H) 2.10-1.80 (m, 2H). 
 
Basic deprotection with NaOH aq./THF mixture. Optimal conditions 
 
HOMOPOLYMER 
In a round bottom flask, PGA (5.1μmol, 9761g/mol, n=45 GA 
units) was dissolved in THF (16mL) at room temperature. Then, the 
solution was cool down up to 4°C and maintained in agitation. In a vial, 
1.5eq of NaOH per carboxylic group (7.7μmol, 40g/mol) were 
dissolved in 2mL of ddH2O and then added dropwise to the main 
solution. Turbidity was found after NaOH addition. The solutions were 
left under vigorous stirring for 16h. Afterwards, THF was evaporated 
and the residue was diluted with ddH2O, purified and concentrated by 
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ultrafiltration (Vivaspin®, 3000Da). Upper part of the tube was freeze-
dried yielding a white solid that was analysed by NMR (D2O). 
Yield: 40-60%, PGA homopolymer: 1H-NMR (300 MHz, D2O) δ: 4.31-
4.26 (m, 1H), 2.38-2.14 (m, 2H) 2.10-1.80 (m, 2H) 2.10-1.80 (m, 2H) 
DIBLOCK 
In a 50mL round bottom flask, protected diblock (0.184mmol, 
12208 g/mol, n=47 GA units) was dissolved in 16mL of THF at room 
temperature. Then, the solution was cool down up to 4°C and stirred. 
In a vial, 2eq of NaOH per carboxylic group of the polypeptide block 
(0.369mol, 40g/mol) were dissolved in 2mL of ddH2O and then added 
dropwise to the main solution. Turbidity was found after NaOH 
addition. The solutions were left under vigorous stirring for 16h. 
Afterwards, THF was evaporated and the residue was diluted with 
ddH2O, purified and concentrated by ultrafiltration (Vivaspin®, 
3000Da). Upper part of the tube was freeze-dried yielding a white 
solid that was analysed by NMR (D2O). 
 
Yield: 40-70%, 1H NMR (300 MHz, D2O) δ (ppm) 4.16 (1H, t), 1.76-1.89 
(2H, m), 2.13 (2H, m), 3.45 (xH, s), i.e. DB50 δ (ppm) 1.76-1.89 (100H, 
m), 2.13 (100H, m), 3.45 (172H, s), 4.16 (50H, t). 
 
Optimisation for NaOH aq/ THF deprotection study  
 
50mg of polymer (PGA or PEG-b-PGA, TABLE II. 18) was 
dissolved in THF at room temperature. Then, solution was cool down 
and maintained in agitation at 4°C. Finally the NaOH solution was 
added dropwise. Turbidity was found in all the cases once the NaOH 
was added. The solutions were left under vigorous stirring the desire 
time. All conditions exploited (reaction time, NaOH equivalents and 
addH2O/THF ratio) are detailed in TABLE II. 8, TABLE II. 9,TABLE II. 10, 
TABLE II. 13 and TABLE II. 14. The organic solvent was removed under 
vacuum, and the aqueous phase was purified by ultracentrifugation 
using a Vivaspin® (MWCO=3000Da). The samples were concentrated, 
filtered (0.2μm) and freeze-dried. 
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Study was monitored by polarimeter measurements for 
evaluating the coefficient of deviation of polarised light [α]. Each 
sample was dissolved in ddH2O at 10mg/mL concentration and 
average data was obtained after 20 measurements. The obtained 
products were analysed by 1H-NMR- to prove complete deprotection. 
 
 
initiator Mn Mw PDI GA units 
PGA50 npt- 9761 11752 1.2 45 
PEG-b-PGA50 PEG- 12208 13731 1.1 47 
TABLE II. 18 Protected polymers information 
. 
II. 4. 3 POST-POLYMERISATION TECHNIQUES: INCORPORATION OF 
ALKYNE AND AMIDE FUNCTIONALITIES  
 
II. 4. 3. 1 Alkyne modification for click-chemistry (21) 
 
Synthesis scheme of alkyne coupling to TB (21) is depicted in 
FIGURE II. 33. 
For 25%mol modification: in one round bottom flask, 100mg of 
PGA (0.78mmol, GA units, 1eq) were suspended in 10mL of ddH2O. In 
a vial, DMTMM·Cl- (0,39mmol, 0.5eq, 276.7g/mol) was dissolved in 
5mL of ddH2O and then added to the main solution. After 10 minutes 
in agitation, propargylamine (0.78mmol, 1eq, 0.86g/cm3, 55.04g/mol) 
were added and the pH was checked to 8 (if pH was lower, it was 
adjusted with NaHCO3  1M solution). The reaction was allowed to 
proceed stirring at 25°C for 16h. Product purification was carried out 
by ultrafiltration (Vivaspin®, MWCO=3000Da) and after concentration, 
upper part of the tube was freeze-dried. White solid obtained was 
analysed by 1H-NMR (D2O) to determine the degree of modification.   
 
Note: Ultrafiltration was preferred in case of large amount of starting 
material. For small amounts, size exclusion chromatography 
(SephadexTM G25, PD-10) reduced the lost of material. Acid/base 
precipitation of the modified PGA was also tested since PGA is 
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insoluble in aqueous media in it is as carboxylic acid form and soluble 
in its sodium salt form. In addition, all by-products were water soluble. 
Precipitation was carried out by acidification of the reaction solution 
(adding dropwise HCl 1M) until pH 3 to 4 and resolution by basification 
with sodium bicarbonate. The process was repeated three times to 
yield white polymers after freeze-drying of the soluble form. 
 
Yield: 80-90%, 1H-NMR (300 MHz, D2O) δ: 4.30 – 4.02 (m, 1H), 3.81 
(s)*, 2.48 (s)*, 2.35 –2.02 (m, 2H), 2.01- 1.65 (m, 2H).  
*The number of corresponding hydrogens depends on the 
percentage of functionalisation of the polymer backbone. 
 
II. 4. 3. 2 Amine modification  
 
First of all, as the TB was obtained in its sodium salt form it 
had to be acidified to become soluble in DMF. Acidification was carried 
out by dissolving the polymer in the minimum volume of ddH2O and 
HCl 6M was dropwise added while pH was controlled. At pH around 4-
3, precipitation was observed. After centrifugation, pellet and 
supernatant were freeze-dried and 1H-NMR analysis (DMF-d7) of both 
was performed.  
 
Method for 100% amine insertion.  
Synthesis scheme of diamine coupling to TB (24) is depicted in 
FIGURE II. 34. 
In a round bottom flask, 34.5mg of TB200 (0.19mmol GA units, 
1eq, average MW unit of glutamic acid=102.4g/mol, 56.63% COOH) 
were dissolved in 5mL of anhydrous DMF at 25°C under N2 flow. After 
dissolution, 1.5eq of DIC (0.806g/mL, 126.2g/mol) were added and, 
after 5 min, 1.5eq of HOBt (135.13 g/mol). After 10min stirring, the 
mono protected Fmoc-diamine ((2-(2(Fmoc-amino)ethoxy)ethylamine 
hydrochloride, 0.095mmol, 1eq 362.85 g/mL)was added in the 
reaction. The pH was adjusted to 8 with DIEA and the reaction was left 
to proceed for 24 h and monitored by TLC. The solvent was 
evaporated under vacuum and non-reacted Fmoc-diamine was 
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removed washing the residue with 8-10mL CHCl3: acetone (4:1 ratio). 
The washing mixture was collected, evaporated and redissolved in a 
known volume of MeOH. Absorbance (λ=290nm) was evaluated for 
non-reacted Fmoc-diamine quantification. The solid residue was dried 
under high vacuum. The next step was to deprotect the Fmoc-diamine 
coupled to the polymer. Deprotection was performed with a mixture 
of DMF:piperidine (20% v/v) at 25°C under inert atmosphere. The 
reaction was left in agitation 1 h. Then, the solvent was again removed 
under evaporation. Again, the solid residue was washed with a CHCl3: 
acetone mixture (4:1 ratio, v/v) for dissolving the Fmoc group and 
quantify it as described. The solid residue was dried under vacuum and 
kept at -20°C until next reaction. For grafting efficiency calculation, 
absorbance measurements of non-reacted Fmoc-diamine and released 
Fmoc- were used to calculate their concentration. By subtraction, 
percentage of diamine coupled was obtained.  
 
Yield: 80%, % amine coupling: 30%mol. 
 
Note: Other post-polymerisation procedures for sulfhydryl group 
introduction or an alternative method for amine insertion using a Boc-
monoprotected diamine had been performed in this thesis. Protocols 
are detailed in section III.2.3 because of their use as linkers for 
targeting ligand conjugation.  
 
II. 4. 4 ROUTINE TECHNIQUES IN POLYMER CHARACTERISATION 
 
In polymer chemistry synthesis routine techniques like NMR 
spectroscopy or GPC provide essential information as compound 
identity, MW or Ɖ determination. Both techniques have different 
background basis and apart from their inherent advantages and 
disadvantages, they represent the accepted standard methodology for 
polymer characterisation. FT-IR was utilised in this work as an extra-
tool for polymerisation monitoring technique in parallel with GPC.  In 
addition, circular dicroism (CD) provides information on the secondary 
structure of the analysed sample, which remains important in our 
synthesised polypeptides for future clinical applications.  
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II. 4. 4. 1 Sample characterisation by NMR Spectroscopy 
 
NMR analysis provided and confirmed the identity of the 
analysed compound. 1H and 13C-NMR analysis of all obtained 
compounds were done at least with approx. 20mg of compound and 
dissolved in 0.5-0.6mL of the appropriate deuterated solvent. The PGA 
protected form was dissolved in CDCl3, DMSO-d6 or DMF-d7; the PGA 
deprotected form o in DMSO-d6 or DMF-d7 and the sodium salts form 
in D2O. 
 
For the determination of the Mw by this methodology, 
characteristic peaks of the repeating unit (GA) were compared to the 
initiator peak (also to peaks of a different block such as PEG, to 
determine block ratios in block copolymers). Accuracy of MW 
determination depended on [M]/[I] ratio, being decreased in larger 
polymers. It has to be remarked that polymer chains not containing 
the added initiator could lead to an overestimation of the MW 
(polymerisation initiated by impurities,..).For the protected samples 
the 2 benzylic protons (-CH2-C6H5) were used and the average of the 
values obtained for α-proton and side group-protons (-CH2-CH2-) was 
used for the chain length determination of deprotected samples. 
Bidimensional experiments as COSY or diffusion studies by 2D-
DOSY were also carried out with the synthesised polymer conjugates.   
All the experiments were done at 25°C. NMR analysis was 
operating in frequencies of 300 MHz or 500MHz. All data processed 
and analysed using the TopSpin® 2.0 software. 
 
II. 4. 4. 2 GPC analysis of protected polymers 
 
Gel permeation chromatography (GPC) is an established 
method to determine true MW distributions of polymers that follows 
size exclusion chromatography (SEC) principles. Molecules are 
separated according to their hydrodynamic volume. Mw is determined 
from the measured retention volume (RV) by means of a calibration 
curve. It is important to remark that calibration curve also depends on 
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the polymer used, thus calibration standards and the samples have to 
be of the same or similar nature. The signals obtained by all detectors 
(refractive index, viscosity, light scattering) depend solely on 
concentration what requires a careful control on injected sample 
concentration.  
 
GPC analysis of polypeptides using PMMA (polymethyl 
methacrylate)standards for calibration may lead to errors in Mw 
determination. The structures are not completely comparable and 
same hydrodynamic radius in solution may not have the same Mw.  
 
In this project, GPC measurements were performed in organic 
solvent: DMF (0.1%LiBr) as mobile phase, 0.8-1mL/min at 70°C.  
Samples were carefully weighted and diluted (to a known 
concentration, usually 6 to 8mg/mL) using the same mobile phase and 
filtered (0.2µm) before injection. 100µL of the dilution was injected 
and analysed for 45min.  Standards use for calibration were 
poly(methyl methacrylate) (PMMA)/DMF standards. They allow a 
relative comparison of the MW and polydispersity of the injected 
samples. Exact determination of Mw by GPC for polymers corresponds 
to those with random coil conformation. In our case, polypeptides are 
often organised in stable secondary or tertiary structures like parallel 
β-sheet, anti-parallel β-sheet or α-helix.  To solve this, mobile phases 
with effective hydrogen bonds disruption ability are suitable. DMF 
posses this characteristic although do not fully disrupt secondary 
structures of homo-polypeptides. As solution, parallel measurements 
in a better solvent able to diminish formation of suprastructures: 
hexafluoro-2-propanol (HFIP) as solvent, were carried out in order to 
compare results (experiments carried out in Mainz, Germany), as well 
as CD to ensure absence of secondary structures of the synthesised 
polypeptides. Therefore, GPC was also performed with HFIP containing 
3g/L potassium trifluoroacetate as eluent at 40°C. The columns were 
packed with Modified silica (PFG columns particle size: 7μm, porosity: 
100 & 1000Å, PSS). A refractive index detector (G 1362A RID) was used 
to detect the polymer. MWs were calculated using a calibration 
performed with PMMA standards (Polymer Standards Services GmbH) 
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and Toluene as internal standard. 
 
II. 4. 4. 3 Circular dicroism (CD) analysis  
 
As mentioned above, CD analysis was carried out in Mainz 
(Germany). The protected polymers were dissolved in hexafluoro-2-
propanol (containing 3g/L trifluoroacetate) at a concentration of 
1mg/mL and diluted to 0.25mg/mL. The deprotected samples were 
dissolved in water and diluted to a concentration of 0.25 mg/mL.  
The UV Absorption at 205nm of all subsequently measured 
samples (same desired concentration of 0.25mg/mL) was averaged, 
and the CD spectra were corrected by dividing all values by the value 
of absorption of the sample at 205nm and then multiplying it by the 
averaged value. This was done to even small concentration variations 
during sampling). The measured ellipticity was converted to molar 
ellipticity per amino acid (concentration, MW of the amino acid and 
path length in the sample were calculated out of the ellipticity 
resulting in [deg cm² dmol-1]). 
 
 
 
II. 4. 4. 4 Infrared (IR) spectroscopy analysis for polymerisation 
monitoring  
 
To get information about the kinetics of the polymerisation 
process, the reaction solution was analysed by infrared (IR) 
spectroscopy performing a time course experiment. IR permits to 
identify the bonds existing in the analysed molecule. The 
transformation of monomer into polymer can be easily identified 
through the disappearing of specific bands from monomer bonds. 
Polymerisation reactions were carried out in DMF media, 
therefore a cell for liquids was used. All samples analysed were under 
solution or previously dissolved in DMF. Analysis was carried out at 
25˚C.  
𝜃𝑚  (𝜆) =  
𝜃 𝜆  ×  𝑀
10 ×  𝑐 ×  𝑙
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DMF strongly absorbs in the IR region, therefore suitable peaks 
to follow the reaction had to be found. FIGURE II. 14 shows the IR 
spectra of pure DMF, Glu(Bz)NCA dissolved in DMF and p-L-Glu(Bz) in 
DMF. Discarding peaks obscured by DMF and those matching with the 
polymer, peaks corresponding only to the NCA monomer were 
localised at 1857, 1785 cm-1 and  920cm-1.. Peaks at 1785 and 920cm-1 
were selected due to their lower signal-to-noise ratio.
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CHAPTER III. LABELLED AND TARGETED POLYGLUTAMATES 
 
In order to biologically evaluate the potential of the 
polyglutamates synthesised and described in chapter 1 as drug carriers 
and to understand polymer in vitro/in vivo fate, two complementary 
approaches were followed. 
 
First, carriers can exploit not only their inherent passive 
targeting (by the EPR effect, see introduction chapter) but also a 
specific active targeting to an organ, cell or even an intracellular 
organelle [1]. This could be achieved by the conjugation of targeting 
ligands. In this project, active targeted conjugates by the linkage of 
protein (transferrin), antibody (mAbOX26) or peptidic sequences 
(Angiopep-2 and cPEP) have been designed to surpass the blood-brain 
barrier (BBB) by means of transcytosis (section I.1.4). With this aim, 
the preferred type of covalent bond to be used was the disulphide 
bond as this bioreversible linkage allows the ligands to be released in 
presence of a reductive environment or by disulfide reductases 
encountered in the brain following transcytosis [2]. In vivo proof of 
concept of this fact was demonstrated with a peptide inducing 
enhanced cerebral flow [3]. The chemical steps done towards this aim 
were based on ligand derivatisation in order to add sulfhydryl groups 
for later conjugation or to use/expose those already present in their 
structure.  
 
Second, their polyvalent character given by the 
multifunctionality enables to exploit labelling approaches by probe 
conjugation to investigate their in vivo biodistribution, 
pharmacokinetics (PK), cell trafficking or cell localisation. The 
effectiveness of the administered nanomedicine as well as disease 
progression and therapeutic response could be literally observed. On 
this basis, conjugate monitoring, with or without drug/targeting 
ligand, was carried out in this thesis by means of several non-invasive 
imaging modalities either in vitro or in vivo (see Chapter IV). Different 
tracers or probes named in TABLE III. 19 have been covalently bound 
to allow monitoring of the synthesised polyglutamates.  
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Labelling 
moiety  
Technique 
Labelled 
systems 
REF 
Type of 
bond 
Rhodamine Fluorophore 
Fluorescence 
in vitro 
TB 
 
amide 
Oregon 
green 
Fluorophore 
Fluorescence 
in vitro 
TB 
 
amide 
  
Fluorescence 
in vivo 
TB 
 
amide 
Cyane 5.5 NRI dye 
Optical 
imaging 
in vivo 
PGA 
 
click 
  
PGA-Doxy 
 
amide 
  
DB 
 
amide 
  
DB-Tf 
 
amide 
DTPA/Gd 
Contrast 
agent MRI 
TB 
 
amide 
  
TB-mAbOX26 
 
amide 
Tyramine/
18
F 
 
PET TB 
 
amide 
DOTA/
68
Ga 
 PET 
PGA 
 
amide 
  
PGA-Doxy 
 
amide 
   
DB 
 
amide 
TABLE III. 19 Imaging probes utilised for polyglutamate labelling. 
 
III. 1 RESULTS AND DISCUSSION 
 
III. 1. 1 GENERAL SYNTHETIC METHODOLOGIES FOR POLYMER 
LABELLING  
PGA multivalency can be exploited not only for tailoring drug 
loading but also for dye labelling. Labelled-PGA can be readily 
detected in biological fluids and tissues when a fluorescent dye or a 
radioactive tracer is conjugated to its backbone. Derivatisation of the 
carboxylic acid pendant groups offers a vast number of possibilities for 
probe conjugation, from a highly selective linkage through click 
chemistry (triazol) to a simple amide bond [4]. 
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An essential step for validation of a novel polymeric carrier is 
the exploration of its trafficking properties in vitro as well as its 
biodistribution and fate in vivo. The synthesised polyglutamates 
presented distinct levels of complexity featured by their variations in 
size (MW) and composition (presence of one or two PEG blocks) which 
lead to differences in conformation. These characteristics offer the 
opportunity of setting carriers with different purposes depending on 
the cell internalisation pathway followed, facility for crossing any 
biological barrier, body distribution as well as secretion route 
exploited. This information could be gain by the introduction of 
labelling moieties into the polymer chain. Furthermore, labelling 
combined with drug conjugation could be included under the concept 
named ´theranostics´ [5, 6]. 
 
PGA pendant groups enable probe conjugation, which can be 
modulated thanks to its number of GA units. In the present project, 
several probes have been tested covering two different approaches: 
molecular imaging (optical imaging and magnetic resonance imaging 
(MRI)) and radionuclide imaging (positron emission tomography, PET). 
Polyglutamates have been tagged using fluorescent molecules such as 
Oregon Green (OG), Rhodamine (Rho) or the near-infrared (NIR) dye 
Cyane5.5; imaging contrast agents as diethylenetriaminepenta-acetic 
acid dianhydride (DTPA)/Gd and PET tracers as 1,4,7,10-
tetraazacyclododecane-N,N’’,N’’’,N’’’’-tetraacetic acid (DOTA)/68Ga or 
Tyramine/18F. Bioimaging of the CNS encompasses techniques 
involving nuclear medicine studies such PET and single photon 
emission computed tomography (SPECT). Morphological studies 
include MRI and computed tomography (CT). Nowadays, combination 
of this neuroimaging tests are essential to provide diagnostic support 
and provide the advantage to identify underlying neurological 
processes involved in disease progression [7]. 
 
In order to obtain the selected type of bond between the 
probe and the polymer post-polymerisation modification approaches 
were followed. In many cases, not only for labelling, these strategies 
were used to attach targeting moieties (section III.3.2.3) or to allow 
drug conjugation (section V.3.1.3). Post-polymerisation modification 
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constitutes an attractive approach for the synthesis of functional 
polymers overcoming the limited functional group tolerance of many 
controlled polymerisation techniques. Due to all the advantages of the 
above-described methodology of NCA polymerisation, the exploration 
of the post-polymerisation modification of the well-defined 
polyglutamates was studied with a view to the incorporation of 
functionalities for site specific conjugation.  
 
With this objective in mind, carboxyl pendant groups of the 
PGA block were modified in order to obtain different ending 
functionalities (-NH2,-SH, -C≡CH,…) allowing conjugation of targeting 
ligands, drugs through spacers and/or fluorescence or radioactive 
probes. 
 
III. 1. 1 .1 Fluorescence labelling 
 
The conjugation of fluorescent probes to PGA enabled to study 
the cellular uptake and trafficking in an endothelial cell line and to 
investigate in vivo biodistribution of the novel synthesised triblocks.  
Optical imaging is a traditional and well established tool in 
biomedicine. Use of light for imaging has the advantages of simplicity, 
low-cost and uncomplicated equipment. It is a non-invasive and non-
ionising technique, which allows repeated doses without damaging the 
animal. It also permits multicolour fluorescence detection and 
therefore resolution of multiple targets using fluorescent labels able to 
be spectrally resolved. In addition, the use of fluorescent optical 
agents enables visualisation of otherwise invisible cellular and sub-
cellular processes.  
 
Limitations of the technique are related to the scattering. For 
in vivo monitoring, thick tissues diffuse and absorb light reducing 
significantly the resolution, therefore, the low penetration capabilities 
cannot provide depth and size information. Moreover the use of 
fluorescence probes that show concentration and/or pH-dependent 
quenching and that are released from the carrier following 
internalisation lead to misinterpretation of images [8, 9].  
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For macromolecular therapeutics and nano-sized drug delivery 
systems, fluorescent labelling uses are focused on determining 
intracellular trafficking, conjugate cell-specific localisation and/or in 
vivo fate and PK. Epifluorescence and fluorescence laser scanning 
confocal microscopy can be used to study the intracellular fate of 
delivery systems. In particular, live cell confocal imaging allows 
visualising trafficking between multiple compartments within 
individual living cells over time avoiding any possible artefact derived 
from fixation protocols [10]. 
 
Regarding in vivo optical imaging, many novel fluorophores 
have been developed to fluoresce in the NIR optical window (700-
1000nm), where optical absorption is negligible and light can 
penetrate deeply. Traditionally, PK and biodistribution studies were 
based on quantifying the therapeutic agent by HPLC, mass 
spectroscopy or measuring radioactivity. Today, optical imaging using 
NIR fluorescent or luminescent tools facilitates this task. It involves the 
injection of fluorescent probes, transgenic cells or species able to 
express fluorescent proteins when activated in a particular manner. 
Fluorescence imaging has been successfully translated from 
microscopy level to small animal imaging and even to the clinics [11]. 
NIR fluorescent dye Cy5.5 has proved to be a promising agent for in 
vivo demarcation, highly exploited in tumour studies such gliomas [12, 
13].  
 
In the present thesis, the fluorophore OG was chosen for in 
vitro studies (cell internalisation) and the NIR dye cyane5.5 (Cy5.5) for 
in vivo biodistribution studies. Conjugation was performed (i) through 
amide bonds between amino derivatised fluorophores and the PGA 
block (or PEG terminal group in case of blocks) or (ii) through click-
chemistry involving a prior post-polymerisation modification of the 
PGA carboxyl groups with an azide derivative of the fluorophore.  
Common protocols developed in this thesis involved the activation of 
the carboxyl groups of the polypeptide block. For this purpose, 
different methods had been used: (i) activation by carbodiimides (DIC, 
DCC), (ii) NHS activation and (ii) 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
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methylmorpholiniuym chloride (DMTMM) coupling reagent [4]. 
Carbodiimides are common acylating agents used in amino acid 
coupling procedures either in organic or aqueous media. 1,3-
dicyclohexylcarbodiimide (DCC) and 1,3-diisopropilcarbodiimide are 
the most used reagents towards amide or ester formation. Main 
drawback is the generation of insoluble byproducts (dicyclohexylurea 
or diisopropylurea) during activation/acylation, but this can be 
prevented by the addition of HOBt (1-hydroxybenzotriazole). This 
reagent increases the reactivity of the intermediate, improving the 
carboxyl activation [14](FIGURE III. 36). 
 (A) 
 
(B)
 
FIGURE III. 36 Carbodiimide coupling scheme (example with DCC). (A) 
Mechanism for amide formation. A side product is observed when DCC is 
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used alone (transition O to N-acylurea, path A), (B) HOBt addition suppresses 
N-acylurea formation by protonation of the O-acylisourea (Path B). 
 
In aqueous media, N-(3-dimethylaminopropyl)-N-
ethylcarbodiimide (EDC or EDAC) is also a popular condensing 
agent[15].  NHS or sulfo-NHS are moieties coupled to carboxylic acids 
after its activation. In organic or aqueous media (respectively), these 
groups increase coupling efficiently or create a stable amine-reactive 
product. DMAP (dimethylamino pyridine) is often used as catalyst in 
the amino- or alcohol- later coupling (sulpho-NHS is detailed in 
Chapter V). On the other hand, DMTMM enables an efficient one-step 
condensation and byproducts or reagents in excess are easily removed 
(Scheme in FIGURE III. 37). Furthermore, it is compatible with many 
solvents including water, alcohols, THF, DMF, etc. and no rigorous pH 
control is necessary [16, 17]. 
 
FIGURE III. 37 DMTMM coupling scheme to form an amide bond. 
 
Methodology for labelling with Rhodamine (Rho) 
 
 
FIGURE III. 38 Scheme of Rhodamine labelling. 
 
Rhodamine (N-(6-Aminohexyl)rhodamine 6G-amide 
bis(trifluoroacetate))  is a widely used dye for multiple cell assays. In 
this case, the amino group of the Rho derivative was conjugated to the 
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TB200 (9) through the carboxylic groups of PGA block by means of a 
DIC-coupling mediated reaction (FIGURE III. 38) (0.5 %mol Rho, 24.5% 
yield (FIGURE III. 39)) giving the conjugate TB-Rho (17). However, the 
fluorescence detection after conjugation resulted unsatisfactory both 
via fluorometer and even by HPLC analysis: its emission was not easily 
detected. This low output could difficult future in vivo assays. As a 
result, Oregon Green cadaverine (OG) was chosen as alternative. 
 
FIGURE III. 39 Representative images of the elution profile of TB-Rho 
(17) used to quantify Rho polymer loading. 
 
Methodology for labelling with Oregon Green (OG) cadaverine. 
 
OG labelling was a successful methodology independently of the 
selected PGA derivative: homopolymer, diblock or triblock (Scheme in 
FIGURE III. 40). Conjugation yields ranged from 80 to 90%. In FIGURE 
III. 41 an elution profile of a triblock labelling is shown and TABLE III. 
20 compiles an example of the species labelled with this fluorophore. 
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FIGURE III. 40 Scheme of OG-cadaverine labelling. 
 
 
 
FIGURE III. 41 Elution profile after purification of triblock labelling with 
Oregon green moiety. Fluorescent measurement of each fraction after 
dilution. 
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Polymeric carrier DP %OG mol 
TB 200 0.90 
 
200 0.6 
 
200 1.3 
 
200 0.6 
 
200 1.7 
 
200 1.6 
 
150 0.72 
 
150 0.78 
 
100 0.83 
 
100 0.80 
 
100 0.76 
 
100 0.45 
TABLE III. 20 Examples of triblocks (9) labelled with Oregon green. 
 
                          (A)                                                              (B) 
 
FIGURE III. 42 Quenching phenomena of OG and TBO.(A) Oregon green and 
(B) TBO. 
 
This probe has been reported to be stable against changes in 
pH [10]A proof was performed to test this statement trying to mimic 
later polymer extraction of in vivo experiments, resulting in reduced 
signal under acidic conditions and not affected by basic environment.  
Same behaviour was found for TBO (20) (FIGURE III. 43). In order to 
transfer this knowledge to our in vivo studies, fluorescent 
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measurements considered the pH of the media as well as sample 
dilutions to identify possible false measurements due to quenching 
effect. 
FIGURE III. 43 pH sensitivity of OG probe and TBO under acidic or basic 
conditions. 
 
Methodology for labelling with Cyane5.5 (Cy5.5) 
 
Two derivates of Cy5.5 were selected for labelling PGA 
homopolymer and DB, both with an average of 100 GA units. On one 
hand, PGA homopolymer modified with alkyne moieties (21) was 
conjugated to Cy5.5-azide (22) (see FIGURE III. 44(A)). As expected, 
click chemistry reaction showed a high chemoselectivity under mild 
reaction conditions and enabled us to obtain a non biodegradable 
linker. In organic solvents, CuBr/N,N,N’,N’,N’’-
pentamethyldiethylenetriamine (PMDTA) are the most common 
reagents. The active specie is Copper (I), which can be readily oxidised 
to Copper (II) in presence of water. For this reason, the systems were 
always carefully degassed before and after catalyst addition. PMDTA 
function is to stabilise Cu(I) in solution thanks to its tridentate 
structure.  
 
DB100 (5) labelling was performed with Cy5.5-NH2 (34), via an 
amide bond. The synthetic scheme is depicted in FIGURE III. 44 (B). 
Dye loading was calculated after analysing the fractions obtained from 
a PD10 column in a fluorometer (see experimental section for details) 
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(FIGURE III. 45 (A,B)). The results obtained are summarised in TABLE III. 
21. 
(A)
 
(B) 
 
FIGURE III. 44 Cyane5.5 labelling (A) PGA through click-chemistry (22), (B) DB 
through amide bonding (34). 
 
 (A)                                                (B) 
 
FIGURE III. 45 Fluorescent measurement of fractions from purification 
of (A) PGA-Cy5. (22), (B) DB-Cy5.5 (34). 
 
REF %mol Cy5.5 %labelling yield REF 
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PGA100 4, 11 1.80 87 22 
DB100 7 1.63 91 34 
TABLE III. 21 Results of Cy5.5 polymer labelling. 
 
III. 1. 1 .2 Contrast agents labelling. DTPA/Gd complex. 
 
Magnetic resonance imaging (MRI) is a non-invasive technique 
commonly used in medical imaging to produce high quality images of 
the inside body. It does not use ionising radiation and provides 3D 
images of anatomic structures with high spatial resolution [18]. 
 
Briefly, MRI process basis relies on creating images from the 
manipulation of hydrogen atoms under magnetic fields. Atoms with 
and odd number of protons and neutrons such as hydrogen possess a 
specific quantum property called ´spin angular momentum´. Spin is 
where an atom rotates about its own axis, atoms are charged particles 
and therefore they create small magnetic fields. The atoms are able to 
occupy multiple different states of spin, but are normally randomly 
distributed between them. However, in presence of an external 
magnetic field (B0) the atoms will align either with (lower energy level) 
or against (high energy level) the field, the difference between the two 
energy levels being proportional to B0 [19].  This phenomenon results 
in giving the object inside the magnetic field a very weak magnetic 
charge described by what is known as the net magnetisation vector 
(NMV). Hydrogen atoms dominate the NMV caused by placing a body 
(human body is primarily fat and water, both have many hydrogen 
atoms, approx 63%) in an external magnetic field. The image creation 
is based on measuring of the return of the NMV back to its original 
orientation. This is defined as relaxation. Each tissue differs from other 
due to velocity of this relaxation, then, MRI allows differentiating 
between body tissues. MRI contemplates two types of relaxation 
constants: T1, which is the time constant for the NMR to return to 
their equilibrium state with the external magnetic field (longitudinal) 
and T2, which is the time constant for the NMV to leave the plane 
perpendicular to the external magnetic field (transverse) [20]. These 
constants specifically depend on the water content of the material. For 
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instance, tightly packed solid tissues with close interaction between 
hydrogen nucleus relax more quickly than loosely structured liquids, so 
tissues such as skeletal muscle have a shorter T2s while e.g. 
cerebrospinal fluid possess a longer T2. Relaxation emits energy, which 
is detected by a scanner and mathematically converted into an image.  
In order to extract more information from imaging, contrast agents 
have been employed. These compounds are used to improve the MRI 
visibility of internal body structures by altering the relaxation times of 
the tissue atoms. Paramagnetic metals used for enhance MRI signal 
(Gd(III) [21], Fe(III), Cr(III), Mn(II)) have permanent magnetic fields, 
although the magnetic moments of individual domains are unaligned. 
After exposure to an external magnetic field, individual domain 
moments become aligned, generating a strong local field. 
Paramagnetic metal ions interact with water molecules increasing 
relaxation of the water molecules due to the water-metal complex, 
decreasing remarkably the T1 value from the water molecules and 
enhancing the signal of the proton [19]. MRI contrast agents can be 
classified by their administration route, chemical composition, 
magnetic properties, effect on the image, metal centre nature or 
biodistribution and applications (e.g. extracellular fluid agents, blood 
pool agents, organ specific agents, active targeting/cell labelling 
agents,…).   
 
Scientific research utilises MRI as a useful tool for non-invasive 
and real-time evaluation for drug delivery. Contrast agents enhance 
the signal in target tissue for accurate diagnosis or detection. MRI is 
among the modalities which require a certain quantity of reporter 
groups to accumulate in the area under observation, as occurred in 
optical imaging technique. To reach the needed local concentration of 
the contrast agent, conjugation to polymer vehicles, such as poly-L-
glutamic acid, has been already advocated since ability to carry 
multiple reporter moieties increase efficiency of the agents [18, 22].  
 
Nowadays, almost 30% of all MRI scans today use some type 
of non-specific gadolinium-based contrast agent [21, 23]. The 
administered contrast agent typically makes diseased tissue appear 
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brighter (or in determined cases darker) than the surrounding tissue. 
The first approved contrast agent, Gd-DTPA (gadopentetate 
dimeglumine, Magnevist®) appeared in 1988 and several other 
compounds have followed it. Usually, gadolinium-based agents are 
administered i.v. As mentioned in the Chapter I, an intravascular 
contrast agent based on a large dendrimer containing 24 gadolinium 
ions (Gadomer-17, MW 30-35kDa)was transferred to the clinics 
although recently it has been retired due to a non-adequate PK profile 
[24]. 
 
The purpose of utilising MRI in this project was to monitor BBB 
crossing. MRI technique has achieved greater advances in this body 
area, providing accurate information about changes in cerebral 
function in brain in vivo. It should be remarked that Gd(III) chelates do 
not pass by itself the BBB because their hydrophilic character. 
 
Methodology for labelling for MRI analysis by DTPA/Gd conjugation  
 
Aiming at complexing Gd(III), carboxylic groups of the PGA 
block previously functionalised with a di-amine (2-[2(Fmoc-
amino)ethoxy]cethylamine hydrochloride) by DIC-coupling (section 
II.2.2.5) provided a free amine group for DTPA conjugation The 
monoprotected di-amine avoids cross-linking reactions. The synthetic 
scheme is shown in FIGURE III. 46. The degree of DTPA substitution 
was determined by titration with a solution of GdCl3 later evaluated 
with 4-(2-pyridylazo)resorcinol as Gd(III) indication, observing a clear 
variation from yellow (complexed Gd) to orange (free Gd). Results are 
summarised in TABLE III. 22. 
 
For in vivo studies, gadolinium chelation was performed 
adding dropwise a solution of GdCl3 in water to an aqueous solution of 
TB-diamine-DTPA (25), giving the complex TB-diamine-DTPA/Gd (26). 
Then purification was carried out to remove free Gd using the 
resorcinol indicator described above until absence of Gd. Mass 
percentage of complexed Gd is detailed for all the TB tested in TABLE 
III. 22. Taking into account that length of PGA block can be varied 
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during the polymerisation, percentage of complexed Gd(III)could be 
also customised. 
 
(A) 
 
(B) 
 
FIGURE III. 46 Scheme of synthesis for DTPA / Gd labelling procedure. 
 
Compound DP 
Degree of diamine 
substitution (mol/mol of 
COOH) 
1eq DTPA:1eq Gd 
Gd content (%w/w) 
TB-diamine 200 6 5.7 
TB-diamine 200 30 25.2 
TB-diamine 100 8 8.9 
TB-diamine 100 30 29.0 
TABLE III. 22 Results for TB-diamine-DTPA labelling. 
 
III. 1. 1 .3 Labelling with radionuclides  
 
Radionuclide imaging techniques are non-invasive, highly 
sensitive, quantitative and enable whole body scanning. Oppositely, 
poor spatial and temporal resolution or limited half-life of the 
radioactive compounds count as their main disadvantages. Focusing 
on patients treatment, this ionising radiation limit their repeated use 
[25]. PET application in diagnosis and biomedical research is 
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outstanding. In particular, its use for brain study and heart functions 
has become essential. It allows monitoring through positron emitter-
labelled compounds and it has been proved to be more sensitive than 
MRI or computed tomography (CT) although high costs and required 
equipment limit its applicability [11].  
 
In brief, a chemical compound labelled with a short-lived 
positron-emitting radionuclide of carbon, oxygen, nitrogen, or fluorine 
is injected into the body. The activity of such a radiopharmaceutical is 
quantitatively measured by means of photomultiplier-scintillator 
detectors. As the radionuclide decays, positrons are annihilated by 
electrons, giving rise to gamma rays that are detected simultaneously. 
While fluorescence emission is limited by a low penetration depth, PET 
ability to detect organ accumulation is highly accurate, regardless of 
tissue depth [26]. 
 
In this work, positron emitters (18 F, 68Ga) were incorporated 
into the PGAs through covalent or complexation chemistry. This 
strategy is tedious and lengthy although in most cases it does not 
significantly alter the platform structure. Usually, a non-metal PET 
nuclide like 18F is incorporated by means of covalent attachment, but a 
metal radioisotope such as 68Ga needs a chelator, which usually 
provides high yields. For stable complexation, chelating agents based 
on polyamine carboxylic acids e.g. DTPA, DOTA or 1,4,7-
triazacyclododecane-N,N’’,N’’’-tetraacetic acid (NOTA). Thus far, 
complex 68Ga-DOTA is one of the most widely used and therefore, it 
was the selected for our purposes.  
 
Methodology for labelling with Tyramine for PET monitoring after 18F 
conjugation 
 
First step involved the coupling of tyramine to the PGAs 
(scheme in FIGURE III. 47). The phenolic compound named tyramine 
was covalently linked to the triblocks (27) of different length: 100, 150, 
200, achieving percentages detailed in TABLE III. 23.  
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FIGURE III. 47 Tyramine labelling synthetic scheme. 
 
 
Theoretical Experimental 
Compound 
%mol 
Tyramine 
%mol 
Tyramine 
TB150 5 3 
TB150 12 0.3 
TB200 20 16 
   TABLE III. 23 Total tyramine content in the TBs-Ty (27). 
 
Tyramine conjugation aim was to later coupling a 
[18F]fluoralkyl synthon9. The synthon used was the 2-[18F]fluoroethyl-1-
tosylate ([18F]FETos) which allows for site-specific radiofluorination at 
phenolic groups, and should not influence the structural properties of 
the self-assembled nanosystems itself. Labelling protocol is described 
in reference [27] and the fluorination step was performed in the 
Institute of Nuclear Chemistry, Johannes Gutenberg-University Mainz, 
Germany by Dorothea Moderegger. 
                                                          
9
 SYNTHONS are prosthetic groups.  
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Fluorination process yielded low 18F content. In order to create 
the needed nucleophile, products were dissolved in DMF and NaOH 
was added to get the O- nucleophile from the tyramine units. In our 
products, carboxyl groups from the PGA were firstly deprotonated 
instead the hydroxyl benzyl ones. To solve the problem, solubility of 
the systems in organic aprotic solvents had to be achieved. Calcium, 
ammonium and lithium salts of PGA were synthesised by cation 
exchange with the sodium PGA salt and later desalted by SEC.  Ion 
exchange was successfully achieved and the resulting calcium and 
lithium salts were soluble in DMSO. Lithium salt was selected to 
continue with the experiments although the labelling percentage 
achieved was again not sufficient to perform biodistribution 
experiments. Therefore, this labelling methodology was dismissed. 
  
Methodology for labelling with DOTA/ Ga for PET monitoring  
 
 
FIGURE III. 48 Synthetic approach followed for DOTA labelling. 
R1=nBu, PEG. 
 
DOTA is one of the most popular chelators used for 
radiolabelling purposes due to its capability to form stable complexes 
with various M2+ and M3+ ions, e.g. 68Ga, 90Y, 111In, and 177Lu. Our 
strategy consisted on the linkage of a DOTA amino derivative through 
an amide bond to the PGAs: homopolymer and DB both with 100 GA 
units (scheme in FIGURE III. 48). Varying the initial equivalents of 
DOTA, several coupling percentages were achieved (TABLE III. 24). 
Reactions proceeded quantitatively giving labellings of 2 to 11%mol of 
DOTA, calculated after 1H-NMR analysis (FIGURE III. 49). 
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 Theoretical eq. DOTA 
(x) 
Real 
% mass yield 
 
DP %mol DOTA %mol DOTA
*
 
PGA100 106 5 0.05 2 94 
 
106 10 0.1 9.8 80 
DB100 94 11.5 0.115 11 71 
 
 
 
*
calculated by 
1
H-NMR. 
TABLE III. 24 Results for DOTA polymer labelling: PGA-DOTA (28) and DB-
DOTA (29). 
 
 
FIGURE III. 49 
1
H-NMR of PGA-DOTA 10% labelled. Example of molar 
percentage calculation. 
 
 DOTA protecting groups allow solubility in most organic 
solvents, and the tert-butyl ester removal procedures do not need 
strong conditions, which could affect the polypeptide chain. 
Deprotection conditions used in this work were optimised to achieve 
an optimal result in the shortest time without damaging the carrier 
either systems where ligands are already coupled (peptidic sequences 
owning disulphide bonds). Initial protocol involved 15h in agitation in 
TFA although 3h in a mixture TFA/H2O/TIPS (95:2.5:2.5) enabled a 
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satisfactory result, being profitable for other purposes (FIGURE III. 50). 
(A) 
 
(B) 
 
FIGURE III. 50 DOTA deprotection 
1
H-NMR spectra: (A) PGA-DOTA (43), (B) 
DB-DOTA-diamine-N-Boc (45) deprotection. 
Gallium labelling was performed at the CIEMAT (Madrid). 
DOTA
tBu-
protected
deprotected
DOTA tBu-
NBoc-
protected
deprotected
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Radiochemical yields were in all cases 86.3%±3.4 (n=5). Radionuclide 
purity was calculated as the ratio activities of 68Ge versus 68Ga in the 
eluate, corrected for decay expressed in %. The RNP was <3.4·10-4 %± 
0.4·10-4 in all cases. 
III. 1. 2 TARGETING LIGAND CONJUGATION FOR BBB CROSSING 
THROUGH ACTIVE TRANSPORT  
 
For the purpose of blood-brain barrier crossing, the PGA family 
presented in this project has been designed to gather multiple 
possibilities exploiting active targeting strategies through covalent 
binding of ligands for brain receptors: (i) availability of different 
regions in the polymer backbone (which serve for site-specific 
conjugation together with the option of post-polymerisation 
modifications) and (ii) insertion of cleavable linkers in specific 
environmental situations. Insertion of PEG blocks as well as 
modulation of the PGA block length block were also proposed with the 
aim of obtaining conjugates with different solution conformation, 
which could help BBB crossing. 
 
As mentioned in the introduction, the selected strategy to 
achieve this goal has been active transport: drug delivery systems 
conjugated to ligands capable of binding receptors overexpressed in 
BBB (sections I.1.4 and I.1.7). In particular, the transferrin receptor 
(TfR) and the low-density lipoprotein receptor-related protein-1 (LRP1) 
were selected as target. In the case of TfR, not only the natural ligand 
but also a monoclonal antibody (mAbOX26) [3, 28, 29] or an iron-
mimicking cyclic peptide [30] were evaluated. For LRP1, Angiopep-2 
peptide was chosen due to its recent progress in clinical trials [31, 32]. 
 
Regarding type of linkage, the use of disulphide bonds 
guaranties site-specific conjugation in the different block copolymers 
synthesised, either achieved by the introduction of –SH groups in the 
terminal PEG block or through post-polymerisation modification of the 
PGA side-chains. As an alternative, the use of amide linkers has been 
also explored e.g. with the cyclic peptide.  
 
On the other hand, the selected ligand (protein, antibody or 
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peptide) should also bear the adequate functionality (-SH) and this 
group should not be linked to bioactive roles, if not, it should be 
chemically introduced to allow conjugation without compromising 
their inherent biological activity. Introduction of extra cysteine (Cys) 
residues or small molecules with sulfhydryl groups is commonly used 
to achieve chemoselective derivatisation. In contrast, those ligand 
disulfide bridges not implicated in essential roles, can be mildly 
reduced to gain–SH anchoring points for polymer conjugation [33-35].  
 
For instance, in the present work Tf was thiolated with 2-
iminothiolane and mAbOX26 was exposed to mild reductive conditions 
to cleave S-S bridge. Angiopep-2 was derivatised with an extra cysteine 
at C- terminal. 
 
III. 1. 2. 1 Transferrin (Tf) 
As stated in the introduction, TfR is expressed in the BBB and 
its function relies on iron transcytosis pathway.  On this basis, Tf was 
coupled to the synthesised polyglutamates to evaluate their future 
potential as drug delivery systems across the BBB. 
 
 
 
FIGURE III. 51 Transferrin (Tf) thiolation procedure. 
 
First, Tf thiolation process was successfully achieved by means 
of different concentrations of 2-iminothiolane (FIGURE III. 51) and 
(TABLE III. 25). The purification procedure was monitored by 
absorbance (Tf (280nm) and 2-iminothiolane (240nm)) (FIGURE III. 52). 
The number of SH groups was calculated by MS MALDI TOF (Tf 
MW=78KDa) (FIGURE III. 53).  
 
 
S H 2 N 
N H 2 H S N 
H 
N H 2 
C l 
P P 
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[Tf] mmol % excess 
[2-iminothiolane] 
mmol 
Yield 
-SH groups 
introduced 
58 76.2 44 80 24-46 
64 30.0 19 68 9-15 
TABLE III. 25 Results for Tf thiolation (Tfthio). 
 
(A)                                                    (B) 
 
(C)                                                     (D) 
 
FIGURE III. 52 Tfthio purification through PD10 column. Detection of protein 
fraction location by means of absorbance (Nanodrop®). (a) Spectra of Tf, 
detection at 220 and 280nm. (b) Spectra of 2-iminothiolane, maximum at 
240nm (c) Overlay of spectra from fractions 8 to 19. (d) Overlay of spectra 
from fractions 20 to 40. 
 
 
FIGURE III. 53  Comparison of MS MALDI TOF spectra from Tf and thiolated Tf. 
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For later conjugation, thiolated transferrin was synthesised 
and used immediately after its purification and quantification. To 
establish the most suitable ratio between carrier and protein, Tf 
conjugation to block copolymers was firstly optimised (FIGURE III. 54 
and TABLE III. 26).  
 
 
 
FIGURE III. 54 Tf conjugation to polyglutamate systems. 
 
In the first attempts, Tf conjugation was monitored through 
Bradford assay. With the equivalent ratio 1:1, coupling efficiency was 
not 100% and free protein was observed (FIGURE III. 55). 
Subsequently, polymer equivalents were increased from 1 to 6, 
achieving better results (FIGURE III. 56 and FIGURE III. 57). From all 
polymers tested (100, 150 and 200), 200 unit PGA gave the best results 
with better conjugation efficiency and absence of unreacted protein 
(FIGURE III. 56).   
 
POLYMER DP eq. eq. Tfthio 
TB 200 1 1 
 
200 1.5 1 
 
200 6 1 
 
200 6 1 
 
150 1.5 1 
 
150 3 1 
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100 0.4 1 
 
100 2.5 1 
TBO 200 0.7 1 
 
200 2.5 1 
 
200 6 1 
DB-Cy5.5 100 1 6 
TABLE III. 26 Tf polymer conjugation to TB (5), TBO (20) and DB-Cy5.5 (34). 
DP=degree of polymerisation. 
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(C) 
 
FIGURE III. 55 Tf conjugation to TB200. Analysis of the fractions after FPLC 
purification of the reaction. (A)Bradford measurement for Tf quantification of 
each fraction. (B) 
1
H-NMR analysis for TB detection of each fraction. (C) SDS-
PAGE gel analysis of the fractions 1, 2 and 3. 
 
TB200-Tf f.4
TB200-Tf f.3
TB200-Tf f.2
TB200-Tf f. 1
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FIGURE III. 56. Tf-thio conjugation to different TBs. Reaction monitoring 
through SDS-PAGE analysis. 
 
This result was reproducible for OG labelled TB200 (FIGURE III. 
57), although purification was needed to remove unreacted protein. 
Unfortunately, initial fluorescence decreased after Tf conjugation by 
half. Therefore, use of Oregon green was discharged, changing to 
Cy5.5. This NRI dye proved to provide a better and more stable 
fluorescent output. 
 
FIGURE III. 57 Tf-thio conjugation to OG labelled TB (33) and TB200 (32). 
Reaction monitoring through SDS-PAGE analysis. 
 
Cyane labelled DB was conjugated to Tf using the optimised 
protocol (1eq DB: 6eq Tfthio).  As it can be seen in the SDS-PAGE gel 
showed in FIGURE III. 58, a successful protein conjugation was 
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achieved. Purification by FPLC and quantification of protein content by 
Nanodrop® yielded a 65% Tf conjugation. 
 
 
FIGURE III. 58 Tfthio conjugation to Cy5.5 labelled DB (DB-Tf-Cy5.5, 35). 
Reaction monitoring through SDS-PAGE analysis. 
III. 1. 2. 2 Monoclonal antibody OX26 (mAbOX26) 
 
Ligand-mediated drug delivery to the brain has also exploited 
the chimeric peptide technology, wherein a non-transportable drug is 
conjugated to a BBB transport vector [29]. An example is a receptor-
specific monoclonal antibody that undergoes receptor-mediated 
transcytosis through the BBB in vivo. Transferrin is limited as a brain 
targeted vector since its receptors are almost saturated under 
physiologic conditions due to high endogenous Tf plasma 
concentration. However, antibodies directed to TfR have been shown 
selective BBB endothelium binding due to the high expression levels of 
TfR in these cells. Therefore, these antibodies can be considered 
potential carriers for the delivery of therapeutic agents to the CNS. 
Intense work with mAbs against the TfR (e.g. mAbOX26) demonstrated 
preclinical efficacy in animal models, although a translation into 
clinical applications met with far less effective results. On this basis, 
mAbOX26 was selected as an alternative to the Tf protein [28, 29, 36]. 
 
mAbOX26 was reduced under mild conditions with 
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dithiothreitol (DTT) in order to expose its own reactive sulfhydryl 
groups (scheme in FIGURE III. 59). The reduced antibody purification 
was successfully achieved as demonstrated by the absorbance analysis 
(280nm) of the obtained fractions (FIGURE III. 60).  
 
Immediately after reduction, antibody was conjugated to the 
polymeric platform (FIGURE III. 61). In this case, platform selected was 
TB200-di-DTPA/Gd (26) (68% yield) to allow further MRI analysis in vivo. 
OX26-conjugates were maintained in solution (PBS pH=7.4) prior to its 
use to avoid reconstitution problems after lyophilisation.  
 
 
FIGURE III. 59 Mild reduction of the mAbOX26. 
 
 
FIGURE III. 60 Fractions absorbance (280nm) of mAbOX26 reduction 
purification. 
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FIGURE III. 61 Reduced mAbOX26 conjugation to TB-diamine-
DTPA/Gd. 
 
III. 1. 2. 3 Peptidic sequences 
 
Active transport is an upward trend and introduction of 
peptide-based strategies provide an alternative platform capable of 
breaching the BBB. Hence, we proposed two peptide sequences with 
demonstrated potential for this goal by means of targeted polymer-
drug conjugates: the Angiopep-2 peptide [31, 32]and the iron-
mimicking cyclic peptide [30]. 
 
In this first attempt, both peptides have been conjugated to 
the PGAn and PEG-b-PGAn diblock (both with n=100) by means of a 
small spacer linked to the pendant carboxyl groups, able to provide 
the desired ending point for their covalent coupling: a disulphide bond 
for the derivate Angiopep-2 (FIGURE III. 62(A)) and an amide linkage 
for the cyclic peptide (FIGURE III. 62(B)). 
 
- Angiopep-2 
 
To provide sulfhydryl pendant groups, 3-aminopropane-1-thiol 
was coupled to the COOH from PGA side-chains. The post-
polymerisation modifications were performed successfully, achieving 6 
and 10%mol functionalisation for PGA homopolymer and DB, 
respectively (calculation by NMR, FIGURE III. 50). Do to the presence of 
disulphide bridges, DOTA deprotection methodology was optimised to 
avoid disulphide breakage and therefore 4TP group maintenance. 
Basic deprotection by means of tBuOK was not successful due to 
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solubility issues. Finally, acidic deprotection was carried out with 
excellent results after careful optimisation (reaction time) (detailed 
protocol in Section III.3.2.3) to yield to quantitative deprotections. 
 
Angiopep-2 derivative was successfully conjugated to PGA (41) 
and DB (42) through disulphide bonds. The purification of the 
conjugate was monitored by absorbance in Nanodrop® (FIGURE III. 
63). Peptide loading was estimated by 1H-NMR and confirmed by 
amino acid analysis. Total peptide loadings achieved are detailed in 
TABLE III. 27. 
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(A) 
 
(B) 
 
 
FIGURE III. 62 Synthesis scheme of peptide conjugation: (A) Angiopep-2, (B) cPEP. 
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(A)  
 
 (B)  
 
FIGURE III. 63 Absorbance analysis of PGA-Angiopep2 / DB-Angiopep2 
fractions after purification: (A) PGA (41), (B) DB (42). 
 
 
(A) 
Conjugate REF 
mmol 
conj 
MW unit 
(g/mol) 
eq. 
Angiopep2 
mmol 
eq 
PGA-DOTA10%-Cys4TP6% 39 0.225 200.41 0.05 0.011 
DB-DOTA11%-Cys4TP10% 40 0.106 230.63 0.05 0.005 
 
(B) 
Conjugate REF 
mmol 
conj 
MW unit 
(g/mol) 
eq. 
cPEP 
mmol 
eq 
PGA-DOTA2%-ethylenediamine9% 45 0.1398 160.94 0.09 0.0126 
DB-DOTA11%-ethylenediamine11% 46 0.1145 218.24 0.11 0.0126 
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
4,50
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
m
g
 p
ro
te
in
a/
m
L
#fraction
0,00
0,50
1,00
1,50
2,00
2,50
3,00
3,50
4,00
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
m
g
 p
ro
te
in
a/
m
L
#fraction
[CHAPTER III.] 
[288] 
 
(C) 
 
   
%mol peptide 
Conjugate 
REF %mol 
DOTA 
% mol 
linker 
1
H-NMR AA analysis 
PGA-DOTA-Ang 41 11 9 4.7 3.9 
DB-DOTA-Ang 42 11 10 4.5 3.5 
PGA-DOTA-cPEP 47 2 9 2.75 n.d. 
DB-DOTA-cPEP 48 11 11 3.4 2.8 
AA=amino acid, n.d.=not determined 
TABLE III. 27. Peptide conjugation to DOTA labelled PGA and DB. (A) Cys4TP 
linker conjugation. (B) Boc-ethylendiamine linker conjugation. (C) Angiopep-2 
or cPEP conjugation. 
 
- Iron-mimicking cyclic peptide (cPEP) 
 
In order to introduce amino pendant groups into PGA side-
chains N-Boc-ethylenamine was employed. The post-polymerisation 
modification was performed successfully either in PGA or DB (11% mol 
funcionalisation) (calculation by NMR, FIGURE III. 50). 
 
Deprotection conditions of the diamine were optimised in 
order to remove at once the Boc protecting group and the DOTA t-
butyl groups. The protocol described above was used either for homo-
PGA or PEG-b-PGA block. cPEP coupling point to the polymeric carrier 
was a carboxylic acid of one of its amino acids. With the aim of 
enhancing the success of the reaction, NHS activation was performed 
previous to the conjugation step. Full activation was accomplished as 
detected by 1H-NMR (DMSO-d6) and then cPEP was conjugated to PGA 
homopolymer and DB. Peptide loading was estimated by 1H-NMR and 
confirmed by amino acid analysis (TABLE III. 27). 
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III. 2 CONCLUSIONS 
 
The forthcoming aim for the synthesised polyglutamates 
(homopolymer, diblocks and triblocks) was their evaluation as polymer 
drug carriers. First requisite was to label them with molecular probes 
to allow monitoring in future in vitro and in vivo studies. Furthermore, 
polyglutames were conjugated to different targeting ligands aiming to 
use them as drug delivery carriers able to cross the brain protecting 
barrier.  
 
In this chapter, optimisation of the conjugation conditions for 
probes as well as targeting moieties to targeted and non-targeted 
systems has been performed. Depending on the monitoring technique 
expected to be used, the most appropriate label moiety was selected. 
In all cases, the chemistry approach was based in a covalent linkage, 
either an amine or a triazole bond. Both unions remain stable under 
the biological conditions for the required time of study, which is 
necessary to monitor the conjugate and not the free probe. 
Furthermore, all the processes were always done trying to link the 
minimum amount of probe able to produce the adequate signal for 
detection. This rational design enables to extrapolate the results to the 
polymer carriers themselves.  
 
For optical imaging studies the fluorophores Rhodamine (Rh), 
Oregon Green (OG) and Cyane5.5 (Cy5.5) were chosen. Initial 
conjugation of an amine derivative of Rh did not result in enough 
fluorescence output of the conjugate complicating its latter detection 
in cells or animals. Therefore, an amine derivative of OG (OG-
cadaverine) replaced it giving good labelling yields with TB (DP=100, 
150, 200). This probe was linked via amide bond to the PGA block. 
Purification of the conjugates was performed by SEC columns and the 
percentage of conjugated OG was easily calculated after fluorescence 
measurement of the recovered fractions. These labelled systems were 
tested to reveal if future exposure to different pHs and concentration 
will mask real fluorescence and consequently the result. Studies of pH 
stability showed that fluorescence of the free or conjugated OG 
decreased in acidic media while not in basic environment, contrarily to 
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that reported [10].This consequence was taken into account regarding 
the organ extraction procedures, in order to recover the fluorescence 
signal. Investigation of quenching properties also demonstrated 
differences between the limits of detection from OG and TBO. To 
incorporate this result in future studies, the dilution of the obtained 
samples was always performed to determine and confirm the real 
concentration. 
 
Aiming to perform biodistribution studies of the novel 
obtained polymeric platforms, Cy5.5 was conjugated to PGA 
homopolymer and diblock copolymer. Post-polymerisation 
modifications increase the options for probe conjugation. Therefore in 
the first case, a previous derivation was done by introducing alkyne 
groups for further conjugation with an azide-cy5.5 derivative.  Due to 
the high selectivity of this click chemistry reaction, conjugation process 
resulted very simple and with good labelling yields. The diblock 
labelling was carried out through the amide bonding with an amino 
derivative of this dye. Again synthesis gave good degree of probe 
conjugation for later studies. 
 
To explore other monitoring techniques and in parallel 
searching for the most appropriate to observe BBB crossing, other 
probes were conjugated to our polymers. MRI fulfilled both 
statements and therefore the chelator DTPA was conjugated to TB 
systems (DP=100,200) for Gd complexion. The selected DTPA was an 
anhydride derivative in order to avoid crosslinking reactions with our 
polymers. Again a post-polymerisation modification was performed to 
introduce amine groups for DTPA linkage. Final Gd(III) addition was 
monitored by titration with an indicator (4-(2-pyridylazo)resorcinol. 
TB-diamine-DTPA/Gd was successfully obtained, varying the 
gadolinium content thanks to the different GA units of each starting TB 
used.  
 
Another leading technique in the named area is PET. The labels 
used to take profit of this methodology were the radionuclides 18F and 
68Ga. A previous step needed before labelling with both elements was 
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the conjugation of moieties such as tyramine and DOTA, respectively. 
In the first case, tyramine conjugation to TB was performed via amidic 
bond and TBs with DP 100 and 200 were used. Different percentages 
of modification were achieved to be able to tune 18F labelling for 
appropriate detection. Unfortunately, fluorination process did not 
succeed due to the need of tyramine units deprotonation. PGA 
carboxylic groups complicated this process due to their favoured 
deprotonation instead of the hydroxyl benzyl ones. Thus, this labelling 
procedure was dismissed. 
 
In the case of gallium, an amino derivative of DOTA was 
initially coupled to the carboxyl groups of PGA100 and DB100. Reactions 
rendered high yields and deprotection protocols were successfully 
carried out as demonstrated by their 1H-NMR analysis.  
 
PGAs were designed aiming to display different behaviour for 
crossing biological barriers due to its conformation in solution, 
presenting mixed mechanisms of internalisation. In any case, to 
enhance future drug delivery into the brain, targeting ligand 
conjugation was performed. All the employed moieties presented the 
property of being internalised by receptor-mediated endocytosis. The 
chemical approahc developed in this work was mainly based on (i) the 
specific point of linkage of the ligand (in the PEG block of the TBs or 
DBs or in the PGA chain) and (ii) the use of a biodegradable bond 
which allowed the separation from the polymer-drug conjugate once 
the target was reached avoiding its recycling outside the brain.  
 
TfR was the first attempt in the project and for it, its natural 
ligand Tf was conjugated. The protein was first derivatised with 2-
aminothiolane to introduce SH- groups for disulphide bonding 
achieving the best conjugation with the TB200 (PEG-b-PGA200-b-PEG-SS-
4TP) with 1:6 equivalent ratio (TB:Tfthio), where no free protein was 
observed by Western blot analysis. Same protocol was used for linking 
the thiolated protein to the OG labelled TB (TBO), although 
fluorescence of the final conjugate decreased significantly making 
difficult its use in animal/cell studies in order to compare the data with 
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the non-targeted carrier. Two alternatives were proposed: first the use 
of Cy5.5 and therefore, DB100-Cy5.5 was successfully conjugated to 
thiolated Tf using the same chemical scheme. Secondly the 
substitution of the ligand by a more selective one without problems of 
receptor saturation like Tf.  The mAbOX26 was proposed and to follow 
within the same chemistry strategy its -SH were exposed for 
conjugation by means of a mild reduction. The antibody was later 
conjugated to TB200-DTPA/Gd for comparing biodistribution with the 
non-targeted TB. mAb conjugation was easily detected by absorbance 
measurement. Working with this type of ligands could come into 
solubility problems due to it should be kept the biomolecule structure. 
Denaturation may promote non-recognition by the receptor and other 
problems. Therefore, the final product had to be maintained in 
solution to avoid precipitation which was not able to be redissolved.  
 
Finally as a simpler strategy, we chose peptides targeting the 
TfR with an iron-mimicking cyclic peptide or the low-density 
lipoprotein receptor-related protein-1 (LRP1) with the Angiopep-2. 
These molecules offer higher manageability along the chemical 
modifications and are not subjected to structural conformations 
essential for the recognition by the receptor. They were effectively 
conjugated to PGA100 and DB100. Both platforms were previously 
modified after polymerisation to introduce -SH groups to conjugate 
the Angiopep-2 and with amine groups for the cyclic peptide. In the 
last one, disulphide bond was not used because of the presence of an 
internal disulphide bond in the peptide to simplify the conjugation 
chemistry. For this approach, the chelator moiety DOTA was initially 
coupled to the polymer platforms for PET analysis. All the chemistry 
used rendered good yields along the whole process.  
 
Summing up, several labelling techniques were accomplished 
and different targeting moieties were successfully conjugated to the 
homopolymers, diblocks and triblocks. Next step was to evaluate (i) 
internalisation pathway in cells and (ii) their respective biodistribution 
(specially for BBB crossing) between targeted and non-targeted PGAs 
as well as among the homo- and the block copolymers. 
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III. 3 MATERIALS AND METHODS 
 
III. 3. 1 GENERAL SYNTHETIC METHODOLOGIES FOR POLYMER 
LABELLING  
 
III. 3. 1. 1 Synthesis of fluorescently-labelled conjugates  
 
 Methodology for labelling with Rhodamine (Rho) 
Scheme of TB-Rho (17) synthesis is depicted in FIGURE III. 38.  
Under nitrogen flow, TB200 (0.277mmol, 1eq, average Mw 
unit=102.4 g/mol, 56.63%COOH groups) was dissolved in anh. DMF 
(10mL). Then, DIC (1.5eq per carboxyl group, 0.86g/mL, 126.2 g/mol) 
was added and after 5 min, the same equivalents of HOBT (135.13 
g/mol). In order to achieve a 2% molar of conjugated Rho, 0.055mmol 
of Rhodamine (740.73 g/mol) were added after 10 minutes. DIEA was 
added to increase the pH up to 8. The reaction was left stirring 18h 
under inter conditions and at RT. After removal of DMF under high 
vacuum, the residue was re-suspended in the minimum amount of 
NaHCO3 1. Solution was purified through a PD-10 column packed with 
SephadexTM G-25M in order to remove the un-conjugated Rho. 
Fluorescence of the collected fractions was monitored with a 
spectrofluorometer Victor (λEx=528 nm, λEm=553nm). 
 
Yield: 73%. Labelling efficiency: 25% (0.05mol% labelling) 
 
Methodology for labelling with Oregon Green (OG) cadaverine. 
Synthesis scheme of OG labelling is depicted in FIGURE III. 40.  
HOMOPOLYMER (18) 
In a two neck round bottom flask, 29mg of polyglutamic acid 
(0.22mmol GA units, 1eq, 129g/mol) was weighted and dissolved in 
1mL of anh. DMF under N2 flow. Then, DIC (0.00674mmol, 0.03eq, 
0.806g/mL, 126.13g/mol) was added and the reaction was left to 
proceed for 5 minutes. After that, HOBt (6.74µmol, 0.03eq, 
135.13g/mol) was added in solid form. 10min later, Oregon Green 
(OG) cadaverine (2.01µmol, 0.009eq, 496.47g/mol) of Oregon Green 
Cadaverine was added. The pH was adjusted to 8 with DIEA. The 
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mixture was left stirring for 16-18h protected from light. Finally, the 
solvent was removed under high vacuum. The obtained residue was 
dissolved in the minimum amount of NaHCO3 1M and purified with a 
PD-10 column packed with SephadexTM G-25M using ddH2O as eluent. 
OG loading was calculated by fluorescence spectroscopy by 
registration of the fluorescence in all the fractions collected from the 
column. 
 
Yield: 80-85%. Labelling efficiency: 80-90 %.  
 
TRIBLOCK (TBO)(20) 
In a two neck round bottom flask, 14.4mg of TB200 (0.08mmol 
GA units, 1eq, average MW unit of glutamic acid=102.4g/mol, 
56.63%COOH) was weighted and dissolved in 1mL of anh. DMF under 
N2 flow. Then, DIC (0.24mmol, 3eq, 0.806g/cm
3, 126.13g/mol) was 
added and the reaction was left to proceed for 5 minutes. Afterwards, 
HOBt (0.24mmol, 3eq, 135.1 g/mol) was added directly as solid. 10min 
later, OG cadaverine (1.6·10-3mmol, 2%mol theoretical, 496.47g/mol) 
was added. The pH was adjusted to 8 with DIEA. The mixture was left 
stirring for 24h protected from light. Solvent was removed under high 
vacuum. The obtained residue was dissolved in the minimum amount 
of NaHCO3 1M and purified with a PD-10 column packed with 
SephadexTM G-25M using ddH2O as eluent. OG loading was calculated 
by fluorescence spectroscopy by registration of the fluorescence in all 
the fractions collected from the column. 
 
Yield: 80-85%. Labelling efficiency: 84%  
 
Oregon Green pH stability study and quenching properties 
For pH study, OG and TB200-OG (0.72%mol OG) solutions were 
mixed with solutions 1M of NaOH aq. and 1M HCl. Fluorescence 
measurement was done at wavelengths λem=535nm, λex=485nm. 
In case of observation of fluorescence quenching, independent 
solutions of OG and TB200-OG in DMSO were prepared and different 
concentrations. Dilutions fluorescence was measured as explained 
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previously. 
 
Methodology for labelling with Cyane5.5 
Synthesis scheme of Cy5.5 labelling is depicted in FIGURE III. 
44.  
HOMOPOLYMER: PGA-click-Cy (22) 
Cy5.5 azide derivative conjugation. Copper catalysed alkyne-azide 
coupling (CuACC). 
 
In a Schlenk tube, 1eq of copolymer (PGA-propargylamine, 
0.5μmol, 20000g/mol) was dissolved in anh. DMF. Reactor was purged 
with N2 flow and degassed by performing two freeze-pump-thaw 
cycles. In a vial, a solution of CuBr and PMDTA was prepared by 
dissolving both reagents in anh. DMF (CuBr: 1eq, 143.45g/mol; 
PMDTA: 1eq, 173.3g/mol), bubbling nitrogen through the solution for 
20min to prevent oxidation of Cu(I). Once the CuPMDTA complex was 
dissolved, it was added to the solution and after that, the probe Cy5.5-
azide derivate (3eq, 743.42g/mol). The mixture was deoxygenated by 
freeze-pump-thaw cycles. The resulting mixture was stirred at 40°C 
under a nitrogen atmosphere for 48h, protected from light. The 
solvent was removed under evaporation at high vacuum and the 
residue was redissolved with the minimum amount of NaHCO3 1M. 
Solution was purified through a PD-10 column packed with 
SephadexTM G-25M. Fractions were analysed by fluorometer device to 
evaluate the percentage of Cy5.5 conjugated and those containing the 
conjugate signal were joined and freeze dried.  
 
Max ex/em wavelength of the labelled PGA=629/692nm. 
Labelling efficiency: 87% (1.8%molCy5.5).  
 
DIBLOCK-Cy5.5 (34) 
In one round bottom flask, 100mg of DB200 (PGA100–PEG-SS-
4TP, 0.72mmol, 1eq, average MW unit of glutamic acid (sodium salt 
form)=160.5g/mol) were suspended in 8mL of ddH2O. For a 2%mol 
labelling, next steps were followed: in a vial, DMTMM·Cl- 
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(0.0217mmol, 0.03eq, 276.7g/mol) was dissolved in 1mL of ddH2O and 
then added to the main solution. After 10 minutes in agitation, 
Cyane5.5-NH2 derivate (0.0144mmol, 0.02eq, 589.25g/mol) previously 
dissolved in 7mL ddH2O was added to the main solution. Finally, pH 
was checked to 8 (if pH was lower, it was adjusted with NaHCO3 1M 
solution). The reaction was monitored by TLC (MeOH) and it was left 
under agitation at RT for 40h. The mixture was freezed-dried and the 
blue powder obtained was redissolved in ddH2O and purified through 
a PD-10 column packed with SephadexTM G-25M using ddH2O as 
eluent. Fractions collected were analysed by fluorometer device.   
In addition, 4TP release assay was performed to ensure its stability 
after the reaction. 
 
Max ex/em wavelength of the labelled PGA=598/655nm. 
Labelling efficiency: 90.86% (1.63%molCy5.5), 4TP assay: positive. 
 
III. 3. 1. 2 Contrast agents labelling. DTPA/Gd complex. 
 
Methodology for labelling for MRI analysis by DTPA/Gd conjugation  
 
DTPA conjugation to TB-diamine. 
Synthesis scheme of DTPA conjugation to TB is depicted in 
FIGURE III. 46. 35mg of TB200-diamine30% (24) (0.19mmol GA units, 1eq, 
average MW unit=188g/mol) were weighted and dissolved in 4mL of 
anh. DMF under N2 flow. Amino pendant groups were activated with 
DIC (0.08mmol, 0.45eq, 0.806g/cm3, 126.13g/mol) as the coupling 
reagent for 5 minutes. After that time, HOBt (0.08mmol, 0.45eq, 135.1 
g/mol) was added directly in solid form. The reaction was then left to 
proceed for 10minutes more. Afterwards, DTPA anhydride 
(0.056mmol, 0.3eq, 357.32g/mol) was added. The pH was adjusted to 
8 with DIEA. At the end of the reaction, solvent was removed under 
evaporation and product was dissolved in NaHCO3 1M for further 
purification by ultrafiltration (Vivaspin® MWCO3000) or PD-10 column. 
Then, the fractions were lyophilised and product was collected. The 
degree of DTPA substitution was determined by titrating DTPA with 
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GdCl3 solution using 4-(2-pyridylazoi)-resorcinol as Gd(III) indicator. 
 
Gd(III) chelation 
Complexation scheme of Gd(III) is depicted in FIGURE III. 46.  
For Gd(III) chelation, the ratio 1:1eq DTPA:GdCl3 was 
considered. TB200-diamine-DTPA (as sodium salt) (24) (was dissolved in 
PBS 0.1M pH=7.4, while GdCl3 (0.001mmol, stock: 100mg/mL, 
263.61g/mol) was dissolved in ddH2O and dropped into the main 
solution. During this procedure, pH was monitored and remained 
constant to 8. In parallel, the degree of Gd(III) complexation was 
determined by titrating aliquots using 4-(2-pyridylazo)resorcinol 
(which turns from yellow to orange in presence of free Gd). After 4.5h 
of reaction, no free Gd was detected and the reaction was stopped by 
freeze-drying the reaction mixture [37]. The white powder obtained 
was purified through a PD-10 column for desalting.  
 
Yield: 100% 
 
III. 3. 1. 3 Labelling with radionuclides 
 
Methodology for labelling with Tyramine for PET monitoring after 18F 
conjugation 
Synthesis scheme of tyramine labelling to TB is depicted in 
FIGURE III. 47.  
In a round bottom flask, triblock PEG-b-PGAn-b-PEG-SS-4TP (9) 
(1eq, 0.15mmol of GA unit) was placed and the system was purged 
with nitrogen flow. Then, it was dissolved in 15mL of anh. DMF under 
stirring at 35°C in an oil bath under inert atmosphere. Then, DIC 
(1.5eq, 0.22mmol, 0.806g/mL, 126.2g/mol) was added and after 5min, 
the same equivalents of HOBT (1.5eq, 0.22mmol, 135.13 g/mol) as 
solid. Ten minutes later, tyramine (for 20%mol: 0.028mmol, 137.18 
g/mol) were added to the reaction. The pH was adjusted to 8 with 
DIEA. The reaction was left under constant agitation at 35°C protected 
from light, under N2 atm. After 24h, DMF was evaporated under 
vacuum. The residue was perfectly re-suspended in 1mL of DMF and it 
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was purified through LH20 column (using DMF as eluent). 30 fractions 
of 1mL were collected and afterwards each fraction was evaporated 
under vacuum individually. Then, ddH2O was added to freeze-dry the 
tubes and dry them properly. 1H-NMR and COSY analysis (DMF-d7)) 
were done of each product obtained. TABLE III. 23 shows the different 
TBs labelled with tyramine. 
 
Yield: 85%. 1H-NMR (300 MHz, DMF-d7) δ (ppm) 1.76-1.89 (2H, m), 
2.13 (2H, m), 3.45 (xH, s), 4.16 (1H, t), 6.97 (d, nH), 6.70 (nH), 7.60 (d) 
8.40 (zH, s). 
(PEG proton signals (x and z) were related to DP of the PGA block and 
tyramine signals (n) depended on the percentage coupled (when 
conjugated, tyramine benzyl signals are broader and doublet is not 
recognisable, i.e. TB100-16%mol tyramine: δ (ppm) 1.76-1.89 (200H, m), 
2.13 (200H, m), 3.45 (455H, s), 4.16 (100H, t), 6.97 (d, 32H), 6.70 (d, 
32H),  7.60 (2H, d) 8.40 (2H, s). 
 
Methodology for labelling with DOTA/Ga for PET monitoring  
 
DOTA conjugation 
 General procedure for DOTA/Ga conjugation is depicted in 
FIGURE III. 48. 
 
HOMOPOLYMER (PGA-DOTAtBu) (28) 
In a round bottom flask, PGA100 (11) 2.32mmol, 1eq, average 
MW GA unit=129g/mol) was placed and system was purged under 
constant nitrogen flow. Product was dissolved with 20mL of anh. DMF. 
Then, 1.5eq of DIC (0.35mmol, 0.836g/cm3, 126.20g/mol) was added 
to the reaction and after 5min, 1.5eq of HOBt (0.35mmol, 
135.10g/mol) was incorporated as a solid. 10min later, DOTA-NH2 
derivate (tert-butyl 2,2´,2´´-(10-(2-(2aminoethylamino)-2oxoethyl)-
1,4,7-tetrazacyclododecane-1,4,7-triyl)triacetate (for 10%mol: 
0.23mmol, 0.1eq, 614.82/mol) dissolved in anhydrous DMF was 
dropped to the reaction. Depending on the degree of conjugation 
desired, DOTA equivalents were modified (TABLE III. 24). The pH was 
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adjusted to 8 with DIEA. After 48h stirring at RT, solution was 
concentrated under high vacuum. Purification was performed by 
precipitation of the concentrated solution in an excess of cold acetone. 
Pale yellow precipitate was recovered after centrifugation (2600rpm, 
4°C, 10min) and dried under vacuum. Percentage of DOTA conjugation 
was calculated by 1H-NMR analysis (D2O). 
 
Yield: 88%. %mol DOTA: 9.8, 1H-NMR (300 MHz, D2O) (9.8%mol DOTA): 
δ 4.24 (1H), 2.31 – 1.76 (m, 4H), 1.41 (s, 2.7H). 
 
DIBLOCK (DB-DOTAtBu) (29) 
In a round bottom flask, diblock mPEG-b-PGAn (7) (n=100, 
0.7166mmol, 1eq, average MW GA unit (salt form)=171.31g/mol) was 
placed and then dissolved with 5mL ddH2O. Then, DMTMM·Cl 
(0.0717mmol, 0.115eq, 0.836g/cm3, 126.20g/mol) was added to the 
reaction and after 10min, DOTA-NH2 derivate (for 11.5%mol: 
0.0717mmol, 0.115eq, 614.82/mol) previously dissolved in anh. DMF 
(1mL) was dropped to the reaction. pH was adjusted to 8 with DIEA. 
After 48h stirring at RT, solution was concentrated under high vacuum. 
Purification was performed by precipitation of the concentrated 
solution in an excess of cold acetone. Pale yellow precipitate was 
recovered after centrifugation (2600rpm, 4°C, 10min) and dried under 
vacuum. Percentage of DOTA conjugation was calculated by 1H-NMR 
analysis (D2O). 
 
Yield: 71%. %mol DOTA: 10.8. 1H-NMR: (300 MHz, D2O)(10.8%mol 
DOTA): δ 4.24 (1H), 3.6 (s), 2.31 – 1.76 (m, 4H),  1.41 (s, 2.9H). 
 
DOTA deprotection 
Deprotection scheme of tBu groups from conjugated DOTA 
moiety is depicted in FIGURE III. 48.  
To avoid crosslinking reactions, carboxyl groups of DOTA 
moiety are usually protected. In the present derivative, ending groups 
were protected by t-butyl groups. Carboxyl groups were deprotected 
with the protocol described below, before 68Ga complexation. 
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(A) The PGA-DOTAtBu conjugate was dissolved in CH2Cl2 /TFA (3:2, 
v/v) mixture and left under agitation 15h at room temperature. 
Afterwards, solution was precipitated into an excess of cold diethyl 
ether. Yellow solid obtained was collected, washed with fresh ether 
and dried over vacuum. Full deprotection was checked by 1H-NMR 
analysis. 
Yield: 91%. Deprotection yield: 100% 
 
(B) The PGA-DOTAtBu conjugate was dissolved in TFA/H2O/TIS 
(95:2.5:2.5 v/v) mixture and left under agitation 3h at room 
temperature. Afterwards, solution was precipitated into an excess of 
cold diethyl ether. Yellow solid obtained was collected, washed with 
fresh ether and dried over vacuum. Full deprotection was checked by 
1H-NMR analysis. 
Yield: 89%. Deprotection yield: 100% 
 
Gallium labelling 
 For 68Ga labelling, first this radionuclide was eluted, purified 
and concentrated. Then, the obtained 68Ga was transferred into 
microwave tube and the pH was adjusted to 3.5-4 by adding HEPES 
buffer. Immediately, the DOTA labelled system (e.g. PGA-DOTA 
(8.61mg) in aqueous solution was added 500µL. The mixture reaction 
was heated at 90°C for 5min by a microwave laboratory with 
monomodal radiation (Discover Benchmate, CEM). Then, purification 
was performed with a exclusion molecular chromatography cartridge 
(Bio Gel P-6 Bio Rad) using PB pH=7 as eluent. The elution profile was 
determined by fractionating and measuring the fractions with an 
activimeter (VDC 405 Veenstra). Radiochemical yield (RY) was 
calculated as percentage of the activity in each fraction eluated from 
the molecular exclusion cartridge of the total activity purified, 
corrected for the decay. 
Radionuclide purity (RNP) was assessed by γ-spectrometry 
(HPBGe detector) immediately and after 24-48h in order to determine 
the 68Ga breakthrough. 
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III. 3. 2 Targeting ligands conjugation for BBB crossing through active 
transport  
 
III. 3. 2. 1 Transferrin  
 
Firstly, sulfhydryl groups were introduced in the protein by the 
reaction of its own amino groups with 2-iminothiolane. These –SH 
groups are the specific linkage point to conjugate the PEG-SS-4TP 
block of diblock or triblock systems.  
 
Methodology for Tf thiolation  
Synthetic scheme of thiolated Tf is depicted in FIGURE III. 51.  
The protocol from Ulbrich et al. detailed in ref [38] was used with 
few modifications. In a round bottom flask, human holo-transferrin 
(0.58mmol, 1eq, 78KDa) was dissolved at a concentration of 10mg/mL 
in phosphate buffer pH=8.0 and incubated with a solution 6.9mg/mL 
of 2-iminothiolane (76.2molar excess, 44mmol, 137.63g/mol) in the 
dark for 1.5h at RT and constant shaking. Purification was performed 
with two methodologies described below.  
(i) The thiolated Tf was purified directly through a Sephadex G25 
column using PB pH=8 as eluent. In each fraction, protein amount was 
checked twice by absorbance measurement with Nanodrop® 
(λmax=220, 280nm, Ɛ=82.74 mM
-1 cm-1) measurement and Bradford 
assay (protocol detailed in appendix III). Fractions were joined and 
total amount of protein was measured with the named methodologies 
and percentage of SH-groups introduced was calculated after MS 
MALDI-TOF analysis. 
(ii) The mixture was purified by Ultrafiltration (Vivaspin® 
MWCO=10000Da) and using PB pH=8 as eluent. Washes were 
performed until no absorbance signal of 2-iminothiolane (λmax=240nm, 
Nanodrop® measurement) was detected. Finally, protein 
concentration was determined by Nanodrop® (λmax=220, 280nm) and 
MW by MS MALDI TOF analysis. 
Protein was used in solution for next reaction immediately after its 
synthesis. 
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Thiolated transferrin conjugation to polyglutamates systems 
Synthetic scheme of conjugate TB-Tf (33) is depicted in FIGURE III. 
54.  
 
Thio-Tf conjugation to TB-OG 
Synthetic scheme of OG labelling of TB-Tf (33) is depicted in 
FIGURE III. 40.  
In a 10mL round bottom flask, 6.8mg of TBO (n=200, 1.6%mol 
OG, 6eq) were dissolved in 2mL of PB pH=8 and 1eq of thiolated Tf (in 
solution, 81KDa) was added under agitation. The reaction was purged 
with nitrogen flow, protected from light and left under constant 
agitation at RT. After 24, reaction was placed at 4°C for 24h. Aliquots 
(20μL) from the solution were taken at different time points for SDS-
PAGE gel analysis (protocol detailed in appendix III), with and without 
reduction conditions. Then, the reaction volume was reduced by 
Ultrafiltration (Vivaspin® MWCO=2000Da) and purified through FPLC 
equipped with a size exclusion column (Sephacryl S300 column, flow 
rate=1mL/min, solvent A: PB pH=8; isocratic method, wavelength=215, 
254, 280nm). Collected fractions were analysed by Nanodrop® for 
protein detection and quantification; and OG presence was detected 
visually and confirmed by fluorescence measurement by Victor® 
spectrophotometer. 
 
Thio-Tf conjugation to DB-Cy5.5 
Synthetic scheme of Cy5.5 labelling of DB-Tf (35) is depicted in 
FIGURE III. 44.  
In a round bottom flask, DB100-Cy5.5 (34)(1.63%mol Cy5.5, 
8.4eq) was dissolved in 2mL of ddH2O and 1eq of thiolated Tf (in 
solution) was added. The reaction was purged with nitrogen flow, 
protected from light and left under constant agitation at RT. After 24, 
reaction was placed at 4°C for 48h. Aliquots (20μL) from the solution 
were taken at different time points for SDS-PAGE gel analysis (protocol 
detailed in appendix III) with and without reduction conditions.   
When reaction progress had stopped, the volume was reduced by 
Ultrafiltration (Vivaspin® MWCO=2000Da) and purified through FPLC 
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equipped with a size exclusion column (Sephacryl S300 column, flow 
rate=1mL/min, solvent A: PB pH=8; isocratic method, wavelength=215, 
254, 280nm). Collected fractions were analysed by Nanodrop® for 
protein detection and quantification; and Cy5.5 presence was 
detected visually and confirmed by fluorometer measurement. 
 
III. 3. 2. 2 mAbOX26 
 
Protocol for mild reduction of the mAbOX26 
Reduction scheme of mAb is depicted in FIGURE III. 59.  
In a 50mL round bottom flask, mAbOX26 (0.19mmol, 95kDa 
aprox.) was reduced under inert atmosphere (N2 flow) with DTT (final 
concentration in reaction: 50μM, 154.3g/mol) in 18mL of PBS 0.1M, 
for 30min under stirring at RT. Then, reaction solution was purified 
through a PD-10 column packed with SephadexTM G-25M and 
absorbance of the fractions collected was analysed by Nanodrop® 
measurement (alternative purification was done by ultracentrifugation 
(Vivaspin®, MWCO=10000Da) at 4°C, until DTT absorbance in the low 
part of the tube disappeared). Bradford assay was also performed in 
order to confirm Ab presence in the purified solution. Once all 
fractions were joined, Ab concentration was determined by 
Nanodrop® (λ=280nm). 
 
Reduced antibody remained always in solution to avoid difficulties 
in re-dissolution and it was added immediately to the selected PGAs 
for further reaction. 
 
Reduced antibody conjugation 
Synthetic scheme of mAb conjugation to TB-DTPA/Gd is depicted 
in FIGURE III. 61.  
The concentrated solution of the reduced antibody (0.74mmol, 
1eq, 95KDa) was added dropwise to the reaction flask with the 
labelled TB-DTPA/Gd (26) (1eq) already dissolved in PBS 0.1M pH=7.4. 
Reaction was left stirring for 24 h at RT under N2 atmosphere.  To 
concentrate the volume of the reaction for further purification, 
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mixture was ultracentrifugated (MWCO=10000Da) at 8000rpm and 
4°C. Upper part of the ultracentrifugation was analysed to test the Ab 
presence and concentration by means of Bradford assay and 
absorbance measurement with Nanodrop®. Purification was carried 
out by means of FPLC equipped with a size exclusion column 
(Sephacryl S300 column, flow rate=1mL/min, solvent A: PBS pH=7.4, 
isocratic method, wavelength =215, 254, 280nm).  Fractions were the 
antibody conjugate were found, were mixed and concentrated again 
by ultracentrifugation. Product was storage in solution until further 
use at 4°C. 
 
III. 3. 2. 3 Peptidic sequences 
 
Angiopep-2 
 
4TP activated 3-aminopropane-1-thiol coupling. Spacer between 
peptide and polymer. 
Protocol described below was calculated for achieving a 
theoretical 10%mol introduction of -SH groups onto the main 
polymeric chain. 
In a round bottom flask, PGA100-DOTAtBu (28) (1.06mmol, 1eq, 
10%mol DOTA, average MW unit=188.7g/mol) was dissolved in 6mL of 
anh. DMF under N2 flow. DIC-coupling of the 4TP activated 3-
aminopropane-1-thiol was performed as follows: DIC (0.159mmol, 
0.075eq, 0.815g/cm3, 126g/mol) was incorporated to the reaction and 
5min after, HOBt as solid form (0.159mmol, 0.075eq, 135.13g/mol). 
10min later, 4TP activated 3-aminopropane-1-thiol (0.106mmol, 0.1eq, 
1.012g/cm3, 186.03g/mol) was added to the reaction solution. The pH 
was adjusted to 8 with DIEA. The reaction was left to proceed stirring 
at RT and inert atmosphere for 48h. Product purification was done by 
precipitating in cold acetone the reaction volume, which was placed 
afterwards at -20°C to facilitate complete precipitation. The obtained 
light brown solid was recovered by centrifugation and supernatant 
was discharged. Solid was dried under high vacuum and characterised 
by 1H-NMR analysis (D2O). 
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Yield: 96%. % coupling: 6%mol (homopolymer), 11% mol (DB)  
1H-NMR: 
Homopolymer (6%mol Cys-4TP) 1H NMR (300 MHz, D2O) δ 8.32 (s, 
0.6H), 7.60 (d, 0.6H), 7.34 (d, 0.6H), 7.19 (s, 0.6H), 4.23 (s, 1H), 1.26 (s). 
DB (PEG-b-PGA) (10%mol Cys-4TP) 1H NMR (300 MHz, D2O) δ 8.31 (s, 
0.10H), 7.72 (s, 0.26H), 7.18 (s, 0.10H), 3.63 (s, xH), 2.13 (d, 3.73H), 
1.36 (s, 2.98H).Note: protons at 3.63ppm correspond to PEG chain. 
 
Labelled DOTA deprotection. t-butyl removal. 
Protocol described below was used either for homopolymer 
(PGA) or PEG-b-PGA block copolymer. 
PGA-DOTAtBu-Cys-4TP (37) (0.083mmol, average MW per 
unit=217.24g/mol) was dissolved in TFA/TIPS/ddH2O (95:2.5:2.5 v/v) 
and left 3h under constant agitation at RT. Then, solution was 
precipitated into an excess of cold diethyl ether. The yellow solid 
obtained was collected, washed with fresh ether and dried over 
vacuum. Complete deprotection was checked by 1H-NMR analysis. 
 
Yield: 100%. Deprotection: 100%  
 
Conjugation of derivative Angiopep-2 to the polymer platform by 
disulphide bond formation 
For Angiopep-2 conjugation either to PGA or DB, same 
equivalents of peptide than the introduced linker were used (TABLE III. 
27). E.g. PGA conjugation: 45mg of PGA-DOTA11%-Cys4TP6% (39) 
(0.225mmol, 1eq, MW unit=200.41g/mol) were dissolved in 
ammonium acetate 150mM pH=5 (4mL). At the same time, the 
peptide (0.011mmol, 0.05eq, 2300g/mol) was dissolved in 3mL HEPES 
10mM pH=7.4 buffer. The two solutions were mixed up reaching a pH 
of 6. The reaction was left to proceed for 16h under agitation.  
Afterwards, product was purified through a PD-10 column and 
fractions were analysed by absorbance measurement (Nanodrop®) 
(FIGURE III. 63) and 1H-NMR (D2O). Peptide quantification was 
performed by amino acid analysis performed in the University of 
Barcelona (Unitat de Tècniques Separatives i Síntesi de Pèptids Centres 
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Científics I Tecnològics).  
 
Yield: 68%(homopolymer), 70 % (diblock) 
Molar % peptide coupling: 
 
 
 % Angiopep-2 
 
REF 
1
H-NMR 
(ppm) 
AA content 
(%mol) 
PGA-DOTA-SS-Cys-Angiopep2 41 4.7 3.9 
DB-DOTA-SS-Cys-Angiopep2 42 4.5 3.5 
AA=amino acid 
 
Iron-mimicking cyclic peptide 
 
Di-amine monoprotected coupling. Spacer between peptide and 
polymer. 
 
HOMOPOLYMER (PGA-DOTAtBu-BOCdiamine) (43) 
Protocol described below was calculated for achieving a 
theoretical 5%mol introduction of -NH2 groups onto the main 
polymeric chain. 
In a round bottom flask, PGA-DOTAtBu (28) (0.53mmol, 1eq, 
10%mol DOTA, average MW unit=188.7g/mol) was dissolved in 3mL of 
anh. DMF under nitrogen flow. Once dissolved, DIC-coupling of the N-
Boc-ethylenamine was performed as follows: DIC (0.0397mmol, 
0.075eq, 0.815g/cm3, 126g/mol) was incorporated to the reaction and 
5min after, HOBt as solid form (0.0397mmol, 0.075eq, 135.13g/mol). 
10min later, N-Boc-ethylamine (0.0265mmol, 0.05eq, 1.012g/cm3, 
160.21g/mol) was added to the reaction solution. pH was adjusted to 
8 with DIEA. Afterwards, reaction was left to proceed under constant 
agitation at RT and inert atmosphere for 48h. 
Product purification was done by precipitating in cold acetone 
the reaction volume, which was placed afterwards at -20°C to facilitate 
complete precipitation. Pale yellow product was recovered by 
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centrifugation and supernatant was discharged. Solid was dried under 
high vacuum and characterised by 1H-NMR analysis (D2O). 
 
Yield: 100%. % diamine content: 9% (determined by 1H NMR (300 MHz, 
D2O): δ 4.23 (1H), 1.37 (d, 3.76H)). 
 
DIBLOCK (DB-DOTAtBu-BOCdiamine) (44) 
Protocol described below was calculated for achieving a 
theoretical 5%mol introduction of -NH2 groups onto the main 
polymeric chain. 
In a round bottom flask, mPEG-b-PGAn-DOTAtBu (29) 
(0.17mmol, 1eq, 11%mol DOTA, average MW unit (salt 
form)=234.6g/mol) was suspended in 3mL of ddH2O. Once dissolved, 
DMTMM-coupling of the n-Boc-ethylenamine was performed as 
follows:  2.4mg of DMTMM·Cl (0.0085mmol, 0.05 eq, 276.77g/mol) 
was added dissolved in 1mL of ddH2O. After 10 minutes, N-Boc-
ethylendiamine (0.0085mmol, 0.5eq, 1.012g/cm3, 160.21g/mol) was 
added. The pH of the mixture was 8. The reaction was allowed to 
proceed over 48h at room temperature. 
Then, the reaction solution was purified by ultrafiltration 
(Vivaspin®, MWCO=3000Da) using ddH2O. Once the volume was 
concentrated, solution in the upper part of the tube was freeze-dried. 
The obtained white solid was dried under high vacuum and 
characterised by 1H-NMR analysis (D2O). 
 
Yield: 78% 
% diamine content: 11%mol (determined by 1H-NMR (300 MHz, D2O): 
δ 4.25 (s, 1H), 3.63(s, xH), 2.21 (s, 2H), 1.96 (s, 2H), 1.42 (d, J=25.1 Hz, 
4H)). Note: protons at 3.63ppm correspond to PEG chain. 
 
Di-amine deprotection. N-Boc group removal. 
PGA-DOTAtBu-n-Boc-ethylenediamine (43) (0.43mmol, 
average MW per unit=161.69g/mol) was dissolved in CH2Cl2:TFA (6:4, 
v/v) and left 15h under constant agitation at room temperature. Then, 
solution was precipitated into an excess of cold diethyl ether. The 
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yellow solid obtained was collected, washed with fresh ether and dried 
over vacuum. Complete deprotection was checked by 1H-NMR 
analysis. 
 
Yield: 90%. Deprotection: 100% 
 
NHS activation of the cyclic peptide (cPEP). 
Under inert environment, 30mg of cPEP (0.032mmol, 1eq, 
940g/mol) were dissolved in anh. DMSO (0,5mL). After complete 
dissolution, DCC (0.042mmol, 1.3eq, 206.33g/mol) was added. After 
5min, NHS (0.042mol, 1.3eq, 115.09g/mol) was incorporated to the 
reaction mixture and it was left to proceed for 16h at RT and N2 atm. 
After that time, reaction was precipitated into cold ether and pellet 
was freeze-dried. Percentage of activation was obtained after NMR 
signals integration. 
 
Yield: 30mg. %NHS activation: 100% (determined by 1H-NMR, peak at 
2.6ppm). 
 
Conjugation of the cyclic peptide to the polymer platform 
For conjugation to the polymeric platform, same equivalents 
of peptide than the introduced linker were used (TABLE III. 27). E.g. 
PGA conjugation: 22.25mg of PGA-DOTA2%-ethylendieamine9% (45) 
(0.1398mmol, 1eq, MW unit=160.94g/mol) were dissolved in PBS 
buffer pH=7.4 (4mL). Then, 13mg of cPEP-NHS (0.0126mmol, 0.09eq, 
1033g/mol) were added. Reaction was left under agitation for 5h. 
Afterwards, product was purified through a PD-10 column and 
fractions were analysed by 1H-NMR (D2O). Peptide quantification was 
performed by amino acid analysis in the University of Barcelona 
(Unitat de Tècniques Separatives i Síntesi de Pèptids Centres Científics I 
Tecnològics). 
 
Yield: 80% (homopolymer), 75%(diblock) 
Molar % peptide coupling: 
 
 
[CHAPTER III.] 
[309] 
 
 
% cPEP 
 
REF 
1
H-NMR 
(ppm) 
AA content 
(%mol) 
PGA-DOTA-cPEP 47 2.75 n.d. 
DB-DOTA-cPEP 48 3.40 2.8 
AA=amino acid, n.d.=not determined 
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CHAPTER IV. BIOLOGICAL CHARACTERISATION OF 
POLYGLUTAMATES  
 
Biological evaluation in cell models, in vitro tests, usually 
precede in vivo evaluation of every therapeutic. The objectives include 
the evaluation of toxicity, the determination of the cell internalisation 
pathway and cell trafficking, proof of efficient targeting and activity 
studies. Besides, selection of the appropriated cell line will facilitate 
data extrapolation to posterior in vivo assays.  
 
BBB physiology and pathology has capture scientific and 
industrial interest, leading to a massive number of in vitro BBB models, 
from which those based on cells of non-cerebral origin have been 
significantly reported [1].  Endothelial and epithelial cells of non-
cerebral origin have been deeply used to study different aspects of 
BBB function. Specifically, endothelial cells are the most important cell 
types of the BBB as they form a continuous sheet covering the inner 
surface of the capillaries. As stated in the introduction section I.1.3.1, 
these cells are interconnected by tight junctions (TJs) which form a 
belt-like structure at the apical side, constructing the physical feature 
of the barrier.  
 
Herein, the cell line HUVEC (human umbilical vein endothelial 
cell line) was chosen due to their endothelial origin for carrying out 
preliminary cell viability studies as well as to explore the possible 
internalisation mechanisms followed by the synthesised 
polyglutamates. HUVEC cells are a non-cerebral cell type of human 
origin, which are able to be isolated from the umbilical cord. They are 
one of the most widely used endothelial cells [1, 2]. As it has been 
already mentioned, the use of cell models in co-culture rather than 
monoculture represents better the BBB [3] and the introduction of 
flow systems even go a step further [4]. It is planned to use these 
more advanced models as future work in order to evaluate the 
capacity of targeted PGAs to cross the BBB. In addition, HeLa cells 
were exploited in toxicity and internalisation studies as an extra cell 
line with non-endothelial origin to compare the behaviour of our 
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PGAs. This cell type is an immortal cell line derived from cervical 
cancer cells; the oldest and most commonly used human cell line in 
research [5]. 
 
Next step in the evaluation of PDCs involves its in vivo study, 
including biodistribution and pharmacokinetics (PK) studies as well as 
the proof of the therapeutic activity in the adequate animal model. 
Characteristics such as PK, biodistribution and metabolic clearance are 
important parameters directly related with the overall effectiveness of 
novel macromolecular delivery vectors (FIGURE IV. 1). The 
determination of conjugates distribution into the body after systemic 
administration has been catalogued as a top priority [6] and the 
polymeric carrier together with the bioresponsive polymer-drug linker 
used clearly determine drug distribution in vivo and drug fate. 
 
There are required factors to achieve an adequate 
biodistribution, i.e. non-specific accumulation, non-alteration of the 
immune system, blood circulation extravasation to reach the site of 
action (i.e. diseased organ, inflammation or tumourogenic area, etc…) 
and binding to a molecular target and/or undergoing cellular 
internalisation. Physicochemical properties of the polymeric backbone 
such as chemical composition, size, MW, polydispersity, conformation 
in solution (shape), charge or hydrophobic-hydrophilic blocks ratio 
(among others) could significantly modify all these parameters. Size, 
along with chemical composition, influences in hepatic filtration tissue 
extravasation, tissue diffusion and kidney excretion. Charge could 
induce different patterns of behaviour e.g. higher uptake by 
phagocytosis, shorter blood circulation half-life due to positive 
charges.  It is well recognised that neutral or negatively charged 
systems have a reduced plasma protein adsorption and low rate of 
non-specific cellular uptake, decreasing side-effects of unexpected 
toxicity. Moreover, aggregation processes derived from these 
characteristics may also influence the final distribution [7]. Solution 
conformation (shape and size) adopted after polymer conjugate 
administration is a key feature that determine conjugate 
biodistribution [8]. In this context, one of the hypotheses from the 
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present work was that the length of the inner polypeptide block as 
well as the presence of one or two PEG terminal blocks will be 
translated onto a different biodistribution and PK profile due to the 
different solution conformation adopted.  
 
FIGURE IV. 1 Drug ADME routes in the human body. Redrawn from ref. [8]. 
 
The purpose of the experiments carried out in this chapter was 
to validate in vivo the synthesised family of amphiphilic block 
copolymers as polymer carriers for targeted drug delivery. 
Biodistribution studies allowed monitoring the compound of interest 
into the body after i.v. administration, identifying organ distribution 
and the ultimate routes of metabolism and clearance (FIGURE IV.  2). 
 
Different techniques available for conjugate monitoring have 
been already tested with PT, being able to quantitate the free and 
bound drug in biological fluids and tissues by means of radioactivity, 
HPLC, atomic absorption spectroscopy (AAS), and in the clinics using 
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probes for gamma camera imaging [10, 11], MRI and PET [12].  Lately, 
the use of near infra-red (NIR) fluorescent and luminescent tools to 
visualise nanomaterials had become popular in preclinical models 
although proper quantitation is difficult due to the problems 
associated with signal tissue penetration and artefacts [13, 14].  
 
 
FIGURE IV.  2 Diagrammatic representation of the mice biodistribution model 
and organ region model. Adapted from ref.[9]. 
   
Independent biodistribution studies with non-targeted and 
targeted systems were performed. Non-invasive imaging techniques 
were selected for our purpose, namely: fluorescence labelling for 
optical imaging, MRI and PET. It has to be considered the impact of the 
labelling probe on the size, shape and physicochemical properties of 
the final conjugate; in case of high MW conjugates modifications will 
be always milder than in low MW. Regardless, the intrinsic nature of 
the probe itself (hydrophobicity, charges) as in the case of some Cy5.5 
derivates could significantly alter the real biodistribution of the 
labelled polymer if not carefully controlled. 
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IV. 1 RESULTS AND DISCUSSIONS 
 
IV. 1. 1 IN VITRO EVALUATION IN AN ENDOTHELIAL CELL LINE 
 
IV. 1. 1. 1 Evaluation of polymer cell viability by MTT assay 
 
The MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide) assay is a colorimetric assay that measures cell proliferation 
as well as reduction in cell viability when metabolic events lead to cell 
death (apoptosis and/or necrosis). It can also be used to assess the 
rate of survival of a given cell line when it is incubated in the presence 
of xenobiotics and in the derivation of cell growth curves. The 
reduction of tetrazolium salts is accepted as a reliable process to 
analyse cell proliferation as the yellow tetrazolium MTT is only 
reduced when mitochondrial reductase enzymes are active, and 
therefore conversion can be directly related to the number of viable 
(living) cells.  Reduction results in the intracellular formation of purple 
formazan crystals that are insoluble in aqueous media, which are 
spectrophotometrically measured after solubilisation with DMSO (see 
FIGURE IV.  3). The effectiveness or toxicity of the agent in causing cell 
death is determined through a dose-response curve.  
 
 
FIGURE IV.  3 Chemical structure of MTT (yellow colour) and its reduced 
formazan product (violet). This transformation is performed by mitochondrial 
reductases in live cells. 
 
The MTT test compares favourably to other methods, such as 
trypan blue which only evaluates cell membrane integrity and only 
qualitative, or the [3H]-thymidine incorporation assays which requires 
handling of radioactive substances, is time-consuming and involves cell 
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harvesting or medium changes. MTT provides a linear relationship 
between cell activity and absorbance based in the cellular metabolic 
activity. In addition, it is a quantitative method adaptable for high-
throughput screening. 
 
The MTT assay was used in the present work to assess the cell 
viability of the synthesised family of PGAs, including the novel triblock 
co-polymers (TBs) against HeLa and HUVEC cell lines at different 
concentrations up to 72 h incubation. Results are summarised in 
FIGURE IV.  4. Cell viability was calculated as a percentage of the viable 
untreated control cells. 
 
The graphs below revealed the absence of cell toxicity with 
TB100 and TB150 against HUVEC cells up to 72h. A slight decrease in 
cell viability was observed after 72h with TB200 possibly due to a 
different solution conformation (FIGURE IV.  4). Rest of compounds 
(PGA homopolymers and DB systems) showed cell viability higher than 
80% above 2mg/mL concentrations at both time periods in both cell 
lines.  
 
(A) 
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(B) 
 
FIGURE IV.  4 Dose-response curves for cell viability in HUVEC (A,B) and HeLa 
(A) cells treated with TB200 (A) or TB100, TB150 (B). Error bars correspond to 
standard deviation from five independent measurements. 
 
IV. 1. 1. 2 Cellular internalisation studies of triblock co-polymers by 
flow cytometry and confocal fluorescent microscopy 
 
Fluorescent technology has greatly facilitated the study of 
biological processes [15, 16]. Through fluorescent probe 
bioconjugation onto polymeric nanosystems it has been evidenced the 
possibility of investigate their internalisation pathways. 
 
Probes such as the fluorophore OG have been extensively 
reviewed for cellular studies to determine cell trafficking [16-19] and 
for in vivo studies although in a minor extent [20].  In this type of 
experiments it is recommended to use of non-toxic polymer 
concentrations, to ensure the absence of free dye and to define 
potential artefacts resulting from pH and/or concentration-dependant 
fluorescent quenching phenomena. In theory, minimal probe loading is 
desirable to avoid data misinterpretation as explained above, 
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fluorescent probes could drive conjugate cellular and in vivo fate 
(charge, modification of original solution conformation of the 
vehicle,…). Moreover, linkage with the fluorophore as well as the 
fluorophore itself should be biologically stable to ensure adequate 
carrier monitoring. Herein, polymers labelled with the fluorescent 
probe OG (OG labelled triblock co-polymers (PEG-b-PGAn-b-PEG, 
n=100, 150 and 200) were used for cell internalisation studies. 
Explanation on internalisation pathways is given in sections I.2.3 and 
I.2.4. 
 
Well known techniques, such as, flow cytometry (FACS) (cell 
uptake) together with live-cell confocal microscopy analysis 
(subcellular fate and pathway) in HUVEC cells, were used aiming to 
study cellular trafficking of the labelled polyglutamates. By FACS, 
experiments were also carried out at different temperatures, 37°C 
(total uptake) and 4°C (cell binding) to determine the presence of 
energy dependent or non-dependent internalisation mechanisms, 
such as endocytosis or diffusion, respectively (FIGURE IV.  6). It is 
noteworthy to remark that all experiments were done in the presence 
of leupeptine (a protease inhibitor), to avoid lysosomal degradation of 
PGA along the incubation periods. 
 
Previous studies carried out in our laboratory in HeLa cells 
showed that TB100-OMe-OG (non published data) was  internalised by 
a mixed mechanism combining endocytosis and diffusion but an 
absence of cell binding (FIGURE IV.  5). This was the starting point to 
think that this carrier could be applied to cross BBB.  
 
Unfortunately, this result was not that evident in HUVEC cells 
for any of the novel systems and mostly endocytic uptake mechanisms 
were observed although in specific example similar results were again 
encountered (FIGURE IV.  6 and FIGURE IV.  7) (see detailed 
explanation below). 
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FIGURE IV.  5 Confocal microscopy study with TB100-OMe and TB200-OMe 
labelled with OG (green fluorescence) in HeLa cells. Red fluorescence 
corresponds to the membrane marker FM 4-64. 
 
The main difference encountered with the tested triblocks was 
the length of the polypeptide block, which was expected to play a role 
in solution conformation influencing cell uptake kinetics. The time 
dependent profiles of all TB showed an energy dependent uptake 
mechanism as indicated the decreased internalisation at low 
temperature (FIGURE IV.  6). It is important to note that, after careful 
physicochemical analysis of the different TB, the theoretical DP (200, 
400 and 800) was determined as 200, 150 and 100, respectively due to 
the experimental issues described in chapter 1 with the first 
methodology of polymerisation (section II.2.2.2). Taking into account 
that equivalents of OG were equal for all TBs (0.0125mgOG/mL) it 
could be conclude that theoretically higher DP polymers were faster 
internalised at short times (15,30min) than those with lower DP, 
reaching also a greater uptake after 5h. TB200 reached a plateau after 
2h whereas TB100 and TB150 continued their internalisation in a time-
dependent manner. TB150 was the only system with a different profile 
(similar to that observed previously in HeLa cells with TB100-OMe-OG, 
FIGURE IV.  5), which could indicate a complementary internalisation 
mechanism at short incubation times (passive diffusion). This fact was 
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not corroborated by live-cell confocal microscopy study. 
 
Due to differences in the osmotic pressure, it has been already 
reported that bigger compounds can be endocytosed more rapidly 
increasing their accumulation inside the cell. Analysing our results, 
higher MW carrier displayed the higher internalisation which can be 
explained that by the different solution conformation adopted, with a 
greater size vesicle-like formation in the case of TB150 due to self-
assembling rearrangements. Conformation in solution plays a role in 
cell internalisation and therefore DLS studies are going to be carried 
out to confirm this hypothesis. 
(A) TB100 
 
(B) TB150 
 
0
100
200
300
400
500
600
0 50 100 150 200 250 300 350
G
e
o
m
e
tr
ic
m
e
an
t (min)
37ºC 4ºC Real uptake
0
50
100
150
200
250
300
350
400
450
0 50 100 150 200 250 300 350
G
e
o
m
e
tr
ic
m
e
an
t (min)
37ºC 4ºC Real uptake
[CHAPTER IV.] 
[326] 
(C) TB200 
 
FIGURE IV.  6 Time dependent cell-association of OG-labelled triblocks with 
HUVEC cells at 37 and 4 °C, by flow cytometry. Panel A, B and C shows the 
time-dependent association at 37°C, 4 °C and the real uptake (A)TB100, 
(B)TB150, (C)TB200. The values represent mean ± S.E.M.; n > 3. TB200-OG, 
TB150-OG, TB100-OG. 
 
TB200-OG was more deeply studied due to the more 
controlled synthetic aspects. As expected, a vesicular labelling and co-
localisation with lysosomal marker was observed (FIGURE IV.  7, TB200) 
demonstrating a lysosomotropic delivery mechanism of TB200-OG. 
Green fluorescence (TBO signal) increased over time inside cells, 
importantly, co-localisation with the red fluorescent signal of the 
lysosomal marker Texas Red-dextran (TRD) was also achieved.  
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FIGURE IV.  7 Confocal microscopy live cell images of HUVEC cells  incubated 
at 37°C with TB200-OG at 0, 5, 30min and 1, 2, 5h. 
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In a parallel experiment, TB (PEG-b-PGAn-b-PEG-X) with 
n=100,150 and 200 and X=PEG-SS-4TP or PEG-OMe were evaluated 
after 1h incubation in HUVEC cell lines. This incubation time was 
selected due as explained for FIGURE IV.  5. An example of the images 
obtained is illustrated in FIGURE IV.  8. Fluorescence output of each 
compound was different depending on the species, showing lower 
signal the methylated TBs. This is an important issue to consider, in 
order to correctly interpret the obtained data. Both TB150 showed 
again a possible mixed mechanism, combining endocytosis (energy 
dependent) and passive diffusion (non-energy dependent). This is 
assumed due to the observation of the green vesicular forms plus the 
cytosolic diffused green. This behaviour is more remarked in the 
methylated TB although TB-OMe were determined to have lower MW 
than the one expected due to problems in the PGA block deprotection 
(HBr affected to PEG blocks promoting their degradation).   
 
It is important to note that, these TBs are complex dynamic 
systems with conformation highly dependent on concentration used. 
Deeper studies on solution conformation are being carried out by 
means of SANS in order to understand the above-described cell uptake 
differences between TBs. 
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(A) 
 
(B) 
 
FIGURE IV.  8 Confocal microscopy live cell images of HUVEC cells  incubated 
at 37°C at 1h with OG labelled (A) TB200, TB150, TB100  and  (B) TB200-OMe, 
TB150-OMe, TB100-OMe. 
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IV. 1. 2 IN VIVO STUDIES. BIODISTRIBUTION EXPERIMENTS 
 
In vivo imaging modalities. Brief introduction. 
 
In vivo imaging methodologies are gaining fast acceptance in 
biomedical research. These techniques have improved in vitro analyses 
of tissue samples collected from cohorts of treatment groups. These 
technologies are non-invasive and non-traumatic over a time. Their 
differences rely on sensitivity, specificity, resolution, ease of use and 
cost (FIGURE IV.  9). In this work, starting experiments were done with 
fluorescence optical imaging. This technique allows easy labelling of 
the polymers and a variety of fluorescent probes (wavelengths) to 
work with. In addition, spatial resolution is good and it is a non ionising 
radiation. Main limitation comes from their limited tissue penetration, 
poor anatomical resolution (1mm) and difficulties in quantification. 
However, for whole body distribution detection, fluorescence optical 
imaging is still considered an efficient tool.  
 
 
FIGURE IV.  9 In vivo imaging modalities. BLI=bioluminescence imaging, 
MRI=magnetic resonance imaging, PET=positron emission tomography, 
FLI=fluorescence imaging, CT=computed tomography, US=ultrasounds, 
SPECT=Single Photon Emission Computed Tomography. 
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MRI is able to overcome fluorescence limitations providing 
higher spatial resolution. This fact provides better assessment of 
polymer detection in specific areas like the brain. In contrast, MRI has 
low sensitivity. Finally, PET also improves fluorescence output related 
with spatial resolution and tissue penetration. However, PET 
limitations lies on relatively short half-lives of some radionuclides and 
the need of the adequate facilities to perform the experiments.  
 
IV. 1. 2. 1 Biodistribution studies of non-targeted polyglutamates 
 
Before moving towards biodistribution studies of the targeted 
systems, a technique validation proof of concept was performed. Non-
targeted PGA homopolymer (4, 11), diblock PGA-b-PEG (5, 7) and 
triblock (PEG-b-PGA-b-PEG-SS-4TP, (9) structures were evaluated in 
vivo to test the possible toxicity, routes of clearance and to determine 
polymer circulation half-life time (t1/2). 
 
IV. 1. 2. 1. 1 Ex vivo biodistribution of TB200-OG in rats 
 
OG labelled TB200 (20) was i.v. administrated to healthy male 
Wistar rats (0.005mg OG/kg). As a control groups, non-labelled TB200 
and free OG were i.v. administrated in equal equivalents. First group of 
animals were sacrificed 4h post administration; second after 24h. In 
this experiment, it was only collected ex-vivo data through 
homogenisation of the blood and extracted organs by fluorescence 
quantification. The results are shown in FIGURE IV.  10. 
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(A) 
 
(B) 
 
FIGURE IV.  10 TBO (TB200-OG) biodistribution (A) organs analysis 
(fluorescence per gram of tissue) and (B) plasma under different treatments. 
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well as to estimate t1/2 of the TB (FIGURE IV.  10 (B)). Plasma signal was 
measured directly (bar ), after HClO4 solution addition (bar ), after 
washing with MeOH the pellet of the latest treatment (bar ) and 
after pellet washed with ACN (bar ). It was observed that serum 
fluorescence decreased dramatically after HClO4 treatment. This 
reduction was possibly produced by TB200-OG precipitation together 
with plasmatic proteins. Due to this fact, the extraction protocol was 
modified. NaHCO3 washed of the pellet was performed in the 
homogenated tissues in order to obtain the sodium salt of the TB and 
solubilise it to the aqueous phase for its subsequent fluorescence 
measuring. Regarding the t1/2, due to practical issues, t=0min group 
was omitted therefore a proper calculation was not able to be 
performed. Despite of it, fluorescence at 4h indicates that compound 
was still detected in blood circulation and after 24h detected 
fluorescence triplicated the control measurements. These experiments 
were corroborated by means of other technique as described below. 
 
In FIGURE IV.  10 (A) it is represented the normalised data of 
homogenated tissue. For fluorescence total quantification, data from 
HClO4 and NaHCO3 treatments were combined. Non-specific 
accumulation of TBO was observed in any analysed organ. The higher 
fluorescence intensities were detected in the liver for OG and in the 
kidneys for TBO, suggesting the respective preferred secretion routes. 
  
IV. 1. 2. 1. 2 In vivo biodistribution of TB200-DY787 and DB-
Cy5.5 
 
To carry out in vivo monitoring, dye properties should include 
good tissue penetration. In this respect, NIR dyes overtake other 
fluorescence probes. Main reasons for changing the methodology as 
well as the animal model were (i) diminishing the amount of conjugate 
needed for administration and (ii) a NIR dye to obtain better signal 
output continuing with low molar percentage of conjugated labelling 
probe. To carry out in vivo monitoring, NIR properties of the dyes 
Cy5.5 or DY787 allow better tissue penetration than OG and mice need 
lower doses than rats for a proper detection. First, in order to 
corroborate the ex vivo results described above, TB200 (9) was labelled 
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with the NIR dye DY-781 (Dyomics, GmbH) and in vivo biodistribution 
studies were carried out in Halle, Germany by Prof. Mäder group. 
TB200-DY781 was i.v. administered to 4 nude mice instead of rats due 
to FLI penetration limitations. The labelled TB was monitored in vivo 
and also ex vivo (FIGURE IV.  11). In vivo images were taken by 
Maestro™ in vivo fluorescence imaging system and fluorescence 
intensities of the unmixed DY781 images were quantified using 
Maestro software (FIGURE IV.  11(C)). In the first hours after injection 
the fluorescence intensity increased due to conjugate invasion in 
tissues, whereas immediately after injection it is circulating in large 
blood vessels. Later, fluorescence intensity decreased to 10% of the 
initial fluorescence after 66h.  Possible degradation processes could 
co-exist and after long periods fluorescence could be assigned to free 
dye and not to the conjugate. One important observation to note is 
the strong kidney signal obtained even after 22 hours (FIGURE IV.  
11(A, B)). A closer analysis seemed to showed accumulation of the 
fluorescence probe in the renal tubules (nephrons). Further analyses 
are being performed in order to explain this unexpected result. 
 
In parallel, at CIPF, Cy5.5 labelled diblock co-polymer DB200 
(PGAn-PEG, 5) biodistribution assay was monitored by FLI and organ 
fluorescence quantification was determined by fluorometer analysis. 
Athymic nude mice were injected via the tail vein with a single dose of 
2mg Cy5.5/kg of DB200-Cy5.5. At 2, 4, 6 and 24h post administration, 
the mice were anesthetised and fluorescence images were acquired by 
IVIS®Spectrum imaging system to track in vivo whole-body 
biodistribution of the diblock co-polymer. After i.v. injection, labelled 
DB was distributed in the blood and transiently directed to the 
excretory organs. As observed in the FIGURE IV.  19, fluorescence 
signal is localised in the kidneys (dorsal view) and bladder (ventral 
view) which confirms the renal secretion of the polymer carrier. To 
further corroborate this result, after 4h, animals were euthanized and 
blood, liver, spleen, kidneys, heart and spleen were collected. All 
tissues were analysed by ex vivo FLI (FIGURE IV.  20) and fluorescence 
was quantified by spectrofluorometer after homogenising the organs 
(FIGURE IV.  22). In vivo, ex vivo and quantitation data confirmed the 
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renal excretion route as well as the absence of non-specific 
accumulation in any other organ.  
 
(A) 
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(B) 
 
(C) 
 
FIGURE IV.  11 TB200 biodistribution monitoring through FLI. (a) Unmixed DY-
781 gray scale fluorescence images. Fluorescence intensities are white. (b) 
Organs 22 hours after injection of 1 mg TB200-DY781 conjugate. Photo (left) 
and fluorescence image (right). (c) Decrease of fluorescence intensity from 
abdominal mice images over time. 
  
These preliminary data on biodistribution based on fluorescent 
studies comparing triblock and diblock systems (DP=200) could be 
summarised in a clear renal secretion of both systems with a non-
specific accumulation in the other studied organs. Further studies with 
a greater number of animals are being carried out in Halle to allow a 
better comparison between TB and DB pharmacokinetic parameters 
by FLI. 
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IV. 1. 2. 1. 3 TB biodistribution: use of contrast agents 
(DTPA/Gd) for MRI 
 
Our final aim in this project was to ensure whether our novel 
amphiphilic carriers were capable of crossing the blood-brain barrier 
by their inherent properties. Taking into account that percentage of 
the total administered dose accumulated inside the brain would be 
very small (as reported max. 4% of administered dose [21-25]), 
sensitivity of the monitoring technique has to be greater than that 
offered by fluorescence approaches. Therefore, MRI was proposed 
and selected as an appropriate technique for in vivo brain imaging. 
This imaging methodology stands out because of its precision and 
accuracy. Its spatial resolution among similar but not identical tissues 
is particularly useful for lesion or tumour detection, perceiving 
abnormalities earlier than with other imaging tools. The 
methodological aspects and the full technique description have been 
already detailed in section IV.3.2.1.3 and IV.1.2, respectively. MRI in 
vivo studies were performed in collaboration with O. Cauli and V. 
Felipo from the Neurobiology Laboratory of the Centro de 
Investigación Príncipe Felipe (Valencia) and experiments were carried 
out in Madrid at Instituto de Investigaciones Biomédicas “Alberto Sols” 
(CSIC/UAM).  
 
The MRI contrast enhancement for the TB-DTPA/Gd 
conjugates was preliminary evaluated in healthy male Wistar rats. 
Animals were anesthetised and control parameters were fixed before 
starting the experiment. The labelled triblock co-polymers (PEG-b-
PGAn-b-PEG) with n=100 and 200 were injected i.v. in a tail vein at a 
dose of 0.2mmol Gd/kg (TABLE IV. 1). FIGURE IV.  12 shows the images 
of the rat head before contrast and after the injection of the polymer 
conjugate TB100-DTPA/Gd. Animals were monitored in vivo looking for 
brain detection (0, 1, 6 and 24h post-administration), investigating if 
the carrier owned inherent properties which allowed BBB crossing. In 
all cases studied, signal of the triblock co-polymers produced 
significant contrast enhancement in the blood vessels, (red arrows in 
FIGURE IV.  12) even in the brain ventricles. As expected with non-
targeted conjugates, no signal was observed at any time point in the 
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rat brain. Same results were observed for both triblock co-polymers 
with different polypeptide block length (TB100 and TB200). Therefore, 
it was clear the need of a targeting vector to promote active transport 
of the conjugates across BBB.  
 
Product name Total mass (g) 
GdCl3 amount (aprox.) mmol 
mmol of Gd
3+
 OX26 
TB100-DTPA/Gd 0,044 0,055 - 
TB200-DTPA/Gd 0,053 0,042 - 
TB100-OX26-DTPA/Gd 0,066 0,057 1·10
-5
 
TB200-OX26-DTPA/Gd 0,036 0,084 5·10
-5
 
TABLE IV. 1 Targeted /non-targeted gadolinium labelled triblock co-polymers 
for MRI biodistribution studies. 
 
 
FIGURE IV.  12 Magnetic resonance image of TB200-DTPA/Gd (26): T1-
weighted image of the rat head (left) after and (right) before the injection. 
Arrows indicate signal observed from the conjugated complexed agent. 
 
 
IV. 1. 2. 1. 4 PGA-homopolymer biodistribution: radio-tracer 
conjugation of DOTA/Ga for PET  
 
AFTERBEFORE
brain
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PET is a good alternative to MRI with greater sensibility and 
therefore resolution. Therefore it was also studied to complement 
previous data. Once PGA derivatives were conjugated with DOTA, 
gallium labelling and animal experiments were carried out by the Unit 
of Biomedical Applications of Radioisotopes and Pharmacokinetics at 
the CIEMAT (Madrid). 
 
In the case of PGAn homopolymer (11) evaluation, FVB/NJ mice 
(n=25) were injected PGA100-DOTA/Ga i.v. a dose between 0.2 and 1.4 
MBq of PGA-[68Ga]-DOTA (21± 4 µg compound/g body weight). 
Animals were monitored up to 3h (FIGURE IV.  13) and 5 mice per time 
were sacrificed (0.25, 0.5, 1, 2 and 3h) extracting the organs for 
radioactivity measurement (FIGURE IV.  14). The biodistribution study 
clearly revealed the expected renal excretion route (signal in bladder 
and kidneys) of the homopolymer which is confirmed in the ex vivo 
analysis data. The highest percentage of the injected dose was found 
in the kidney, along compound secretion. The results only covered 3h 
after administration due to gallium decay. PK analysis was performed 
considering a compartmental model. Half life time estimation of the 
conjugate was 0.59h. This value was in good agreement with data 
obtained in studies carried out with PGA-Cy5.5 and other PGA-drug 
conjugates in our laboratory (data non published) using the same 
protocol detailed for fluorescence analysis agreed with the 
biodistribution profile found out after PET studies with PGA-DOTA/Ga 
and also with the estimated t1/2. 
 
Reviewing the presented data in mice biodistribution of the non-
targeted polyglutamates (homopolymer, DB and TB), all of them had in 
common similar PK profiles, with a clear renal elimination and non-
accumulation in any other specific tissue. Differences in size (PGA100, 
DB200 and TB200) showed a prolonged t1/2 in bigger MW species. None 
of the tested polyglutamates demonstrated a significant accumulation 
in the brain, therefore BBB crossing without targeting was not 
achieved. 
(A) 
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(B) 
 
 
(C) 
 
FIGURE IV.  13 PET imaging of PGA-DOTA/
68
Ga (50,5 µCi) in healthy mice. (A) 
Sagittal, coronal and transverse images captured 18minutes post-
administration, (B) 160min. (C) sagittal planes with different saturation 
degrees. 
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FIGURE IV.  14 PGA100 labelled with DOTA/Ga biodistribution. Data expressed 
as normalised %ID vs. time. 
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IV. 1. 2. 2 Biodistribution studies of targeted polyglutamates 
 
Active targeting can be implemented additionally to the inherent 
passive targeting of polymeric nanocarriers with the possibility of 
overcoming critical biological barriers such as the BBB. This approach is 
expected to lead to higher and faster accumulation in the targeted 
organ increasing drug concentration. Design bases is once more a 
critical point because chemical properties of the additional ligand may 
have important effects on the entire conjugate by influencing on the 
cellular uptake [26] or resulting in lower efficiency [27]. Although BBB 
in vitro models are under constant evolution trying to accurately 
reproduce the complex features of this biological barrier, there is still 
no fully effective system reported. Undoubtedly, and even with prior 
in vitro evaluation, the evaluation of the constructs in vivo is a 
mandatory examination to confirm their success or failure as 
transporters across BBB and drug delivery carriers into the brain. 
Therefore and due to the absence of the optimal in vitro models to 
date, in the present work we have only used in vivo models to evaluate 
BBB crossing. Methodology to examine effectiveness of our targeted 
polyglutamates vehicles cover the techniques explained in sections 
I.1.6.2, I.2.5 and IV.1.2. 
 
IV. 1. 2. 2. 1 Brain detection by immunohistochemistry. 
Transferrin-TB conjugate 
 
With the purpose of detecting if Tf conjugates were able to 
cross the BBB, Western Blot technique (protocol detailed in appendix 
III) was selected to detect endogenous Tf from brain homogenate 
samples. Human Tf covalently conjugated to TB carrier was 
administrated i.v. in rats and after 4h post-injection, animal was 
sacrificed and brain harvested and preserved for the proposed study.  
 
Previous to the in vivo analysis, anti-Tf antibody binding 
affinity and limit of detection for free and conjugated human Tf were 
examined. Samples numbered in  FIGURE IV.  15were analysed first by 
electrophoresis and then by immunobloting. Proteins were isolated 
from fresh-frozen brain and cerebellum tissues homogenates. 
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(A) 
 
(B) 
 
 FIGURE IV.  15 Immunohistochemical analysis of (A) human Tf, thiolated Tf 
and TB200-Tf and homogenated rat brain without treatment and (B) treated 
rats with TB200-Tf and Tf. 
 
A preliminary test on the biodistribution of the Tf targeted 
triblock co-polymer TB200 (33) was performed in healthy Wistar 4h 
post-injection. Free Tf and TB200-Tf were administered to rats 
intravenously at a dose of 16mgTf/kg in a single bolus of 0.5mL. In this 
case, non-labelled conjugate was used aiming to detect the Tf through 
immunohistochemistry analysis. 
 
1 2 3 4 5 6 7
1 Homogenated rat brain
2 Homogenated rat brain
3 Tf  0.3·10-3 mg/mL
4 Tf  0.3·10-3 mg/mL
5 Tf  1,6·10-3 mg/mL
6 Tfthio 1,6·10
-3 mg/mL
7 Tf  0,5mg/mL
8 Tfthio 0,5mg/mL
1 2 3 4
1 Tfthio 0.5mg/mL
2 Tfthio 5·10
-3 mg/mL
3 TB200-Tf  5·10-3 mg/mL
4 TB200-Tf  2.4·10-3 mg/mL
76K
76K
1 Mw marker
2 Cerebellum ctrl
3 Cerebellum Tf
4 Cerebellum TB-Tf
5 -
6 Brain ctrl
7 BrainTf
8 BrainTB-Tf
1 2 3 4 5 6 7 8
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Preliminary data showed that Human Tf was recognised in the 
brain by the anti-Tf monoclonal antibody even after its thiolation ( 
FIGURE IV.  15 (A)). Besides, after Tf conjugation detection was still 
possible allowing us to identify in a qualitative manner our conjugate 
in the brain mass ( FIGURE IV.  15(A)). The lowest concentrations 
tested were 0.0024mgTf/mL for TB and 0.0003mgTf/mL for Tf. As 
control, brain homogenates of non-injected animals were exposed to 
anti-Tf antibody to explore crossed reactivity with the own rat Tf. As it 
can be appreciated in  FIGURE IV.  15(A), cross reactivity was not 
significant . Results are compiled in  FIGURE IV.  15(B). Even though 
equivalent amount of protein was administrated to the animals, higher 
detection in both organs was achieved for the free protein. As 
conclusion it is possible to say that, TB200-Tf was able to cross the BBB 
although remarkably less than free Tf.  
 
IV. 1. 2. 2. 2 Biodistribution study by Optical Imaging. 
Transferrin-DB-Cy5.5 conjugate 
 
As described in section IV.1.2.1.2, FLI using IVIS® Spectrum was 
performed for the DB200-Cy5.5 (34) in order to validate this polymer as 
a drug delivery platform. In parallel, the same vector was covalently 
conjugated to Tf (35) and its capacity for BBB crossing in vivo was 
evaluated under the same technique. This study was performed in the 
Molecular Biology and Biochemistry Research Centre for 
Nanomedicine (CIBBIM-Nanomedicine, Vall d’Hebron Hospital, 
Barcelona). Following the same protocol (section IV.1.2.1.2), DB200-Tf-
Cy5.5 (35) was given through i.v. injection at a dose of 0.3mg Cy5.5/mL 
in athymic nude mice. Compounds and schedule are detailed in TABLE 
IV. 2. 
  
COMPOUND number of animals End time points (h) 
CTRL 3 4 / 24 
Cy5.5 2 4 / 24 
DB-Cy5.5 1 4 
DB-Tf-Cy5.5 5 4 / 24 
[CHAPTER IV.] 
[345] 
TABLE IV. 2. Fluorescent labelled systems for biodistribution experiments by 
fluorescence imaging. Number of animals and sacrificing time schedule. 
Analysis of whole body imaging datasets for the targeted DB 
represented in FIGURE IV.  16 yielded temporal information on organ 
distribution. Free Cy5.5 was spread into the whole body, observing 
accumulation in kidneys, liver (dorsal view, FIGURE IV.  16 (A)), 
intestines, salivary glands (ventral view, FIGURE IV.  16(B)) and brain 
(FIGURE IV.  16 (C)). Comparing the fluorescence output with the 
labelled conjugate, free cy5.5 is not an appropriate control due to the 
different signal obtained. The tissue uptake of free Cy5.5 was highly 
pronounced compared with the uptake of DB-Tf-Cy5.5, even though 
the Cy5.5 administered concentration was 1/7 times less than the 
present in the DB. It is clear that original fluorescence of the dye is 
dramatically diminished after polymer conjugation In the case of DB-
Tf-Cy5.5 fluorescence signal was observed in the kidneys and the 
bladder indicating renal secretion. Concerning the brain, in vivo 
monitoring could be attributed to the conjugate presence in blood 
vessels surrounding the brain. Accumulation in this organ along the 
time was not observed. 
 
After ex vivo analysis, free dye showed its presence in all 
organs analysed (FIGURE IV.  17, FIGURE IV.  18, FIGURE IV.  19,  
FIGURE IV.  20) 4h post-administration with clear disappearance after 
24h except in the kidneys. On the contrary, DB200-Tf-Cy was again only 
localised in kidney, liver and in less extent in the spleen. As expected, 
polymer conjugation significantly alters PK and biodistribution of low 
MW molecules such as the NIR dye used. Results were compared with 
the non-targeted DB-Cy5.5 (34). Although in ex vivo images a higher 
signal was identified in the liver for DB-Tf (FIGURE IV.  20), 
quantification by fluorimetry did not show any significant difference 
between the targeted (Tf-DB-Cy5.5) and non-targeted carrier (DB-
Cy5.5) (FIGURE IV.  22). Renal secretion was again the predominant 
secretion pathway for the targeted diblock. Unfortunately, non-
significant differences were found between treated and control mice 
after spectrofluorometer analysis. After 24h, DB-Tf-Cy5.5 conjugate 
was not longer detected in the blood stream as shown in fluorescence 
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measurement arriving to basal levels (FIGURE IV.  21).  
 
(A) Dorsal view
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(B) Ventral view
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(D) Head zoom 
 
FIGURE IV.  16  Non-invasive monitoring of the Cy5.5 labelled DB200-Tf (35) 
and the free dye overtime after i.v. administration at 4 and 24h post-
injection: (A) dorsal view (B) ventral view (c) head zoom. 
 
In conclusion, through FLI technique renal secretion was 
demonstrated for DB-Tf conjugate as well as non-specific 
accumulation in any analysed organ, however, this technique did not 
show any brain uptake. It is believed optical imaging techniques are 
not adequate to study transport to the brain due to the limit of 
detection as this technique is not sensitive enough and the evaluation 
of the images was not a simple due to the low fluorescence registered 
in the organ (FIGURE IV.  20). 
 
 
 
 
 
 
 
[CHAPTER IV.] 
[349] 
(A) Brain 
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(B) Liver
 
 
[CHAPTER IV.] 
[351] 
(C) Kidneys 
 
 
 
FIGURE IV.  17 Ex vivo fluorescence images of organs retrieved from the mice 
after i.v. injection of Cy5.5-labeled DB200-Tf and free dye: (A) brain, (B) liver 
and (C) kidneys. 
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(A) 
 
 
 
(B) 
 
FIGURE IV.  18 Ex vivo fluorescence images of organs retrieved from the mice 
after i.v. injection of Cy5.5-labeled DB200-Tf and free dye at 4 and 24h post-
injection. (A) Heart, lungs and spleen.  (B) Stomach and intestines. 
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FIGURE IV.  19. Comparison study among the targeted and non-targeted 
DB200. In vivo monitoring images: (A) dorsal view (left) and ventral view 
(right). (B) Head image zoom. 
 
 
 
[CHAPTER IV.] 
[354] 
 
(A) Brain 
 
 
(B) Liver 
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(C) Kidneys
 
(D) 
 
 
 
 
 
(E) 
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FIGURE IV.  20 Ex vivo fluorescence images of organs retrieved from the mice 
4h after i.v. injection of the cyane labelled DB200 and DB200-Tf systems: (A) 
brain, (B) liver and (C) kidney. In all images, both side of each organs were 
captured, upper photo is side 1 (S1) and lower photo is the other (S2). (D) 
Quantification of the labelled triblocks (targeted/non-targeted) in brain, liver 
and kidneys compared with non-injected animals. Relative fluorescence 
intensities were normalised with tissue weight.(E) Ex vivo monitoring of heart, 
lungs, spleen, stomach and intestines. 
 
 
FIGURE IV.  21 Fluorescence analysis of plasma from Cy5.5, DB200-Cy5.5 and 
DB200-Tf-Cy5.5 injected animals after 4 and 24h.
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FIGURE IV.  22 Quantification of fluorescence signal from the excised organs normalised per gram of tissue. Data correspond to Cy5.5, 
DB200-Cy5.5 and DB200-Tf-Cy5.5 treated mice.
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IV. 1. 2. 2. 3 Biodistribution study by MRI. Monoclonal 
antibody OX26 (mAb OX26)-TB-DTPA/Gd conjugate 
 
A strategy to circumvent endogenous competition of Tf while 
targeting the TfR, is by means of antibodies against this receptor. The 
mAbOX26 does not bind the natural ligand site but another epitope. 
Pardridge et al. reported that mAbOX26 has approximately fourfold 
greater BBB permeability than cationised albumin [25]. With this 
targeting motif, several compounds have been successfully targeted to 
the brain (section I.1.8). For this reason, mAb OX26 was conjugated to 
our carriers (TB). After the discouraging results obtained with optical 
imaging approaches, it was decided to use MRI as detection technique 
aiming to detect a conjugate brain accumulation; this was achieved by 
labelling the carriers with DTPA/Gd complexes. Preliminary in vivo 
experiments were performed with TB100-DTPA/Gd-OX26 (26), although 
gadolinium signal was not detectable. Therefore, a higher MW TB was 
use in order to increase DTPA functionalisation and consequently Gd3+ 
loading in the conjugate. However, the increase of DTPA/Gd loading 
significantly decrease the solubility of the carrier and consequently 
limitation of the administered dose to the animals were encountered. 
 
TB200-DTPA/Gd-OX26 (26) was administrated i.v. at a dose of 
0.2mmol Gd/kg (TABLE IV. 1). Due to solubility problems, the 
conjugate was highly diluted and 2mL had to be injected by perfusion 
during 1min. Unfortunately, after 24h no signal was observed either in 
the blood circulation or in the brain. It should be considered that Gd 
content was lower than that required to achieve a good MRI signal. 
Usually, percentage of the total dose injected able to cross the BBB is 
between 1-4% which depending on the sensitivity of the employed 
technique could be undetectable. Ex-vivo analysis was not performed 
and should be considered to finally determine if conjugates crossed or 
not. 
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COMPOUND REF %DOTA
A
 %pep 
A
 %pep 
B
 
MW unit 
(g/mol)
A
 
GA 
units
C
 
PGA-Angiopep2-
DOTA 
41 10 4.7 3.95 301,98 106 
DB-Angiopep2-
DOTA 
42 11 4.5 3.54 323,25 94 
PGA-cPEP-DOTA 47 2 2.75 n.d. 207,61 106 
DB-cPEP-DOTA 48 11 3.4 2.81 261,61 94 
pep=peptide, A=determined by 
1
H-NMR, B=determined by amino acid analysis, 
C=determined by GPC, n.d.=not determined 
TABLE IV. 3. DOTA labelled systems (PGA100 and PEG-b-PGA100) for 
biodistribution experiments with PET technique. Quantification of DOTA and 
peptide loading. 
 
This methodology was finally discarded due to its low 
sensitivity and the solubility problems presented when antibody was 
conjugated with the labelled polymeric systems with the Gd3+ 
complexation.  
 
IV. 1. 2. 2. 4 Biodistribution studies by PET. Targeting 
peptides conjugated to PGA-DOTA and DB-DOTA 
 
Work performed with Tf and the mAb OX26 set up the 
chemical basis for conjugation to the polymer carrier as well as 
directed the study towards a more suitable brain monitoring 
technique, such as PET. After all results obtained, peptidic targeting 
residues instead of protein or antibodies were considered to be a 
more feasible approach towards the design of carrier capable to cross 
BBB due to experimental and possible future industrial issues 
(scalability, costs, etc).  It is important to remind that, three polymeric 
platforms were evaluated with and/or without targeting motif: PGA 
homopolymer, triblock and diblock co-polymers.  
For these reasons, two peptides were selected to move 
forward with our aim. In first place and to continue the exploitation of 
the Tf receptor, an iron-mimic peptide was proposed: cyclic peptide 
[CHAPTER IV.] 
[360] 
cPEP. This peptide can recognise the Tf as demonstrated in vivo 
studies in healthy mice and into xenografts of human malignant 
gliomas [28]. Peptide chemical structure homes an internal disulphide 
bond that can trigger cross-linking problems if disulphide bond is used 
as conjugation strategy. Therefore, an amide bond was used as linker. 
The second peptide chosen was the Angiopep-2 derivatised with a 
cysteine group in the C-terminal. This peptide is the most advanced 
motif in clinical trials for treatment of brain gliomas [29]. However, Tf 
is not its target receptor. Angiopep-2 is endocytosed by the low-
density lipoprotein receptor-related protein (LRP-1). Disulphide-bridge 
chemistry was applied for this peptide in its conjugation to the 
polymeric carrier.  
 
Regarding all the monitoring techniques so far used, PET was 
selected as offered (i) the appropriate sensitivity to detect brain 
accumulation, (ii) the need of a low percentage of tracer, which makes 
the results resemble to the real outcome of the non-labelled conjugate 
and (iii) an easy work-out to quantitate the signal of single organs in ex 
vivo experiments, avoiding extraction procedures.  
 
As a pilot study, PGA homopolymer (11) and diblock co-
polymer (n=100) (7) were used due to the simple chemistry required in 
their polymerisations and as a starting point. Once DOTA labelling was 
optimised (section III.1.1.3), polymer post-polymerisation steps were 
done prior to the conjugation of any of the peptides. With this 
strategy, higher loadings of the targeting molecules were obtained. In 
summary, four systems labelled with DOTA/68Ga were evaluated in an 
in vivo preliminary experiment to be used as screening to select the 
best carrier/vector (carried out at CIEMAT, Madrid): PGA-angiopep2, 
DB-Angiopep2, PGA-cPEP and DB-cPEP (TABLE IV. 3). FVB/NJ mice 
were injected intravenously with a dose between 0.2 and 1.4MBq of 
the labelled [68Ga]-DOTA compounds (21± 4 µg compound/g body 
weight) and monitored up to 3h (FIGURE IV.  13). Then, at specific time 
points (0.25, 0.5, 1, 2 and 3h) a mouse was sacrificed and the extracted 
organs used for radioactivity measurements (FIGURE IV.  14).  
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Biodistribution studies corroborated the renal excretion route 
as the elimination pathway for all the analysed compounds (signal in 
bladder and kidneys, (FIGURE IV.  23 to FIGURE IV.  26). Organs were 
excised and radioactivity signals was measured and normalised with 
the grams of tissue. The collected data is represented in FIGURE IV.  
27. Again, a major signal was identified in the kidneys. Biodistribution 
assay had to be concluded after 3h post-injection, before a complete 
clearance from the blood stream occurred, due to the short half-life of 
the radio-nuclei, 68 min. It is important to mention that, with other 
imaging techniques (optical fluorescence imaging), DB or PGA 
clearance from the kidneys was demonstrated (image of FIGURE IV.  
13(PGA) and FIGURE IV.  16 (DB)).  
 
(A) 
 
(B) 
 
FIGURE IV.  23 PET imaging of DB100-Angiopep2-DOTA/
68
Ga (42) in healthy 
mice. Sagittal, coronal and transverse images captured immediately after 
administration (superior), sagittal planes with different saturation degrees 
(inferior). 
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FIGURE IV.  24 PET imaging of PGA100-Angiopep2-DOTA/
68
Ga (41) in healthy 
mice. Sagittal, coronal and transverse images captured immediately after 
administration (superior), sagittal planes with different saturation degrees 
(inferior). 
 
FIGURE IV.  25. PET imaging of DB100-cPEP-DOTA/
68
Ga (47) in healthy mice. 
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Sagittal, coronal and transverse images captured immediately after 
administration (superior), sagittal planes with different saturation degrees 
(inferior). 
 
 
FIGURE IV.  26 PET imaging of DB100-cPEP-DOTA/
68
Ga (48) in healthy mice. 
Sagittal, coronal and transverse images captured immediately after 
administration (superior), sagittal planes with different saturation degrees 
(inferior). 
 
Concerning the brain, our main interest in this biodistribution 
experiment, the highest radioactive signal was detected for the 
Angiopep-2 conjugates. Angiopep-2 labelled systems showed the 
major accumulation in brain at 30min post administration and cPEP at 
1h. Signal reduction could be attributed either to conjugates pump-out 
of the brain by efflux systems or that signal observed belongs to blood 
vessels surrounding the brain. The low levels of internalisation could 
be explained to low exposure of the peptide ligands to the receptors 
due to polymer solution conformation as conjugation through side-
chains were used as first approach. 
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FIGURE IV.  27  Normalised data of radioactivity signal of each organ respect 
the injected dose (ID). Time course experiment. All polyglutamates had 
DP=100. 
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With both peptides, diblocks achieved lower percentages than 
homopolymers. The proposed reason was a lower peptide recognition 
due to PEG blocks forming an outershell hiding peptide molecules 
attached in the polypeptide block.  
 
Currently, new studies are ongoing trying to solve this issue. 
For that, PEG has been use as a semitelechelic block providing a 
unique conjugation point for the targeting moiety. Meanwhile TB 
synthesis is still under optimisation, these studies are being performed 
with DB-4TP (5) and PGA homopolymer with a star-like architecture, 
aiming to improve the BBB crossing. 
 
Main advantage will rely on a better control of ligand 
conjugation and a better exposure in solution of the peptides for 
receptor recognition.  
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IV. 2 CONCLUSIONS 
 
 After optimising the polymerisation process (chapter II) and 
labelling/targeting steps (chapter III), the obtained PGA-based 
polymeric carriers were evaluated in vitro and in vivo. The novel 
polyglutamate system: the triblock PEG-b-PGAn-b-PEG-4TP was firstly 
evaluated to test its cell viability. With n=100, 150 and 200 Glu units, 
preliminary assays were carried out in the human endothelial cell line 
HUVEC. This assay validated the TBs as acceptable drug carriers.  
 
 Then, identification of the internalisation mechanism studies 
through flow cytometry and confocal microscopy techniques were 
carried out. In this study, several samples were incubated in presence 
of the lysosomal marker Texas Red-dextran (TRD) to identify possible 
co-localisation with the labelled polymers and therefore establish a 
lysosomotropic intracellular pathway. These studies demonstrated 
that all members of the TB family entered in the cells via an energy 
dependent pathway, endocytosis.  Higher DP TBs were faster 
internalised as expected for bigger systems. Solution conformation 
studies by SANS are ongoing to corroborate these results. 
 
Previous studies in our laboratory showed a mixed 
internalisation pathway of the TB200-OG (PEG-b-PGA200-b-PEG-OMe), 
combining endocytosis with diffusion.  An extra study was performed 
aiming to compare two terminal groups: methyl and activated 
disulphide group. However, the observed diffusion behaviour was not 
reproduced in any of the analysed TB. This fact dismissed the 
possibility of exploiting inherent properties of TB conformation for 
diffusion through biological barriers. Therefore, the conjugation of 
targeting moieties came to the fore instead of its supplementary role. 
 
After in vitro evaluation, the different systems (PGA, DB and 
TB) were subjected to in vivo studies. On one side, each member by 
itself had to prove their biocompatibility, safety, non accumulation in 
any specific organ and adequate secretion. On the second hand, our 
systems were proposed as candidates for BBB drug delivery systems. 
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After discard diffusion processes and considering the difficulty of the 
barrier, active targeting was required to reach our goal. Hence, 
biodistribution experiments were performed with targeted systems for 
comparing advantages of the selected ligands and the parent 
polyglutamates. 
 
Several techniques were evaluated, ranging from optical 
imaging with a fluorescent probe or a NIR dye, MRI with a contrast 
agent or PET with a radionuclide. Regarding the non-targeted systems, 
PGA (PGA-DOTA), DB (DB-Cy5.5) and TB (TBO) showed renal secretion, 
non specific accumulation and none of them presented inherent 
properties for BBB crossing. Accumulation in liver was also observed 
but significantly less than that observed in the kidney. The 
experiments performed with all the different imaging techniques 
pointed out that for brain crossing detection PET were the best. The 
percentage of the injected dose able to cross BBB is usually very low (< 
4% of the injected dose) so the most sensitive technique is required 
for brain detection.  
 
Among the BBB ligands evaluated, TB-Tf was detected in rat 
brain after i.v. injection after WB analysis. However, comparison with 
the same administered dose of free Tf showed a significant reduction 
on the internalised amount. DB and DB-Tf biodistributions were 
compared by means of fluorescence imaging and no differences were 
detected at brain region.  As at normal levels Tf receptor remains 
saturated and possibilities for BBB crossing by means of the 
endogenous Tf are reduced, the mAbOX26 was suggested as an 
alternative ligand. By means of MRI, TB-OX26-DTPA/Gd was not 
detected in the mouse brain after i.v. Problems on solubility of the 
final conjugate resulted in highly diluted doses, which possibly 
hindered the compound detection. Finally, with the objective of 
simplify the whole procedure, peptidic sequences were chosen as 
targeting moieties. Angiopep-2 is the most advanced peptide ligand in 
clinical trials [29, 30], this and a cyclic peptide mimicking the iron 
molecule [28]were studied. At this stage, we had already decided that 
DB output concerning biodistribution was similar to TB, presenting 
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also an easier synthetic pathway with better yields. Therefore, PGA 
homopolymer and DB were selected for comparison with these two 
novel targeting vectors. Preliminary studies evidenced higher 
radioactivity for the angiopep-2 conjugates than for the cPEP in the 
brain although concentration was not maintained. Either conjugates 
were pumped out or not internalised due to a failed exposure of the 
peptides for receptor recognition. The results observed could be 
attributed to low exposure of the peptide ligands to the receptors due 
to polymer conformation. DB systems gave in both cases lower 
percentages perhaps because PEG blocks formed an outershell hiding 
the peptide molecules attached in the polypeptide block. The 
suggested solution was to use PEG as semitelechelic block providing a 
unique conjugation point for targeting moiety, which probably will be 
more accessible for receptor recognition. DB-4TP synthesis was 
optimised and, while TB is ongoing, this system will be tested in vivo as 
well as branched PGAs (star). Main advantage will rely on a better 
control of ligand conjugation and availability in solution of the 
peptides for receptor recognition. BBB crossing is still a goal to 
achieve. However, many steps on the right direction had been set up 
the most optimal technique for visualising and quantifying BBB 
crossing of our conjugates. PET, as well as all of our novel systems had 
been evaluated and with the last conjugates synthesised better results 
are expected due to a better exposure of the peptidic residues. 
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IV. 3 MATERIALS AND METHODS 
 
IV. 3. 1 IN VITRO EVALUATION IN AN ENDOTHELIAL CELL LINE 
 
IV. 3. 1. 1 Cell culture protocol 
HUVEC cells were cultured in Medium 200 supplemented with 
Low Serum Growth Supplement (LSGS). Once split, cells were 
maintained at 37°C in an atmosphere of 5% CO2 and 95% air. After 
24h, cells were already adhered. Medium was replaced each 2-3 days 
and underwent passage once weekly when 80% of cell confluence was 
reached [31].  
 
IV. 3. 1. 2 Evaluation of polymer toxicity and cell recovery through 
the MTT assay 
 
MTT assay conditions 
 
The cytotoxicity of the triblocks (TB100, TB150 and TB200) was 
evaluated using the MTT cell viability assay (24 and 72 h incubation) 
with HUVEC and HeLa cells. Both cell lines were seeded into sterile 96-
well microtitre plates (density (cell/cm2) in TABLE IV. 4) in their 
correspondent medium (TABLE IV. 4). They were incubated for 1 day 
before the test compounds (0.2µm filter-sterilised) were added to give 
a final concentration in the range of 0 - 2 mg/mL drug-equiv. After 
further 67 h incubation, MTT (20µL of a 5 mg/mL solution in PBS) was 
added to each well, and the cells were incubated for 4h. After removal 
of the medium, the precipitated formazan crystals were dissolved in 
optical grade DMSO (100µL), and the plates were read 
spectrophotometrically at 570 nm after 30 min using a microtitre plate 
reader. Cell viability was expressed as a percentage of the viability of 
untreated control cells. FIGURE IV.  28 shows the map followed in the 
assay. The absorbance values were represented as the percentage of 
cell viability having as reference (100% cell viability) the non-treated 
cells.   
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cell density (cells/cm
2
) cell media 
HUVEC 20000 Medium200 + 2% (v/v) LSGS 
HeLa 15000 DMEM + 10% (v/v) FBS 
FBS=fetal bovine serum, LSGS=low serum growth supplement, HUVEC=human 
umbilical vein endothelial cells, HeLa= human cervix 
TABLE IV. 4 Cell lines exploited for cytotoxicity experiments of the 
polyglutamates. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
            B 
 
0 0,01 0,05 0,1 0,02 0,4 0,8 1 1,5 2 
 C 
 
0 0,01 0,05 0,1 0,02 0,4 0,8 1 1,5 2 
 D 
 
0 0,01 0,05 0,1 0,02 0,4 0,8 1 1,5 2 
 E 
 
0 0,01 0,05 0,1 0,02 0,4 0,8 1 1,5 2 
 F 
 
0 0,01 0,05 0,1 0,02 0,4 0,8 1 1,5 2 
 G 
            FIGURE IV.  28 Example of a map of MTT assay in a 96 well plate. 
Concentrations units:  mg/mL. 
 
Note: For MTT assay optimisation, growth curves of the named 
cell lines were done at different cell concentrations for finding proper 
cell density to carry out the experiment. A cell growth study could be 
follow during 7days. Each day, 20μL MTT solution was added to each 
well of the plate and the cells were incubated for 4h. Then, the 
medium from the wells in this row (n=6) was removed and replaced 
with optical grade DMSO (100 μL/well) to solubilise the formazan 
crystals. Once dissolved, absorbance was determined as explained 
before.  Then, the formazan-DMSO mixture was removed from the 
wells and replaced with PBS (100μL/well). Plates were placed back into 
the incubator and same process was continued daily over 7 days. 
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IV. 3. 1. 3 Evaluation studies of the mechanism of the cellular entry 
Confocal fluorescent microscopy: Live-cell imaging 
 
For live-cell imaging, HUVEC cells were seeded in glass bottom 
culture dishes (10000cell/cm2) and left to adhere to the coverslips for 
> 12 h. To assess the subcellular localisation of the polymers, cells 
were incubated for either 15 min or 1 h at 37°C in complete medium (1 
mL) containing OG-labelled conjugates (10μL of 0.01mg/mL OG-equiv. 
stock) and leupeptine (10μL of 10mM stock). Before visualisation, 
medium containing the polymers was removed from the cells by 
aspiration, and the cells were washed three times with fresh medium 
(37°C). Finally, clear complete media was added and cells were 
subsequently viewed for a maximum of 30 min. Pulse and chase 
experiments were performed (TABLE IV. 5).  
In some studies, previous to polymer incubation or in parallel, 
5μL of a TRD solution (50mg/mL in sterile PBS) were added to the cells. 
After 1h of incubation, medium was removed and replaced with fresh 
one. Cells were incubated 5h at 37°C. After chase time cells were 
washed trice with PBS supplemented with 10%(v/v) of FBS (3mL) and 
the glass was removed and set on the microscope chamber. 
Samples were analysed under the microscope and images 
were captured after excitation of the fluorophore. Images were 
captured with an inverted DM IRE2 microscope equipped with a λ-blue 
60 x oil immersion objective and handled with a TCS SP2 system, 
equipped with an Acoustic Optical Beam Splitter (AOBS). Excitation 
was performed with an argon laser ((OG 496nm) and HeNe laser 
(Texas Red-dextran 594nm). Images were captured at an 8-bit grey 
scale and processed with LCS software (version 2.5.1347a, Leica 
Germany) containing multicolour, macro and 3D components.  
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Time point Pulse time Chase time 
0min 0min 0min 
5min 5min 5min 
30min 15min 30min 
1h 1h 1h 
2h 1h 2h 
5h 1h 5h 
TABLE IV. 5 Confocal microscopy study time points. Pulse and chase times 
exploited for the internalisation in vitro studies. 
 
Cellular uptake by fluorescent activated cell sorting (FACS) 
 
Binding and uptake of OG-labelled triblocks by HUVEC cells 
HUVEC cells were seeded in 6-well plates at a density of 
15000cel/cm2 (1 mL cell suspension per well) and allowed to adhere 
for 24 h. In the binding experiments conducted at 4°C, the cells were 
pre-incubated at this temperature for 30 min prior to addition of 
conjugate. 10μL of OG-labelled polymers (0.01mg OG/mL) and 10µL of 
leupeptine 10mM were added and the cells incubated for 0 to 300 min 
either at 37°C or 4°C. At each sample time, cells were placed on ice, 
then washed three times with ice-chilled PBS (5 mL), and PBS (1 mL) 
was added before the cells were scraped from the plate with a rubber 
policeman and collected in falcon tubes. The cell suspension was 
centrifuged at 4°C (600 x g for 10 min). The cell pellet was re- 
suspended in ice-chilled PBS (200 μL). Cell-associated fluorescence was 
then analysed using a Becton Dickinson FACSCalibur cytometer 
(California, USA) equipped with an argon laser (488 nm) and emission 
filter for 550 nm. Data collection involved 25,000 counts per sample, 
and the data were analysed using CELLQuestTM version 3.3 software. 
Data are expressed by plotting the shift in geometric mean of the 
entire population (i.e. geometric mean after incubation with the 
polymer-geometric mean in absence of polymer). Cells incubated 
without polymer conjugate were used to account for the background 
fluorescence. 
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IV. 3. 2 BIODISTRIBUTION EXPERIMENTS 
IV. 3. 2. 1 Biodistribution studies of non-targeted polyglutamates  
IV. 3. 2. 1. 1 Triblock biodistribution by ex vivo Optical Imaging 
Analysis 
OG labelled triblock (TB200-OG, 0.72%mol OG) was dissolved in 
serum saline at 14mg/mL, injected intravenously (i.v.) as a single dose 
in male Wistar rats (n=3) and sacrificed 4h post-injection. A second 
group (n=3) was injected with the same dose and sacrificed 24h later. 
As control, mice (n=3) were injected equivalent dose of the polymer 
without labelling (TB200).  
Immediately after sacrificing, the blood was collected in 
heparinised eppendorfs and placed on ice. Blood was centrifuged 
(4000rpm, 10min, 4°C) and serum (supernatant) was collected and 
frozen for later analysis. Organs (brain, cerebellum, heart, spleen, liver, 
bladder, stomach, gut, muscle and fat) were excised, weighted, frozen 
in liquid nitrogen and stored at -80°C for following examination. Each 
organ was treated individually with a cold solution composed of HClO4 
6% / EtOH 40% at a proportion 1g tissue/4mL and placed in ice. Then, 
samples were homogenised using an Ultraturrax® Homogenizer. Also 
serum samples were treated with the same protocol but adding the 
same sample volume of perchloric acid solution. The suspension was 
centrifuged (60min, 4000rpm, 4°C) and the supernatant stored for 
analysis (sup1).  In order to improve the extraction of the labelled 
polymer, pellets were sonicated for 60min in 1mL of NaHCO3 1M / 2mL 
of H2O, centrifuged in the same conditions as described above and the 
supernatant stored for further analysis (sup2). As it was found that OG 
is pH sensitive (the fluorescence is inhibited by acidic pH), the HClO4 
supernatants (sup1) were neutralised with NaOH, freeze-dried and 
resuspended in 1mL of PBS at pH 7.4 (sup3) for further analysis. All the 
samples (sup1, sup2, sup3) were analysed with a spectrofluorometer 
(λex=485nm, λem=535nm). Serum fluorescence was also directly 
measured before any treatment. Final data was normalised by dividing 
fluorescence signal per organ mass. 
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IV. 3. 2. 1. 2 DB-Cy5.5 biodistribution: in vivo and ex vivo monitoring 
by fluorescence imaging 
Cy5.5 labelled DB200 (34) (1.63%molCy5.5) biodistribution was 
conducted in nude mice in order to determine organ distribution as 
well as conjugate t1/2 in blood. As control, free Cy5.5 was injected. 
Compounds distribution in vivo as well as ex vivo was monitored by 
means of tissue fluorescence imaging (FLI) using the IVIS® Spectrum.  
Athymic nude mice (Harlam, 8 weeks) were treated 
intravenously with a single dose of 2mg Cy5.5/Kg of DB-Cy5.5 
resuspended in serum saline.  Animals were anesthetised using 1-3% 
isoflurane. The whole-body biodistribution of the labelled diblock was 
monitored non-invasively by FLI using the IVIS® Spectrum Imaging 
System with excitation and emission wavelengths of 675/720nm, 
respectively. Five mice were imaged at a time and imaging settings of 
the experiment (exposure time, binning, field of view, f/stop, field of 
view) were set during the experiment to capture optimal fluorescent 
output. Time course experiment was carried out (0, 2h, 4h, 24h). The 
light emitted from the fluorescent DB-Cy5.5 was detected, digitalised 
and electronically displayed as a pseudocolor overlay onto a gray scale 
animal image. Regions of interest (ROI) from displayed images were 
drawn manually selecting the fluorescent signals and quantified as 
Efficiency. Mice were euthanized at 4 and 24h post administration. 
Blood was collected individually by cardiac puncture and processed for 
plasma obtaining by centrifugation (4000rmg, 10min, 4°C) and placed 
in ice or frost until evaluation. Organs of interest (heart, lungs, spleen, 
kidneys, liver and brain) were dissected from mice, and fluorescence 
images of excised tissues were obtained by ex vivo FLI. Tissue samples 
were also stored at -80°C to quantify fluorescence after compound 
extraction from the organ. 
 
Blood and organ analysis 
Cy5.5 detection in excised organs was optimised for 
fluorescence quantification. Protocol for organ homogenation 
described in section IV.3.2.1.1 was reproduced. Once all the 
supernatants were collected (sup1, sup2, sup3), they were analysed 
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with a spectrofluorometer (λex=595nm, λem=680). Serum fluorescence 
was also measured directly before any treatment. Final data was 
normalised by dividing fluorescence signal by the organ mass. 
 
IV. 3. 2. 1. 3 TB biodistribution: use of contrast agents (DTPA/Gd) for 
MRI 
 For this experiment, triblock systems (PEG-b-PGAn-PEG, n=100 
and n=200) covalently conjugated to DTPA/Gd were resuspended in 
serum saline in a concentration 0.2mmol Gd3+/Kg animal. Male Wistar 
rats (m=220±5g) were used. Anaesthesia was initiated by inhalation of 
oxygen (1 L/min) containing 3% isofluorane and maintained during the 
experiment employing a mask and 2% isofluorane in O2. Animal 
temperature was maintained at approx. 37°C with a heated probe. The 
physiological state of the rats was monitored using a Biotrig 
physiological monitor (Bruker, Germany) that controlled the 
respiratory rate and body temperature. 
For anatomical reference, a multi-slice rapid acquisition and 
relaxation enhancement (RARE) sequence was performed with the 
following parameters: RARE factor=8, time of repetition (TR) = 3000 
ms, effective echo time (TE)=60ms, averages=2, 6 coronal slices, slice 
thickness 1.2 mm, field of view (FOV)=3.8 cm, matrix=256 x 256. Then, 
regional contrast agent uptake was assessed. A series of T1- weighted 
spin echo images were sequentially acquired over one hour following 
the injection of the contrast agent. The acquisition parameters were: 
number of repetitions 30, TR=300ms, TE=9.5ms, averages=6, slice 
thickness 1.5 mm and number of sections with axial orientation=20, 
FOV=3.8 cm x 3.8cm, matrix=256 x 256 which corresponds with a 
resolution of 148 x 148m2. The compounds were administered 
intravenously through the vein tail as a bolus 9min after initiate the 
acquisition. Animals were monitored immediately after administration 
and at 1, 6 and 24h.  
In each MRI experiment, T1-weighted (T1-W) spin-echo 
anatomical images were acquired with a multi slice multi echo (MSME) 
sequence in axial orientations. In all animals, the same five coronal 
slices were imaged to obtain parametric maps generated on a pixel by 
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pixel basis. As explained, Gd is a paramagnetic metal that increase T1 
relaxation time of water protons. This phenomenon is detected in MRI 
images with an increased hyperintensity quantified by ImageJ software 
that analyses grey intensities in selected brain areas.  
 
IV. 3. 2. 1. 4 PGA homopolymer biodistribution by PET 
FVB/NJ mice (CIEMAT Laboratory Animals Facility, Madrid) were 
housed on a 12-hour light and 12-hour dark cycle. Free access to food 
and water was allowed at all times. All animal protocols were 
approved by the Institutional Animal Care and Use Committee at 
CIEMAT (Madrid). Mice weight was 25±4g.  
For the pharmacokinetics and biodistribution study, 50 mice (n = 
5 per group and time point) were anesthetised with 1.5% isofluorane, 
and between 0.2 and 1.4MBq PGA-[68Ga]-DOTA (21±4µg compound/g 
body weight) per mouse was injected intravenously through the tail 
vein. At 0.25, 0.5, 1, 2, and 3 hours post-injection, blood samples were 
obtained from mice by terminal bleeding via cardiac puncture 
following isoflurane anaesthesia; organs (lungs, heart, spleen, kidneys, 
liver and brain) and some tissues (muscle, fat) were isolated, rinsed 
with normal saline, weighted, and the radioactivity was measured 
using the Cobra II auto-gamma counter. The blood samples were 
centrifuged (3000rpm, 10min, 25°C) and the supernatant of plasma 
was collected. The %ID (injected dose) and the %ID/g were calculated 
by comparison with standards taken from the injected solution for 
each animal. The data were expressed as the mean ± SD. 
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IV. 3. 2. 2 Biodistribution studies of targeted polyglutamates  
 
Note: Except especified cases, experiments detailed below were done 
with healthy Balb/c mice (9-12month old), which were used as mouse 
model for the in vivo biodistribution studies. For in vivo FLI 
experiments, animals were first anesthetised and shaved to remove 
hair interference with fluorescence signal.  
 
IV. 3. 2. 2. 1 TB-Tf detection in brain through immunohistochemistry 
 
Tissue Preparation 
TB200-Tf was dissolved in serum saline (1.75mg Tf/mL) as well 
as human Tf (1.75mg Tf/mL). Compounds were administered 
individually by i.v. route (0.5mL, tail vein) to Wistar rats which were 
sacrificed 4h after injection, together with a non-injected rat as 
control. Brain and cerebellum were removed and immediately frozen 
at -80°C until analysis. Organs were homogenised (10%w/v) in ice-cold 
Tris saline buffer (20mM Tris-HCl pH=7.5, EDTA 10mM, PMSF 0.2mM) 
supplemented with a cocktail of proteinase inhibitors (Complete, 
Roche Diagnostics GmbH, Germany). Then, the homogenates were 
sonicated and protein concentration was measured with the BCA 
(bicinchoninic acid) protein test (Thermo Fisher Sci.). All process was 
performed at 4˚C and samples were stored at 80˚ until further 
analysis.  
 
SDS-PAGE and western blotting 
Polyacrylamide gel (8%) was prepared. Tissue proteins were 
suspended in LB 2X buffer (with or without DTT) and heated at 95°C 
for 7min (appendix III). Together with molecular weight marker, 
samples were loaded into the gel wells and electrophoresis was 
performed. Proteins were transferred electrophoretically from the gels 
to a PVDF membrane, which afterwards was incubated with 10% skim 
milk in PBS Tween20 for blocking. Subsequently, membrane was 
incubated with the mouse anti-Tf antibody (1:5000). After overnight 
incubation at 4°C, membrane was washed and incubated with the 
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HRP-conjugated secondary antibody anti-mouse. After washing, 
staining was developed with the HRP-conjugated substrate kit. 
 
IV. 3. 2. 2. 2 DB-Tf-Cy5.5 biodistribution: in vivo and ex vivo 
monitoring by fluorescence imaging 
 
The biodistribution of transferrin (Tf) conjugated DB was 
evaluated by FLI using the IVIS®Spectrum Imaging System, following 
the protocol described in section IV.3.2.1.2 100µL of a solution of 2mg 
Cy5.5/mL of Tf-DB-Cy5.5 (1.86%mol Cy.5) was intravenously 
administrated to each mouse (n=5). Imaging time points were done at 
0, 2, 4 and 24h while end time points at 4 and 24h. 
 
IV. 3. 2. 2. 3 Monoclonal antibody OX26 conjugated to TB-DTPA/Gd 
 
Same methodology explained in section IV.3.2.1.3 was used 
for biodistribution of the targeted TB100 with the reduced mAbOX26. 
 
IV. 3. 2. 2. 4 Targeting peptides conjugated to PGA-DOTA and DB-
DOTA 
 
Experimental protocol as described in section IV.3.2.1.4.  
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CHAPTER V. THERAPEUTICAL APPLICATION APPROACH: POLYMER 
DRUG CONJUGATES FOR THE TREATMENT OF FAMILIAL 
AMYLOIDOTIC POLYNEUROPATHY 
 
After achieving clinical arena, a second generation of polymer 
conjugates is now focused on improved polymer structures, to 
implement polymer-based combination therapies and to design 
conjugates towards novel molecular targets which will further 
progress this platform technology [1-3]. Second generation conjugates 
has undertaken the challenge of targeting diseases other than cancer. 
Therefore, innovation in polymer conjugates application is also driving 
new areas such as the regenerative medicine and other chronic and 
debilitating diseases. Although industrialisation framework is slowly 
evolving regarding these scenarios these novel chemical entities have 
already shown promising data [4-7]. 
 
As coined in the introduction (sections I.1 and I.4), amongst 
the different types of amyloidosis Alzheimer’s (AD) and Parkinson’s 
(PD) diseases are renowned examples. Familial amyloid 
polyneuropathies (FAP) also constitute a group of inherited 
amyloidosis [8]. One of the most common FAP is caused by a mutated 
protein called transthyretin (TTR), which forms amyloid deposits 
mainly in the peripheral nervous system. TTR has been proposed to 
trigger neurodegeneration through engagement with the RAGE 
receptor. Prof. M.J. Saraiva et al. have discovered a specific peptidic 
sequence named RAGE peptide able to suppress TTR aggregate-
induced cytotoxicity in cell culture  [9]. A reduced version of that 
peptide containing six amino acids (aa) (RAGEpep) was showed to 
maintain the activity and the affinity of the initial peptide (unpublished 
sequence). The same laboratory proved that doxycycline (doxy) acts as 
a TTR fibril disrupter in vitro and in vivo [10, 11]. Based on both 
statements, avoidance of TTR aggregates (TTRagg) cytotoxicity and 
breaking up TTR fibrils are promising targets for therapeutic proposes, 
and even more their combination. 
 
In this chapter, the design of polymer drug conjugates for the 
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treatment of a rare amyloidotic diseased named Familial Amyloidotic 
Polyneuropathy (FAP) (section I.4) is described. Conjugation to 
polymers of two bioactive molecules for FAP treatment was proposed 
in order to confer the unique properties of PDCs to exhibit higher 
therapeutic effect than the corresponding therapeutics alone. For both 
bioactives, a rational for design was implemented selecting the 
appropriate polymeric vehicle and suitable linkers with/without 
bioresponsiveness under the extracellular scenario where their activity 
should be displayed. 
 
As already described, polymer conjugation promotes changes 
in the biodistribution compared to the parent drug, avoiding undesired 
accumulation in non-affected organs and diminishing the administered 
dose and/or its frequency.  In the case of doxy, poly-L-glutamic acid 
(PGA) has been chosen due its multivalence, biodegradability and 
biocompatibility. Thanks to the side-chain functionalities of the carrier, 
drug loading has been tailored through different linkers yielding 
conjugates ranging from 2 to 60ωt% total doxy content (FIGURE V.  1).  
 
For RAGEpep, polyethylene glycol (PEG) derivatives have been 
selected to covalently link the peptide through two different types of 
linkages: disulphide and peptidic bond (FIGURE V.  2). PEG is a well-
known polymeric carrier characterised by its semi-telechelic properties 
ideal for peptide and protein conjugation. PEG is FDA approved and 
has already demonstrated in the clinics its capacity of increasing 
compound stability and reduce its immunogenicity; thus increasing its 
therapeutic index [12].  
 
Both conjugate families have been synthesised, characterised 
through several physico-chemical techniques, tested in vitro, 
evaluated in healthy animals for biodistribution studies and finally, 
preliminary activity experiments in a FAP in vivo model have been also 
carried out. 
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FIGURE V.  1 Synthesised family of PGA-X-Doxy conjugates. 
 
 
FIGURE V.  2 Synthesised family of PEG-RAGEpep conjugates. 
 
 
As a final remark, the concept of polymer-based combination 
therapy [3] has been introduced in this project by combining both 
single conjugates (PGA-Doxy + PEG-RAGEpep). A first approach 
selecting the best polymer conjugate candidate from each bioactive 
molecule has been drive towards preliminary in vitro and in vivo test. 
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Further experiments are ongoing in order to design the best possible 
combinations. 
 
The aim of this study relied on obtaining novel polymer drug 
conjugates for treating FAP, for the first time in the field, being able to 
use those systems as single agents or in combination therapy.
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V. 1 RESULTS AND DISCUSSIONS 
 
V. 1. 1 SYNTHESIS AND CHARACTERISATION OF THE POLYMER-DRUG 
CONJUGATES  
 
V. 1. 1. 1  PGA-X-Doxy conjugates 
 
In FAP, fibril deposits are localised extracellularly. 
Consequently, doxy must act extracellularly and intracellular release 
and excretion was not considered an issue as PGA is a biodegradable 
polymer. Areas of TTR deposition are characterised by the surrounding 
inflammation [13, 14]. This fact constitutes an advantage for polymer 
conjugate accumulation due to the passive targeting by the EPR effect 
(section I.2.2).  
 
Taking this into consideration, two different linkages were 
exploited to investigate if drug release was a requirement for an 
effective response: a biodegradable (ester) and a non biodegradable 
bond (amide). For this goal, the drug was conjugated to PGA either (i) 
directly (by its own alcohol groups) or (ii) after its derivatisation by 
introducing an amine group in its benzyl group (FIGURE V.  3) or (iii) 
indirectly through peptidic sequences used as linkers (Gly-Gly and Leu-
Gly,(FIGURE V.  3). Previous to conjugation of doxy-NH2 derivative (49), 
its own activity was tested in vitro finding out comparable results to 
the parent drug (FIGURE V.  30). Chemistry strategy was based on 
post-polymerisation modification of PGA side chains by activation 
through NHS, DIC/HOBt or DMTMM (section III.1.1.1 ) [15]. Several 
examples of the different conjugates obtained together with their 
reaction conditions are shown in TABLE V.  1.  
 
A family of conjugates with different total drug loading was 
achieved in order to determine the most efficient conjugates. 
Parameters such as, drug availability due to solution conformation or 
kinetics of drug release can be directly correlated with drug loading. 
Total drug content (ωt%) was determined by UV (273nm) [16] taken a 
doxy calibration curve as reference (FIGURE V.  4). 
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FIGURE V.  3 Doxycycline chemical structure and their derivatives. 
 
Free drug content in the conjugates synthesised was 
determined by LCMS and HPLC. In LCMS analysis, doxy and doxy-NH2 
were detected (MW=444g/mol, [M+1]=445g/mol; and MW=459g/mol, 
[M+1]=460g/mol, respectively) at retention time around 10min 
(FIGURE V.  5). Direct evaluation of PBS aliquots of PGA-X-Doxy 
conjugates did not detect free doxy (detection limit <0.012mg/mL). 
Second attempt in which samples were lyophilised and extracted with 
MeOH confirmed the result (FIGURE V.  5(C)). Again, in all cases drug 
signals were undetectable concluding that free drug was under the 
accepted limit for clinical development.  In parallel, free drug content 
was also measured by HPLC (see flow conditions in experimental 
methods) (FIGURE V.  6). The absence of any signal determined a free 
drug concentration under the limit of detection of the used technique 
(0.01mg/mL).  
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Reaction 
conditions 
Total drug 
content 
(ωt%)
A 
Free drug 
content (ωt% of 
total drug)
B
 
PGA-COO-DOXY 
conj. 
PGA-NHS/DMAP 26 <0.04 
PGA-NHS/DMAP 2 <0.50 
 
PGA-NHS/DMAP 26 <0.04 
PGA-NHS/DMAP 22 <0.05 
 PGA-NHS/DMAP 33 <0.03 
PGA-LG-NH-DOXY 
conj.  
DMTMM·Cl/DMF 9 <0.11 
DMTMM·Cl/DMF 9 <0.11 
PGA-GG-NH-DOXY 
conj. 
DMTMM·Cl/DMF 6 <0.17 
DMTMM·Cl/DMF 14 <0.07 
PGA-NH-DOXY conj. 
DIC/HOBt 15 <0.07 
DIC/HOBt 22 <0.05 
 DIC/HOBt 26 <0.04 
 
DIC/HOBt 33 <0.03 
 
DIC/HOBt 35 <0.03 
 
DMTMM·Cl/DMF 18 <0.06 
 
DMTMM·BF4/H2O 20 <0.05 
 
DMTMM·BF4/H2O 51 <0.02 
 
PGA-NHS/DMAP 14 <0.07 
 
PGA-NHS/DMAP 17 <0.06 
 
PGA-NHS/DMAP 30 <0.03 
 
PGA-NHS/DMAP 43 <0.02 
 
PGA-NHS/DMAP 59 <0.02 
A=data obtained by UV, B=data obtained by HPLC or LCMS 
TABLE V.  1 Examples of the synthesised PGA-X-Doxy conjugates. Reaction 
conditions used, total drug loading and free drug content. 
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FIGURE V.  4 Calibration curve of doxycycline in water. Absorbance measured 
at 273nm. 
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(C) 
 
FIGURE V.  5  Doxycycline (D1) analysis by LCMS. (A) UPLC spectra (B) MS 
spectra (C) Free drug test (black line=doxy, blue line=PGA-CONH-doxy 
15ωt%). 
 
 
FIGURE V.  6 Example of a PGA-Doxy GPC trace (absorbance at 273nm, mobile 
phase: PBS pH7.4, tR=12min) 
 
V. 1. 1. 2 Synthesis of RAGEpep derivates including PEG-RAGEpep 
conjugates  
 
Peptide therapeutics themselves display well known 
challenges for in vivo use, e.g. low stability, poor PK and potential 
immunogenicity [17]. PEGylation emerged as a robust alternative for 
p/p delivery (section I.2.4.1) achieving the clinical arena and with 
many conjugates under development. This technique has evolved over 
time not only varying MW of the polymer carrier as well as its 
architecture but also covering all type of linkages such as disulphide, 
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hydrazone, triazole, etc [18-20]. Currently, PEG also plays a relevant 
role in combination with other polymeric carriers in many different 
structures contributing with their inherent properties. 
 
Our bioactive molecule in this case was a 6aa peptide 
sequence named RAGE peptide (unpublished sequence), a truncated 
sequence derived from and with similar properties as the originally 
reported RAGE peptide[9]. Due to its semitelechelic properties, in a 
first stage PEG was selected as carrier for its delivery.  Peptide function 
is base on the recognition of the TTRagg in order to bind them. This 
union avoids interaction between TTRagg and the RAGE receptor. 
When TTRagg-RAGE receptor binding is inhibited, the apoptosis 
cascade is stopped and, therefore it could be said that, RAGEpep is 
able to diminish cell toxicity triggered by the TTR aggregates. RAGE 
peptide and its derivatives (RAGE peptide-Gly, PEP1 and RAGE 
peptide-Gly-Cys, PEP2, FIGURE V.  7) were obtained by Fmoc-based 
solid phase peptide synthesis (SPPS) (section V.3.1.3).  
FIGURE V.  8 shows yield, purity and MW of the final products. 
Figure X shows an example of the obtained results. 
 
 
 
FIGURE V.  7 RAGE peptide derivatives. 
 
Within the same scope than that explained above for PGA-
doxy conjugates, RAGEpep was linked through biodegradable and non-
biodegradable linkers in order to study if its release was required for 
activity. In addition, mono- and bifunctional PEG was used as carrier in 
order to better understand the importance of solution conformation 
and drug loading on binding affinity, an consequently,  in the final 
therapeutic output. 
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(A) 
Peptide Nomemclature Purity (%)
A
 MW (g/mol)
 B
 
RAGE peptide 
 
94.5 855 
RAGE peptide-Gly PEP1 97.8 912 
RAGE peptide-Gly-Cys PEP2 96.3 1015 
 
A=calculated by HPLC, B=calculated by MS 
 
(B) 
 
FIGURE V.  8 (A) Purity and molecular weight of the RAGE peptide derivatives 
synthesised by Fmoc-SPPS (B) HPLC trace and MS-MALDI TOF analysis of the 
RAGE peptide. 
 
First attempt of conjugation was done with a di-carboxyl 
activated PEG (NHS-PEG-NHS) using the RAGE peptide sequence, 
although low conjugation yields were obtained. Possibly, this was due 
to steric hindrance or to the reduced nucleophilicity of the amino 
group from the N-terminal fragment. Therefore, a spacer was placed. 
This led to increased conjugation efficiency but also conferred greater 
mobility to the peptide in order to enhance TTRagg recognition. The 
simplest amino acid was selected: glycine (Gly). Mono- and bi-
functional conjugates (C1P1 and C2P1, respectively) were then 
synthesised (schemes in FIGURE V.  9) and purified.  
 
In parallel, conjugates where peptide could be released in 
presence of a reductive environment (such inflammation areas or in 
cytosol) were also synthesised. For that, the spacer glycine-cysteine 
(Gly-Cys) was coupled to the RAGEpep using the same methodology. In 
this case, the PEG derivative used was OPSS-PEG-OPSS (FIGURE V.  10).  
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(A) 
 
(B) 
 
FIGURE V.  9 Synthesis of the RAGE peptide conjugates (A) C1P1 (61) and (B) 
C2P1 (60). 
 
 
 
FIGURE V.  10 Synthesis of the RAGE peptide conjugates C1P2 (63) and C2P2 
(64). 
 
Successful separation of unconjugated reagents was 
performed by means of FPLC (see appendix III for details) using a 
cationic exchange column (Macrocap SP) (FIGURE V.  11, FIGURE V.  
12). Using a fraction collector, tubes containing the product were 
joined, desalted and lyophilised. 
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FIGURE V.  11 FPLC chromatogram of C2P1 and C1P1 purification. 
(absorbance=280nm) 
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FIGURE V.  12 FPLC chromatogram of C1P2 and C2P2 purification. 
(absorbance=215nm) 
V. 1. 1. 3 Synthesis of fluorescently labelled conjugates 
 
As explained in Chapter IV, the conjugation of NIR dye Cy5.5 
was selected as strategy to perform in vivo biodistribution analysis of 
the novel PDCs. For this aim, an amino derivative of this fluorophore 
(FIGURE V.  13) was used in order to react with the carboxylic acid 
pendant groups of the PGA or the activated carboxyl terminal group of 
the bi-functionalised PEG.  
 
 
FIGURE V.  13 Cyane5.5 derivative with an amino group (6S-IDCC). 
V. 1. 1. 3. 1 PGA-CONH-Doxy conjugate fluorescence labelling 
 
PGA-Doxy conjugate was obtained as sodium salt, then this 
conjugate was only soluble in aqueous solutions. Consequently, the 
activation of carboxyl groups for conjugation of the fluorophore was 
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carried out in buffer media. Sulfo-NHS esters are identical to NHS 
except for the sulfonate (-SO3) group on the ring that confers water 
solubility allowing the reaction in aqueous media. The mechanism of 
the reaction is shown in the figure below (FIGURE V.  14). 
 
 
 
FIGURE V.  14 EDC-mediated reaction through the formation of a sulfo-NHS 
ester intermediate. Using the water-soluble carbodiimide EDC, a carboxylate-
containing molecule can be transformed into an active ester by reaction in 
sulfo—NHS esters. This hydrophilic active groups couple rapidly with amines 
[21]. 
 
 Conditions were obtained from reference [22]. Labelling was 
only performed on that conjugate showing the best in vitro activity 
and therefore chosen for in vivo activity studies (51, 17ωt%). The 
scheme of the reaction is depicted in FIGURE V.  15. Labelled 
conjugate was purified with a PD-10 column packed with SephadexTM 
G-25 and the total fluorescence of each aliquot was quantified with a 
fluorescence spectrometer (em=595, exc:=680). Labelling efficiency 
yielded a 1.07%mol Cy5.5, i.e. 0.007mg Cy5.5 in 9mg of final 
conjugate.  
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FIGURE V.  15 PGA-CONH-Doxy labelled with the fluorescence probe Cy5.5. 
 
V. 1. 1. 3. 2 PEG-PEP1 conjugate fluorescence labelling 
 
The PEG carrier used for RAGEpep conjugation was mono- or 
bi-functionalised. Consequently, one of the two extremes had to be 
linked to the fluorophore and the other to the bioactive molecule 
(scheme in FIGURE V.  16). Then, C1P1 was selected to carry out the 
biodistribution assay. Labelled conjugate (67) was purified by SEC (a 
PD-10 column packed with SephadexTM G-25) and the total 
fluorescence of each aliquot was quantified with a fluorescence 
spectrometer (em: 595, exc: 680). Labelling efficiency 0.11%mol Cy5.5, 
i.e. 0.005mg Cy5.5 in 16mg of final conjugate. 
 
 
FIGURE V.  16 C1P1 fluorescence labelling synthesis. 
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V. 1. 1. 4 Synthesis of radioactive labelled PGA-Doxy conjugate  
  
As a comparative methodology for biodistribution studies, 
PGA-CONH-Doxy was labelled with the chelating-agent DOTA for 68 Ga 
complexation and subsequent PET analysis (scheme in FIGURE V.  17).  
 
FIGURE V.  17 DOTA labelling of the conjugate PGA-Doxy. 
 
Polymer drug conjugate was first linked to tBu-DOTA achieving 
an 8%mol functionalisation as calculated by 1H-NMR (D2O) (FIGURE V.  
18). Previous studies demonstrated doxy stability in acidic media thus 
DOTA deprotection under the optimised conditions (section III.1.1.3 
and III.3.2.3) was performed with satisfactory results, obtaining the 
PGA-Doxy-DOTA (65). Then, 68Ga complexation was carried out by the 
Unit of Biomedical Applications of Radioisotopes and 
Pharmacokinetics at the CIEMAT (Madrid) in order to perform in vivo 
biodistribution experiments. Radiochemical yield was 86.3%±3.4. 
Radionuclide purity was calculated as the ratio activities of 68Ge versus 
68Ga in the eluate, corrected for decay expressed in %. The RNP was 
<3.4·10-4%±0.4·10-4. 
 
 
 
 
 
 
 
 
R1
ONa
H
N
m
NH
OH O
OH
OH
OH
O
NH2
O
OH
N
N
H
O
O
H
z
R1
N
H
O
ONaO
HN
H
N
O
N
N N
N
O NHO
HO
OHO O
OH
NH
OH O
OH
OH
OH
O
NH2
O
OH
N
N
H
O
O
H
O
O
O
x y z
DMTMM·Cl / DOTA-NH2
H2O
TFA / TIPS /H2O
[CHAPTER V.] 
[401] 
 
(A)  
 
 
(B) 
 
FIGURE V.  18 (A) 
1
H-NMR spectrum of PGA-DOTAtBu-Doxy for %mol DOTA 
calculation. (B) 
1
H-NMR comparison before and after deprotection. 
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V. 1. 2 PHYSICO-CHEMICAL CHARACTERISATION OF THE POLYMER-
DRUG CONJUGATES 
 
It has become evident that careful physico–chemical 
characterisation of polymer conjugates is essential to understand 
biological behaviour in vitro and in vivo, and to aid the prediction of 
optimum structure for development of a clinical candidate e.g. 
comparison between HPMA copolymer-Dox (PK1) and HPMA 
copolymer-Dox-galactosamine (PK2) both in phase I/II clinical trials [7, 
17, 23, 24]. Innovative and validated methodologies use is increasing 
due to their usefulness to ensure optimisation of properties relevant 
to finally achieve the clinical setting [2, 7, 23, 25]. As it has been 
emphasised in the introduction (section I.2.5.2), it is important to 
report key conjugate properties, such as, the conformation adopted in 
solution or the stability of the bonds between drug and carrier in the 
different scenarios they will undergo once injected into the body.  
These characteristics include, among others, MW and polydispersity, 
size, hydrophilicity and hydrophobicity, solution conformation as well 
as stability or degradation profiles within biological settings.  
 
In this thesis, all these parameters had been set up though the 
techniques explained below. A general example of the properties 
analysed and usual techniques for polymer-drug conjugates 
characterisation is summarised in TABLE V.  2 and further detailed in 
appendix III 
 
PDC property Technique 
Covalent drug conjugation NMR, FT-IR, MS 
Total and free drug content HPLC, UV, NMR 
MW, PDI GPC, MS, Light Scattering 
Size, conformation in solution 
SANS, SAXS, DLS, TEM, SEM, PGSE-
NMR 
Formation of supramolecular 
assemblies 
SAXS, NMR, DLS 
TABLE V.  2 Routine techniques for polymer-drug conjugates physicochemical 
characterisation. From ref [26]. 
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V. 1. 2. 1 Conformation in solution, plasma stability and pH 
degradation studies of PGA-X-Doxy conjugates  
 
Conjugate solution conformation. Determination of the 
Hydrodynamic Radius (Rh) 
Conformation in solution is a useful tool to explain conjugate 
activity either in vitro or in vivo. Drug availability in the adopted 
conformation could be directly related with the observed activity.  
Size distribution and hydrodynamic diameter of our polydispersed 
population of PGA-X-Doxy conjugates with different drug loading was 
measured by DLS (appendix III). The conjugates were dissolved in PBS 
at 10mg/mL. Similar hydrodynamic diameter was demonstrated for 
PGA-CONH-Doxy (51) with different drug loadings,(i. e. 15 and 43ωt%, 
with 6.2±1.3nm and 7.5±0.7nm) (FIGURE V.  19).  
 
 (A)  PGA-CONH-Doxy 15ωt% 
 
(B) PGA-CONH-Doxy 43ωt% 
 
FIGURE V.  19 DLS profiles for (1) PGA-CONH-Doxy 15ωt% and (B) PGA-CONH-
Doxy 43ωt% in PBS. 
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In order to further elucidate if drug loading differences 
triggered different size and/or shape of the doxy conjugates, SANS 
studies (appendix III) were performed with the same conjugates. These 
studies were done at the Institute Laue-Langevin in Grenoble (France) 
with our collaborators from the School of Chemistry in the Cardiff 
University (Cardiff, UK). PGA-CONH-Doxy 15ωt% and PGA-CONH-Doxy 
43ωt% were dissolved at 10mg/mL in deuterated PBS at 37°C to mimic 
biological conditions. All assays were performed in 2mm quartz cells 
performing measurements of 1h per sample.  
 The scattering data for the PGA conjugates was fitted to form 
factors for polydiperse Gaussian coils, spherical and rods and the 
values obtained are presented in TABLE V.  3 (graphics are depicted in 
FIGURE V.  20). The scattering data was corrected for the scattering 
and transmission of the solvent and quartz cell and normalised by 
placing on an absolute intensity scale with a well characterised 
standard. 
 
  
DLS SANS 
 
% ωt Volume (d, nm) r / L 
PGA-CONH-Doxy 15 6.2±1.3 40 / 400 
   
32 / 8.5 
PGA-CONH-Doxy 43 7.5±0.7 36 / 95 
   
23 / 13.5 
TABLE V.  3 Conformation in solution data of PGA-CONH-Doxy conjugates 
analysed by DLS and SANS. r=radius, L=length. 
 
After analysing the data obtained from SANS, the structures 
present do not fit to simple models such as coils or spheres, but in any 
case, it could be concluded that even if the conjugate with greater 
loading (43ωt%) seemed to have a larger hydrodynamic radius, there 
were not significant changes in the solution conformation when both 
conjugates were compared. 
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FIGURE V.  20 SANS diagram of conjugates solutions in deuterated PBS 
(10mg/mL). PGA-CONH-Doxy 43ωt% (squares), PGA-CONH-Doxy 17ωt% 
(triangles), PGA (circles). 
 
DLS and SANS analysis were in good agreement showing that 
conformation in solution is not major difference between the PGA-
Doxy conjugates synthesised. Importantly, SANS analysis 
demonstrated that doxy conjugation significantly changes the original 
PGA conformation (circles in FIGURE V.  20). 
. 
Drug release studies under hydrolytical conditions 
Polymer conjugates are designed aiming to achieve a stable 
system in the blood stream and after reaching the desired target 
trigger drug release under a specific physiological scenario. For 
example, inflammation reduces local pH to 5.5 or even lower, 
therefore sensitive pH-labile linkers (acetal, hydrazone, ester, etc) will 
be susceptible to be hydrolysed. Besides, controlled drug release could 
be achieved for a prolonged period of time. 
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Concerning this thesis, the aim of the drug release studies 
performed was to observe the stability of the synthesised PGA-Doxy 
conjugates under physiological conditions encountered in cell and in 
vivo experiments.  
 
First, analysis of conjugates’ stability in plasma revealed non-
significant doxy release after 24h (FIGURE V.  21).  
 
 
FIGURE V.  21 Plasma stability of PGA-Doxy conjugates. HPLC detection of 
drug release. 
 
Mimicking the in vitro conditions as well as the acidic pH 
expected in the drug site of action, PGA-Doxy conjugates families were 
incubated up to 17 days at 37°C in PBS at different pHs 5.5 and 7.4. 
Sample analysis was done by directly analysis of the conjugates 
monitoring the absorbance of the whole conjugate after its injection 
through a GPC column (appendix III). Results here were difficult to 
interpret and further analyses are ongoing in order to better 
understand the behaviour of the conjugates under hydrolytical 
conditions. 
 
In parallel, drug release in in vitro conditions (PBS, pH=7.4, 
37°C, 17days) was also evaluated. By means of LCMS (appendix III), it 
was proved that in the case of the amide conjugates no release was 
0
20
40
60
80
100
120
0 10 20 30
%
 fr
ee
 d
ru
g
t(h)
Plasma control PGA-CONH-Doxy 17wt%
PGA-CONH-Doxy 33wt% Free drug
[CHAPTER V.] 
[407] 
observed after 22days of incubation (detection limit under 
0.012mg/mL). However, 1.9% of total ester conjugate drug was 
released (FIGURE V.  22(B1-B3)). Same result was observed for the 
HPLC analysis (FIGURE V.  22(A)), where the area under the curve 
(AUC) of the total conjugate decreased while remained almost 
constant for the rest of the PGA-Doxy families. 
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(B1) SIR 445  F10 t=22days F10 t=6days D1 t=0min D1 t=0min  
 
(B2) Zoom SIR 445   F10 t=22days   F10 t=6days D1 t=0min D1 t=0min 
 
(B3) Zoom comparison  SIR 460 D2 F4 t=17days 
FIGURE V.  22 Stability of PGA-X-Doxy conjugates in in vitro conditions. (A) HPLC 
representation of the percentage of area under the curve (AUC) vs the incubation time 
(days) in PBS at 37°C; and HPLC chromatograms of PGA-CONH-Doxy 15ωt% along the 
time course analysis, (B) LCMS analysis of the aliquots to detect the released drug: 
(B1) Data from PGA-COO-Doxy 22ωt%  (F10) compared with doxy (D1) ; (B2) Zoom of 
(B1); (B3) Data  from PGA-CONH-Doxy 15ωt% (F4) compared with doxy-NH2 (D2). 
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V. 1. 2. 2 Characterisation of RAGE peptide conjugates: stability in 
different conditions, conformation in solution and TTR affinity 
studies  
Molecular weight determination  
Techniques like NMR and MS spectroscopy were used to 
achieve identity of the PEG conjugate synthesised (appendix III) 
(FIGURE V.  23(A). FIGURE V.  23(B) shows the MS MALDI-TOF results 
of the PEGylated peptides. The polydispersity of PEG is reflected into 
the polydispersity of the conjugate. Integration of peptide 1H-NMR 
signals (aromatic H) clearly identified the number of peptide molecules 
per PEG chain (FIGURE V.  24).  
 
(A) 
  Type of bond 
Ratio 
PEG:pep 
MW
A
 
(Da) Ɖ 
C1P1 non bio-degradable 1:1 3933 1.02 
C2P1 non bio-degradable 1:2 4971 1.02 
C1P2 degradable 1:1 4899 1.05 
C2P2 degradable 1:2 5873 1.05 
 
(B) 
 
FIGURE V.  23 Characterisation data of the CXPX conjugates. (A) Table with 
measurement of MW by MS MALDI-TOF and PEG:PEP ratio by NMR-
1
H (D2O), 
(B) example of the characterisation of C2P1 with a MS spectra. 
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(A) C1P1 
 
 
(B) C2P1 
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(C) C1P2 
 
 
(D) C2P2 
 
FIGURE V.  24 
1
H –NMR spectrums of the CXPX conjugates in D2O: (A) C1P1: 
mPEG-PEP1, (B) PEP1-PEG-PEP1, (C) PEG-PEP2, (D) PEP2-PEG-PEP2. 
 
Stability studies 
Next step on characterisation was to evaluate their stability 
under different physiological conditions: in cell media for in vitro tests 
and in plasma for in vivo studies. The conjugates were dissolved in cell 
media or plasma and incubated at 37°C. A time course experiment was 
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performed by extracting aliquots which were analysed by HPLC 
(FIGURE V.  25) and MS spectroscopy (TABLE V.  4), respectively.   
 
(A) 
 
(B) 
 
FIGURE V.  25 Stability studies of the conjugates synthesised in presence of 
cell media. (A) Chromatograms of conjugates C2P1 and C1P2, (B) 
representation of the percentage of degradation (area under the curve (AUC) 
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vs. time for conjugates C1P1, C2P2 and C1P2. 
t (h) MW C1P1 (g/mol) %MW loss MW C2P1 (g/mol) %MW loss 
0 4019,8 100.0 5024.5 100.0 
5 3701 92.1 4907.0 97.7 
24 3618,3 90.0 4409.7 87.8 
TABLE V.  4 Plasma stability studies of (a) C2P1 and (b) C1P1, MW determined 
by MS-MALDI TOF analysis. 
 
As FIGURE V.  25(A) shows, conjugates with peptidic linkage 
were more stable than conjugates with disulphide bond in cell media 
after 48h of incubation. Free peptide was not dissolving in cell media; 
therefore, PEG confers a major advantage in this scenario allowing the 
RAGEpep to become a possible FAP treatment. In plasma, same 
behaviour was observed due to the lack of peptide solubility while all 
conjugates did solubilise. After 48h, conjugates were not still fully 
degraded and at least a molecule of peptide remained attached as 
shown by MW calculation. Summarising, PEG as carrier greatly 
enhanced RAGE peptide solubility and significantly diminished fast 
peptide degradation. 
 
Conjugate Solution Conformation 
It has been already demonstrated that conjugate solution 
conformation is critical on its therapeutic output [27-33]. Although in 
the present study polymer must protect peptide from protease 
degradation once in the body, peptide inhibitory activity also requires 
certain grade of exposition to be able to be recognised by and bind to 
the RAGE receptor. PEG conjugates were analysed by DLS in PBS media 
at neutral pH finding differences depending on the number of peptide 
molecules attached and the type of bond used.  
 
From FIGURE V.  26(A) it can be concluded that only C2P2 exhibits 
differences in solution conformation, displaying the highest 
hydrodynamic ratio (nm) of the conjugate family as well as the most 
irreproducible behaviour compared to C1P1, C2P1 and C1P2.  
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(A) 
 
 
(B) 
 
FIGURE V.  26 (A) Hydrodynamic radius (nm) measurement by DLS of the 
CXPX conjugates in PBS 0.020M media (B) Conformation in solution proposed 
based on the results obtained. 
 
To explore if this behaviour was concentration dependent, a 
second study was performed. DLS is able to determine the critical 
micelle concentration (CMC) [34], finding out if aggregation relied on 
micelle formation. Below the CMC the intensity of scattered light 
detected from each concentration is similar to that obtained from the 
media. However, once the CMC is reached this intensity increases due 
to the presence of micelles and the intercepts obtained in the 
correlation functions are much higher (see an example in FIGURE V.  
27). 
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FIGURE V.  27 A compound can exist as different phases depending upon the 
concentration of the sample. At low concentrations macromolecules may be 
unassociated monomers. As concentration increases, the 
hydrophilic/hydrophobic forces may cause self-aggregation resulting in the 
formation of monolayers or micelles [34]. 
 
 Comparing this with our data (FIGURE V.  28), size (blue line) 
remains constant in C1P1, C1P2, C1P2 (Rh=0.6-3nm) while 
concentration varied. PEG of 5000g/mol has been reported to be 
around 2nm [35], which is in god agreement with our DLS data. On the 
contrary, C2P2 presented variations together with fluctuating intensity 
data. A possible CMC could be assigned around 7.5mg/mL, a relatively 
high concentration for these type of systems.  In FIGURE V.  26(B), 
there is a cartoon with the possible structures that could be 
encountered in solution for the different conjugates according to the 
obtained sizes.  It was also confirmed that the type of linkage use 
could influence the final conformation adopted by the conjugate. 
Consequently, the existence of unimers is proposed for conjugate 
C2P1 whereas the formation of dynamic micelle–like structures are 
expected from conjugate C2P2. 
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FIGURE V.  28 A plot of the intensity of scattered light (in kilo counts per 
second, kps) and hydrodynamic diameter (in nm) obtained for various 
concentrations of the PEG conjugates (CXPX) prepared in PBS 0.02M pH7.4. 
The intersection of the two lines may corresponds to the critical micelle 
concentration (CMC). 
 
TTR aggregates binding assays 
The interaction of RAGEpep with TTRagg was firstly studied by 
competition binding assays using 125I-labelled TTR. The peptide and its 
conjugates were adsorbed to the plate wells at a constant 
concentration of 5µg RAGE/well. Unlabelled TTR was tested for its 
ability to compete with the labelled protein for binding to the 
adsorbed peptide or the PEGylated forms. However, in any of the four 
experiments performed results were conclusive. Positive and negative 
controls together with the compounds exhibited rare behaviours 
which were difficult to interpret. For that reason, an alternative 
methodology for binding experiments was proposed. Surface plasmon 
resonance (SPR) method was used in order to find out if the affinity of 
the peptides for the TTRagg was maintained after PEGylation. 
BIAcore® device utilise the natural phenomenon of SPR to find out the 
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affinity of the interaction between the compounds tested. In our 
study, TTRagg were immobilised on a chip and its affinity with RAGE 
peptide conjugates was tested. 
 
SPR or Biacore, is a standard technology for interactional study 
of biomolecules. This technology has the advantage of being able to 
work with biomolecules in their native forms, without the need of 
introduction of a label or tag. The SPR-based technology continuously 
monitors the changes of mass deposition on the detector surface, and 
allows sensitive and reliable characterisation of biomolecular 
interactions and provides information such as association/dissociation 
rate and affinity. 
 
The sensor chip selected was a CM5. Its matrix was a 
carboxymethylated dextran covalently attached to a gold 
surface. Molecules were covalently coupled to the sensor 
surface via amine, thiol, aldehyde or carboxyl groups.  Selected 
via for TTR attaching to this chip was the amine coupling. Amine 
coupling makes use of the N-terminus and ε-amino groups of 
lysine residues of the ligand. Below a typical sensorgram of the 
immobilisation of a ligand to a CM5 sensor chip using this 
procedure is shown (FIGURE V.  29). The numbered points refer 
to the different theoretical stages in the immobilisation 
procedure. 
 
In this experiment, TTR aggregates were covalently 
immobilised on the sensor chip surface while the peptides/conjugates 
were injected across the sensor surface, using cell media as vehicle 
and 37°C to mimic in vitro conditions. The interaction found between 
TTR and  PEP1 or amide conjugates (C1P1, C2P1) was reversible and 
regeneration step after the run was not needed, while with PEP2 or 
disulphide conjugates (C1P2, C2P2) was irreversible and chip 
regeneration was carried out injecting Gly 10mM pH=2.5. 
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FIGURE V.  29 Amine coupling of a protein onto the sensor chip. Steps: (1) 
Baseline for the unmodified sensor chip surface with continuous flow. (2) 
Injection of NHS/EDC to activate the surface by modification of the 
carboxymethyl groups to N-Hydroxysuccinimide esters. (3) Baseline after 
activation. Activation of the surface has only a very slight effect on the SPR 
signal. (4) Injection of ligand leads to electrostatic attraction and coupling to 
the surface matrix. At this point, the ligand solution is still in contact with the 
sensor surface, and response includes both immobilised and non-covalently 
bound ligand. The NHS esters react spontaneously with the amines on the 
ligand to form covalent links. (5) Immobilised ligand before deactivation. The 
ligand has passed the sensor surface and most of the protein that is not 
covalently bound is eluted. (6) Deactivation of unreacted NHS-esters using 
ethanolamine hydrochlorid 1M adjusted to pH 8.5 with NaOH. The increased 
SPR signal is due to a change in the bulk refractive index. The deactivation 
process also removes any remaining electrostatically bound ligand. (7) Point 7 
minus Point 3 gives the amount of immobilised ligand after deactivation. 
 
Results recorded are compiled in TABLE V.  5. All peptides and 
conjugates, except C2P2, bind TTR with different KD values, therefore 
recognising the protein. C2P2 data were not reproducible and 
statistical parameter χ2 was not in the acceptable range. Summarising, 
in general it could be said that PEGylation was not affecting to the 
capability of binding of the original peptide to TTRagg, its molecular 
target.  
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Conjugate KD (M) 
χ
2
 
(average*) 
RAGEpep 
 
0.0016 1.43 
PEP1 
 
0.0017 0.13 
PEP2 
 
n.r. > 10 
PEG–pep1 C1P1 0.0028 0.78 
pep1–PEG–pep1 C2P1 0.0065 4.16 
PEG–pep2 C1P2 0.001 3.17 
pep2–PEG–pep2 C2P2 n.r. >10 
n.r.=non reproducible data, *n=10 
TABLE V.  5  BIAcore® data. Binding constant between TTR protein and the 
CXPX conjugates. 
 
V. 1. 3 IN VITRO ACTIVITY STUDIES OF THE POLYMER-DRUG 
CONJUGATES 
 
Once both novel polymer conjugate families were fully 
characterised and batch-to-batch reproducibility was achieved, their in 
vitro evaluation was performed. Activity assays reproducing those 
performed with the parent drugs were carried out to asses that 
conjugation was not decreasing their inherent properties.  
 
Doxy disrupting action in vitro was demonstrated after its 
incubation with TTR fibrils. These fibrils were produced with the 
variant TTR Leu55Pro, which is described as one of the most aggressive 
mutations in the FAP disease and tends to form fibrils in vitro under 
physiological conditions (PBS pH=7.4) [36]. In the case of RAGE peptide 
conjugates, RAGE peptide protecting effect was evaluated in a 
established in vitro FAP model with the RN22 cells [9]. RN22 cells are a 
rat Schwannoma cell line characterised by their Schwann cell like 
phenotype. Schwan cells are the principal glia of the peripheral 
nervous system (PNS). TTR amyloid deposits can be found in any part 
of the PNS, including the nerve trunks, plexuses and sensory and 
autonomic ganglia. In peripheral nerve, deposition occurs 
extracellularly, mainly in the endoneurium close to Schwann cells and 
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to collagen fibrils. In FAP, TTR mature fibrils have been described as 
the causative agent of disease but the protein is not toxic in this state 
while initial aggregates are [36].  
 
V. 1. 3. 1 TTR fibril disruption studies of the PGA-X-Doxy conjugates 
 
Assessment of fibril formation was monitored by Transmission 
Electron Microscopy (TEM). Examples of the obtained images are 
shown in FIGURE V.  30. Before starting conjugate incubation with the 
fibrils, a homogenous batch of fibrils with similar length was prepared. 
 
Screening for TTR fibril disrupters 
Tetracyclines have already demonstrated anti-amyloidogenic 
properties toward Aβ-amyloid not only in the inhibition of fibril 
formation but also to disaggregate the already formed fibrils [37]. In 
the case of doxycycline, previous findings revealed that it acts as a TTR 
fibril disrupter in vitro and in vivo, in fact this drug is currently in 
clinical trials for AD [10, 11, 38]. Prior to the in vivo assays, a selection 
of PGA-X-Doxy conjugates (TABLE V.  6) was evaluated for its capability 
to break the TTR formed fibrils in order to select the most active 
candidate. 
 
Visualisation of samples by TEM revealed that, at a drug 
concentration of 180μM/100µg fibrils, many conjugates were able to 
disrupt the fibrils after 3days (PGA-CONH-Doxy 15ωt%) or 6 days (PGA-
CONH-Doxy 30ωt%, PGA-GG-Doxy 6ωt%), as can be observed in 
FIGURE V.  30. This fact was determined due to the appearance of 
fibrils of smaller extension or a complete disaggregation. Named 
conjugates demonstrated higher activity than parent drug at equal 
drug concentration (FIGURE V.  30) Hence, PGA conjugation 
demonstrated not only to maintain original activity after its linkage but 
also to enhance it. This property has been found very interesting. From 
this experiment it was also discovered that PGA conceals activity as 
itself (FIGURE V.  30).Fibrils were disrupted after 6 days of incubation 
although at higher lengths than conjugates. Disaggregating effect 
could be attributed to a possible polymer intercalation where negative 
charges of the carboxyl groups promote fibril disruption. In nature, 
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other polyanions such as gycosaminoglycans or proteoglycans have 
been described to be involved in the formation of amyloid deposits. 
Comparable promoting effects have been attributed to polycations like 
PEI, polyLys or polyArg [39]. Thus, further studies to elucidate PGA 
behavior will be carried out in order to determine its possible inherent 
capability for fibril disaggregation as polymeric drug. Overall, the 
highest activity observed at shorter time belonged to a member of the 
amide linkage family: PGA-CONH-Doxy 15ωt%.  
 
Conjugate % ωt Doxy 3.6mM Doxy 
PGA-NH-DOXY conj. 51.29 3.61 mg / mL 
 
15.00 12.33 mg / mL 
PGA-COO-DOXY conj. 26.00 7.12 mg / mL 
 
21.50 8.60 mg / mL 
 
33.00 5.61 mg / mL 
 
30.05 6.16 mg / mL 
PGA-LG-NH-DOXY conj. 9.00 20.56 mg / mL 
 
8.50 21.76 mg / mL 
PGA-GG-NH-DOXY conj. 13.60 13.60 mg / mL 
 
6.10 30.33 mg / mL 
DOXY 
 
1.85 mg / mL 
DOXY-NH2 
 
2.01 mg / mL 
TABLE V.  6 PGA-X-Doxy conjugates tested in vitro. 
 
After compiling the results of solution conformation and bond 
stability studies, it could be concluded that doxy release is not a 
requirement for activity (see FIGURE V.  22 where no release was 
detected in the PBS stability study after 3days or where LCMS data 
revealed no free doxy existence even after 17days). Conjugate solution 
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conformation looking at different drug loading did not reveal any 
significant differences (see section V.1.2.1), which could indicate that 
drug exposure is either not an issue for activity. 
 
Regarding DLS analysis, aliquots were taken at the same 
moment and time point than TEM samples. Results are depicted in 
FIGURE V.  31. Vast majority of the treated fibril samples were 
significantly different (p<0.05) from the control fibrils after 6 days of 
incubation. It was observed that the progression in particle size 
(radius, r (nm)) with time differed according to whether drug or 
conjugate was present or not. Control TTR showed a heterogeneous 
preparation with species with radii of around 700nm. The incubated 
fibrils for 6 days with conjugates resulted in smaller particle sizes, 
ranging from 300-530nm.  
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Control fibrils t=0 
 
PGA-CONH-Doxy 15ωt%, t=6d 
 
PGA-CONH-Doxy 30ωt%, t=6d 
 
PGA-CONH-gly-gly-Doxy 14ωt%, t=6d 
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(B) Doxycycline, t=10d     (C) Doxy-NH2, t=10d 
 
(D) PGA, t=6d 
 
FIGURE V.  30 Effect of Doxycycline conjugates was tested on the in vitro 
assembly of TTR L55P fibrils followed by TEM. In the control situation, after 13 
days incubation at 37°C, TTR initial aggregates are organised into mature 
fibrils.(A) When doxy conjugates were active (i.e.. PGA-CONH-Doxy 15ωt%, 
PGA-CONH-Doxy 30ωt%, PGA-GG-Doxy 14ωt%), fibrils were disrupted 
producing small round particles and shorter fibrils. (B) When doxy 
concentration was increased, activity was observed. (C) Doxy-NH2 showed 
comparable activity to the original parent drug. (D) Unexpectedly, PGA 
(added as a negative control) produced fibril reduction and round particles 
were observed. 
 
200 nm
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FIGURE V.  31 Particle size (hydrodynamic radius (nm)) measured by DLS. 
(*=significant data respect control (t=3days), #=significant data respect 
control (t=6days), p<0.05). 
 
Sizes obtained by DLS cannot be comparable with those 
lengths measured by TEM. It is important to remark that, both 
techniques underwent in different scenarios and therefore, final data 
could not be interpreted in the same manner. In the case of TEM, 
fibrils are adsorbed onto the grid and after the staining, they remain 
dry. Single fibrils are observed. On the other hand, DLS measurements 
are carried out in solution. Sizes given were a result of a theoretical 
spherical particle. Most probably, radius data was directly related with 
the size of fibrils and reduction in fibril size entailed a reduction in the 
radius of the fibril aggregate particle. 
 
Considering the results obtained, it has been clearly ratified 
that PGA-X-Doxy conjugates act as fibril disruptors at lower drug 
equivalent concentrations than the parent drug. PGA-CONH-Doxy 
15ωt% was selected for further studies.  
 
V. 1. 3. 2 Cytotoxicity of the species resulting from the action of PGA-
X-Doxy 
 
In FAP, TTRagg have been identified as the cytotoxic species 
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oppositely to the mature fibrils that although they could be considered 
as non‐toxic, they could instead trigger apoptosis after their 
deposition[36]. This assay was proposed trying to understand if 
structures resulting from fibril disruption were able to promote cell 
death mechanisms. Using the RN22 cell line, cytotoxicity of the species 
resulting from fibril disruption by the most active doxy conjugates was 
evaluated and compared with the fibrils and the aggregates. 
Conjugates selected for this study were PGA-CONH-Doxy 15ωt% (51), 
30ωt% and PGA-GG-Doxy 6ωt% (52). 
 
A first study (FIGURE V.  32(A)) concluded that toxicity of the 
sub‐products were similar than that for mature fibrils and not higher 
than that obtained for the aggregates. TEM images revealed a non-
homogenous population after the treatment in the control sample 
(data not shown) probably due to non-mature enough samples. A 
second experiment did not arise either any concluding results as no 
significant differences were obtained, toxicity of the fibrils treated 
with the conjugates were similar to the fibrils (FIGURE V.  32(B)). 
 
From the experiments it was concluded that toxicity of the 
fragments were not significantly different to fibrils. However, free 
doxy did not improve cell bioavailability while the conjugate PGA-
CONH-Doxy 15ωt% showed better output. Repetition of the assay and 
further evaluation in vivo would confirm if these fragments could 
induced any other effect.  
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 (A) 
 
(B) 
 
FIGURE V.  32 (A) First trial of caspases-3 test after fibril incubation with PGA 
conjugates (B) Second trial of caspase-3 test after fibril incubation with PGA 
conjugates. 
 
V. 1. 3. 3 Activity of the RAGE peptide conjugates as inhibitors of 
TTRagg induced toxicity. Caspase-3 assay 
 
To investigate the pharmacological activity of the PEG-RAGE 
peptide conjugates they were first incubated with TTRaggs before 
incubating with RN22 cells for 24h or 48h. Apoptotic cell death was 
then quantified using a caspase–3 activity fluorometric assay based on 
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the hydrolysis of the peptidic substrate acetyl–Asp–Glu–Val–Asp–7–
amido–4–methylcoumarin (A–DEVD–AMC) resulting in the release of 
7–amino–4–methylcoumarin (AMC) fluorescent moiety. In order to 
normalise the data, the protein content of the RN22 cells was 
determined using Bradford assay (appendix III).  
 
The PEG-RAGEpep conjugates retained RAGE peptide activity 
(FIGURE V.  33). In all the experiments performed, the conjugate C2P1 
(PEP1-PEG-PEP1) was the best inhibitor of TTR-agg induced 
cytotoxicity in Schwann cells at 24h. Those conjugates containing 
disulphide linkers produced less reproducible data and lower activity, 
therefore, it could be concluded that PEG-RAGE conjugates with the 
amide linker are more effective in preventing cytotoxicity induced by 
the TTRagg at 24h. It is important to note that addition of the PEG 
polymer alone appears to promote growth after 24h PEG could act as 
‘nutrient’ (assay is carried out at 1% serum to avoid confluence during 
the incubation period) balancing the effect of toxicity caused by 
TTRagg. However, this effect disappears after 48h. 
 
 
FIGURE V.  33 Activation of caspase-3 in RN22 cells exposed 24 and 48h to 
10μM of RAGE peptide after incubation alone, with their derivatives or with 
the RAGE peptide conjugates. PEG was used as control. *Significantly 
different from aggregates (*, p<0.05; **, p<0.005). 
 
Conformation in solution may explain activity in vitro where 
C2P2 activity resulted in the lowest of the group. Rest of conjugates 
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demonstrated to have a stable conformation in solution (Rh=0.6-3nm) 
non-concentration dependent where possibly peptide availability is 
better for TTRagg interaction therefore improving conjugate activity. 
 
In conclusion, the data relating to TTR binding affinity, 
conjugate linker stability and the solution conformation of PEG-RAGE 
peptide conjugates indicate that the PEG RAGE peptide conjugates 
containing amide linkers have the greatest potential for future 
development as FAP inhibitors. Moreover, this novel conjugate has 
potential as a FAP therapeutic to be used alone in the early stages of 
the disease or as part of rationally designed combination therapy.  
 
V. 1. 3. 4 Haemolysis assay of the synthesised polymer-drug 
conjugates 
 
As PEG-RAGEpep conjugates are proposed for administration 
by the intravenous (i.v.) route their ability to induce red blood cell 
(RBC) lysis in vitro was studied as a preliminary measure of 
haematocompatibility [28]. PEI and dextran represented the positive 
and the negative control, respectively.  Dextran is used as a plasma 
volume expander and PEI is a cationic polymer with a marked 
haemolytic character. Haemolytic profiles of PGA-Doxy and PEG-
RAGEpep conjugates were evaluated and results are represented in 
FIGURE V.  34. None of the conjugates showed haemolytic properties 
indicating their suitability for i.v. administration. 
 
FIGURE V.  34 Haemolytic activity of PGA-CONH-Doxy (51) conjugate and the 
PEGylated RAGE peptide C2P1 (60) at 1h. Data expressed as mean (n=3). 
[CHAPTER V.] 
[430] 
V. 1. 4 IN VIVO EVALUATION STUDIES OF THE POLYMER-DRUG 
CONJUGATES 
 
Polymer-drug conjugates evaluation continues with 
biodistribution studies and proof of activity in vivo. Efficacy of the 
novel conjugates lies in their PK, biodistribution and metabolic 
clearance. The pathway involves circulation in the blood, interaction 
with major organs (e.g., liver, kidneys, etc); transport to target tissue 
and cells ending with the effective drug action (with an appropriate 
release if necessary). Traditional studies were sometimes invasive and 
cannot accurately provide real time information on the interaction 
between polymers with organs and tissues, the delivery efficiency of 
the whole system or the therapeutic response. Nowadays, biomedical 
imaging technology advances provide efficient systems for non-
invasive and monitoring in vivo drug delivery.  Techniques explained in 
Chapter III, are some examples of how labelling the PDC allows to 
accomplish the reported objectives. 
 
Concerning activity experiments, already reported PDCs’ in 
vivo studies has clearly demonstrate the benefits of drug conjugation 
to polymer carriers [40]. Conjugation of the NIR dye Cy5.5 and the 
DOTA/68 Ga complex were the selected tags. Both strategies enabled 
to monitor and quantify the biodistribution and PK parameters of the 
conjugates in vivo as well as ex vivo. Preliminary activity studies had 
been performed in a FAP young mice model also evaluating the 
possibilities of a combination therapy. Recently, it has been proposed 
that therapy entailing action on signalling pathways involving RAGE or 
other mediators together with fibril disruption can be considered as a 
novel potential pharmacological approach in FAP [41].  
 
V. 1. 4. 1 Polymer-drug conjugates biodistribution studies in mice  
 
PGA-DOXY conjugate biodistribution 
 
PGA-CONH-Doxy-Cy5.5 
Body distribution study was carried out in healthy Balb/c mice 
(9-12month-old male/female). As in Chapter IV, the Cy5.5 labelled 
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conjugate tissue distribution was measured by means of FLI the IVIS® 
Spectrum imaging system. Mice were injected i.v. with 1.15mg doxy 
eq/kg of PGA-Doxy17ωt%-Cy5.5 (66). As a control, non-injected mice 
were used. Mice were monitored (dorsal and ventral view) after i.v. 
injection and a time course experiment was performed (TABLE V.  
7(A)).For this assay, mice were shaved to avoid fluorescent 
interference from the fur. FIGURE V.  35 shows the in vivo FLI images 
over time. The fluorescence signal was quantified in Radiant Efficiency. 
To further confirm the results, groups of mice for each time point were 
euthanised and blood, liver, kidney, spleen, brain, lungs and heart 
were collected. All tissues were analysed by ex vivo FLI (FIGURE V.  36) 
and total content of fluorescence was determined by VICTOR® analysis 
after homogenisation. Quantification data is shown as Cy5.5 
fluorescence per weight of tissue at each time-point (FIGURE V. 37). As 
expected for a PGA conjugate, results showed no specific 
accumulation in any organ and renal clearance. The conjugate did not 
accumulate in heart, lungs, kidney or liver (FIGURE V.  38). Ex vivo FLI 
intensities and fluorescence data of the homogenated tissues showed 
good correlations, validating FLI intensity determinations as a good 
methodology to estimate non-invasively tissue-accumulations. 
 
(A)                                             (B) 
Time point n (animals)   Time point n (animals) 
0 min 5   0 min 4 
30 min 3   30 min 4 
1h 4   4h 4 
4h 4   24h 4 
24h 4   Control 4 
96h 3     
Control 4     
TABLE V.  7 Time points for fluorescent in vivo measuring or animal sacrificing 
during the biodistribution study: (A) PGA-Doxy-Cy5.5, (B) Cy5.5-PEG-PEP1. 
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FIGURE V.  35 Whole-body biodistribution of PGA-Doxy-Cy5.5 measured by 
the means of in vivo FLI from the dorsal and ventral views using the 
IVIS®Spectrum. 
 
Ctrl Treated Ctrl Treated
Dorsal Ventral
t=0min
t=4h
t=1h
t=24h
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FIGURE V.  36 Ex vivo monitoring of PGA-Doxy-Cy5.5 overtime. Pseudocolor 
scale bars were consistent for all images in order to show relative changes 
with time. 
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FIGURE V. 37 
Normalised data of 
fluorescence 
obtained after 
homogenation of the 
excised organs from 
PGA-Doxy-Cy5.5 
biodistribution: 
(A) Same “y” axis 
scale  
(B) Different “y” axis. 
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FIGURE V.  38 Comparison among kidney and liver normalised fluorescence of 
the in vivo distribution of PGA-CONH-Doxy-Cy5.5. 
 
Regarding plasma analysis, fluorescence measurements were 
done directly without any extraction due to signal lost if treatments 
with organic solvents, acid or base are used. Results are graphed in 
FIGURE V.  39. Surprisingly, PGA-Doxy conjugate t1/2 was found to be 
approximately 10min, very short t1/2 for this type of conjugates. 
Reported t1/2 for other clinically-relevant PGA conjugates are from 30 
min to 5 hours [42-45]. It is believe that experimental issues could 
occur, such as, the binding or co-precipitation in during plasma 
isolation as doxy readily binds to plasma protein binding drug [46]. 
These experiments should be discharged as at that time pellet was not 
further analysed. Instead, t1/2 was calculated by PET analysis. 
 
 
FIGURE V.  39 Half-life time (t1/2) study of PGA-CONH-Doxy. 
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FVB/NJ mice were injected i.v. a dose of 21±4µg compound/g 
body weight of PGA-Doxy-DOTA/68Ga (0.2 and 1.4MBq 68Ga activity). 
The selected dose was adequate for a proper detection of the signal 
not for therapeutic proposes. Time course analysis of the radioactivity 
signal showed, as already seen for the control compound (PGA-DOTA), 
a marked signal in the kidneys (FIGURE V.  40(A)/(B)), suggesting renal 
secretion. However, the radioactivity levels detected in the liver or 
spleen of the PDC were significantly higher than the control) (FIGURE 
V.  40(a1)). This result suggested that drug conjugation may promote a 
different (probably bigger, as suggested by SANS data) solution 
conformation favouring liver uptake. In addition, DOTA content in the 
PGA-Doxy (18%) conjugate was higher than in the PGA (2%), which 
may also contribute to the different conformation. Slight differences 
were also found in the spleen and the lungs, with higher values in the 
labelled polymer-drug conjugate. However signal decreased indicates 
that compound was along the secretion process, as expected. 
 
The PK analysis using a bicompartimental model gave key 
parameters to compare PGA-Doxy conjugate vs. PGA control. The 
volume of distribution was similar for both, approximately 5.3mL. The 
AUC is larger for PGA-Doxy as well as its Clearance rate (11,8mL/h vs. 
7mL/h for PGA-Doxy vs. PGA, respectively). Importantly, t1/2 of the 
DOTA labelled PGA-Doxy demonstrated greater value than for PGA 
control, 0.98h vs. 0.59h, respectively. This time, data in good 
agreement for that reported with PGA conjugates.  
 
 
(a1) 
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(B continues)
 
FIGURE V.  40 PET images PGA-Doxy-DOTA/
68
Ga (46,9 µCi) (A) (a1) PET image 
acquired during 30min immediately after i.v. injection (a2,a3) images with 
different grades of signal saturation.(B) Normalised data of radioactivity signal 
of each organ respect the injected dose (ID). Time course experiment. All 
polyglutamates had DP=100. 
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PEP1-PEG-Cy5.5 conjugate biodistribution 
 
Body biodistribution study was carried out in healthy Balb/c 
mice (6-8month-old male/female). As in Chapter IV, the Cy5.5 labelled 
conjugate tissue distribution was monitored by means by FLI using the 
IVIS® Spectrum imaging system. Mice were injected via the tail vein 
with 0.57mg PEP1 eq/kg of C1P1-Cy5.5 (67). Non-injected mice were 
used as control. Mice (previously shaved) were monitored in vivo after 
i.v. injection and a time course experiment was performed (TABLE V.  
7(B)). FIGURE V.  43 shows the in vivo images taken over time. The 
fluorescence signal was quantified in Radiant Efficiency. In parallel, 
groups of mice for each time point were euthanised and blood, liver, 
kidney, spleen, brain, lungs and heart were collected. All tissues were 
analysed by ex vivo FLI (FIGURE V.  41) and total content of 
fluorescence was determined by VICTOR® analysis after 
homogenisation. Quantifications are shown as Cy5.5 fluorescence per 
weight of tissue at each corresponding time-point (FIGURE V.  42).  
 
 
FIGURE V.  41 Ex vivo fluorescence of animal organs after Cy-PEG-PEP1 
conjugate administration. 
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As named before, PEG is a non biodegradable polymer. Its 
amphiphilic character allows its gradual translocation from blood to 
peripheral compartments according the permeability of the biological 
barriers depending on its MW and the structural conformation. PEG is 
predominantly cleared in the urine, through glomerula filtration. 
Hepatic component in secretion increases as MW does, although urine 
always predominates. PEG tissue distribution has been proved to be 
MW dependent, in which large PEGS from 20 to 170kDa undergo 
slower extravasation and are retained in the peripheral organ areas for 
a long time. Furthermore, liver clearance requires a mass below 40-
60kDa [47]. With this information and the PEGylated products 
currently in the market and in clinical trials (PEG 5-40kDa), the MW of 
the PEG selected for the RAGEpep studies was low (3000-4000g/mol). 
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(B) 
 
FIGURE V.  42 Normalised data of fluorescence obtained after homogenation 
of the excised organs from Cy-PEG-PEP1 biodistribution. (A) Same “Y”axis (B) 
Different “Y” axis to allow better comparison. 
 
Images as well as fluorescence quantification showed no 
specific accumulation in any organ and secretion by kidney and urine. 
Main percentage of the administered dose was found in kidney 
(FIGURE V.  42) in comparison with the other organs analysed, and 
signal decreases over time. The signal observed in the spinal cord 
could be attributed to the -SO3
- groups present in the dye; this pattern 
corresponds to charged compounds captured by macrophages and 
therefore observed in this part of the body. PEG does not follow this 
behaviour. As conclusion, these images were not considered as a 
reality because Cy5.5 significantly modified the conjugate 
biodistribution. Biodistribution studies through PET or radioactivity 
(14C or 3H labelling) have been proposed as alternatives for this PEG 
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conjugate.  
 
For t1/2 calculation of the PEG conjugate, blood was also 
collected at the 0 min, 30min, 4h and 24h. After centrifugation, 
fluorescence measurement of the plasma was done directly without 
any extraction. Results are represented in FIGURE V.  44. t1/2 
corresponded approximately to 10min, lower than expected.  The 
reported t1/2 for PEG conjugates range from 18min to 24h as the MW 
goes from 3 to 190kDa [48, 49]. This fact could be probably explained 
as the peptide sequence used is quite small and the size of the 
selected conjugates are around 2 nm, smaller than those reported 
with larger peptides or proteins. It is also important to note the 
presence of negative charges of the sulphate groups from the NIR dye 
structure (FIGURE V.  13) that could alter the real in vivo fate of this 
small PEG conjugates as these negatively charged compounds have 
been described to be captured by macrophages.  When C1P1-Cy5.5 
was monitored in vivo, this pattern was found (FIGURE V.  43). 
Therefore, PET imaging would be a better alternative and these 
studies are ongoing. 
 
To sum up, biodistribution in healthy mice of Cy5.5 labelled 
PEG-RAGEpep conjugate showed a favourable body distribution with 
no specific accumulation in any organ and renal excretion. In addition, 
the major achievement of this conjugate is the enhanced solubility, 
stability and availability of the peptide.  
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FIGURE V.  43 Whole-body biodistribution of Cy-PEG-PEP1 measured by the 
means of in vivo FLI from the dorsal and ventral views using the IVIS
®
 
Spectrum. 
 
 
FIGURE V.  44 Half-life time (t1/2) study of C1P1-Cy5.5. 
 
 
CtrlTreated
Dorsal Ventral
t=30min
t=6h
t=2h
t=16h 
t=24h 
Treated Ctrl
100
11
1 1
0
20
40
60
80
100
120
0 30 240 1440
%
 d
o
se
 in
 b
lo
o
d
 s
tr
e
am
t (min)
[CHAPTER V.] 
[444] 
V. 1. 4. 2 Preliminary activity studies in FAP mice model 
 
Majority of FAP in vivo models are based on transgenic mice 
carrying human mutations on the TTR protein, being the TTRVal30Met 
the most common one. In this model, it was discovered that non-
fibrillar amyloid TTR evolved to amyloid deposits with time thus 
mimicking the human pathological characteristics, although non 
depositions in peripheral nerves were found [11]. In humans, FAP 
patients can be classified according to the degree and type of 
deposition in nerves and fibber degeneration [50]: FAP 0, no fibber 
degeneration, no amyloid but non-fibrillar TTR deposition; FAP 1, mild 
degeneration, discrete TTR fibrils; FAP 2, considerable degeneration, 
abundant amyloid and FAP 3, severe degeneration and extensive 
amyloid deposits . 
 
In the present animal model, animals in advanced phases of 
the disease (16-25months) showed TTR fibril deposits [51]; in early 
stages (9-11months), non-fibrillar TTR deposits were detected. Main 
activity in the disease is detected in the gastrointestinal path: 
oesophagus, stomach, small and large intestines. Old mice present 
both non-fibrillar deposits and TTR amyloid at the same time, 
certifying a kinetic evolution between these two species of the 
aggregation cascade. 
 
Saraiva et al. evaluated doxy in vivo activity by oral 
administration following different treatment schemes optimising 
duration of treatment, concentration and mice model. Results 
confirmed its ability as TTR fibril disrupter [10, 38]. On the other hand, 
it was unable to remove non-fibrillar TTR or diminish non-fibrillar TTR-
associated markers. Concerning the RAGEpep, in vivo evaluation of the 
peptide itself has not been performed due to the limitations from 
peptide intrinsic properties. Its conjugation to a polymer was a 
required step to enable this assay. RAGEpep test should be studied in 
young mice were the aggregates (non-fibrillar TTR) are present and 
promote disease development. 
 
Thus, a preliminary activity test in vivo of the synthesised and 
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characterised polymer-drug conjugates was carried out. Three groups 
of animals (9-11 month of age, n=8) were treated intravenously with 
the conjugates detailed in TABLE V.  8. It has to be emphasised that in 
vivo experiment was focused to mainly test the activity of the 
RAGEpep conjugates in young FAP mice model. As a first trial, a 
combination group treated with doxycycline conjugate was also 
incorporated. A final group to control PGA-Doxy activity was also 
include. 
 
Group Conjugates 
ωt% Drug amount 
drug loading per dose 
1 and 2 pep1-PEG-pep1 36 0.036mg drug/Kg 
2 PGA-CONH-Doxy 17 8mg drug/Kg 
3 PGA-CONH-Doxy 43 8mg drug/Kg 
 
SCHEDULE 6 weeks 
  2 doses (i.v.) weeks 
  8 mice per group 
TABLE V.  8 In vivo experimental set up
10
. 
 
Doses were adjusted based on preliminary data (in vitro and in 
vivo) and literature on the topic. For doxy, previous in vivo studies of 
Saraiva et al. concluded that an oral dose of 8mg/Kg per day and a 
maximum of 15 days maintained fibril disaggregation. RAGEpep has 
never been administered in vivo. All conjugates were administered 
intravenously. Final dose and scheme of administration schedule is 
                                                          
10
 Animals were given 2 doses per week during 6 weeks. Group 1 was treated 
with the conjugate C2P1 (60), group 2 was treated with two conjugates in the 
same dose (combination group): C2P1 and PGA-CONH-Doxy (51 and 60, 
respectively) and group 3 with PGA-CONH-Doxy (51). Non-treated mice with 
FAP disease were used as positive controls as well as healthy mice as negative 
ones. 
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detailed in TABLE V.  8. When assay was finished, mice were sacrificed 
and organs (TABLE V.  9) were excised and processed for further 
analysis. 
 
ORGANS 
skin, heart, lung, salivary glands, tongue, eye 
liver, intestine (I1, I2, I3, I4), oesophagus 
kidney, spleen, pancreas, muscle w/nerve, brain, testis/uterus 
9 DRGs, sciatic nerve 
TABLE V.  9 Organs dissected from mice in the activity study. 
 
Immunohistochemistry (IHC) studies of the organs from the treated 
mice 
TTR non-fibrillar deposits (lacking the characteristic of Congo 
red birefringence) trigger apoptosis as well as activate oxidation 
pathways. Several biomarkers have been associated with TTR 
deposition, namely ER stress markers BiP and P-eIF2α, the Fas death 
receptor and oxidation products such as 3-nitrotyrosine [11]. Briefly, 
Fas plays a key role in apoptotic cell death regulation (induced in this 
assay by the non-fibrillar TTR). Fas is a tumour-necrosis receptor that 
binds the Fas ligand resulting in death-inducing signalling complex 
ending in the apoptosis cascade. BiP is a molecular chaperon 
synthesised in higher levels when protein folding is disturbed. Then, 
the process is directly related to cell stress. When TTR is present, levels 
of these markers increase. On the contrary, a treatment reducing TTR 
toxic aggregates will produce a significantly reducing rate on them. 
 
Firstly, TTR-non fibrillar deposition in the extracted tissues was 
evaluated by IHC analysis. FIGURE V.  45(A/B) compiles the results of 
the experiment. Unexpectedly, control animals presented lower 
amount of TTR than treated animals. Therefore, controls were 
discharged and comparisons between the groups receiving treatment 
were done. 
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(A) 
Oesophagus
 
Stomach 
 
Liver
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(B) 
 
FIGURE V.  45 Non-fibrillar TTR deposition immunochemistry study in organs 
(oesophagus, stomach and liver) of the treated animals. (A) Representative 
immunohistochemistry analysis of TTR, (B) Semi-quantitative representation 
of the results. INT.=intestine 
 
In the FAP animal model used, the gastrointestinal (GI) tract is 
the most affected organ regarding fibrillar deposition. 
Immunohistochemistry results (FIGURE V.  45(B)) showed similar 
outcomes although combination group result in lower deposition 
compared with C2P1 group or PGA-Doxy alone in small intestine, large 
intestine, and oesophagus.  
IHC assays of Fas and BiP did not produce any profitable result. 
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All groups corresponding to treated animals had the same pattern 
than control animals with disease. However, representing a semi-
quantitative graphic (FIGURE V.  46(B)) of BiP analysis it can be figured 
out that again lower amount is detected in the combination group in 
organs like large intestine and oesophagus. Stomach depicture was 
similar than PGA-Doxy group. Small intestine data cannot be used for 
conclusions due to the absence of good controls. 
 
FIGURE V.  46 Immunohistochemistry analysis of BiP. Semi-quantitative 
representations of the antibody detection assay. 
From preliminary experiment it can be deduced that possibly 
the dosage use for C2P1 was not sufficient to observe disease 
regression and a dose study should be performed. Possible synergism 
of PEG-RAGEpep and PGA-Doxy is not discharged, for a determinant 
confirmation the in vivo study should be performed with older mice as 
explained above.   
 
Histological analysis of the organs from the treated mice  
Besides IHC, organ slices were also evaluated trying to find any 
possible indicator of toxicity induced by these deposits in presence or 
absence of conjugate(s) treatment. Histological analysis enables a 
better assessment of severe damage. Paraffin-embedded sections 
were stained with haematoxylin/eosin solution (H&E). H&E-stained 
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slice sections were thoroughly examined under low (25× and 50×) and 
medium (100× and 200×) magnification. This study was performed by 
our collaborator Amparo Ruiz, from the Pathology Department, 
University of Valencia. Organs analysed were liver, small and large 
intestine, kidneys and liver in all animal groups (TABLE V.  10). Organs 
include in the gastrointestinal path were analysed due to TTR 
deposition and the rest due to the conjugate excretion routes. 
 
 
GROUP 1 Group treated with C2P1 (PEP1-PEG-PEP1) 
GROUP 2 Group treated with compound C2P1 + PGA-Doxy (17ωt%) 
GROUP 3 Group treated with compound PGA-Doxy (43ωt%) 
GROUP 4 Group control (with disease) 
GROUP 5 Group control without disease 
TABLE V.  10 Description of the animal groups used for the in vivo activity 
study. 
 
Following examination, stained slices from all groups and 
organs showed a normal morphology with non toxic evidences due to 
the treatments. An exception was found for the livers from group 4 
(control group with disease), where focal necrosis, moderate 
inflammatory infiltrate and vascular congestion was observed. FIGURE 
V.  47 illustrates some of the results of the experiment. Kidney 
conclusions were excluded from the study because animal sacrificing 
methodology destroyed this tissue impeding a proper analysis. 
 
Summarising, the findings indicate that treated animals did not 
show toxicity attributed to the administered conjugates, alone or in 
combination. Furthermore, all animals treated showed more normal 
patterns for liver regarding tissue morphology than the disease control 
animals, a possible indicator of a good performance of the conjugates 
as liver protectants.  As mentioned above, liver is not affected by TTR 
deposits, however, it is the main producer of the protein.  
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Large Intestine (I4) 
 
FIGURE V.  47 Examples of histology images (H&E staining) from sliced and 
fixed organs (liver, small and large intestine). 
 
Group 1 Group 2 Group 3
Group 4 Group 5
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V. 2  CONCLUSIONS 
 
In this chapter, polymer-drug conjugates for the treatment of 
FAP, an inherited rare amyloidosis, had been proposed for the first 
time in the area. Two bioactive molecules with recognised therapeutic 
properties: the low MW antibiotic drug doxycycline [10, 11, 38, 52, 53] 
and a novel peptide sequence derived from the original RAGE peptide 
[9] were conjugated to polymeric carriers. In this neuropathic disease, 
PNS is the main target and therefore BBB crossing was not the main 
issue for our PDCs although it will be an extra advantage in case this 
tissue was affected. 
 
In relation to biological environment in which the PDCs will 
exert their action, polymer-drug linkage may confer certain capabilities 
for drug activity. In our case, both drugs act extracellularly therefore 
no intracellular internalisation was required. To investigate if drug 
efficacy required release from the polymer, biodegradable and non-
biodegradable covalent bonds were studied.  
 
Doxycycline conjugates 
Doxycycline target are the fibrillar deposits. It disrupts these 
formations and decreases their associated standard markers. PGA was 
chosen as the polymer carrier. Besides conferring the benefits of 
polymer-drug conjugation (section I.2.4.2) and the well-known 
characteristics of the PGA itself, main purpose was to obtain a 
nanoconjugate capable to enhance TTRagg disruption. 
 
A library of conjugates with 2 to 60ωt% drug loading was 
synthesised and characterised, linking the drug directly through ester 
and amide bonds or by means of a dipeptide spacer. Screening their 
activity as fibril disrupters, PGA-CONH-Doxy conjugates with 15 and 
30ωt% demonstrated the highest response, they not only maintained 
the original activity but also enhanced at equal free drug 
concentration. This characteristic may influence in latter treatments 
improving the therapeutic value of the drug. 
 
To justify the better output of a more stable linker (the amide), 
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physico-chemical studies were performed. Conformational studies by 
SANS and DLS revealed that differences on ωt% did not significantly 
influence the polymer conformation, which will ratify the similar 
activity observed in vitro with the named conjugates. However, 
significant differences were observed when compared with the parent 
PGA polymer. 
 
Concerning linker stability, the designed conjugates tackle with 
biological surroundings as blood (in vivo) or cell media (in vitro). 
Covalent union between polymer and drug must remain stable until 
target arrival. By reproducing the conditions used for the in vitro test, 
drug release evaluation by LCMS and HPLC resulted in no drug release 
in the amide conjugates while ester-bearing conjugates did. 
Consequently, it was confirmed that for TTR fibril disruption there was 
no need for drug release in order to induce activity. Finally, PGA-X-
Doxy conjugates were not haemolytic and were stable after plasma 
incubation, which confirmed the stability of the linkage and their 
suitability for i.v. administration.  
 
With the selected candidate, biodistribution experiments were 
performed through optical imaging and PET techniques. From both 
studies, data showed a clear renal elimination of the conjugate and a 
non-specific accumulation in any organ, which confirmed the 
suitability of the carrier for the purposed objective. Any accumulation 
in an undesired organ or a marked secretion through the hepatic route 
will entail side effects. The radioactive labelled conjugate had a t1/2 of 
0.98h. Compared to the PGA study (t1/2=0.59h), it can be concluded 
that the higher size of the conjugate in solution ends in a longer 
residence into the body. 
 
RAGE peptide conjugates 
In early stages of the disease, TTR aggregates trigger cell 
death. Then, in the advanced phase they coexists with TTR-fibrils [11]. 
For that reason, a drug focused on these species was proposed to be 
administered in combination with doxy: the RAGE peptide. 
 
PEG is the most known polymer carrier for protein and 
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peptide. This semitelequelic carrier offers, among other advantages, 
protection against proteolytic degradation enhancing the t1/2 in blood 
circulation and therefore increasing their activity. 
 
With a parallel reasoning than in doxy conjugation, RAGEpep 
was derivatised for testing if drug release was required for exert its 
activity. Amide and disulphide linkages were selected, entailing 
original peptide derivatisation. A set of conjugates was synthesised 
and characterised. Studying their conformation in solution, DLS 
analysis determined critic differences among the conjugate C2P2 and 
the rest, confirming that linkage and number of conjugated peptide 
moieties could influence on conformation adopted in solution. 
Disulphide conjugates showed peptide release when they were 
subjected to in vitro and in vivo scenarios while amide ones remained 
stable. Additionally, amide conjugate did not show haemolytic activity. 
It is worthy to remark that RAGEpep or its derivatives were insoluble in 
plasma, even in presence of common solubilisers, pointing out that 
PEGylation confers the mayor advantage towards the therapeutical 
approach. Following with the ideal path, target recognising was the 
next stage. Maintenance of original peptide binding capability was 
tested through Surface Plasmon Resonance (SPR). All peptides and 
conjugates, except C2P2, bind TTR with different KD values, therefore 
recognising the protein. PEGylation was not affecting to the capability 
of binding the TTR aggregates. . 
 
In their in vitro evaluation, peptide derivatives demonstrated 
to retain RAGEpep activity and the conjugate C2P1 displayed the best 
inhibition of TTR-agg cytotoxicity at both time points. Disulphide bond 
conjugates results lead to less reproducible data and lower activity, 
remarkably in the case of C2P2. These results confirmed that a more 
stable polymer-peptide linker could be required in order to allow 
TTRagg binding and prevent cytotoxicity, as well as a stable 
conformation in solution where possibly exists  higher peptide 
availability improving conjugate activity. 
 
In conclusion, PEG-RAGEpep conjugates containing amide 
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linkers have greatest potential for further development as FAP 
inhibitors. Moreover, this novel conjugate has potential as a FAP 
therapeutic to be used alone in the early stages of the disease or as 
part of rationally designed combination therapy.  
 
Combination therapy 
One of our aims pursued the combination treatment merging 
the best conjugates of each family: PGA-CONH-Doxy and C2P1. As a 
preliminary study an in vivo activity experiment was carried out in an 
FAP mice model, in which the gastrointestinal tract is the principal 
system affected. Animals in early stages of the disease (9-11months) 
were used as the ideal model for the RAGEpep conjugates. This 
peptide has not been evaluated in vivo, mainly due to the problems 
associated with these small molecules which are overcome after 
polymer conjugation. As a complementary test, it was decided to test 
simultaneously the possible effects of PGA-Doxy in this model.  
 
The animals were classified in three groups: Group 1 was 
treated with the conjugate C2P1, group 2 (combination group): C2P1 
and PGA-CONH-Doxy and group 3 with PGA-CONH-Doxy. Non-treated 
mice with FAP disease were used as positive controls as well as healthy 
mice as negative control. After the treatment period (6weeks, 2doses 
per week), animals were sacrificed and organs were evaluated.  
 
First analysis was performed by immunohistochemistry, 
investigating known markers of the TTR deposition. TTR-non fibrillar 
deposition in control animals was lower than in the rest of groups, 
complicating results interpretation. When treated groups were 
compared, lower deposition was found in the combination group 
when compared with the individual conjugates in small and large 
intestine, and esophagus. Other molecular markers did not arise to 
profitable conclusions due to non differences among the treated 
groups was obtained. These outcomes can conclude that RAGEpep 
conjugate dose should be optimised to promote reliable activity and 
that possible synergism with doxy may be found in an appropriate 
mice model (old animals). 
[CHAPTER V.] 
[457] 
 
Secondly, organ toxicity evaluation of the administered 
conjugates was performed. Liver and kidneys were reviewed due to 
their implication in the secretion routes of PDCs; and small/large 
intestine for their implication in TTR deposition.  By means of 
histological analysis, results highlighted that all groups of animals 
presented a typical morphology structure without toxic evidences 
induced by the treatments, corroborating the safety of the PDCs. The 
observed liver morphological recovery in treated animals suggested a 
possible role of the conjugates as liver protectants.  As mention above, 
liver is not affected by TTR deposits, however, it is the main producer 
of the protein. Reasons for this achievement had not been clarified. 
 
Future directions will encompass a proper test in vivo within 
an old FAP model of our conjugates with an optimisation test of the 
most appropriate dose. We really encourage the use of combination at 
this stage due to their target molecules coexist at advanced phases. 
Moreover, we firmly proposed the use per separate of pegylated RAGE 
peptide conjugate C2P1 in early stages of the disease or the PGA-
CONH-Doxy alone in advanced ones. To define the best combination 
conjugate (both agents in the same polymer matrix or conjugated into 
different polymers), extra combinations studies may be carried out 
either in vitro and in vivo. As targets can be located in different parts 
of the extracellular emplacement, it can be suggested that conjugates 
per separate will display the best output. 
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V. 3 MATERIALS AND METHODS 
V. 3. 1 SYNTHESIS AND CHARACTERISATION OF THE POLYMER-DRUG 
CONJUGATES 
V. 3. 1. 1 Derivatisation procedure of doxycycline (doxy-NH2) 
 
The general derivation procedure of doxycycline which results 
in doxy-NH2 obtaining (49) is depicted in FIGURE V.  48.  
 
 
FIGURE V.  48 Synthesis of the amino derivated doxycycline (doxy-NH2). 
 
Doxycycline hydrochloride (0.5000g, 512.94g/mol) was slowly 
added to concentrated H2SO4 (1.75mL). After gas evolution had 
stopped, the orange solution was slowly precipitated into 100mL of 
cooled diethyl ether in an ice bath. The hydrosulphate salt was 
collected by filtration, washed with ether and dried under N2 flow. The 
orange powder (542.12g/mol) was redissolved in H2SO4 (5mL), cooled 
to 0°C and NaNO3 (1.56eq, 101mg, 84.99g/mol) was added over 10min 
while the reaction was stirring. After 3h at 0°C, reaction was directly 
precipitated into 200mL of cool diethyl ether and the mixture was 
filtered under vacuum. The precipitate was washed with ether and air-
dried to give an orange powder which was used without further 
purification.1H-NMR (MeOD) analysis was carried out. Nitration can 
occur in two different positions (orto-(C9) and para-(C7) positions 
respect to the hydroxyl group. C9 is occurring preferably. Crude 
product (0.3634g) was dissolved in 5mL of MeOH and 10%Pd/C (25mg) 
was added. The system was purged with H2 and left under H2 pressure. 
Reaction was stirred for 2h. After filtration of the catalyst through 
celite, the solution was diluted with 7.5mL of MeOH and precipitated 
in 100mL of cold diethyl ether. Solvent was removed after 
centrifugation (8000rpm, 4°C, 5min) and pouring off the ether. Orange 
solid was dried under nitrogen flow and 1H-NMR (MeOD) and MS-
MALDI TOF analysis were carried out (FIGURE V.  49). 
(A)
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(B)
 
FIGURE V.  49 Characterisation of the amino-derivatised doxycycline (doxy-
NH2). by (A) NMR-
1
H (300Hz, MeOD), (B) MS-MALDI TOF analysis. 
 
Yield: 70% (derivate in C9 80%).  1H-NMR (300 MHz, MeOD) derivate in 
C9 δ 7.57ppm (d, J=8.3 Hz, 1H), 7.06ppm (d, J=8.4 Hz, 1H), derivate in 
C7 δ 7.15ppm (s, 1H). MS analysis: [M+1]=460.1180g/mol. 
 
V. 3. 1. 2 Doxy hydrolytical stability  
15mg of doxy (0.029mmol) were dissolved in 500µL D2O under 
acid (TFA) or basic (NaOH 6M) conditions. 1H-NMR analysis were 
performed (Bruker 300 MHz, 64ns, appendix III). Signals in acidic 
environment were not altered after 37h but in presence of base new 
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signals were observed and also yellow colour changed to dark brown. 
V. 3. 1. 3 Synthesis of PGA-X-Doxy conjugates  
 
General method for doxycycline conjugation through ester linkage 
(PGA-COO-Doxy) 
 
The general synthesis of PGA-COO-Doxy conjugate (50) is 
depicted in FIGURE V.  50.  
 
 
FIGURE V.  50 Synthesis of PGA-COO-Doxy conjugate. 
 
Briefly, carboxyl groups of PGA were previously activated with 
N-hydroxysuccinimide. PGA-NHS (average MW unit of glutamic 
acid=179.6g/mol) was added to a round bottom flask and dissolved in 
anhydrous DMF under N2 atmosphere. Separately, the corresponding 
amount for the desired molar percentage of doxy (see TABLE V. 11), 
512.94g/mol) was dissolved in the same conditions and dropped in the 
PGA-NHS solution. Next, a catalytic amount of DMAP was incorporated 
and pH was adjusted to 8 with DIEA.  After 12-16h under agitation at 
room temperature, DMF was evaporated under high vacuum until 
product was dried. Non-reacted drug as well as reaction organic 
soluble subproducts were removed by washing the crude with a 
mixture of CHCl3:acetone (4:1) and placed in ice for 30min. Thereafter, 
solvent was removed by centrifugation and the solid residue was dried 
under vacuum. After obtaining the polymer conjugate salt form 
(NaHCO3 1M), crude was purified by SEC chromatography (Sephadex
TM 
G-25 / G-10; ddH2O as eluent). Fractions were analysed by HPLC/GPC 
techniques (UV, λ=273nm), tR=12min. Method: isocratic gradient with 
PBS 0.1M pH=7.4 as mobile phase, flow rate=1mL/min, 50min (FIGURE 
V.  6). Fractions containing the conjugate were mixed and after 
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lyophilisation, compound was characterised as detailed in section 
V.3.2.1. 
Note: varying doxycycline equivalents, different ωt% loadings were 
achieved (TABLE V. 11). 
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Carboxyl 
activation 
method 
MW GA 
unit 
mmol 
PGA 
Reaction conditions 
%moltheo 
doxy 
Drug mmol 
%ωt 
doxy 
%mol* 
Yield 
(%) 
PGA-NHS NHS/DMAP 
52%mol NHS, 
179.6g/mol 
0.29 anh. DMF, pH=8 15 Doxy 0.044 26 9.3 90 
PGA-NHS NHS/DMAP 
46.5%mol NHS, 
164.4g/mol 
3.86 anh. DMF, pH=8 5 Doxy-NH2 0.193 18 6.4 92 
PGA-NHS NHS/DMAP 
20%mol NHS, 
148.6g/mol 
0.24 anh. DMF, pH=8 22 Doxy-NH2 0.054 35 12.5 55 
PGA 
(acid form) 
DIC/HOBt 129.1g/mol 0.23 
0.35mmol DIC/HOBt, 
anh. DMF, pH=8 
15 Doxy-NH2 0.0345 15 5.4 50 
PGA 
(salt form) 
DMTMM·Cl 129.1g/mol 0.39 
0.12mmol DMTMM 
(for a 30%act.), 
ddH2O pH=7 
10 Doxy-NH2 0.12 10 3.5 40 
PGA 
(acid form) 
DMTMM·BF4 129.1g/mol 0.11 
0.025mmol DMTMM 
(for a 30%act.), anh. 
DMF pH=8 
10 Doxy-LG-NH2 0.008 9 3.2 51 
 
TABLE V.  11 Representative reaction conditions for doxy conjugation. (*)=estimated. 
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Methodology for Doxy-NH2 conjugation through amide linkage (PGA-
CONH-Doxy) 
 
The general synthesis of PGA-CONH-Doxy conjugate (51) is 
depicted in figure below. 
 
FIGURE V.  51 Synthesis of PGA-CONH-Doxy. 
 
Method A: NHS,DMAP 
Previous activated PGA (PGA-NHS, 52%mol activation, average 
MW unit of glutamic acid=179.6g/mol) was added to a round bottom 
flask and dissolved in anhydrous DMF under N2 atmosphere. 
Separately, doxy-NH2 (49) (see TABLE V. 11, 557.13g/mol) was 
dissolved in the same conditions. Once dissolved, doxy-NH2 was 
dropped in the solution of PGA-NHS. Next, a catalytic amount of DMAP 
was added and pH was adjusted to 8 with DIEA. After 5h under 
agitation at room temperature, DMF was evaporated under high 
vacuum until product was dried. Non-reacted drug and the reaction 
organic soluble subproducts were removed by washing the crude with 
a mixture of CHCl3:acetone (4:1) and placed in ice for 30min. 
Thereafter, solvent was removed by centrifugation and the solid 
residue was dried under vacuum. After obtaining the polymer 
conjugate salt form (NaHCO3 1M), crude was purified by SEC 
chromatography (SephadexTM G-25 / G-10; ddH2O as eluent). Fractions 
were analysed by HPLC/GPC techniques (UV, λ=273nm), tR=12min. 
Method: isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, 
flow rate=1mL/min, 50min (FIGURE V.  6). Fractions containing the 
conjugate were mixed and after lyophilisation, compound was 
characterised as detailed in section V.3.2.1. 
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Note: varying doxycycline equivalents, different ωt% loadings were 
achieved (TABLE V. 11). 
Method B: DIC/HOBt 
PGA (average MW unit of glutamic acid=129.1/mol) was added 
to a round bottom flask and dissolved in anhydrous DMF under N2 
atmosphere. Depending on the molar percentage of drug loading, 
reagents amount was varied. Next protocol is detailed for 15%mol. DIC 
(0.035mmol, 1.5eq per carboxyl group, 0.836g/cm3, 126.20g/mol) was 
added to the reaction and after 5min, HOBt (0.035mmol, 1.5eq per 
carboxyl group, 135.10g/mol) was incorporated as a solid. 10min later, 
doxy-NH2 (49) (0.035mmol, 557.13g/mol) dissolved in anhydrous DMF 
was dropped to the reaction. pH was adjusted to 8 with DIEA. After 12-
16h under agitation at room temperature, DMF was evaporated under 
high vacuum until product was dried. Non-reacted drug as well as 
reaction organic soluble subproducts were removed by washing the 
crude with a mixture of CHCl3:acetone (4:1) and placed in ice for 
30min. Thereafter, solvent was removed by centrifugation and the 
solid residue was dried under vacuum. After obtaining the polymer 
conjugate salt form (NaHCO3 1M), crude was purified by SEC 
chromatography (SephadexTM G-25 / G-10; ddH2O as eluent). Fractions 
were analysed by HPLC/GPC techniques (UV, λ=273nm). tR=12min. 
Method: isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, 
flow rate=1mL/min, 50min (FIGURE V.  6). Fractions containing the 
conjugate were mixed and after lyophilisation, compound was 
characterised as detailed in section V.3.2.1. 
Note: varying doxycycline equivalents, different ωt% loadings were 
achieved (TABLE V. 11). 
TABLE V.  11 
Method C: DMTMM coupling 
Previously, sodium salt form of PGA (0.66mmol, MW unit of 
glutamic acid=151g/mol) was placed in a round bottom flask and 
dissolved in ddH2O. For 30% carboxyl activation and 15%mol doxy 
loading: Separately, doxy-NH2 (49) (0.2mmol, 557.53g/mol) and 
DMTMM·Cl (0.2mmol, 276.77g/mol)) were dissolved in also ddH2O 
and then added to the flask. The reaction pH was 8. Reaction was left 
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under agitation 24h at room temperature and protected from light. 
Then, product was dried by lyophilisation and purified by SEC 
chromatography (SephadexTM G-25 / G-10; ddH2O as eluent). Fractions 
were analysed by HPLC/GPC techniques (UV, λ=273nm), tR=12min. 
Method: isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, 
flow rate=1mL/min, 50min (FIGURE V.  6). Fractions containing the 
conjugate were mixed and after lyophilisation, compound was 
characterised as detailed in section V.3.2.1. 
Note: varying doxycycline equivalents, different ωt% loadings were 
achieved (TABLE V. 11). 
 
Synthesis of PGA-CONH-AA-Doxy  
 
The general synthesis of PGA-CONH-AA-Doxy conjugates (52) 
is depicted in FIGURE V.  52.  
 
 
FIGURE V.  52 Synthesis scheme of PGA-CONH-AA-Doxy conjugates. 
 
First, the amino-protected peptidil linker (Gly-Gly or Leu-Gly) 
was first linked to the drug, then deprotected and finally conjugated 
through an amide bond to the polymeric carrier. 
Synthesis of Leu-Gly-NH-Doxy (54) 
Z-Leu-Gly-OH (53) (0.064mmol, 322.36g/mol) was added to a 
round bottom flask and dissolved in 0.5mL anhydrous DMF under N2 
atm. and continuous agitation. Afterwards, DMTMM·BF4 (0.07mmol, 
1.1eq, 328.07g/mol) was added dissolved in 0.5mL of anhydrous DMF. 
After 10minutes, doxy-NH2 (0.014mmol, 2.2eq, 557.13g/mol) was 
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added dissolved in 2mL of anhydrous DMF. pH was checked to be 8. 
The reaction was allowed to proceed for 14h stirring at room 
temperature and protected from light.   After this, solvent was 
removed under vacuum and residue was washed several times with 
2mL of ddH2O through centrifugation (4°C, 4000rpm, 10min). 
Supernatant was collected and lyophilised. The solid obtained 
(28.3mg) was analysed by 1H-NMR and afterwards it was dissolved in 
5mL of MeOH for proceeding to remove the protecting group of the 
amino acid sequence. The solution was placed in a round bottom flask 
fitted with a septum and a stirring bar. Then, a catalytic amount of 
Pd(OH)2 Charcoal was added and the flask was purged with N2 to 
remove the air and later flask was purged with H2. Reaction was left 
stirring for 12h under H2 pressure. Afterwards, reaction was filtered 
though a celite column and precipitated over cold diethyl ether. Ether 
was removed by centrifugation and the gel obtained was dried over 
vacuum.  
 
Yield: 70%. 1H-NMR Doxy-NH-Gly-Leu-Z (300 MHz, MeOD) δ 7.64(m, 
1H, C8 Doxy-NH-), 7.40 – 7.08 (m, 5H+1H C7 Doxy-NH-), 5.19 – 4.93 
(m, 2H), 4.14 (dd, J=9.5, 5.3 Hz, 3H), 4.02 – 3.63 (m, 3H), 1.80 – 1.41 
(m, 3H), 0.88 (t, J=6.5 Hz, 6H),etc. MS analysis Doxy-NH-Gly-Leu 
(deprotected): [M+1]=673.26g/mol 
Synthesis of Gly-Gly-Doxy (56) 
Z-Gly-Gly-OH (55) (0.079mmol, 266.25/mol) was added to a 
round bottom flask and dissolved in 0.5mL anhydrous DMF under N2 
atm. and continuous agitation. Afterwards, DMTMM·BF4 (0.087mmol, 
1.1eq, 328.07g/mol was added dissolved in 0.5mL of anhydrous DMF. 
After 10minutes, doxy-NH2 (0.18mmol, 2.2eq, 557.13g/mol) was 
added dissolved in 2mL of anhydrous DMF. pH was checked to be 8. 
The reaction was allowed to proceed for 14h stirring at room 
temperature and protected from light. After this, solvent was removed 
under vacuum and residue was washed several times with 2mL of 
ddH2O through centrifugation (4°C, 4000rpm, 10min). Supernatant 
was collected and lyophilised. The solid obtained (27.1mg) was 
analysed by 1H-NMR and afterwards it was dissolved in 5mL of MeOH 
for proceeding to remove the protecting group of the amino acid 
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sequence. The solution was placed in a round bottom flask fitted with 
a septum and a stirring bar. Then, a catalytic amount of Pd(OH)2 
Charcoal was added and the flask was purged with N2 to remove the 
air and later flask was purged with H2. Reaction was left stirring for 
12h under H2 pressure. Afterwards, reaction was filtered through a 
celite column and precipitated over cold diethyl ether. Ether was 
removed by centrifugation and the gel obtained was dried over 
vacuum.  
 
Yield: 70%. 1H-NMR Doxy-NH-Gly-Gly-Z (300 MHz, MeOD) δ 7.64(m, 
1H, C8 Doxy-NH-), 7.26 (5H+1H C7 Doxy-NH-), 4.96 (s, 2H), 3.69 (d, 2H), 
3.57 (2H), etc. MS analysis Doxy-NH-Gly-Gly (deprotected): 
[M+1]=617.20g/mol. 
Synthesis of PGA-CONH-AA-DOXY 
PGA (1 eq, 0.4mmol unit of glutamic acid, 129g/mol) was 
placed in a round bottom flask and dissolved in anhydrous DMF (5mL) 
under agitation and N2 atmosphere. Carboxyl pendant groups were 
activated with DMTMM·BF4 (i.e. for a 30% activation, 0.06mmol, 
328.07g/mol), which were added to main reaction previously dissolved 
in anh. DMF. After 10min, AA-doxy-NH2 was added already dissolved in 
anh. DMF (used equivalents depended on desired molar drug 
percentage. In all cases, doxy derivate equivalents were double than 
DMTMM eq.) pH was assessed to be 8.  Reaction was left under 
agitation for 24h protected from light at room temperature. 
Afterwards, solvent was removed by evaporation and residue was 
washed with acetone at 4°C. After remove the supernatant by 
centrifugation, solid product was dried. Polymer conjugate salt form 
was obtained (NaHCO3 1M), crude was purified by SEC 
chromatography (SephadexTM G-25 / G-10; ddH2O as eluent). Fractions 
were analysed by HPLC/GPC techniques (UV, λ=273nm), tR=12min. 
Method: isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, 
flow rate=1mL/min, 50min. Fractions containing the conjugate were 
mixed and after lyophilisation, compound was characterised as 
detailed in section V.3.2.1. 
Note: varying doxycycline equivalents, different ωt% loadings were 
achieved (TABLE V. 11). 
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Yield: 50%.  
 
V. 3. 1. 3 Synthesis of RAGE peptide and its derivatives  
 
General considerations about Solid Phase Peptide Synthesis (SPPS) 
 
The solid-phase peptide synthesis (SPPS) was invented and 
developed by R.B. Merrifield [54], a simple and fast methodology for 
synthesising peptides and small protein sequences. Basically, SPPS 
concept is to attach covalently a growing peptide chain to an insoluble 
polymeric support by means of chemistry in solution. The anchored 
peptide is extended by serial deprotection/coupling cycles (FIGURE V.  
53), which often are reproducible and result in high yields. Unlike the 
synthesis of peptides in solution, SPPS does not require intermediates 
purification since the amino acids and reagents are added in excess to 
drive the reactions to as to close to 100% completion as possible and 
the excess reagents are removed by filtration. Furthermore, reactions 
proceed at room temperature and only a prudent purification and 
characterisation is needed to verify product identity [55]. 
The polymeric support (resin) is selected regarding its 
mechanical stability, physicochemical characteristics and swollen 
properties and the appropriate functional groups onto which the first 
amino acid can be anchored. Regarding the chemistry design, 
attention may be paid in protection of the groups of the amino acid. 
Once a residue has been incorporated to the resin-bound peptide 
chain, it may still undergo irreversible structural modification or 
rearrangement during next synthetic steps. 
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Resin deprotection 
 
Amino acid coupling 
 
Kaiser Test 
 
Resin peptide cutting 
 
FIGURE V.  53 Synthetic scheme for Fmoc-based SPPS. 
 
Two levels of protecting group stability are needed: groups 
which must remain “permanent” to prevent branching or similar 
problems on the side-chains and “temporary” groups able to be 
removed to allow for continuing the amino acid coupling.  Orthogonal 
schemes offer the possibility of substantially milder overall conditions, 
because selectivity can be attained on the basis of differences in 
chemistry rather than in reaction rates. There are two different 
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protection schemes for the temporary groups of the Nα-amino groups: 
Fmoc- and Boc- based SPPS. Comparing both, Fmoc technique is by far 
the more common approach since it does not require treatment with 
hazardous HF, which requires specialised equipment and training to 
cleave the peptide from the resin and it does not require harsh and 
repeated strong acid treatments[56]. In this thesis, Fmoc-SPPS has 
been the selected one for peptide synthesis. Fmoc group provides 
single hydrogen on the β-carbon very acidic, and therefore susceptible 
to be removed by weak bases like piperidine or piperazine. 
“Permanent” protection compatible groups within this methodology 
are ethers, ester, and urethane derivatives based on tert-butanol. 
Those derivatives are cleaved at once by use of TFA at RT [57].   
 
Protocol 
A polystyrene resin was used for Fmoc-solid phase synthesis 
(SPPS) of the RAGE peptide and its derivatives PEP1 (57) and PEP2 (58) 
(FIGURE V.  7). All synthetic procedures detailed below were carried 
out under an inert atmosphere and after each step the excess 
reagents were removed by filtration.  
 
Fmoc-Rink-amide AM polystyrene resin (100-200mesh, 
loading: 0.63 mmol/g) was swelled with DMF (5 mL, 1 min x 3) and 
CH2Cl2 (3 x 5 mL x 1 min), and the Fmoc group was cleaved by treating 
with piperidine-DMF (1:4). Several washes were performed until 
complete deprotection was achieved. The absorbance of the collected 
solutions was measured to determine the percentage of the released 
Fmoc (UV Vis, λ=280nm, Ɛ=4950M-1cm-1). Afterwards, resin was 
washed (1min, 5mL DMF x 3; 2min, 5mL MeOH x 3, and 1min, 5mL of 
CH2Cl2). 
 
Based on the loading, the protected amino acids were 
incorporated as follows. In a 10mL glass vial equipped with a stopper 
and a stirring bar, 4 equivalents of the corresponding amino acid 
(Fmoc-NH-AA-COOH) were dissolved in 4mL of anhydrous DMF under 
N2 flow. Once dissolved, DIC (12eq, 0.836g/cm
3, 126.20g/mol) were 
added to the reaction and 5 minutes later, HOBt (12eq, 135.10g/mol) 
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were added. Reaction was left under agitation 10min and then the 
whole mixture was added to the resin and pH was adjusted to 8 with 
DIEA. Cleavage of the Fmoc group was achieved by treatment with 
piperidine:DMF (1:4). Washes between couplings and deprotections 
were performed with the same protocol detailed before.  
 
 Completeness of the amino acid coupling was tested with the 
Kaiser-test [58] (FIGURE V.  53). Intensive blue colour is generated by 
reaction of ninhydrin with free primary amines. This test can be used 
to monitor the presence of free amine after not complete coupling 
(dark blue colour) and the complete amino acid coupling (yellow 
colour) after the reaction. It involves the use of three solutions: (1) 
phenol, 80% in ethanol, (2) KCN in H2O/ pyridine, and (3) ninhydrin, 
6% in ethanol. To a few well dried resin beads, three drops of each 
solution were added and then the mixture was heated for 5 minutes at 
80°C. Colour of the solution determined the success or incompleteness 
of the amino acid coupling. In case of not full conversion, reaction was 
repeated decreasing the equivalents of all reagents. 
 
 The resin with the coupled peptide sequence was treated with 
TFA:H2O (95:5,v/v) (3mL), left under agitation at 25 °C for 10h. Then, 
the solution obtained from the filtration was directly precipitated in 
cold t-butylmethylether (40mL). The resin was washed again with 2mL 
of TFA:H2O (95:5,v/v) and precipitated in the same t-butylmethylether. 
The suspension was centrifuged for three times (at 2000rpm, 5min), 
and then re-dissolved in H2O and lyophilised. Crude peptide was re-
dissolved and purified by semi–preparative HPLC (LiChrocart®250–10, 
LiChrospher®100 RP–18 (10 μm), flow rate = 1 mL/min, solvent A: 
ddH2O 0.1 %TFA, solvent B: ACN 0.1 %TFA; method: 0 min A 90 %, 5 
min A 70 %, 10 min A 70 %, 25 min A 10 %, 30 min A 90 %, 35 min A 95 
%; wavelength = 220nm). The fractions containing the purified product 
were pooled, lyophilised and their identity was confirmed by analysis 
with HPLC and MS MALDI TOF. The crude peptide was re-dissolved in 
milli–Q water and purified by semi–preparative HPLC with a gradient 
of 20–100% solvent B over 40 min. Results (purity and MW of each 
peptide) are summarised in  
FIGURE V.  8. 
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V. 3. 1. 5 Synthesis of RAGE peptide conjugates 
V. 3. 1. 5. 1 Synthesis of PEP1-PEG-PEP1 (C2P1) 
 
The general synthesis of PEP1-PEG-PEP1 conjugate (60) is 
depicted in FIGURE V.  9. PEP1 describes the modified RAGE peptide 
illustrated in FIGURE V.  7, where in N-terminal point a glycine (Gly) 
was incorporated. 
 
NHS-PEG-NHS (0.014mmol, 1eq, 3023g/mol) was dissolved in 
4mL of anhydrous DMSO under inert atmosphere at RT. PEP1 (57) 
(0.03mmol, 2eq, 912.05g/mol) was dissolved under the same 
conditions in 4mL of anhydrous DMSO and dropped into the main 
solution. Afterwards, catalytic amount of DMAP was added and pH 
was adjusted to 8 with DIEA. Reaction was left under agitation and 
inert atmosphere for 48h.  Then the solvent was removed under 
vacuum, and the residue obtained was dissolved in 1mL of ddH2O and 
purified by FPLC (Macrocap SP column, flow rate=1mL/min, solvent A: 
ddH2O, solvent B: NaCl 1M; method t=0min, A 100% 60 min, gradient: 
100% solvent B in 1500min, wavelength=215, 280nm). A typical 
chromatogram is shown in FIGURE V.  11. The fractions were collected; 
lyophilised and the solid residue was desalted by Ultrafiltration 
(Vivaspin® MWCO 2000g/mol). The product obtained was 
characterised by NMR (1H, 13C and COSY, D2O) and MALDI-TOF analysis 
(FIGURE V.  23(A)). 
Yield: 60%. 1H NMR (300 MHz, D2O) δ 6.96 (s, 8H), 6.68 (s, 8H), 3.58 (s, 
275H). MS MALDI-TOF analysis: 4971g/mol. 
V. 3. 1. 5. 2 mPEG-PEP1 (C1P1) 
 
The general synthesis of mPEG-PEP1 conjugate (61) is depicted 
in FIGURE V.  9. PEP1 describes the modified RAGE peptide illustrated 
in FIGURE V.  7, where in N-terminal point a glycine (Gly) was 
incorporated. 
 
mPEG-NHS (0.017mmol, 1eq, 3023g/mol) was dissolved in 
anhydrous DMSO under inert atmosphere at RT. PEP1 (57) (0.02mmol, 
1.2eq, 912.05g/mol) was dissolved under the same conditions in 
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anhydrous DMSO and dropped into the main solution. Total reaction 
volume was 5mL. Then, a catalytic amount of DMAP was added and pH 
was adjusted to 8 with DIEA. Reaction was left under agitation and 
inert atmosphere for 48h.  Then the solvent was removed under 
vacuum and the residue obtained was dissolved in 1mL of ddH2O and 
purified by FPLC (Macrocap SP column, flow rate=1mL/min, solvent A: 
ddH2O, solvent B: NaCl 1M; method: same as in C2P1, 
wavelength=215, 280nm). A typical chromatogram is depicted in 
FIGURE V.  11. The fractions were collected; lyophilised and the solid 
residue was desalted by ultrafiltration (Vivaspin® MWCO 2000g/mol). 
The product obtained was characterised by NMR (1H, 13C and COSY, 
D2O) and MALDI-TOF analysis (FIGURE V.  23(A)).  
Yield: 70%. 1H-NMR (300 MHz, D2O) δ 6.96 (s, 4H), 6.68 (s, 4H), 3.58 (s, 
275H). MS MALDI-TOF analysis: 3933g/mol. 
 
V. 3. 1. 5. 3 Synthesis of PEP2-PEG-PEP2 (C2P2) and PEG-PEP2 (C1P2) 
 
The general synthesis of PEP2-PEG and PEP2-PEG-PEP2 
conjugates (63 and 64, respectively) is depicted in FIGURE V.  10. PEP2 
describes the modified RAGE peptide illustrated in FIGURE V.  7, where 
N-terminal point is modified by addition of the dipeptide: glycine-
cysteine (Gly-Cys). 
 
4TP-SS-PEG-SS-4TP (0.052mmol, 1eq, 3400g/mol) was 
dissolved under agitation in 10mL of acetate ammonium buffer 10mM 
pH=7 at RT. PEP2 (58) (0.057mmol, 1.1eq, 1057.23g/mol) was 
dissolved under the same conditions in 5mL of ddH2O and dropped 
over 20min. The reaction was monitored by UV absorbance at 323nm, 
corresponding to the 4-thiopyridone leaving group [59].  Afterwards, 
reaction was left under agitation and inert atmosphere for 15h.  Then 
the reaction was lyophilised. The residue obtained was dissolved in 
1mL of ddH2O and purified by FPLC (Macrocap SP column, flow 
rate=1mL/min, solvent A: ddH2O, solvent B: NaCl 1M; method t=0min, 
A 100% 60min; gradient: 100% solvent B in 2500min, wavelength=215, 
280nm). A typical chromatogram is depicted in FIGURE V.  12. The 
fractions were collected; lyophilised and the solid residue was desalted 
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with a PD-10 column packed with SephadexTM G-25 using ddH2O as 
eluent. Both products were characterised by NMR (1H, 13C and COSY, 
D2O) and MALDI-TOF analysis (FIGURE V.  23(A)). 
 
C2P2. Yield: 45%. 1H-NMR (300 MHz, D2O) δ 7.00 – 6.90 (m, 1H), 6.67 
(t, J=7.2 Hz, 1H), 3.56 (s, 46H). MS MALDI-TOF analysis: 5873g/mol. 
C1P2. Yield: 50%. 1H-NMR (300 MHz, D2O) δ 8.28 (d, J=4.6 Hz, 1H), 
7.72 (s, 2H), 7.18 (s, 1H), 7.03 – 6.90 (m, 4H), 6.75 – 6.60 (m, 4H), 3.56 
(s, 388H). MS MALDI-TOF analysis: 4899 g/mol. 
 
V. 3. 1. 6 Synthesis of radioactive labelled PGA-Doxy conjugate  
 
The general derivatisation procedure of PGA-DOXY radioactive 
labelling (65) is depicted in FIGURE V.  17.  
 
Briefly, 30mg of PGA-CONH-Doxy conjugate (50) (19ωt% 
(6.8%mol), average MW unit of glutamic acid=161.1g/mol) was added 
to a round bottom flask and dissolved in 1.5mL of ddH2O. Then, 
DMTMM·Cl (0.1eq, 276.77g/mol)) previously dissolved in 1.5mL of 
ddH2O was added and 10min later, DOTA-NH2, 614.82g/mol, 
0.011mmol) diluted in 1mL of DMF was poured into the reaction. pH 
was controlled and adjusted to 8 if needed. The reaction mixture was 
left to proceed under agitation at RT during 48h. After remove the 
solvent, the residue was purified by ultrafiltration (Vivaspin® MWCO 
2000g/mol) and upper part of the tube was lyophilised and 
characterised.   
Yield: 88%. Molar percentage of conjugated DOTA by NMR: 8.2%.  1H-
NMR (300 MHz, D2O) (9.8%mol DOTA): δ 4.24 (1H), 2.31 – 1.76 (m, 
4H),  1.41 (s, 2.25H). 
 
t-Bu protecting groups of DOTA moiety were removed under 
acidic conditions. Labelled conjugate (50mg, MW=225.5g/mol) was 
dissolved in 2.85mL of TFA, 75μL ddH2O and 75μL TIPS and left under 
agitation for 3h. Then, the reaction volume was precipitated into cold 
diethyl ether and product was collected after centrifugation. Once 
dried, sodium salt of the product was formed by solution in NaHCO3. 
Salt excess was removed by ultrafiltration (Vivaspin® MWCO 
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3000g/mol) with ddH2O. Final product was recovered by lyophilisation. 
Deprotection was proved after NMR-1H (D2O) analysis. 
Yield: 94.6%. NMR-1H (D2O) in FIGURE V.  18. 
 
 For 68Ga labelling, first this radionuclide was eluted, purified 
and concentrated. Then, the obtained 68Ga was transferred into 
microwave tube and the pH was adjusted to 3.5-4 by adding HEPES 
buffer. Immediately, the DOTA labelled system (e.g. PGA-Doxy-
DOTA/68Ga (8.58mg) in aqueous solution was added 390µL. The 
mixture reaction was heated at 90°C for 5min by a microwave 
laboratory with monomodal radiation (Discover Benchmate, CEM). 
Then, purification was performed with a exclusion molecular 
chromatography cartridge (Bio Gel P-6 Bio Rad) using PB pH=7 as 
eluent. The elution profile was determined by fractionating and 
measuring the fractions with an activimeter (VDC 405 Veenstra). 
Radiochemical yield (RY) was calculated as percentage of the activity in 
each fraction eluated from the molecular exclusion cartridge of the 
total activity purified, corrected for the decay. 
 
 Radionuclide purity (RNP) was assessed by γ-spectrometry 
(HPBGe detector) immediately and after 24-48h in order to determine 
the 68Ga breakthrough. 
V. 3. 1. 7 Synthesis of fluorescently labelled conjugates  
 
By means of conjugation of a near infrared dye (Cyane 5.5), 
conjugates were labelled for posterior biodistribution studies using 
optical imaging, monitoring in vivo as well as ex vivo fluorescence.  
 
V. 3. 1. 7. 1 PGA-CONH-Doxy conjugate fluorescence labelling 
 
The general derivatisation procedure of PGA-DOXY 
fluorescence labelling (66) is depicted in FIGURE V.  15.  
Briefly, 15mg of PGA-CONH-Doxy conjugate (50) (17ωt% 
(6%mol), average MW unit of glutamic acid=161.1g/mol) was added to 
a round bottom flask and dissolved in 3mL of borate buffer pH=9. 
Then, 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC, 0.004 
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mmol, 155.24g/mol) were added and 10min later, N-
hydroxysulfosuccinimide (sulfo-NHS, 0.004mmol, 217.13g/mol) was 
incorporated. Finally, Cy5.5 (6-SIDCC, 0.001mmol, 1362g/mol) diluted 
in 1mL of buffer solution was poured into the reaction. Reaction 
mixture was left under agitation at RT for 24h. After freeze-drying the 
mixture, residue was purified with a PD-10 column packed with 
SephadexTM G-25 (fractions of 500µL) and fluorescence was measured 
(595/680nm) and fractions with the conjugate were joined. To ensure 
the absence of free Cy in the conjugate, final product was washed with 
ddH2O with Vivaspin® MWCO 3000g/mol.  
Yield: 60%. Labelling efficiency: 0.94mol%Cy5.5. 
 
V. 3. 1. 7. 2 PEG-PEP1 conjugate fluorescence labelling 
 
The general derivatisation procedure of PEG-PEP1 
fluorescence labelling (67) is depicted in FIGURE V.  16.  
In a 10mL round bottom flask, NHS-PEG-PEP1 (0.003mmol, 
3935g/mol) was dissolved in minimum amount of borate buffer pH=9. 
Then, Cy5.5 (0.003mmol, 1eq, 1362g/mol) previously dissolved in 
same buffer, was added. A catalytic amount of DMAP was 
incorporated to the reaction. Final buffer volume was 6mL. Reaction 
was left under agitation at RT protected from light for 72h. Afterwards, 
reaction was lyophilised and residue was purified through a PD-10 
column packed with SephadexTM G-25. Fractions of 500µL were taken 
and their fluorescence was measured by Victor® spectrometer 
(595/680nm). Fractions corresponding to the peak signal of the 
labelled conjugate were joined and lyophilised. To asses that free 
fluorophore was not entrapped in the conjugate, final product was 
washed with ddH2O with Vivaspin® MWCO 3000g/mol. 
Yield: 50%. Labelling efficiency: 0.11%mol Cy5.5. 
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V. 3. 2 PHYSICO-CHEMICAL CHARACTERISATION OF THE POLYMER-
DRUG CONJUGATES 
 
V. 3. 2. 1 Determination of drug loading, solution conformation, 
plasma stability and pH degradation studies of PGA-X-Doxy 
conjugates 
 
Note: PGA-X-Doxy encompasses all doxy conjugates, independently of 
the type of linkage/spacer between the drug and the polymeric 
carrier. 
Determination of total drug loading by UV spectroscopy 
For quantifying doxy content, drug weight percentage was 
determined by UV Vis. Previously, a calibration curve of the parent 
drug was done. A stock solution 1mg/mL of PGA-X-Doxy conjugate in 
ddH2O was prepared. To obtain appropriate and reproducible 
absorbance measurements, samples were diluted using ddH2O. Total 
drug loading of the conjugates was determined by measuring the 
optical density at 273nm in H2O. PGA in the same concentration range 
as conjugate analysed (0-5mg/mL) in H2O was used as blank.  
 
Determination of free drug content by LCMS and HPLC 
PGA-X-Doxy conjugates were dissolved in PBS pH=7.4. 20μL of 
the aliquots (100µL, 6mg/mL PGA-X-Doxy) were injected directly in the 
LCMS without further extraction (Kinetex column (2.6µm, C18, 100A 
100x4.6mm, mobile phases ddH2O/ACN both 0.1% formic acid). In 
addition, remaining volume was evaporated and solid was washed 
with a known volume of MeOH. After sonication and centrifugation, 
supernatants were also evaluated by LCMS. 
In parallel, free drug detection by HPLC was carried out. PGA-
X-Doxy conjugates were dissolved in PBS pH=7.4. Aliquots (100µL, 
6mg/mL PGA-X-Doxy) were lyophilised and the residue was washed 
with 100μL of MeOH. Following centrifugation (12000rpm, 5min, 4°C), 
each supernatant was purified through a POROS 50R2 column to 
extract the free drug. 1mL fractions were collected and analysed by 
HPLC (RP-18 column, flow rate=1mL/min, solvent A: acetonitrile 0.1% 
trifluoroacetic acid, solvent B: H2O 0.1%trifluoroacetic acid; method: 
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t=0 min, B 95%, t=33 min B 5%, t=35 min B 5%, t=40 min B 95%, 
wavelength=273nm).  
 
Determination of mean hydrodynamic diameter of the conjugates  
 DLS measurements were performed at 25°C using a Malvern 
Zetasizer NanoZS instrument, equipped with a 532nm laser at a fixed 
scattering angle of 90°. Polymer conjugate solutions (10mg/mL) were 
prepared in PBS pH=7.4. The solutions were sonicated for 10min and 
filtered through a 0.20μm cellulose membrane filter. Micelle size 
distribution by volume was measured (diameter, nm) for each 
conjugate. Experiment was repeated per triplicate with n>3 
measurements. 
 
Small-angle neutron scattering (SANS) experiments were 
performed on the D11 instrument at the Institute Laue-Langevin in 
Grenoble (France) by our collaborators from the School of Chemistry in 
the Cardiff University (Cardiff, UK). Scattering data are expressed in 
terms of the scattering vector, Q, which is given by Q=4π/λ·sin(/2)  
where λ is wavelength and  the angle at which the neutrons are 
scattered.  The incident neutron wavelengths were 6±1Å and 12Å, 
giving accessible Q-ranges of 0.0017 to 0.42Å -1 using four different 
sample-detector distances.  Sample solutions were prepared at a 
conjugate concentration of 0.5-2ωt% on a 1g scale in D2O (pH=5.5, 
0.1M phosphate buffer) and placed in 2mm path length quartz cells, 
mounted in a sample changer thermostatted at 37°C ( 0.2).  These 
conditions allowed for the study of conjugates at pH, temperature and 
ionic strengths mimicking those experienced during drug release in 
vivo.  Data were corrected for transmission intensity, electronic 
background and normalised against a flat scatterer according to the 
standard procedures for the instrument.  The obtained scattering 
profiles I(Q) vs. Q were analysed according to I(Q)  Vp P(Q) S(Q) + 
Binc where  is the volume fraction and Vp the particle volume.  The 
FISH modelling suite was used for the analysis[60] .  FISH incorporates 
parameterised form factors, P(Q) and structure factors, S(Q), to 
describe the dimensions of the scattering particle and inter-particle 
interactions . 
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Drug release studies under hydrolytical conditions 
 Stability studies under hydrolytical conditions were carried 
out with the PGA-X-Doxy conjugates. Conjugates (6 mg/mL) were 
incubated at 37°C in PBS at pH 5.5 and 7.4 for 17 days. Daily pH was 
checked and adjusted if necessary. 100µL of the sample solutions were 
taken at various time points (0, 3, 5, 9, 14, 17 days). Neutralisation of 
pH with ammonium phosphate buffer (1M) before MW lost analysis 
was performed in order to stop further degradation (tR=12min. 
Method: isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, 
flow rate=1mL/min, 50min). In parallel, free drug of samples at t=0 and 
17d was evaluated to quantify drug release (conditions of plasma 
stability or free drug evaluation studies explained in section V.3.2.1.).  
 
Stability of the PGA-X-Doxy conjugates in in vitro conditions 
Fibril disruption studies were carried out by incubation of the 
conjugates with TTR fibrils in PBS media at 37°C. To test if the drug was 
released from the polymer platform during the in these conditions, a 
PBS stability-test with the same parameters was set up. Conjugates (3-
6 mg/mL) in PBS 0.1M were incubated at 37°C at pH=7.4 for 17 days. 
Sterile conditions were used during all the experiment. 100µL of the 
sample solutions were taken at different time points up to 17 days. 
MW lost was evaluated with GPC columns in a HPLC system using 
methodology and parameters described before. 
Furthermore, free drug extraction was performed and evaluated with 
LCMS system. PBS aliquots were injected directly in the LCMS without 
further extraction (approx. 20µL). Doxycycline was easy to detected 
(MW=444g/mol, [M+1]=445g/mol) at tR=10min, as well as doxy-NH2 
(MW=459g/mol, [M+1]=460g/mol) at tR=5min. As in PBS was not 
possible to observed traces of doxy in any of the degradation samples, 
remaining volume was evaporated and the solid was washed with 
MeOH to redissolved the possible free drug. After double 
centrifugation, supernatant was injected in LCMS.  
 
Stability of PGA-X-Doxy conjugates in plasma 
Stability in plasma was assessed by incubating each of the 
conjugates PGA-X-Doxy (3-6mg/mL), for 24h at 37°C in plasma freshly 
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extracted from rodents. Free drug was used as a positive control and 
plasma without doxy as negative. At several time points (0min, 1h, 4h, 
8h and 24h), aliquots of 100µL were collected. To each sample, 100µL 
of ACN was added to precipitate the plasma proteins. After 
centrifugation (12000rpm, 5min, 4°C), supernatants were collected 
and subjected to analysis by HPLC as described above (supernatant 1). 
Pellets were washed with MeOH (100µL) to extract the free drug out 
of the pellets. To redissolve the free drug in MeOH, the solid was 
vortexed and then sonicated. Subsequent to centrifugation (12000 
rpm, 5 min, 4°C), supernatant 2 was collected and analysed by HPLC as 
reported below.  
 
V. 3. 2. 2 Characteriation of RAGE peptide conjugates: stability in 
different conditions, solution conformation and affinity studies 
 
PEG conjugates characterisation by NMR and MALDI-TOF  
For verifying the identity and purity of each RAGE peptide 
conjugate, NMR studies such as 1H and DOSY were carried out (D2O), 
as well as MS spectra by means of MALDI-TOF. For NMR analysis, 15-
20mg of conjugate were dissolved in 500µl D2O (section NMR in the 
appendix III). For MS MALDI-TOF analysis, 0.5 μL of sample was 
spotted onto the MALDI stainless steel target plate. After droplets 
were air-dried at room temperature, 0.5 μL of matrix (5 mg/mL α-
Cyano-4-hydroxycinnamic acid (CHCA) (Sigma) in 0.1% TFA-ACN/H2O 
(1:1, v/v)) was added and allowed to air-dry at room temperature. The 
samples were analysed with the conditions detailed in the 
instrumental section.  
 
 In the case of NMR analysis, aromatic peaks belonging to 
specific amino acids of the peptides were related with the peak of PEG 
(δ = 3.6ppm) as it is shown in FIGURE V.  24, determining the number 
of peptide molecules conjugated to the polymer. In the case of MALDI-
TOF spectra (FIGURE V.  23), it was subtracted to the MW obtained the 
MW of PEG, figuring out the number of peptide molecules linked. 
 
Stability of the PEG-X-RAGEpep conjugates in cell culture medium 
Cell medium (DMEM, 10%FBS) was freshly prepared and 
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filtered. Under sterile conditions, the RAGE peptide conjugates were 
dissolved at 15mM RAGEpep equivalents. Aliquots (15µL) were taken 
at time 0min, 5h, 24h and 48h, immediately frozen in liquid nitrogen 
and stored at -80°C until evaluation. The samples were thawed, and 
analysed after centrifugation (4000rpm, 15min) by HPLC with a 
Zorbax®column (retention time conjugate CXP1: 2.6min, retention 
time PEP1=4.5min, reference peak of FBS=2.2min. Retention time 
PEP2=3.27min, retention time conjugate CXP2=2.8min. Method: 
isocratic gradient with PBS 0.1M pH=7.4 as mobile phase, flow 
rate=1mL/min, 15min). 
 
Stability of PEG-X-RAGEpep conjugates in plasma 
Stability in plasma was assessed by incubating each of the 
conjugates (10mg/mL), for 24h at 37°C in plasma freshly extracted 
from rodents. Free drug was not possible to be used as a positive 
control due to peptides where insoluble (either directly placed in 
plasma or in previously dissolved media such as water or surfactants 
(low MW PEG, peanut oil,…) where peptide precipitation was 
unavoidable even at low concentrations. Plasma without compound 
was used as negative control. At several time points (0min, 1h, 5h and 
24h), aliquots of 100µL were collected. Samples were analysed by MS 
MALDI-TOF technique to monitor conjugates variation in their 
molecular weight (g/mol).  
 
Conformation in solution of PEG-X-RAGEpep conjugates. DLS study. 
PEG-X-RAGEpep conjugates conformation was analysed by 
DLS. Samples were prepared in PBS 0.20M pH=7.4 at different 
concentrations, ranging from 2-20mg/mL. The solutions were analysed 
without any other additional treatment as well as after filtration 
through a 0.45μm cellulose membrane filter before analysis. The size 
distribution by volume (%) was measured as the hydrodynamic radius 
(Rh, nm) for each conjugate. All measurements were made at 25 °C 
with a detection angle of 173°. The intensity of size distribution was 
obtained from the analysis of the correlation function using multiple 
narrow mode algorithm of the Malvern DTS software. Experiment was 
done per triplicate (with n≥3 measurements each). 
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The binding kinetics of every compound were analysed by 
surface plasmon resonance (SPR) measurements using a Biacore 
T100TM instrument. A CM5 chip (carboxy-methylated dextran sensor 
chip) was coated by standard amine coupling chemistry (NHS/EDC) 
with the TTR mutant L55P (1.861mg/mL, Ɛ280=77660, MW=55kg/mol, 
isoelectric point=4.7) ([61],[46]) to a density of 10000RU. 
Immobilisation was performed in the channel 2 of the sensor chip and 
the channel 1 was used as the reference surface. HBS-EP buffer (HEPES 
buffered saline with EDTA and surfactant P20: 10mM HEPES, 150mM 
NaCl, 3mM EDTA, 0.005% Tween-20) was used as running buffer.  
 
The device was equilibrated with cell culture medium (DMEM 
(low glucose), 1% P/S, 0.05 % sodium azide) and temperature set to 
37°C. Stock solutions of the conjugates were dissolved in cell culture 
media while the RAGE peptides where dissolved in ddH2O (10mM 
RAGEpep eq.).  Measurements were carried out at 37°C, using a flow 
rate of 10µL/min with a contact time of 60s, followed by dissociation 
of 30s. In the case of PEP2 and its conjugates (C1P2, C2P2), the 
regeneration step was required, which consisted in washing with 
10mM glycine pH=2.5, for 120s at the same flow. The peptides and its 
conjugates were injected at concentrations between 0.1 to 2.5nm. The 
kinetic data were obtained after the analysis of the sensograms 
performed with the BIAevaluation software (version 2.0). The 
experiment was repeated until acceptable (ᵡ2>10) and reproducible KD 
values were obtained (n>10).  
 
V. 3. 3 IN VITRO ACTIVITY STUDIES OF THE POLYMER-DRUG 
CONJUGATES 
V. 3. 3. 1 TTR-fibril disruption studies of the PGA-X-Doxy conjugates 
Preparation of amyloid fibrils 
 TTR protein was produced in an Escherichia coli expression 
system (isolated, and purified as described previously [62]. After 
growing the bacteria, the protein was isolated and purified by 
preparative gel electrophoresis after ion exchange chromatography. 
Protein concentration was determined using the Lowry method [63]. 
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TTR Leu55Pro was dialysed against water at pH=7.4 during 24h 
at 4°C. The preparation was centrifuged at 15000g for 30min at 4°C, 
then the pellet was washed, resuspended in sterile PBS and quantified 
by Lowry method [63]. Sample concentration was adjusted to 1mg/mL. 
Protein was later incubated at 37°C for 10-13 days until fibril formation 
was ratified by TEM. 
 
Screening for TTR fibril disrupters 
Stock solutions of all compounds (TABLE V.  6) (3.6mM doxy) 
were dissolved in sterile H2O and filtered-sterile prior to use (0.2μm). 
As controls, PGA, doxy and doxy-NH2 were tested in parallel. Aliquots 
of TTR L55P fibrils (1mg/mL) were prepared and the correspondent 
amount of every compound was added, with a final concentration of 
6.7-fold molar excess of doxy (121µM/100μg fibrils). The preparations 
were incubated at 37°C in the dark. At given times, all aliquots were 
analysed by TEM and DLS to monitor fibril disruption.  
 
Transmission electron microscopy (TEM) 
For TEM analysis, sample aliquots were taken under sterile 
environment, vortexed and adsorbed to glow-discharged carbon-
coated collodion film supported on 200-mesh copper grids. For 
negative staining, the grids were washed with deionised water and 
stained with 1% uranyl acetate solution. The grids were visualised with 
a Zeiss microscope operated at 60kV and exhaustively examined.  
 
Dynamic Light Scattering (DLS) 
The same samples used in TEM analysis were also analysed by 
DLS as a complementary technique, in order to observe variations 
respect to fibrils control after treatment with PGA-X-doxy conjugates. 
Samples were placed in sterile plastic cuvettes. The size of the 
generated species was measured at 633nm on a DLS instrument. All 
measurements were made at 25 °C with a detection angle of 173°. The 
intensity of size distribution was obtained from the analysis of the 
correlation function using multiple narrow mode algorithm of the 
Malvern DTS software. Values shown are the means of triplicates and 
the experiment was repeated three times.  
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V. 3. 3. 2 Cytotoxicity of the species resulting from PGA-X-Doxy 
incubation 
 
Cell culture method 
To optimise the cell density for the in vitro experiments, cell 
growth curves were carried out with the rat Schwannoma cell line 
RN22. Following the MTT protocol (Chapter IV, section IV.3.1.2), the 
experiment was performed with the scheme detailed. RN22 cells were 
seeded at a density of 4500cell/mL in cell culture medium (Dulbecco’s 
minimal essential medium supplemented with 10% FBS and 1% P/S) 
into 25 cm2 flasks maintained at 37°C in a humidified atmosphere of 
95% and 5%CO2.  
 
Cytotoxicity study 
TTR L55P fibrils were grown for 15 days (as previously 
described in section V.3.3.1) and then incubated for 6 days at 37°C 
with PGA-X-Doxy conjugates (FIGURE V.  32) (doxy 180µM /100µg 
fibrils). Fibril disruption was checked as detailed in the named section. 
Then, samples were centrifuged (15000g, 30min, 4°C) and pellet was 
redissolved in cell media. Each preparation was added to cells for 24h 
incubation. The toxicity of the species generated was assessed by 
caspase-3 activation (V. 3. 3. 3). 
 
V. 3. 3. 3 Activity of the RAGE peptide conjugates as inhibitors of the 
TTRagg cytotocicity. Caspase-3 assay 
 
 TTR L55P aggregates were incubated with either the RAGE 
peptides or the PEG-RAGEpep conjugates at a RAGE peptide-
equivalent concentration of 10µM found active in previous studies 
[61]. Under sterile conditions, the TTR L55P aggregates were dissolved 
in cell media (DMEM (low glucose), 1%FBS, 1%P/S) achieving 2µM 
concentration. Then, compounds were added from a stock solution 
(1mM RAGEpep eq.) achieving a final concentration of 10µM RAGEpep 
equivalents and incubated for 5 h at 37 °C under continuous agitation. 
Final volume of each solution was 3mL per compound. 
  
The treated aggregates were then added to the RN22 cells 
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(1.5mL/well, 6-well plate) and the cells incubated for 24 or 48h before 
activation of caspases-3 was evaluated. As controls, cells without 
addition and cells exposed to TTR L55P aggregates were used. 
 
Activation of caspase–3 was measured using the CaspACE 
colorimetric 96–well plate assay, following the manufacturer’s 
instructions (Sigma Aldrich). Cells were trypsinised and harvested 
using a cell scrapper. After centrifugation (5min, 1000rpm), the cell 
pellet was lysed in 100μL of hypotonic lysis (Cell Lysis Buffer: 20mM 
HEPES, pH=7.4, 0.1% CHAPS, 50mM DTT, 2mM EDTA) by four cycles of 
freeze/thawing. 40 μL of each cell lysate was used (in duplicate) was 
used for determination of caspase–3 activation. The remaining cell 
lysate was used to measure total cellular protein concentration with 
the Bio–Rad protein assay kit, using BSA as standard. Values shown are 
the mean of duplicates of three independent experiments. Student’s t 
test statistical analysis was used to determine statistical significance 
between cells exposed to assay media and cells exposed to different 
regulators and P values of less than 0.05 were considered significant 
(*p<0.05, **p<0.005). 
 
V. 3. 3. 4 Haemolysis assay of the synthesised polymer-drug 
conjugates 
 
Erythrocytes (RBC, red blood cells) were isolated from fresh 
whole rat blood, obtained by cardiac puncture after death and placed 
in a heparinised tube on ice[28]. Blood was diluted with PBS pH 7.4 up 
to 10mL and then it was centrifuged (3000 rpm, 10 min, 4 °C) three 
times, removing the supernatant after each centrifugation and re-
suspending the cells in sterile PBS. The final RBC pellet was weighed 
and re-suspended at 2%(v/v) in PBS. To study the haemolytic activity 
of the RAGE peptides and PEG-RAGE peptide conjugates, they were 
dissolved in PBS stock solutions (4mg/mL) adjusted to pH 5.5 or 7.4. 
Then samples were added to wells (n=6, 100µL) covering the 
concentration range 0.8-2mg/mL of RAGE peptide equivalents. PBS 
was used as a control together with the reference compounds; 
dextran (MW=74000g/mol) as a negative control, poly(ethyleneimine) 
(PEI) (750,000g/mol) as a positive control and Triton X–100 1%(w/v) to 
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determine a 100% RBC lysis. The plates were then incubated at 37°C 
for 1h. To assess haemoglobin (Hb) release the plates were then 
centrifuged (3000rpm, 10min, 20°C) and the supernatant of each well 
was transferred into a new plate. The Hb released was assessed by 
measuring the absorbance at 570nm using a microtitre plate reader. 
The percentage of haemolysis of each sample was calculated relative 
to 100% haemolysis obtained from incubation with Triton–X 100. 
 
V. 3. 4 IN VIVO EVALUATION STUDIES OF THE POLYMER-DRUG 
CONJUGATES 
 
V. 3. 4. 1 Polymer-drug conjugates biodistribution studies in healthy 
mice 
PGA-CONH-Doxy-Cy5.5 conjugate biodistribution by optical imaging 
technique 
Healthy Balb/c mice (9-12month old) were used as mouse 
model for the in vivo distribution studies. For in vivo monitoring 
experiments, animals were first anesthetised and shaved to remove 
hair interference in fluorescence signal. The in vivo whole-body 
biodistribution as well as ex vivo monitoring of the labelled conjugate 
was performed through noninvasively fluorescence imaging (FLI) using 
the IVIS®Spectrum Imaging System. Animal care has handled in 
accordance to guidelines for the Care and Use of Laboratory Animals 
of the Centro de Investigación Príncipe Felipe, and the experimental 
procedures were approved by the Animal Experimentation Ethical 
Committee of the institution. 
 
Biodistribution of Cy5.5 labelled PGA-CONH-Doxy conjugate 
(17ωt%) (66) was evaluated by FLI. Conjugate was dissolved in serum 
saline (1.40mg/mL) and animals were injected intravenously a single 
dose of 100µL of the solution. As controls, non-injected mice were 
used. Animals were anesthetised using 1-3% isofluorane. Five mice 
were imaged at a time and imaging settings were set depending on the 
fluorescence of the animals. The light emitted from the labelled 
conjugate was detected, digitalised and electronically displayed as a 
pseudocolor overlay onto a gray scale animal image. Fluorescent 
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signals were quantified as Efficiency. Mice were euthanised at 0, 4 and 
24h post administration. Blood was collected and major organs (liver, 
lungs, spleen, kidneys, heart and brain) were dissected from mice and 
fluorescence images of excised tissues were obtained by ex vivo FLI. 
Tissues samples were harvested and stored at -80°C to quantify 
fluorescence.  
 
Organs were homogenised in PBS pH=7.4 at a specific 
concentration by means of Ultraturrax device (approx. 1min, 
13000rpm). Suspension was centrifuged (4000rpm, 1h, 4°C) and 
supernatants were collected for fluorescence measurement. 
Quantification data is shown in FIGURE V. 37. To assess conjugate total 
extraction, pellets were washed with ddH2O but no significant signal 
was observed. 
 
For blood samples, immediately after extraction they were 
centrifuge (10min, 4000rpm, 4°C) and plasma (supernatant) and pellet 
were frost in liquid nitrogen after analysis. Plasma was directly 
measured (100µL) per triplicate in 96 well-plates by fluorescence 
detector.  
 
PGA-CONH-Doxy-Cy5.5 conjugate biodistribution by Positron 
Emission Tomography (PET) 
A second biodistribution study was done by means of PET. The 
experiment was performed in FVB/NJ mice (25±4g). Animals were 
injected i.v. in the tail vein at a dose of 21±4µg PGA-Doxy-DOTA/68Ga 
(65) per gram of body weight, which corresponded to a dose between 
0.2 and 1.4MBq.  
 
The mice were anesthetised with 1.5% isoflurane and 
monitored up to 3h. In parallel, groups of animals (n=5) were sacrificed 
at 25min, 50min, 1h, 2h and 3h post-injection. Blood and selected 
organs (heart, lungs, spleen, kidneys and liver) were collected. The 
radioactivity was measured and corrected for the decay in a gamma 
counter.  
At 0.25, 0.5, 1, 2, and 3 hours following injection, blood 
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samples were obtained from mice by terminal bleeding via cardiac 
puncture following isoflurane anaesthesia; their organs (lungs, heart, 
spleen, kidneys, liver and brain) and some tissues (muscle, fat) were 
isolated, rinsed with normal saline, weighted, and radioactivity was 
measured using the Cobra II auto-gamma counter. The blood samples 
were centrifuged (10min, 3000rpm, RT) and the supernatant of plasma 
was transferred to a new eppendorf tube. The %ID and the %ID/g 
were calculated by comparison with standards taken from the injected 
solution for each animal. The data were expressed as the mean ± 
standard deviation. 
 
PEP1-PEG-Cy5.5 conjugate biodistribution by Optical Imaging 
technique 
Biodistribution of PEP1-PEG-Cy5.5 (67) was evaluated by 
optical imaging technique. Conjugate was dissolved in serum saline 
(0.66mg/mL) and animals were injected intravenously a single dose of 
100µL of the solution. The in vivo whole-body biodistribution of the 
labelled conjugate was monitored noninvasively by FLI using the 
IVIS®Spectrum Imaging System. As controls, non-injected mice were 
used. Animals (Balb/c mice) were anesthetised using 1-3% isofluorane. 
Five mice were imaged at a time and imaging settings were set 
depending on the fluorescence of the animals. The light emitted from 
the labelled conjugate was detected, digitalised and electronically 
displayed as a pseudocolor overlay onto a gray scale animal image. 
Fluorescent signals were quantified as Efficiency. Mice were 
euthanised at 0, 4 and 24h post administration. Blood was collected 
(also at shorter times) and major organs (liver, lungs, spleen, kidneys, 
heart and brain) were dissected from mice and fluorescence images of 
excised tissues were obtained by ex vivo FLI. Tissues samples were 
harvested and stored at -80°C to quantify fluorescence.  
 
Organs were homogenised in solution of HClO4 6% / EtOH 40% 
at a specific concentration by means of Ultraturrax device (approx. 
1min, 13000rpm). Suspension was centrifuged for 1h at 4000g at 4°C 
and supernatants were collected for fluorescence measurement. To 
assess conjugate total extraction, pellets were washed with ddH2O but 
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no significant signal was observed. For blood samples, immediately 
after extraction they were centrifuge (10min, 4000rpm, 4°C) and 
plasma (supernatant) and pellet were frost in liquid nitrogen after 
analysis. Plasma was directly measured (100µL) per triplicate in 96 
well-plate by fluorescence detector. 
 
V. 3. 4. 2 Preliminary activity studies of conjugates in a young FAP 
mice model  
 
All animals were kept and used strictly in accordance with 
national rules and European Communities Council Directive 
(86/609/EEC), and all studies performed were approved by the 
Portuguese General Veterinarian Board (authorisation number 024976 
from DGV-Portugal). Transgenic mice for human V30M TTR in a TTR 
null background were kindly provided by Professor Suichiro Maeda 
from Yamanashi University. In previous studies, these animals were 
previously analysed and ~60% of the animals over 1 year of age were 
found to have TTR deposition as amyloid, for instance Congo red (CR)-
positive material [51] having non-fibrillar TTR deposits at younger 
ages. 
 
Three groups of animals (9-11month of age, n=8) were treated 
intravenously with the conjugates detailed in TABLE V.  8. Animals 
were given 2 doses per week during 6 weeks. Group 1 was treated 
with the conjugate C2P1 (60), group 2 was treated with two 
conjugates in the same dose (combination group): C2P1 (60) and PGA-
CONH-Doxy (51) and group 3 with PGA-CONH-Doxy (51). Non-treated 
mice were used as controls. 
 
Animals were sacrificed after anaesthesia with 
ketamine/xylazine. Organs (including liver, kidney, oesophagus, 
stomach, small and large intestines, heart, spleen, pancreas) were 
immediately excised and processed. It is important to note that in this 
model the gastrointestinal track present the majority of fibril 
accumulation. Tissues were fixed in 4% neutral buffered formalin and 
embedded in paraffin or immediately frozen, for light microscopy or 
for total protein extraction, respectively. 
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Immunohistochemistry (IHC) studies of the organs from the treated 
mice 
TTR-non fibrillar deposition in the extracted tissues was 
evaluated by immunohistochemistry as well as possible toxicity of 
these deposits (apoptosis).  
 
5μm-thick sections were deparaffinised in xylol and 
dehydrated in a descendent alcohol series. Endogenous peroxidase 
activity was inhibited with 3% hydrogen peroxide/100% methanol and 
sections were blocked in 4% bovine serum and 1% bovine serum 
albumin in phosphate buffered solution (PBS). Primary antibodies used 
were rabbit polyclonal anti- TTR (Dako, 1:1000), rabbit polyclonal anti-
Fas (St.Cruz, 1:200), and rabbit polyclonal anti-3-nitrotyrosine 
(Chemicon, 1:500), which were diluted in blocking solution and 
incubated overnight at 4°C. Antigen visualisation was performed with 
the biotin-extravidin-peroxidase kit (Sigma), using 3-amino-9-ethyl 
carbazole (Sigma) or diaminobenzidine as substrates. 
Immunohistochemistry analysis was carried out by two investigators 
unaware of the tested tissue sections.  
 
Histological analysis of the organs from the treated mice 
For evaluating conjugates toxicity, histological analysis of the 
tissue sections was performed. This technique enables a better 
assessment of severe toxicity. Paraffin-embedded sections were 
stained with haematoxylin/eosin solution (H&E). H&E-stained slice 
sections were thoroughly examined under low (25 × and 50 ×) and 
medium (100 × and 200×) magnification.  
 
Statistical Analysis 
All results are given as means ± SD (n≥3). When only two 
groups were compared, the Student’s t test for small sample size was 
used to estimate statistical significance. If more than two groups were 
compared evaluation of significance was performed using one way-
Analysis Of Variance (ANOVA) followed by Bonferroni post hoc test. 
Graph pad Instant software (Graph Pad Software Inc. CA, USA) was 
used. In all cases, statistical significance was set at p <0.05. 
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GENERAL DISCUSSIONS 
 
Neurodegenerative disorders are considered a great challenge 
due to the growing incidence in advancing age population and the 
difficulty of their treatment beyond the palliative healing. Investigation 
in this area is concentrated on specific site-directed drug delivery and 
prompt diagnosis. The bottleneck for successful approaches lies in the 
difficult drug access to the brain when CNS is affected. This organ is 
protected by a physic and enzymatic biological barrier which confers 
the most unique protection existing into the human body: the blood-
brain barrier (BBB) [1, 2]. 
 
 Herein, polymer therapeutics (PT) had been proposed as a 
therapeutic alternative for the treatment of these diseases. This family 
of new chemical entities are well established polymeric nanomedicines 
with several products in the market, mainly PEGylated proteins and 
polymeric drugs as anticancer agents, and a growing number of 
polymer-drug conjugates in clinical development. Among the fourth 
enounced strategies for the second generation of PT, this work has 
encompassed most of them involving [3-7] (i) the use of biodegradable 
polymeric carriers, such as polyglutamates, which provide the 
opportunity for their use in chronic treatments and CNS disorders, (ii) 
utilising sophisticated methodologies for their physico-chemical 
characterisation allowing a better control on the final product 
together with the most appropriate application for our system 
depending on the physico-chemical behaviour observed, (iii) a novel 
target different than cancer and (iv) the use of combination therapy  
as an extra tool for enhancing the potential of our conjugates by 
means of synergism. 
 
Initial efforts of the present work were directed towards the 
design and synthesis of polymeric platforms based in poly-L-glutamic 
acid (PGA). Based on the current systems able to reach the brain for 
drug delivery, conformation and mechanism for cellular internalisation 
were considered as key features for our designs. Therefore, 
homopolymers, diblock and triblock copolymers with different 
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polypeptidic block lengths as well as hydrophilic/hydrophobic 
character were thought to present good opportunities to achieve brain 
access.  For this objective, NCA-ROP polymerisation was selected due 
to its broad acceptance to obtain polypeptides and polypeptide-based 
block copolymers with quantitative yields, facility to multigram 
scalability and avoidance of racemisation at the chiral centers [8-13]. 
Additionally, the option of using either molecular or macromolecular 
initiators provided the construction of the diblock copolymers. This 
polymerisation requires high purity of every component and specific 
reaction conditions were factors like humidity, CO2 pressure, 
temperature, presence of salts or cleavability  of the protecting 
groups, undesired terminating processes, etc., are determinant 
parameters to achieve successful results. Nowadays, this centenary 
polymerisation procedure presents promising approaches yielding 
well-defined polypeptides based on initiation of highly purified NCAs 
with primary amines under [10-13]. Unfortunately, all methods have 
limitations, e.g. HVT require a complex and expensive experimental 
setup, HMDS amines are sensitive to hydrolytic reactions, while heavy 
metal catalysts must be carefully removed to avoid non-specific 
toxicity in biomedical applications.  
 
For the whole field of nanomedicine is vitally important to 
have methods that allow the large scale (from 100 g to kg) production 
of controlled polymeric carriers with any trace of toxic impurities. To 
circumvent these challenges, here we have used ammonium salts as 
initiators to enable controlled large scale synthesis of well-defined 
polyglutamates covering a wide molecular weight range. In contrast to 
other approaches [14-16], we have substituted the nucleophilic 
chloride by a non-nucleophilic tetrafluoroborate anion (BF4
−), which is 
less hydrophilic and thus better soluble in a broad range of organic 
solvents and it has lower nucleophilicity than the related nitrate or 
halide salts [17-19]. Mechanistically, BF4− anion can be considered 
inert due to the symmetry of the ion leading to an equal charge 
distribution and its composition of highly electronegative fluorine 
atoms, which diminishes the nucleophilicity of the anion and 
consequently, avoiding the undesired reprotonation of the activated 
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monomer during the ROP of NCAs. Therefore, living nature of the 
polymerisation could be achieved enabling the synthesis of well-
defined high molecular weight homo or block-co-polypeptides with 
preserved end group integrity. 
 
Herein, a set of conditions suitable for the obtaining of 
polymers with lower dispersities, reproducibility batch-to-batch and 
scalability has been set up.    Then, it was explored the versatility of 
the reported methodology by polymerisation of (OBzl)Glu-NCA with 
tetrafluoroborone salts of neopentyl amine, butylamine, propargyl 
amine, azide amine as  well as polyethylene glycol mono methylether 
amine yielding controlled block copolymers. The presence of an end 
functionality allows site-specific conjugation of antibodies, proteins or 
imaging probes at the same time that side chain multivalency enables 
the design of advanced theranostics or polymer-based combination 
nanopharmaceutics, limelight topics in this area due to current clinical 
needs. MW can be precisely controlled up to a degree of 
polymerisation of 800 without the use of complex initiators or 
demanding experimental setup. The derived polymers have low 
dispersities indices below 1.2 indicating the well-controlled character 
of the polymerisation itself. 
 
Next step after polymerisation to obtain the final PGA 
polymers is the deprotection, that must ensures full removal of 
protecting groups without racemisation; an issue, which is often not 
considered carefully and could induce important changes in 
nanomedicine behaviour in a clinical setting. Changes in secondary 
structure due to polypeptide racemisation will alter immunological 
properties, degradation profile, and secondary structure. 
Consequently drug release, the pharmacokinetics profile and 
biodistribution maybe unpredictable upon polypeptide-drug 
conjugation.  
 
Deprotection using TFA/HBr or acetic acid/HBr is known to 
lead to deprotection in the absence of racemisation [12]; however, 
these conditions are not suitable for sensitive functional end groups 
derived from functional initiators, e.g. alkyne moieties as well as PEG 
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based block copolymers (i.e. PEG is rapidly degraded under those 
conditions). In respect to those needs a basic deprotection protocol 
was developed avoiding racemisation. The deprotection methodology 
was optimised for homopolymers and diblock co-polymers to achieve 
complete benzyl group removal and non-stereochemical changes.  
 
Finally, multifunctionality of the PGA block offers the 
possibility of tuning the polymeric carrier introducing novel pendant 
groups (alkyne, amine, sulfhydryl, etc) by linking different molecules to 
the PGA carboxyl groups. This strategy, named post-polymerisation, 
contributed in the present work to enlarge the number of members of 
the polyglutamate family by providing site-specific conjugation points, 
overcoming the limited functional group tolerance of most of the 
controlled polymerisation techniques. In the same way, N-terminal 
extreme of the polypeptide block was settled up for conjugation of 
another polymeric block: PEG. Through this synthetic pathway, triblock 
copolymers were obtained as well as diblocks. The insertion of the 
second PEG in TBs was thought to supply a specific-linkage point by 
the presence of an activated sulfhydryl for further conjugation with 
biological ligands as targeting moieties for BBB crossing as well as to 
play a role in solution conformation and consequently in the cellular 
internalisation pathways. To corroborate our hypothesis, labelling of 
the novel polyglutamates as well as conjugation to targeting ligands 
were performed.  
 
In the case of the labelling procedures, the best candidate was 
chosen depending on the monitoring technique. Amides and triazole 
bonds were the selected unions due to their stability under 
physiological conditions use. Later studies on internalisation in an 
endothelial cell line (HUVEC) revealed that the synthesised members 
of the TB family (n=100, 150, 200) were non-cytotoxic in the range of 
concentrations tested and their cell internalisation pathways 
underwent through energy dependent mechanisms: endocytosis. Co-
localisation with lysosomal markers and the reduced internalisation at 
4°C compared with 37°C studies corroborated this fact. In 
consequence, possible co-existence of mixed mechanisms of diffusion 
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and endocytosis (observed in previous experiments in our laboratory) 
were dismissed. Therefore, we proposed the use of targeting ligands 
conjugated to our polyglutamates to accomplish our objective of 
carrying drugs across the BBB. This attractive strategy does not 
interfere with the integrity of the barrier preventing possible brain 
damage. 
 
Prior to ligand conjugation, biodistribution experiments of our 
novel polyglutamates (TB, DB and homopolymer) were carried out 
with optical imaging (DB-Cy5.5 and TBO), by MRI (TB-DTPA/Gd) or by 
PET (PGA-DOTA/Ga). None of the systems presented greater 
differences among the sizes and number of present PEG blocks. Renal 
excretion and non-specific accumulation in other organs were 
observed in all cases. Thus, our systems were validated as adequate 
polymeric carriers for future drug delivery applications. It is important 
to mention that, in vivo differences could still occur on biodistribution 
studies in relation to brain accumulation when different carriers 
varying the length of the inner polypeptidic block or the MW of the 
PEG blocks will be further evaluated. 
 
Regarding active BBB targeting, disulphide bonds were 
preferred polymer-residue linkage due to their bioreversibility, 
allowing ligand release in presence of a reductive environment or by 
disulfide reductases encountered in the brain following transcytosis. 
Our approach concerns the transferrin receptor (TfR) as tool to 
achieve active transport of our systems trough the BBB.  The 
conjugated moieties were the TfR natural ligand (transferrin, Tf), a 
monoclonal antibody (mAb) named OX26 and an iron-mimicking 
peptide (cPEP). Through fluorescence labelling, TB-Tf conjugation was 
optimised and an appropriate biodistribution with renal secretion and 
non-accumulation in any organ was found. Unfortunately, TB-Tf 
percentage encountered in the brain was insignificant if compared 
with the parent Tf. In order to enhance this ratio, the mAbOX26 was 
conjugated to TB. mAbOX26 binds TfR in an epitope different from the 
natural ligand site that under normal conditions remains saturated 
impeding the recognition of endogenous Tf. Thus, we replaced the Tf 
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by the antibody expecting to have better outputs. By means of MRI 
technique, TB-mAb OX26 biodistribution was performed. However, the 
chemistry used for the conjugation drove to solubility issues along the 
synthetic processes and polymer functionalisation did not reach an 
appropriate range for a detectable BBB crossing. Following reported 
data, rats were used as animal model [20, 21] however, in comparison 
o mice, higher doses of conjugates were required and the expensive 
cost of mAb OX26 made this approach not feasible. Moving towards 
mice models and searching for manageable targeting probes, short 
peptides were proposed as an efficient alternative. Together with the 
named Cpep [22], the most advanced BBB targeting vector in the field 
[23] was also evaluated: the Angiopep-2, which targets the low density 
lipoprotein receptor-related protein 1 (LRP-1).  
 
PET was selected as the most appropriate monitoring 
technique after comparison with FLI or MRI due to (i) its sensitivity to 
detect brain accumulation, (ii) the need of a low percentage of tracer 
trying a better resembling with the unlabelled vehicle, and (iii) an 
simpler work-out to quantitate the signal of single organs in ex vivo 
experiments, avoiding extraction procedures as those required in FLI 
protocols. Taking profit of the synthetic approaches optimised with 
the previous ligands, cPEP was conjugated to DB and PGA through 
amide bonds and the Angiopep-2 by disulphide bridges.  
 
In a preliminary test evaluating the differences among both 
peptides and both carriers, none of them achieved a significant brain 
accumulation in the studies performed although the obtained results 
showed promising results for the Angiopep-2 conjugates. Radioactive 
signal in the brain was higher with this vector although the observed 
signal decay could mean a possible pump-out of the systems or their 
presence in the blood surrounding the brain and not into it. With both 
peptides, diblocks achieved lower percentages than homopolymers. 
We believe that polymer conformation in solution could impede ligand 
recognition explaining the low internalisation. To solve this issue, we 
proposed to use PEG as a semitelechelic block providing a unique 
conjugation point for the peptide which favored its availability for 
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receptor recognition. Meanwhile TB-Angiopep2 conjugate synthesis is 
still under optimisation, PET monitoring studies are currently being 
performed with novel Angiopep-2 synthesised conjugates based on 
DB-4TP, PGA homopolymer and PGA star-like architectures, aiming to 
improve the BBB crossing. 
 
As an adequate carrier for brain delivery have not been still 
encountered, in order to explore a neuropathological application non-
fully depending on BBB crossing, a rare inherited amyloidosis named 
Familial Amyloidotic Polyneuropathy (FAP) was targeted. In this 
disease, the main affected area is the peripheral nervous system (PNS) 
[24]. The central nervous system (CNS) is also an amyloid-associated 
tissue although the incidence level is considerably lower in FAP. 
Therefore, crossing the BBB was not the major issue for our PDCs 
although it will be an extra advantage in case this tissue was affected.  
 
One of the most common FAPs is caused by a mutated protein 
called transthyretin (TTR), which forms amyloid deposits, mainly in the 
PNS. The aggregation cascade of this mutated protein, produces a TTR 
aggregate (TTRagg) able to trigger neurodegeneration through 
engagement with the receptor-for-advanced-glycation-end-products 
(RAGE) receptor, which is present on peripheral neurons. In later 
stages of the disease, the cascade evolves up to fibril formation whose 
deposits promote tissue degeneration and organ failure. Saraiva et al 
discovered two biomolecules active against the named TTR species.  
. 
Firstly, a specific peptidic sequence (named RAGE peptide) 
able to suppress TTRagg-induced cytotoxicity in cell culture [25]. A 
reduced version of that peptide containing 6aa was proved to 
maintain the activity and the affinity of the initial peptide (unpublished 
sequence). Although this provides an opportunity to design novel 
therapeutics for FAP treatment, peptide therapeutics themselves 
display well known challenges for in vivo use, e.g. low stability, poor 
pharmacokinetics and potential immunogenicity. Moreover the RAGE 
peptide demonstrates low solubility in plasma limiting its potential for 
i.v. administration. Thus one of the aims of this study was the design of 
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an efficient polymer- RAGEpeptide FAP inhibitor.  
 
Secondly, an antibiotic drug capable of disrupting TTR amyloid 
fibrils in vitro, in the treated animals and also achieved other 
improvements regarding amyloid markers [26, 27]. In this case, 
polymer conjugation of this low MW drug will promote changes in the 
biodistribution compared to the parent drug, avoidance of undesired 
accumulation in non-affected organs, diminution of the administered 
dose and/or its frequency and enhancement of the therapeutic 
response. 
 
Concerning the rational design the adequateness of the 
polymer carrier, targeting site conditions and the labile properties of 
the required covalent bond were considered. As polymer platforms, 
PGA and PEG were again proposed, in this case for drug conjugation. 
Our first idea was to build individual PDCs i.e. to conjugate both drugs 
in independent polymers, and then to combine both drugs in the same 
polymer matrix. For the later, either the diblock or triblock co-polymer 
will accomplish our requisites. All possible combination should be 
evaluated looking for synergism and the best selected for FAP 
treatment. The fact that regions of TTR deposition in the body are 
characterised by a surrounding inflammation provides an additional 
advantage for targeted delivery our conjugates due to the potential for 
passive targeting due to the EPR effect that accompanies inflammation 
[28, 29]. Also the local reductive and slightly acidic pH environment 
can be used to facilitate site–specific drug release from bioresponsive 
linkers.  
 
A small library of PEG-RAGE conjugates were synthesised to 
contain biodegradable (disulphide) and non–biodegradable (amide) 
linkers (to investigate if peptide release was necessary for activity) and 
mono- and bi-functional PEGs used to explore the importance of 
solution conformation. First step involved the synthesis by Fmoc-SPPS 
of the RAGEpep and two derivates for accomplishing the needed end-
functional groups for later PEG conjugation. After confirming the 
identity of each conjugate by NMR and MS spectroscopy analysis, 
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activity studies in vitro in a FAP model (RN22 cell line) were 
performed. Results concluded that the amide conjugate carrying two 
molecules of RAGEpep (C2P1) showed the best inhibition of TTRagg-
induced cytotoxicity in Schwann cells at 24h. Those conjugates 
containing disulphide linkers gave less reproducible data and lower 
activity. Binding affinity studies carried out by surface plasmon 
resonance (SPR) mimicking in vitro assay and the solution in 
conformation by DLS analysis supported this activity due to the 
maintenance of RAGEpep affinity for the aggregates and revealed a 
more stable conformation in solution which may help into RAGEpep 
spatial availability for the interaction. Thus, peptide release was not an 
requisite for its activity. In addition, C2P1 was stable after incubation 
24h in plasma mimicking in vivo situation and did not show haemolytic 
properties as expected, demonstrating its suitability for i.v. 
administration. Biodistribution experiments performed with 
fluorescent derivative showed a renal secretion and non-accumulation 
in undesired areas. 
 
With doxy the same rational design for polymer-drug linkage 
was followed and a library of PGA-Doxy conjugates with drug loading 
ranging from 2 to 60ωt% was synthesised and fully characterised. 
Selected linkages were ester and amide bonds, either directly to the 
polymer or through a dipeptide as linker. Screening their activity as 
TTR fibril disruptors, amide conjugates demonstrated higher response 
at equivalent parent drug dose. Specifically, conjugates with 15 and 
30ωt% drug content showed the best fibril disaggregation profile. 
Trying to explain this fact, physico-chemical studies were performed 
demonstrating that drug release was not a requisite for activity. 
Conformation in solution was analysed by SANS and DLS techniques, 
determining that both conjugates presented analogous conformation, 
although different from unconjugated PGA. Biodistribution studies 
were carried out by optical imaging and PET techniques.  The labelled 
PGA-CONH-Doxy 15ωt% was renally cleared. Half–life time value was 
0.98h greater than parent PGA (0.59h) with smaller size and different 
solution conformation as seen by SANS. The conjugate remain stable 
in plasma without showing haemolytic properties indicating their 
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suitability for i.v. administration. 
 
Finally, a preliminary study applying combination therapy was 
performed in vivo in a young FAP model. Best candidates of each 
family, C2P1 and PGA-CONH-Doxy were selected for the experiment, 
per separate and in combination. Animals were classified in three 
groups: Group 1 was treated with the conjugate C2P1, group 2 with 
C2P1 and PGA-CONH-Doxy and group 3 with PGA-CONH-Doxy. Non-
treated mice with FAP disease were used as positive as well as healthy 
mice as negative controls. Doses were adjusted (0.036mg RAGE 
pep/Kg of C2P1 and 8mg Doxy/Kg for PGA-Doxy conjugates and i.v. 
administered during 6 weeks with 2 doses per week). Results in non-
fibrillar TTR deposition and other molecular markers were not reliable 
compared to the control group. However, combination group 
presented the best output when the three groups were compared. The 
studies should be repeated with a previous dose study together with 
trials in an older FAP model, more appropriate for doxy conjugates. 
Furthermore, histological analysis of key organs (gastrointestinal tract 
and liver) validated the safety of the conjugates. Unexpectedly, 
recovery of the liver morphology was observed in treated animals.  
 
Future directions will encompass a proper in vivo experimental 
set up within an old FAP model of our conjugates with an optimisation 
test of the most appropriate dose. We really encourage the use of 
combination at this stage due to their target molecules coexist at 
advanced phases. Moreover, we also proposed the use per separate of 
pegylated RAGE peptide conjugate C2P1 in early stages of the disease 
or the PGA-CONH-Doxy alone in advanced phases.  
 
To define the best combination conjugate (both agents in the 
same polymer matrix or conjugated into different polymers), extra 
combination tests may be carried out in vitro as well as in vivo. As 
targets can be located in different parts of the extracellular 
emplacement, it could be expected that conjugates per separate will 
display the best output. 
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CHAPTER II 
 
1. A versatile and simple methodology for the preparation of 
well-defined polyglutamates by means of ROP-NCA has been 
described. For the first time ammonium salts with non-nucleophilic 
tetrafluoroborate anions were used as initiators, allowing a multigram 
scale synthesis with defined molecular weight (up to 800 units), low 
polydispersity (<1.2), controlled chain end functionality and adequate 
stereoselectivity and absence of any trace of toxic impurity to allow 
biomedical applications. 
 
2. Varying the initiators, different polyglutamate-based systems 
were obtained, e.g. homopolymers and diblock copolymers, with 
different lengths of the polypeptide block. 
 
 
3. Deprotection of y-benzylpolyglutamates under acid (TFA/HBr) 
as well as basic conditions (NaOH aq./THF) has been optimised in 
order to be exploited without compromising the integrity of PEG-
based block copolymers or the incorporated sensitive functional 
groups.  
 
4. Diblock copolymers (PEG-PGAn) have been obtained either 
through ROP-NCA or after PGAn post-polymerisation. In addition, this 
latest protocol enabled also the synthesis of triblock copolymers (PEG-
PGAn-PEG-X) in which is introduced a unique point of linkage (X) for 
specific anchoring of targeting ligands. 
5. Post-polymerisation processes allowed the construction of 
polyglutamates with different functional groups than carboxylic acid 
for specific and orthogonal conjugation, e.g. amines, sulfhydryls or 
alkynes. 
 
 
CHAPTER III 
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1.  Triblock copolymers (PEG-PGAn-PEG, n=100, 150, 200) were 
successfully labelled with the fluorophore Oregon green (OG) and 
appropriate protocols for fluorescence stability measurements were 
optimised. TBs (n=100, 200) were also labelled with the chelator DTPA 
and later complexed with Gd(III). 
 
2. PGA homopolymer and DB systems (PGAn, PEG-PGAn, 
n=100,200) were effectively conjugated with the NIR dye Cy5.5 via 
click chemistry (PGA) and amide bond (DB). In addition, both systems 
were labelled with the radionuclide complex DOTA/68Ga through 
amide bonds with the polymer platform. 
 
3. Several targeting ligands for BBB crossing through receptor-
mediated endocytosis were conjugated to the polyglutamates.  
 
a. Transferrin (Tf) was previously thiolated for latter 
conjugation to TBs (unlabelled or OG-labelled) and DB-Cy5.5, 
by means of disulphide bonds.  
 
b. The monoclonal antibody OX26, after a mild reduction, 
was successfully conjugated to TB-DTPA/Gd system again 
through disulphide bonds. 
c. The targeting peptides cPEP and Angiopep-2 were 
conjugated to PGA and DB (n=100) previously labelled with 
DOTA/68Ga. 
 
CHAPTER IV 
 
1. Triblock copolymers  (n=100, 150, 200) demonstrated its cell 
viability in a human endothelial cell line (HUVEC) and studies on 
cellular trafficking by means of flow cytometry and live-cell 
fluorescence confocal microscopy established preferentially an 
endocytic internalisation mechanism. 
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2. Targeted and non-targeted polyglutamates were subjected to 
biodistribution studies under different techniques: optical imaging, 
MRI and PET.  
a. Regarding the non-targeted systems, PGA (PGA-DOTA), 
DB (DB-Cy5.5) and TB (TBO) showed renal secretion, non specific 
accumulation in any other organ and none of them presented 
inherent properties for BBB crossing. In these “proof of 
concept” studies, results demonstrated that polyglutamates 
were adequate carriers for drug delivery.  
b. The observed sensitivity of PET experiments pointed 
out this technique as the preferred for conjugate brain crossing 
detection. 
c. Among the targeted polymers, neither the Tf nor the 
mAbOX26 or the peptidic sequences achieved a significant 
accumulation in brain. Nevertheless, the peptides were selected 
as the best ligands due to the simplicity of their handling over 
the chemical process and the most advanced moieties in the 
field for the purposed objective. Novel architectures and PGA-
based constructs are being developed allowing better exposure 
of the peptides and therefore, greater brain targeting results are 
expected. 
 
CHAPTER V 
 
1. For the first time in the field, novel polymer- drug conjugates 
for the treatment of FAP have been synthesised and characterised in 
this study. Two bioactive molecules, a low MW drug (doxycycline) and 
a 6aa peptide (RAPEpep) have been conjugated to polymeric 
platforms: PGA and PEG, respectively.  
 
2. A library of PGA-Doxy conjugates with a drug loading ranging 
from 2 to 60ωt% was synthesised and characterised. Drug linkage was 
performed through ester or amide bonds, either directly to the 
polymer or through a dipeptide as linker. Screening their activity as 
TTR fibril disruptors, amide conjugates demonstrated higher response 
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at equivalent parent drug dose. Specifically, conjugates with 15 and 
30ωt% drug content were the best. Trying to explain this fact, physico-
chemical studies were performed finding out that drug release was not 
a requisite for activity and that conformation in solution for both 
conjugates was analogous, although different from unconjugated PGA. 
Biodistribution studies were carried out by optical imaging and PET 
techniques.  The labelled PGA-CONH-Doxy 15ωt% was renally 
excreted. Half–life time value was 0.98h greater than that obtained for 
PGA (0.59h). All synthesised conjugates are not haemolytic remained 
indicating their suitability for i.v. administration. 
 
3. RAGE peptide and two derivates (PEP1 and PEP2) with one or 
two amino acids extra for amide and disulphide bond linkage to the 
polymer were synthesised by Fmoc-solid phase peptide synthesis and 
characterised. A small library of RAGEpep conjugates was obtained by 
PEGylation and fully characterised. The amide conjugate carrying two 
molecules of RAGEpep (C2P1) showed the best inhibition of TTRagg-
induced cytotoxicity in Schwann cells at 24h. Those conjugates 
containing disulphide linkers gave less reproducible data and lower 
activity. Binding affinity and the solution conformation studies 
supported this activity due to the maintenance of RAGEpep affinity for 
the aggregates and revealed a more stable conformation in solution, 
which may help into RAGEpep spatial availability for the interaction. 
Biodistribution experiments showed a renal secretion and non-
accumulation in undesired areas. 
 
4. A preliminary study in vivo in a young FAP model was carried 
out administering C2P1 and PGA-CONH-Doxy, per separate and in 
combination. Results in non-fibrillar TTR deposition and other 
molecular markers were not reliable compared to the control group. 
However, combination group presented the best output when the 
three groups were compared. The studies should be repeated with a 
previous dose study together with trials in an older FAP model, more 
appropriate for doxy conjugates. Furthermore, histological analysis 
validated the safety of the conjugates. Unexpectedly, recovery of the 
liver morphology was observed in treated animals. 
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APPENDIX I. THESIS PROJECT INDEX, OBJECTIVES, METHODOLOGY 
AND CONCLUSIONS IN SPANISH 
1. INTRODUCCION Y MARCO TEMÁTICO DE LA TESIS 
Nanociencia y nanotecnología son la base de técnicas 
innovadoras para el transporte de fármacos con beneficios potenciales 
para el paciente y nuevos mercados para la industria. La obtención de 
nuevos sistemas de transporte de fármacos más efectivos es uno de 
los principales retos actuales, junto con la mejora del diagnóstico 
tanto in vitro como in vivo y el desarrollo de tecnologías para la 
ingeniería tisular y la medicina regenerativa. Además de ser necesario 
disponer de moléculas con actividad farmacológica para conseguir 
terapias efectivas se necesitan su transporte y liberación controlada 
para llegar a conseguir tratamientos con mayor índice terapéutico. El 
uso de estrategias de direccionabilidad (‘targeting’), tanto activa 
(unión del portador a residuos dirigentes) [1, 2] como pasiva 
(acumulación en zonas enfermas por efecto EPR, Enhanced and 
Permeability Retention effect [3-6]) permite la acumulación del 
fármaco en el tejido enfermo, aumentando la actividad y reduciendo 
la toxicidad sistémica inherente de los fármacos.  En la actualidad 
existen terapias muy interesantes por su actividad terapéutica o 
mecanismo de acción molecular pero, debido a su toxicidad, baja 
solubilidad del compuesto, estabilidad, capacidad de transporte 
intracelular o difícil farmacocinética son abandonadas antes de llegar a 
clínica por no disponer de un sistema de transporte celular adecuado 
que los solubilice, proteja o dirija a su diana molecular, ej: péptidos, 
proteínas o terapias basadas en ácidos nucléicos (DNA, siRNA, 
oligonucleótidos…). 
El desarrollo multidisciplinar de la química de polímeros, la 
biología, la física y la medicina ha dado lugar a los primeros 
nanofármacos poliméricos entre los que se encuentran los ‘Polímeros 
Terapéuticos’ (PT): nanoconstrucciones híbridas que emplean 
polímeros hidrosolubles, tanto de forma bioactiva como parte 
funcional inerte de un complejo multicomponente, donde el agente 
bioactivo se une de forma covalente al portador polimérico mediante 
un enlace que responde frente a condiciones fisiológicas específicas [7, 
8].  Desde un punto de vista industrial, los PT son considerados como 
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nuevas entidades químicas y no como simples sistemas 
convencionales de transporte de fármacos (‘depots’) [9]. Los sistemas 
de transporte tradicionales simplemente atrapan, solubilizan o liberan 
de forma controlada el agente bioactivo sin utilizar una conjugación 
química. Conceptualmente, los Polímeros Terapéuticos comparten 
muchas características con otros fármacos macromoleculares (como 
proteínas, anticuerpos u oligonucleótidos) y profármacos 
macromoleculares, incluyendo los inmunoconjugados. Sin embargo, 
poseen ventajas adicionales como la versatilidad de la química 
sintética, que permite confeccionar el peso molecular y adicionar 
características biomiméticas, o la posibilidad de incluir elementos que 
responden a cambios fisiológicos. El término “Polímeros Terapéuticos” 
engloba cinco grupos de nanoconstrucciones: fármacos poliméricos 
(polímeros con actividad inherente), conjugados polímero-fármaco, 
conjugados polímero-proteína, poliplejos con aplicación como 
vectores no virales en transporte génico y micelas poliméricas con el 
fármaco conjugado de forma covalente a un polímero anfifílico [10, 
11]. 
Tras la salida al mercado de los primeros conjugados polímero-
proteína y el creciente número de conjugados polímero-fármaco en 
fase clínica, los conjugados poliméricos anticancerígenos se establecen 
como terapia efectiva para el tratamiento del cáncer. Actualmente, 
esta plataforma tecnológica se centra en obtener conjugados de 
segunda generación que suplan las dificultades encontradas hasta el 
momento y propongan mejoras considerables respecto a sus 
características y propiedades. Se han aceptado cuatro nuevas 
estrategias para que esta novedosa plataforma tecnológica dé lugar a 
terapias más específicas y efectivas: (i) la búsqueda de nuevos 
soportes poliméricos (polímeros biodegradables con elevado Mw, 
arquitecturas poliméricas definidas y controladas), (ii) la 
caracterización físico-química exhaustiva  de estos sistemas para una 
mejor comprensión de su comportamiento biológico, (iii) su aplicación 
a nuevas dianas terapéuticas en áreas distintas al cáncer y (iv) el uso 
de terapia de combinación para obtener compuestos de mayor índice 
terapéutico [7, 12, 13]. 
Siguiendo estas directrices, en la presente tesis doctoral se han 
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desarrollado varias de las nombradas aproximaciones: la síntesis de 
novedosos portadores poliméricos basados en el ácido poli-L-
glutámico, caracterizado por su biodegradabilidad, multifuncionalidad 
y versatilidad; su utilización como base para obtener conjugados 
polímero-fármaco focalizados en el tratamiento de desordenes 
neurodegenerativos, diana novedosa y actualmente en crecimiento 
exponencial dentro del campo de PT y el uso de terapia de 
combinación como herramienta  para una posible sinergia en el 
tratamiento.  
La propuesta de la diana terapéutica elegida responde al reto 
actual del aumento de la expectativa de vida en nuestra sociedad, el 
cual ha traído consigo un incremento de las enfermedades crónicas 
neurodegenerativas en la población de edad avanzada. Estas 
enfermedades pueden subdividirse dependiendo del sistema nervioso 
al que afecten, el periférico (SNP) o el central (SNC). En este último la 
dificultad se acentúa debido a que su tratamiento requiere atravesar 
una barrera biológica protectora con elevada restricción al paso de 
fármacos al cerebro: la barrera hematoencefálica (BHE) [2, 14-16]. La 
estrategia propuesta en esta tesis doctoral ha sido la utilización de PT 
como plataforma tecnológica para el desarrollo de conjugados 
poliméricos multivalentes con aplicaciones para el tratamiento de la 
neurodegeneración, tanto a nivel periférico como central, siendo 
capaces de atravesar la BHE y liberar el(los) fármaco(s) conjugado(s) 
en el cerebro.  Estos sistemas vencerían las limitaciones mostradas por 
agentes terapéuticos de bajo peso molecular tales como la 
internalización celular y aumentarían la especificidad del tratamiento.  
De entre las diversas metodologías existentes para cruzar la BHE, en el 
presente trabajo se seleccionó el transporte activo. Esta estrategia 
propone el uso de vehículos transportadores (sistemas de transporte 
de fármacos, DDS) para los nutrientes naturales, desarrollando 
complejos moleculares como “caballos de Troya”. Para ello, se utilizan 
residuos dirigentes que sean capaces de ser reconocidos por un 
transportador activo localizado en el área apical de la barrera 
hematoencefálica, como por ejemplo el receptor de transferrina (TfR).  
En un primer lugar y como ejemplo de enfermedad 
neurodegenerativa, el trabajo se ha centrado en la obtención y estudio 
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de conjugados polímero-fármaco para el tratamiento de 
polineuropatías familiares amiloideas (PAF) que principalmente 
afectan a SNP, pero que parcialmente dañan al SNC, por tanto, 
también se han desarrollado  sistemas poliméricos dirigidos para 
atravesar la BHE. Una vez este reto superado, el tratamiento diseñado 
para FAP podría explorarse en otro tipo de enfermedades amiloideas 
como la conocida enfermedad de Alzheimer. 
Las polineuropatías amiloidóticas familiares (PAF) son 
enfermedades neurodegenerativas caracterizadas por una deposición 
sistémica extracelular de fibrillas amiloides de la proteína 
transtirretina (TTR) [17]. La PAF se presenta clínicamente con 
neuropatía periférica, sensitivo-motora y autonómica, produciendo 
una afectación cardíaca, ocular o renal, provocando la muerte 10-15 
años tras iniciarse los primeros síntomas. Aunque con resultados 
variables, el trasplante hepático es la única alternativa terapéutica 
actualmente disponible para prevenir la progresión de la enfermedad. 
Por este motivo, en el presente proyecto se han desarrollado, por 
primera vez en el campo de la nanomedicina, nanoconjugados con 
potencial terapéutico como tratamiento de este tipo de 
enfermedades. Como agentes bioactivos para la conjugación con el 
portador polimérico se han utilizado la doxiciclina [18] y una secuencia 
peptídica específica de receptores RAGE (péptido RAGE) [19]; actividad 
descubierta por la colaboradora del presente proyecto M.J. Saraiva y 
su grupo (IBMC, Portugal). 
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2. OBJETIVOS DE LA INVESTIGACIÓN  
 
El objetivo principal de la presente tesis ha sido el desarrollo de 
una familia de nanoconjugados de segunda generación para el 
tratamiento de enfermedades neurodegenerativas, creando una 
novedosa terapia más efectiva. Éste puede desglosarse en tres 
objetivos específicos: (1) la obtención de nuevos transportadores 
poliméricos basados en el ácido poli-L-glutámico (PGA): un polímero 
biodegradable, multifuncional y versátil, (2) su caracterización fisico-
química exhaustiva para una mejor comprensión de su 
comportamiento biológico y su validación como sistemas para el 
transporte de fármacos, y (3) su uso para el tratamiento de nuevas 
dianas terapéuticas como las enfermedades degenerativas, 
construyendo sistemas dirigidos capaces de atravesar la barrera 
hematoencefálica (BHE) y, por otra parte, la obtención de conjugados 
polímero-fármaco para el tratamiento de PAF.  
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3. METODOLOGÍA 
3.1 Materiales e instrumentación 
 
Todas las reacciones descritas se han llevado a cabo bajo 
atmósfera inerte (nitrógeno o argón), en caso de ser necesario. 
Todos los reactivos y disolventes utilizados eran de grado 
analítico o superior y se utilizaron sin purificación adicional (en caso de 
requerir purificaciones añadidas, se encuentran descritas en el 
correspondiente apartado). 
Cromatografía por exclusión de tamaño (size exclusion 
chromatography, SEC). Se emplearon columnas con resina 
Sephadex®G25/PD10 (ddH2O como eluyente). Para el análisis por HPLC 
se empleó un sistema de Waters (Milford, USA) compuesto por un 
muestreador automático (717), un detector fotodiodo (Z996), un 
sistema de tres bombas (515) y un detector de fluorescencia (modelo 
2475). Para el análisis de conjugados PGA-X-Doxy se utilizaron dos 
columnas en serie TSK-gel (G300 y G25000 PWXL), flujo 1mL/min y PBS 
0.1M como fase móvil en gradiente isocrático. Para la cromatografía 
en fase reversa se empleó una columna LIChroCART®, Cat.1.50943 
LiChrospher®100, RP-18 (125x4mm, 5µm) de Waters Ltd. 
(Hertfordshire, UK) en el mismo sistema, utilizando como método 
gradientes de acetonitrilo 0.1%TFA (v/v) y agua 0.1%TFA (v/v). Para los 
conjugados PEG-péptido se utilizó una columna Zorbax®, flujo 
1mL/min, PBS 0.1M pH=7.4 como fase móvil con gradiente isocrático 
15min.  
Cromatografía líquida (Fast Protein Liquid Chromatography, 
FPLC). Se utilizó un equipo AKTA PURIFIER de Amersham Biosciences el 
cual está formado por un sistema de bombas P900, un monitor pH/C-
900, un inyector (INV-907), un detector UV (UV-900) y un recolector 
de fracciones (FRAC-900). Para los conjugados del péptido RAGE se 
utilizó una columna Macrocap SP de GE Healthcare Bio-Sciences 
usando como fase móvil gradientes de NaCl 1M en ddH2O. Para los 
conjugados de transferrina se empleó una columna HiPrep Sephacryl 
S300 26/60 utilizando como fase móvil PB pH=8 en gradiente 
isocrático. 
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Espectroscopía ultravioleta-visible (UV). Los espectros de UV 
fueron realizados en un espectrofotómetro Jasco V-630 UV/Vis.  
Cromatografía de permeación en gel (GPC). Los análisis se 
realizaron en un Triple Detector Array (TDATM) de Viskotek (TDA3 302)  
complementado con un índice de refracción (RI),  detector de light 
scattering, detector de viscosidad y un detector UV modelo 2501. Las 
columnas empleadas fueron dos TSK-Gel en serie (Styragel HR3 y HR4, 
tamaño partícula 6um, 300x7.8mm). OmniSec 4.1 fue el software 
utilizado. Como fase móvil se utilizó DMF 0.1%LiBr, con el sistema 
equilibrado a 70°C. Se realizaron análisis de las muestras en GPC 
utilizando HFIP (3g/L trifluoroacetato potásico) como fase móvil, 40°C 
y columnas de sílica modificada (PFG, tamaño partícula 7µm, 
porosidad 100 & 1000 Å) en Mainz, Alemania. 
Espectroscopía de infrarrojo (FTIR). Los espectros de IR fueron 
medidos en un sistema Thermo Scientific Nicolet 380. Todas las 
muestras analizadas se encontraban disueltas en DMF. Los análisis se 
realizaron a 25°C. 
Polarimetría. La quiralidad de los polímeros desprotegidos fue 
evaluada mediante con un polarímetro Jasco P-1020, midiendo cada 
muestra por triplicado (20scans/medida) en una celda de vidrio 
cilíndrica (φ 3.5x100mm). Las muestras se prepararon en ddH2O a 10 
mg/ml y se midieron a 25°C. Los datos se analizaron con el software 
Spectra Manager. 
Resonancia magnética nuclear (RMN). Los espectros de 1H, 13C y 
DOSY fueron realizados en un sistema Bruker Advance AC-300 
(300MHz) o AV500 (500MHz). Los espectros se hicieron en disolventes 
deuterados a 300K.  
Cromatografía líquida-espectrometría de masas (LCMS).  El 
equipamiento utilizado consta de un sistema Acquity UPLC (Ultra 
Performance Light Cromatography (Waters) con un detector PDA 
acoplado a un espectrómetro de masas  Micromass ZQ Waters 400 LC 
Single quadrupole. Se utilizó una columna de fase reversa RP-18  
Kinetex (2.6µm x100mm). 
Microscopía de transmisión electrónica  (TEM). Las muestras 
fueron adsorbidas en rejillas de cobre recubiertas por una película de 
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carbón de 200 mallas. Tras someter las rejillas a un proceso de glow-
discharge, las muestras fueron depositadas y se realizó una tinción de 
contraste negativo con una disolución de acetato de uranilo al 1%. Las 
imágenes se adquirieron con un microscopio Zeiss operado a 60kV. 
Dispersión de luz dinámica (DLS).  El tamaño de partícula fue 
medido en un dispositivo Malvern Zetasizer Nano ZS equipado con un 
laser (532nm) a un ángulo de dispersión fijo de 90°. Las medidas se 
realizaron a 25°C. 
Medidas de absorbancia o fluorescencia de ensayos in vitro o 
muestras ex vivo tratadas. Las medidas se realizaron en un equipo 
Victor2 Wallac 1420 Multilabel HTS Counter Perkin Elmer (Northwolk, 
CT, EEUU) utilizando placas de 96 pocillos y las correspondientes 
longitudes de onda (emisión/excitación) propias de cada compuesto. 
Ensayos celulares. Todos los procesos relacionados con el cultivo 
celular se llevaron a cabo en una cabina de flujo laminar recirculante 
vertical con seguridad biológica clase II (Telstar). En todo momento se 
utilizó material estéril. 
Microscopía confocal de fluorescencia. Los estudios de 
internalización celular fueron hechos a través del Servicio de 
Microscopía Confocal del CIPF (Valencia). Las imágenes fueron 
adquiridas con un microscopio (invertido) láser confocal Leica, modelo 
TCS SP2 AOBS (Leica Microsystems Heidelberg GMBH, Mannheim, 
Alemania) usando un objetivo de inmersión de 63X Plan-Apochromat-
Lambda Blue 1.4 N.A. La longitud de onda (λ) usada para excitar el 
fluorocromo fue: 488nm para el Oregon Green (OG), utilizando para 
ello un láser de argón. Las aperturas de los canales para la detección 
de la emisión del OG fueron: de 503 a 604nm. Las imágenes fueron 
tomadas bidimensionalmente y en pseudo color (255 niveles de color), 
con una resolución de 1024x1024 pixeles. Todas las imágenes fueron 
adquiridas bajo las mismas condiciones y los análisis de distribución de 
fluorescencia fueron hechos mediante el software de Leica “Leica Lite” 
versión 2.61. 
Ensayos de imagen óptica in vivo. Para los estudios de 
biodistribución por fluorescencia se utilizó la plataforma 
IVIS®Spectrum equipado con el software Living Image®3.2 (Caliper Life 
[APPENDIX I.] 
[531] 
Sicences, Hopkinton, MA). 
Ensayos mediante imagen por resonancia magnética (MRI). Los 
experimentos de biodistribución por MRI se realizaron  en un 
espectrómetro horizontal Bruker Pharmascan (Bruker medical Bmbh, 
Ettlingen, Alemania) utilizando un imán superconductor de 7.0T, 
equipado con un resonador de volumen selectivo para 1H de 38mm y 
un inserto de gradientes Bruker de 90mm de diámetro. Los estudios 
fueron adquiridos en una consola Hewlett-Packard mediante el 
programa Paravision (Bruker medical Gmbh) operando sobre una 
plataforma Linux. El estudio fue realizado en el Instituto de 
Investigaciones Biomédicas “Alberto Sols” (CSIC/UAM), Madrid. 
Ensayos por tomografía de emisión de positrones (PET). Para el 
estudio de biodistribución mediante PET, se utilizó un aparato Argus 
PET/CT (SEDECAL, Madrid) para la monitorización in vivo y se 
cuantificó la radiactividad ex vivo en un contador de centelleo gamma 
Cobra II auto-gamma. Los ensayos se realizaron en la unidad de 
Aplicaciones Biomédicas y Farmacocinéticas del CIEMAT, Madrid.  
Dispersión de neutrones de ángulo pequeño (SANS). Los 
experimentos de SANS se llevaron a cabo en un instrumento D11 en el 
Institute Laue-Langevin (Grenoble, Francia) para determinar el tamaño 
y forma de los conjugados PGA-Doxy.  Las muestras en disolución 
fueron preparadas con una concentración de conjugado de 10mg/mL 
en PBS deuterado 0.1M y se colocaron en células de cuarzo de 2mm 
de camino óptico, manteniendo una temperatura de 37 °C ( 0.2).  
Estas condiciones permiten el estudio de los conjugados al pH, 
temperatura y fuerza iónica que experimentan los conjugados en los 
experimentos in vivo. El modelo FISH se utilizó para el análisis de los 
datos [20] .   
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3.2 Métodos más relevantes  
3.2.1 Polimerización por apertura de anillo de N-α-carboxianhidridos.  
Síntesis del monómero NCA-L-Glu (ɤ-bencil-L-glutamato N-
Carboxianhidrido) 
H-L-Glu(OBzl)-OH (71.7mmol, 1eq, 237.26g/mol) se añadió en 
un matraz de 500mL de dos bocas equipado con una columna de 
reflujo y un embudo de adición. El sistema fue purgado con nitrógeno. 
Después se añadió THF anhidro (recién destilado) (150mL) y el sistema 
se puso bajo agitación. A continuación, se adicionó gota a gota 
difosgeno (0.043mmol, 0.6eq, 1.6525g/cm3, 197.83g/mol) diluido en 
THF anh. (10mL) mediante el embudo. La mezcla se dejó agitando 
durante 2h a 50oC bajo flujo de nitrógeno. Después, la mezcla fue 
burbujeada con nitrógeno durante 2h para eliminar el HCl, colocando 
la salida del gas en una solución de sosa 1M. Luego el disolvente fue 
evaporado en un rotavapor hasta ¼ del volumen inicial. Se añadió 
etilacetato (16mL) y la mezcla se precipitó sobre hexano frío (500mL). 
El precipitado se aisló por filtración a vació y se lavó con hexano. A 
continuación, el producto fue recristalizado en tolueno anh. (60mL) y 
THF anh (30mL), añadiendo hexano gota a gota hasta inducir la 
cristalización. El matraz se dejó bajo atmósfera inerte a -20oC durante 
16h. Los cristales blancos se filtraron a vacío y se lavaron con hexano 
frío. El producto se secó a vacío. La recristalización fue realizada por 
triplicado. La identidad del producto se confirmó por RMN y punto de 
fusión (p.f.). Nota. La síntesis fue escalada hasta 34g de material inicial. 
 
Síntesis de los iniciadores BF4 
nBuBF4: Butilamina (2.7mmol, 73.14g/mol) se disolvió en 
dietileter (1mL), y se adicionó gota a gota el complejo HBF4.Et2O 
(2.7mmol, 1.18g/cm3, 161.93g/mol), dando lugar a la formación de 
una sal sólida blanca. El producto se secó a vació y se recristalizó en 
etilacetato.  
Npt-BF4: Neopentilamina (36.74mmol, 0.745g/cm
3, 87.16g/mol) 
fue adicionada gota a gota sobre 5mL del complejo HBF4·Et2O 
(34.5mmol, 1.18g/cm3, 161.93g/mol), bajo agitación moderada, 
resultando en la formación de un sólido blanco. Tras secar el sólido a 
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vacío, se recristalizó por duplicado en etilacetato, lavando el sólido 
obtenido con hexano frío. El producto final se secó a vacío. 
mPEG-BF4: En un vial de 5mL, MeO-PEG(2000)-amine (0.3mmol, 
1910g/mol) fue disuelto en THF (3mL) bajo agitación, y HBF4·Et2O 
(0.3mmol, 1.18g/cm3, 161.93g/mol) se añadió a la disolución gota a 
gota formando un sólido de color amarillo pálido. El disolvente se 
evaporó  a vacío y el residuo se lavó por triplicado con hexano (hasta 
obtener un pH no acido). El sólido obtenido se secó a vacío.  
 
Polimerización de N-carboxianhididridos. Síntesis de poli-γ-bencil-L-
glutamato (PBLG) 
Todo el material utilizado para la polimerización fue limpiado de 
forma exhaustiva antes de ser utilizado. Primero, el material se colocó 
en DMF y se aclaró con acetona, a continuación en H2O2 y finalmente 
aclarado con ddH2O. Después, el material se secó durante 24h a 80°C. 
Todos los disolventes utilizados fueron destilados previamente y 
secados sobre tamiz molecular en atmósfera inerte (Ar). Los 
iniciadores se secaron a vacío previo uso y el monómero se sintetizó y 
recristalizó para usarlo de forma inmediata. 
1g de monómero (y-bencil-L-glutamato N-Carboxianhidrido 
(3.8mmol, 264g/mol) se colocó en un tubo Schlenk que se purgó con 
ciclos de vacío y argón. Bajo flujo de argón, DMF anhidro se añadió al 
tubo (concentración: 0.1g/mL). Una vez disuelto bajo agitación, el 
iniciador se añadió a la reacción. La reacción se dejó bajo agitación y 
atmósfera inerte, y se monitorizó por GPC y espectroscopia infrarroja. 
Cuando se detuvo la reacción, la solución se precipitó en dietileter frío 
(50mL). Tras centrifugar la mezcla (2600rpm, 4°C, 10min), se eliminó el 
sobrenadante y el sólido blanco se suspendió en ddH2O y se liofilizó. El 
producto se analizó por GPC (DMF, 0.1%LiBr / HFIP) y por RMN-1H. 
 Desprotección de PBLG 
En medio ácido 
En un matraz de fondo redondo, 100mg de PBLG se disolvieron 
en 3mL de TFA (el volumen de TFA debe ser suficiente para disolver el 
polímero y que no precipite tras la adición de HBr). Después, se 
añadieron gota a gota 2eq de HBr (48%v/v, 1.49g/cm3, 81g/mol) por 
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grupo ácido carboxílico. Tras 5h en agitación, la solución se precipitó 
en dietileter frío obteniendo un sólido blanco que se recuperó por 
filtración a vacío. La mezcla se centrifugó (2600rpm, 4°C, 10min); el 
sólido blanco obtenido se lavó por triplicado con dietileter y se secó a 
vacío. A continuación, se purificó el producto por precipitación ácido-
base (NaHCO3/HCl 6M). Para obtener su forma sal, tras la última 
adición de NaHCO3 se realizó una diálisis o ultrafiltración. Una vez 
desalada la disolución, se liofilizó obteniendo el producto final. Nota: 
para la desprotección a mayor escala (>600mg), se necesitaron 16h 
para una desprotección completa. 
 
En medio básico (única opción en caso de DB, TB) 
Npt-PBLGn, nBu-PBLGn: En un matraz de fondo redondo se 
disolvió el x-PBLGn (5.1μmol, 9761g/mol, n=45 GA unidades) en THF 
(16mL) a temperatura ambiente. Luego, la solución se colocó a 4°C y 
se mantuvo bajo agitación. En un vial, se disolvieron 1.5eqde NaOH 
por grupo carboxilo (7.7μmol, 40g/mol) en 2mL de ddH2O y se 
añadieron gota a gota a la disolución principal. La reacción se dejó bajo 
agitación constante durante 16h. Después,  el THF se evaporó a vacío y 
el residuo se diluyó en ddH2O para su purificación por ultrafiltración 
(Vivaspin®, 3000Da). La parte superior del tubo se liofilizó y el 
producto sólido blanco obtenido se caracterizó por RMN para 
comprobar la desprotección. 
PEG-PGAn: protocolo idéntico al anterior exceptuando el uso de 
2eq de NaOH por grupo carboxilo. 
 
3.2.2 Marcaje de los portadores poliméricos con sondas 
fluorescentes. 
 
Oregon Green (OG) 
 
PEG-PGAn-PEG (TB). En un matraz de fondo redondo se 
disolvieron 14.4mg de TB200 (0.08mmol uds. GA, 1eq, MW ud. 
GA=102.4g/mol, 56.63%COOH) en 1mL de DMF anh. bajo flujo de N2. 
Luego, se adicionó DIC (0.24mmol, 3eq, 0.806g/cm3, 126.13g/mol) y se 
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dejó la reacción agitando 5min. A continuación, se añadió 
directamente HOBt (0.24mmol, 3eq, 135.1 g/mol). 10min después, se 
añadió al matraz de reacción  OG-cadaverine (1.6·10-3mmol, 2%mol, 
496.47g/mol). El pH del medio se ajustó a 8 con DIEA. La mezcla se 
dejó en agitación durante 24h protegida de la luz en atmósfera inerte. 
Se evaporó el disolvente a vacío y el residuo obtenido se disolvió en la 
mínima cantidad de NaHCO3 1M y se purificó a través de una columna 
PD-10 SephadexTM. La carga de OG se calculó mediante espectroscopia 
de fluorescencia midiendo la señal de cada fracción recogida de la 
columna. Las fracciones donde se encontró el producto fueron 
juntadas y liofilizadas. 
 
Cyane5.5 (Cy5.5) 
 
PEG-PGAn (DB). En un matraz de fondo redondo se disolvieron 
100mg de DB200 (PGA100–PEG-SS-4TP, 0.72mmol, 1eq, MW ud. 
GA(forma sal sódica)=160.5g/mol) en 8mL de ddH2O. Para un marcaje 
de 2%mol, se procedió a disolver en un vial aparte DMTMM·Cl- 
(0.0217mmol, 0.03eq, 276.7g/mol) en 1mL de ddH2O que se adicionó 
al matraz de reacción. Tras 10 min en agitación, Cy5.5-NH2 
(0.0144mmol, 0.02eq, 589.25g/mol) previamente disuelto en 7mL de 
ddH2O se añadió a la reacción. El pH se ajustó a 8 (NaHCO3 1M). La 
reacción se monitorizó por TLC (MeOH). Tras 40h a temperatura 
ambiente, la reacción se liofilizó y el sólido azul obtenido se redisolvió 
en la mínima cantidad de ddH2O y se purificó con una columna PD10 
utilizando como eluyente ddH2O. Las fracciones recolectadas se 
analizaron en un fluorímetro para calcular el porcentaje de marcaje. 
Las fracciones donde se encontró el producto se juntaron y liofilizaron. 
En este caso, la estabilidad del grupo 4TP se comprobó tras la 
obtención del producto final (test de absorbancia a 343nm). 
 
DOTA / 68GA 
 
PGAn: Para un porcentaje teórico de 10%mol: PGA100 (2.32mmol, 
1eq, MW ud. GA=129g/mol) se colocó en un matraz de fondo redondo 
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y el sistema fue purgado bajo flujo constante de N2. Tras su disolución 
en 20mL de DMF anh, se adicionaron 1.5eq de DIC (0.35mmol, 
0.836g/cm3, 126.20g/mol). 5minutos después, se añadieron 1.5eq de 
HOBt (0.35mmol, 135.10g/mol). Tras 10 minutos, el derivado DOTA-
NH2 (tert-butil 2,2´,2´´-(10-(2-(2aminoetilamino)-2oxoetil)-1,4,7-
tetrazaciclododecano-1,4,7-triil)triacetato, 0.23mmol, 0.1eq, 
614.82/mol) se disolvió en DMF anh. y se añadió a la reacción 
principal. El pH se ajustó a 8 con DIEA. Tras 48h en agitación a 
temperatura ambiente, la disolución se concentró a vacío y se 
procedió a la purificación del residuo mediante su precipitación en un 
exceso de acetona fría. El precipitado se recolectó tras centrifugar la 
mezcla (2600rpm, 4°C, 10min) y se secó a vacío. El porcentaje 
conjugado de DOTA se calculó tras el análisis del producto por RMN-1H 
(D2O). 
La desprotección de los grupos t-butilo del DOTA se llevó a cabo 
en una mezcla TFA/H2O/TIS (95:2.5:2.5 (v/v)), dejando la reacción bajo 
agitación durante 3h a temperatura ambiente. A continuación, se 
precipitó sobre un exceso de dietileter frío. El sólido obtenido se 
recuperó tras centrifugar la mezcla, se lavó y se secó a vacío. El 
porcentaje de desprotección se evaluó mediante análisis por RMN-1H 
(D2O). 
 
3.2.3 Etiquetado de los portadores poliméricos con ligandos 
directores. 
Transferrina 
 
Tiolación de la transferrina (Tftio) 
 
En un matraz de fondo redondo, holo-transferrina humana 
(0.58mmol, 1eq, 78047g/mol) se disolvió a una concentración de 
10mg/mL en PB pH=9. La disolución se incubó con un exceso molar de 
76.2 de 2-iminotiolano (76.2molar exceso, 44mmol, 137.63g/mol) 
durante 1.5h en constante agitación y protegida de la luz. La 
purificación de la proteína se llevó a cabo con una columna Sephadex 
G25 utilizando PB pH=8 como eluyente. Cada fracción fue analizada 
por Nanodrop® (λmax=220, 280nm, Ɛ=82.74 mM
-1 cm-1) y por el ensayo 
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Bradford (apéndice III). Las fracciones donde se detectó el producto se 
unieron y se analizó la concentración final de proteína por Nanodrop®. 
La cantidad de grupos –SH introducida se calculó tras el análisis por 
MS MALDI TOF. La proteína fue utilizada de forma inmediata para su 
conjugación. 
 
Conjugación de la Tftio 
 
En un matraz de fondo redondo, DB100-Cy5.5 (1.63%mol Cy5.5, 
8.4eq) se disolvió en 2mL de ddH2O y se adicionó 1eq de Tftio (en 
disolución). La reacción se purgó bajo flujo de nitrógeno y se dejó en 
agitación constante 24h a temperatura ambiente y protegida de la luz. 
Después, se dejó 24h más a 4°C. Se tomaron alícuotas (20μL) para 
monitorizar la conjugación por SDS-PAGE (apéndice III). Cuando la 
reacción finalizó, el volumen fue reducido por ultrafiltración (Vivaspin® 
MWCO=2000Da) y purificado por FPLC. De las fracciones recolectadas 
se analizó su absorbancia por Nanodrop®  para detectar la proteína 
conjugada y su fluorescencia (presencia de la sonda Cy5.5) mediante 
fluorimetría.  
 
Angiopep-2 
 
Modificación post-polimerización para introducir grupos sulfidrilo en el 
bloque polipeptídico. Espaciador entre el polímero y el ligando. 
 
Para un 10%mol teórico: en un matraz de fondo redondo, 
PGA100-DOTAtBu (1.06mmol, 1eq, 10%mol DOTA, MW 
ud.=188.7g/mol) se disolvió en 6mL de DMF anh. bajo flujo de N2. 
Mediante un activación mediada por DIC se introdujo el grupo 3-
aminopropano-1-tiol activado con el grupo 4TP: se adicionó DIC 
(0.159mmol, 0.075eq, 0.815g/cm3, 126g/mol) a la disolución y 5 
minutos después, HOBt (0.159mmol, 0.075eq, 135.13g/mol). Tras 
10minutos de reacción, se añadió 3-(piridin-4-ildisulfanil)propan-1-
amino (0.106mmol, 0.1eq, 1.012g/cm3, 186.03g/mol)  a la mezcla. El 
pH se ajustó a 8 con DIEA y la reacción se dejó bajo agitación a 
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temperatura ambiente durante 48h en atmósfera inerte. La 
purificación se realizó por precipitación en acetona fría. El sólido 
obtenido se recuperó tras centrifugar y desechar el sobrenadante. El 
sólido se secó a vacío y se caracterizó por RMN (D2O). Se procedió a la 
desprotección del DOTA. 
 
Conjugación de Angiopep-2 a la plataforma polimérica 
 
Para la conjugación de Angiopep-2, se emplearon los mismos 
equivalentes de péptido que de espaciador introducido. Ej. 45 mg de 
PGA-DOTA11%-Cys4TP6% (0.225mmol, 1eq, MW ud.=200.41g/mol) se 
disolvieron en tampón acetato de amonio 1501mM pH=5 (4mL). A su 
vez, el péptido (0.011mmol, 0.05eq, 2300g/mol) se disolvió en 3mL de 
tampón HEPES 10mM pH=7.4. Las dos soluciones se mezclaron (pH 
final =6) y se dejaron 16h bajo agitación. A continuación, la mezcla se 
purificó a través de una columna PD10. Las fracciones se analizaron 
por Nanodrop® y RMN (D2O). La cuantificación del péptido conjugado 
se realizó por análisis de aminoácidos.  
 
Péptido cíclico (cPEP) 
 
Modificación post-polimerización para introducir grupos amino en el 
bloque polipeptídico. Espaciador entre el polímero y el ligando. 
 
Para un 5%mol teórico: en un matraz de fondo redondo, PGA-
DOTAtBu (0.53mmol, 1eq, 10%mol DOTA, MW ud.=188.7g/mol)  se 
disolvió en 3mL de DMF anh. bajo flujo de N2. Una vez disuelto, se 
añadió DIC (0.0397mmol, 0.075eq, 0.815g/cm3, 126g/mol) y tras 5 
minutos HOBt (0.0397mmol, 0.075eq, 135.13g/mol). 10min después, 
se adicionó N-Boc-etilamina (0.0265mmol, 0.05eq, 1.012g/cm3, 
160.21g/mol) a la reacción principal. El pH se ajustó a 8 con DIEA. La 
reacción se dejó bajo agitación constante y atmósfera inerte durante 
48h. La purificación se realizó por precipitación de la mezcla en 
acetona fría. Tras recuperar el precipitado por centrifugación, se secó 
a alto vacío y se caracterizó por RMN D2O). A continuación se procedió 
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a eliminar el grupo protector N-Boc de la amina introducida. Para ello, 
el producto (0.43mmol, MW ud.=161.69g/mol) se disolvió en una 
mezcla CH2Cl2:TFA (6:4, v/v) y se dejó bajo agitación constante durante 
15 a temperatura ambiente. La solución se precipitó en dietileter  frío. 
El sólido se recuperó, se lavó y se secó a vacío. La desprotección se 
comprobó por RMN.  
 
Conjugación del cPEP a la plataforma polimérica 
 
Tras activar con N-hidroxisuccinimida el grupo carboxilo del 
péptido, se procedió a la conjugación de éste utilizando los mismos 
equivalentes que del espaciador introducido en el bloque 
polipeptídico. Ej. 22.25mg de PGA-DOTA2%-etilendiamina9% 
(0.1398mmol, 1eq, MW ud.=160.94g/mol) se disolvieron en PBS 
pH=7.4 (4mL).  Después, se añadieron 13mg de cPEP-NHS 
(0.0126mmol, 0.09eq, 1033g/mol). La reacción se dejó 5h bajo 
agitación. A continuación, el producto se purificó por columna PD10 
(ddH2O) y las fracciones se analizaron por RMN (D2O). La cuantificación 
del péptido conjugado se realizó por análisis de aminoácidos. 
3.2.4 Síntesis, caracterización y evaluación de conjugados polímero-
fármaco para el tratamiento de PAF: 
 
3.2.4.1 PGA-X-Doxy 
 
Síntesis de los conjugados PGA-X-Doxy 
 
Proceso de derivatización de la doxiciclina (doxy-NH2) 
Doxicilina hidrocloruro (0.5000g, 512.94g/mol) fue añadida 
lentamente a una solución de H2SO4 conc. (1.75mL). Tras finalizar la 
liberación de gas, la solución fue precipitada en dietileter frío (100mL). 
El producto se recogió por filtración, se lavó con éter y se secó bajo 
flujo de N2. El producto (542.12g/mol) se redisolvió en H2SO4 (5 mL), se 
enfrió a 0° C y se añadió NaNO3 (1.56eq, 101 mg, 84.99g/mol) durante 
10 min mientras la reacción se agitaba. Tras 3 horas a 0 ° C, la reacción 
se precipitó directamente en dietileter  y  la mezcla se filtró a vacío. El 
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precipitado se lavó con éter y se secó al aire, obteniendo un polvo 
naranja que se usó sin más purificación. El producto se analizó por 
RMN-1H (MeOD). La nitración se puede producir en dos posiciones 
diferentes: orto-(C9) y para-(C7) respecto al grupo hidroxilo. C9 es 
preferente. El crudo (0.3634g) se disolvió en MeOH (5mL) y  se añadió 
un 10% de Pd/C (25 mg).  El matraz se purgó con H2 y se dejó 
conectado a un globo de H2. La reacción se dejó bajo agitación durante 
2h. Después filtrar la mezcla a través de celite, la solución se diluyó 
con 7.5mL MeOH y se precipitó en éter dietílico previamente enfriado. 
Tras centrifugar (8000rpm, 4 °C, 5min), el éter se decantó y el sólido 
naranja se secó bajo flujo de N2 y se analizó por RMN (MeOD) y MS 
MALDI TOF. 
 
Síntesis de los conjugados PGA-CONH-Doxy. Acoplamiento vía 
DMTMM. 
 
PGA en forma de sal sódica se colocó en un matraz de fondo 
redondo y se disolvió en ddH2O. Para un 30%mol de activación de 
grupos carboxilo (15%mol de fármaco): en viales separados, doxy-NH2 
(0.6 eq, 557.53g/mol) y DMTMM·Cl (0.3eq, 276.77g/mol)) se 
disolvieron en  ddH2O y después se añadieron al matraz del PGA. La 
reacción se dejó bajo agitación 24h a temperatura ambiente y 
protegido de la luz. Después, la mezcla de reacción se liofilizó y se 
purificó a través de una columna G25 (ddH2O). Las fracciones se 
analizaron por GPC/HPLC para identificar el producto.  
 
Caracterización físico-química 
   
La carga total de fármaco en el conjugado se realizó por 
espectroscopia UV (273nm, H2O) teniendo como referencia una curva 
de calibrado del fármaco libre en las mismas condiciones. La 
determinación del contenido de fármaco libre en el conjugado se 
realizó mediante el análisis en LCMS. La estabilidad de los conjugados 
en condiciones hidrolíticas se llevó a cabo tras incubar los conjugados 
(concentración 6mg/mL) en medios con distinto pH (disoluciones de 
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PBS a pH=5.5 y 7.4), mimetizando las condiciones en áreas de 
inflamación y condiciones fisiológicas. Se tomaron alícuotas (100µL) a 
distintos tiempos a 37 °C durante 17 días que fueron analizadas por 
HPLC evaluando la pérdida de peso del conjugado (inyección directa) y 
la detección del fármaco liberado (previa extracción con MeOH y 
purificación en columna POROS 50R2). La estabilidad de los 
conjugados en plasma se llevó a cabo por dilución en plasma 
(concentración 6mg/mL) durante 24h a 37°C. De las alícuotas tomadas 
(100µL) se procedió  a la precipitación de proteína con la adición de 
acetonitrilo. Los sobrenadantes se analizaron por HPLC para evaluar la 
presencia de fármaco. Los pellets fueron lavados y dicho lavado 
también se analizó con el mismo protocolo. La conformación en 
solución se determinó por experimentos de SANS y DLS, disolviendo 
los conjugados en PBS deuterado 0.1M a una concentración de 
10mg/mL. 
 
Evaluación biológica  
 
Estudios de disrupción de fibrillas TTR de los conjugados in vitro 
En condiciones estériles, se prepararon disoluciones madre 
en agua de todos los compuestos a una concentración equivalente de 
fármaco (3.36mM Doxy), se filtraron antes de su uso. Como controles 
se utilizó PGA, Doxy y Doxy-NH2. Tras alicuotar las fibrillas de TTRL55P, 
se añadieron los conjugados y controles en una concentración de 6.7-
veces de exceso molar de doxy (180μM). Todas las muestras fueron 
analizadas por TEM (tinción negativa con acetato de uranilo al 1%) y 
DLS tras 3 y 6 días para monitorizar la rotura de fibrillas. 
 
Ensayos de hemólisis 
Se prepararon disoluciones de PGA-X-Doxy, dextrano 
(74000g/mol) y poli(etilenimina) (Mn~ 60000, Mw~ 750000, 50% en 
peso en H2O) con un rango de concentraciones entre 0-2mg/mL en 
PBS a pH 7.4, 6.5 y 5.5. Se sembraron (100µL) en placas estériles de 96 
pocillos.  Se extrajo sangre de ratones que se colocó en un tubo 
heparinizado en hielo. Los eritrocitos (RBC) se aislaron por 
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centrifugación (3000rpm, 10 min, 4°C). El plasma (sobrenadante) se 
descartó y los eritrocitos se lavaron tres veces con PBS. El sedimento 
(RBC) se dividió en partes iguales y se resuspendieron en disoluciones 
de PBS con los pHs descritos. De cada solución, se añadieron 100µL a 
las placas preparadas con los compuestos. Tritron X-1% w/v se usó 
como referencia del 100% de lisis y PBS como control de absorbancia. 
Las placas se incubaron 16h a 37°C, se centrifugaron  (3000rpm, 
10min). Cada sobrenadante se colocó en una nueva placa y la 
liberación de hemoglobina (Hb) se midió espectrofotométricamente 
(570nm). La liberación de Hb para cada muestra se expresó como 
porcentaje de la liberación producida respecto al Triton-X. PEI y 
dextrano representaron, respectivamente, el control positivo y el 
control negativo del ensayo. 
 
Ensayos de biodistribución 
 
Tras etiquetar el conjugado PGA-Doxy con una sonda 
fluorescente (Cy5.5) o con el complejo DOTA/Ga68, se llevaron a cabo 
estudios de biodistribución mediante imagen óptica y tomografía por 
emisión de positrones (PET), respectivamente. 
 
 Biodistribución del conjugado PGA-CONH-Doxy-Cy5.5 por imagen 
óptica 
PGA-CONH-Doxy-Cy5.5 se disolvió en suero salino (1.40mg 
conj/mL) y los animales (ratones Balb/c) fueron inyectados por vía 
intravenosa una dosis única de 100µL de la solución. Como controles, 
se emplearon ratones no inyectados. Los animales fueron 
anestesiados usando isofluorano (1 al 3%). Cinco ratones fueron 
monitorizados a la vez y la configuración de imagen se ajustó en 
función de la fluorescencia observada. La fluorescencia emitida por el 
conjugado se detectó, se digitalizó y se mostró superpuesta con una 
imagen del animal en escala de grises. La señal fluorescente se 
cuantificó como Eficiencia. A los distintos tiempos elegidos (0, 4 y 24h 
post-inyección) grupos de animales fueron sacrificados y se recolectó 
inmediatamente la sangre y los órganos  principales (hígado, 
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pulmones, bazo, riñones, corazón y cerebro). Los órganos fueron 
analizados con la misma técnica (análisis ex vivo). Los órganos fueron 
pesados, congelados y almacenados a -80 °C para cuantificar la 
fluorescencia posteriormente.  
Los órganos fueron homogenizados en tampón PBS pH=7.4 a 
una determinada concentración mediante un Ultraturrax (aprox. 1min, 
13000rpm). La suspensión fue centrifugada (4000g, 1h, 4°C). Los 
sobrenadantes se recolectaron para medir la fluorescencia 
perteneciente al conjugado acumulado en cada tejido. 
 
3.2.4.2 PEG-péptido RAGE 
 
El péptido RAGE fue derivatizado añadiendo en su 
extremo N-terminal una glicina (PEP1) o el dipéptido glicina-cisteína 
(PEP2). Todos los péptidos fueron sintetizados por medio de síntesis 
en fase sólida (SPPS) a partir de aminoácidos N-Fmoc protegidos y 
caracterizados por HPLC, MS MALDI TOF y RMN. 
 
Síntesis de los conjugados CXPX. 
 
Síntesis de C1P1 y C2P1 
NHS-PEG-NHS (0.014mmol, 1eq, 3023g/mol) se disolvió en 
DMSO anh. (4mL) en atmósfera inerte a temperatura ambiente. En un 
vial, PEP1 (0.03mmol, 2eq, 912.05g/mol) se disolvió en las mismas 
condiciones y se añadió a la solución de PEG. Después, se adicionó una 
cantidad catalítica de DMPA y el pH se ajustó a 8 con DIEA. La reacción 
se dejó agitando en atmósfera inerte durante 48h. El disolvente se 
eliminó bajo evaporación a vacío y el residuo, resuspendido en 1mL 
ddH2O, se purificó por FPLC. Los conjugados se caracterizaron por 
RMN (D2O) y MS MALDI TOF. 
 
Síntesis de C1P2 y C2P2 
4TP-SS-PEG-SS-4TP (0.052mmol, 1eq, 3400g/mol) se disolvió 
en tampón de acetato de amonio 10mM pH=7 a temperatura 
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ambiente. PEP2 (0.057mmol, 1.1eq, 1057.23g/mol) se disolvió en las 
mismas condiciones en 5mL de ddH2O y se adicionó gota a gota 
durante 20min sobre la solución de PEG. La evolución de la reacción se 
monitorizó por UV (323nm) durante 15h en atmósfera inerte. A 
continuación, la reacción se liofilizó y el residuo se redisolvió en 1mL 
ddH2O para su purificación por FPLC. Las fracciones de cada producto 
obtenido se juntaron y se desalaron mediante una columna PD10 
(ddH2O). Los conjugados caracterizaron por RMN (D2O) y MS MALDI 
TOF. 
  
Caracterización físico-química 
 
La estabilidad de los conjugados CXPX bajo las condiciones de 
los ensayos in vitro se llevaron a cabo diluyendo los conjugados 
(15mM péptido) en medio de cultivo (DMEM, 10%FBS) y realizando 
incubaciones hasta 48h a 37°C. Se tomaron alícuotas (15µL) a distintos 
tiempos que fueron evaluadas por HPLC. La estabilidad en plasma se 
evaluó como en el se ha descrito previamente analizando las alícuotas 
por espectroscopia de masas MALDI TOF. La conformación en solución 
se determinó por DLS, realizando estudios de concentración (2-
20mg/mL) en PBS 0.20M a 25°C. La afinidad de los conjugados por los 
agregados de TTR se evaluó por SPR, mediante el aparato 
BiacoreT100TM, mimetizando las condiciones de los ensayos in vitro. Se 
inmovilizó la proteína en un chip CM5 y se hicieron pasar flujos de los 
distintos conjugados y péptidos realizando estudios de cinética. 
 
Evaluación biológica 
 
Ensayo de actividad in vitro.  
Bajo condiciones estériles, los agregados de TTR L55P fueron 
disueltos en medio de cultivo (concentración 2µM). Se añadieron los 
conjugados y péptidos partiendo de sus disoluciones stock hasta 
obtener una concentración final 10µM péptido RAGE. La incubación se 
llevó a cabo durante 5h a 37°C bajo agitación constante. A 
continuación, los agregados tratados se incubaron en células (RN22) 
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durante 24 y 48h, y se evaluó la activación de caspasa-3 utilizando el 
test colorimétrico de CaspACE para ensayo en placas de 96 pocillos. El 
lisado celular obtenido también se utilizó para cuantificar la cantidad 
de proteína mediante el kit Bio-Rad, utilizando BSA como estándar. 
Con estos valores se normalizaron los datos obtenidos de la activación 
de caspasa-3. 
 
Biodistribución del conjugado PEG-péptido RAGE. 
Tras etiquetar el conjugado PEG-PEP1 con una sonda 
fluorescente (Cy5.5) se llevaron a cabo estudios de biodistribución 
mediante imagen óptica, repitiendo el protocolo descrito para PGA-
Doxy-Cy5.5. 
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4. RESULTADOS 
 
4.1 Obtención de nuevos transportadores poliméricos basados en el 
ácido poli-L-glutámico (PGA) (CAPÍTULO II) 
 
Actualmente existe la necesidad de desarrollar portadores 
biodegradables con elevado Mw para aumentar las ventajas de la 
especificidad pasiva mediada por el efecto EPR. Los poliglutamatos son 
degradables por la enzima lisosomal catepsina B y actualmente se 
encuentran en estudio para aplicaciones tan diversas como el cáncer 
[7, 21, 22], los procesos isquémicos [23, 24] o el tratamiento de sepsis 
[25]. Como referencia, el conjugado PGA-paclitaxel (OpaxioTM) se 
encuentra en fase III de ensayos clínicos [26, 27].  
 
En el presente proyecto, se han diseñado nuevos portadores 
poliméricos basados en el ácido poli-L-glutámico con estructura 
definida, peso molecular (Mw) modulable y polidispersidad reducida 
(PDI<1.2)  mediante la técnica de polimerización por apertura de anillo 
(ROP) de N-carboxi-anhídridos (NCA) [28, 29]. El proceso de síntesis 
implicó la optimización de la obtención del monómero (N-
Carboxianhidrido-y-Bencil-L-glutamato), las condiciones de 
polimerización así como el proceso de desprotección de los grupos 
bencilo de los distintos portadores. Se han obtenido y caracterizado 
homo- y co-polímeros de bloque con polietilenglicol (PEG), para su 
posterior evaluación como vehículos de transporte para la liberación 
de fármacos.  
 
Esta familia de co-polímeros de bloque anfifílicos se ha 
caracterizado mediante técnicas físico-químicas para confirmar su 
identidad y su conformación en solución; así como biofísicas para 
estudiar sus mecanismos de internalización celular en modelos in vitro 
mediante citometría de flujo y distribución celular por microscopía 
confocal; y su biodistribución in vivo mediante técnicas de imagen no 
invasiva (imagen óptica o resonancia magnética (MRI, magnetic 
resonance imaging)). 
 
Todo el proceso ha sido patentado por el laboratorio de 
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Polímeros Terapéuticos dirigido por la directora de la presente tesis 
[30]. 
 
La propuesta del uso de sales no nucleófilicas como contraiones 
de las sales de amonio utilizadas como iniciadores del proceso de 
polimerización por ROP-NCA dio lugar a un proceso de reacción 
controlado, obteniendo grados de polimerización del bloque de poli-L-
glutámico modulable (desde 10 a 800 uds.). Tras optimizar y escalar la 
síntesis del monómero, y el ajuste de parámetros como la 
temperatura, tiempo de reacción, el disolvente, la concentración y el 
ratio [monómero/iniciador], así como el uso distintos iniciadores (ej. 
PEG-NH2, neopentilamina, n-butilamina), se obtuvo una familia de 
poliglutamatos lineares definidos (homopolímero, dibloque y 
tribloque, capítulo II) con baja polidispersidad (PDI<1.2). La velocidad 
de reacción se determinó por análisis directo del medio de reacción 
comprobando la desaparición de monómero por espectroscopia 
infrarroja.  
 
Respecto a la desprotección de los grupos carboxilo de los poli-
bencilglutamatos, distintos métodos fueron testados. Como métodos 
óptimos se determinó una desprotección ácida (HBr/TFA) para 
desproteger homopolímeros y una desprotección básica (NaOH 
aq./THF) la válida para cualquier poliglutamato pero en especial 
empleada en el caso de los dibloques / tribloques. Esta desprotección 
básica evita la degradación de los bloques de PEG sin modificar la 
estereoquímica de partida del bloque polipeptídico como pudo 
comprobarse al analizar el grado de rotación de luz polarizada.  
 
La identidad de cada compuesto se determinó por GPC así como 
por RMN, la estructura secundaria (producto protegido o 
desprotegido) por dicroísmo circular confirmando la existencia de la 
hélice α. Los ensayos de viabilidad en la línea celular HUVEC determinó 
tolerabilidades por encima del 80% hasta concentraciones de 2mg/mL 
y los ensayos de citometría y microscopía confocal  de los compuestos 
marcados con una sonda fluorescente (OG) confirmaron la 
internalización por endocitosis (CAPÍTULO III, IV). 
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4.2 Síntesis de portadores poliméricos capaces de atravesar la BHE 
(CAPÍTULO III, IV) 
Una vez obtenidos los portadores poliméricos, se emplearon 
técnicas de bioconjugación para obtener sistemas capaces de cruzar la 
BHE gracias al transporte activo. Para ello, se conjugaron múltiples 
residuos dirigentes: holo-transferrina (Tf), anticuerpo monoclonal 
OX26 (mAOX26) y los péptidos Angiopep-2 [31-34] y CRTIGPCSVC 
(péptido cíclico, cPEP) [35, 36], a los homo- y co-polímeros de bloque 
sintetizados para comparar su biodistribución. En todos los casos se 
llevó a cabo la unión de estas biomoléculas, previamente derivatizadas 
y/o activadas con los grupos funcionales deseados, mediante puntos 
de unión telequélicos de la matriz polimérica, por ejemplo los puentes 
disulfuro. El número de residuos dirigentes conjugados al portador fue 
determinado por espectrometría de masas MALDI-TOF, 1H-RMN o 
análisis de aminoácidos. 
Dado que los estudios in vivo son más adecuados para evaluar la 
capacidad de transporte activo a través de la BHE, se llevó  a cabo el 
etiquetado de los compuestos para estudios de biodistribución 
mediante técnicas de imagen no invasiva: (i) marcaje con sondas 
fluorescentes o en NIR (cyane5.5) para su monitorización a través de la 
plataforma IVIS®spectrum, (ii) marcaje con Gd para resonancia 
magnética de imagen (MRI) donde previamente el portador se 
derivatizó con el complejante DTPA y (iii) marcaje con Ga68 para 
análisis por tomografía por emisión de positrones (PET) previa 
derivatización del vehículo con DOTA. El porcentaje de sonda 
conjugado fue determinado con la técnica requerida (espectrómetro 
de fluorescencia, RMN-1H). 
Los ensayos de biodistribución fueron realizados en ratones 
Balb/c y en todos los casos los compuestos fueron inyectados vía 
intravenosa previa disolución en suero biológico a la concentración 
requerida para observar el nivel de señal necesario. Una vez realizada 
la monitorización in vivo, se procedió al sacrificio del animal para 
evaluar y cuantificar el porcentaje de compuesto existente en cada 
órgano así como en sangre. 
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Los poliglutamatos (homo, dibloque y tribloque) demostraron 
ser biocompatibles y no acumularse específicamente en ningún 
órgano, siendo eliminados vía renal. De los sistemas testados (FIGURE 
V.  1), se determinó que la técnica por detección de fluorescencia no 
aportaba la precisión requerida para determinar el contenido de 
vehículo dirigido que llegaba al cerebro, así como la transferrina y el 
anticuerpo monoclonal OX26 no fueron ligandos satisfactorios para tal 
fin. Los conjugados de los péptidos Angiopep-2 y CRTIGPCSVC fueron 
obtenidos mediante rutas de síntesis con menor problemática que los 
anteriores ligandos. Su evaluación in vivo no mostró acumulación 
significativa en el cerebro. Posiblemente los portadores fueron 
bombeados fuera del cerebro o los ligandos no estuvieran expuestos 
lo suficiente para su reconocimiento por los receptores de la BHE 
debido a la conformación en solución del sistema. Actualmente, 
nuevos sistemas poliméricos, utilizando PEG como punto de unión 
para los ligandos o poliglutamatos con otras arquitecturas (ej. estrella) 
están siendo evaluados con estos mismos ligandos para cruzar la BHE. 
 
4.3 Obtención de conjugados polímero-fármaco para el tratamiento 
de PAF (CAPÍTULO V) 
De forma paralela al desarrollo de los portadores poliméricos, 
tanto PGA como PEG han sido utilizados como polímeros de partida 
para la conjugación de agentes bioactivos para el tratamiento de PAF. 
El diseño racional del enlace polímero-fármaco se planteó como 
crucial para proporcionar los conjugados la estabilidad necesaria en 
circulación y la llegada a su diana terapéutica, así como mantener o 
incrementar la actividad natural de los compuestos bioactivos. 
En el caso de la doxiciclina (doxy), se estudió la reactividad de 
los distintos grupos funcionales de la molécula para realizar su anclaje 
al polímero elegido, PGA, mediante un enlace éster (enlace lábil a pH). 
Se optimizaron las condiciones de reacción y se obtuvieron conjugados 
con distinta carga de fármaco conjugado (ωt%). A su vez, la doxy fue 
derivatizada introduciendo un grupo NH2- en su anillo aromático para 
conjugarla mediante enlace amida al polímero y nuevamente se 
optimizó la reacción así como se obtuvieron conjugados con diferentes 
ωt%. Todos los conjugados fueron caracterizados (carga total de 
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fármaco, conformación en solución, ensayos de estabilidad en plasma 
y en condiciones hidrolíticas, estudios de cinética de liberación de 
fármaco) y su actividad in vitro como inhibidores de formación de 
fibrillas fue testada, eligiendo el candidato óptimo para los ensayos 
biológicos. Dicho conjugado fue etiquetado con una sonda 
fluorescente (Cy5.5) y con el complejo DOTA /Ga para estudiar su 
biodistribución in vivo así como sometido a ensayos preliminares de 
actividad en un modelo animal joven de PAF. 
Respecto al péptido RAGE, se realizaron derivatizaciones de la 
secuencia inicial para obtener dos tipos de enlace al vehículo 
polimérico portador elegido, PEG: biodegradable (puente disulfuro) y 
no biodegradable (amida). La identidad de cada conjugado se confirmó 
por diversas técnicas físico-químicas así como se corroboró su 
capacidad para reconocer a la proteína por ensayos de unión, su 
conformación en solución y estabilidad en plasma. Se llevaron a cabo 
ensayos de actividad in vitro seleccionando el mejor candidato para los 
ensayos in vivo, del cual se realizaron estudios de biodistribución por 
marcaje fluorescente (Cy5.5) y ensayos preliminares de actividad en un 
modelo animal joven de PAF. 
PGA-DOXY 
La familia de conjugados PGA-x-Doxy demostró su estabilidad en 
plasma así como bajo las condiciones empleadas para la disrupción de 
fibrillas. Asimismo, la actividad in vitro observada para los conjugados 
fue mayor que para la doxiciclina libre a la misma concentración de 
fármaco. El conjugado con mejor perfil de actividad fue PGA-CONH-
Doxy (FIGURA 3.), con una carga total de fármaco de 15-20ωt%, el cual 
resultó no ser hemolítico y poseer un tamaño de partícula de ≈ 12 nm 
(determinado por SANS, colaboración con Dr. Paul Cardiff Univ.) Tras 
su etiquetado con Cy5.5, la biodistribución del conjugado mostró una 
eliminación vía renal y no se acumuló de forma específica en ningún 
órgano. El mismo estudio mediante PET confirmó los resultados ya 
obtenidos, completando el estudio al determinar el t1/2 del 
conjugado=0.98h . 
Los conjugados PEG-péptido RAGE sintetizados (FIGURE V.  2.) 
incrementaron la estabilidad en plasma del péptido mejorando su 
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solubilidad. Exceptuando C2P2, el resto de conjugados mantuvo la 
capacidad del péptido para unirse a los agregados, así como mostraron 
una conformación en disolución estable y reproducible. En la 
evaluación de actividad in vitro, C2P1 (enlace amida entre el péptido y 
el PEG, proporción pep:PEG 2:1) fue seleccionado por su perfil para el 
posterior análisis in vivo. Tras su marcaje fluorescente, los estudios de 
biodistribución del péptido peguilado mostraron una eliminación renal 
del conjugado sin acumularse de manera específica en ningún órgano. 
La evaluación preliminar de actividad in vivo mostró resultados 
prometedores al no observarse daño a nivel histológico en los órganos 
donde ocurre la deposición fibrilar/reconocimiento agregados-
receptor y apreciarse mejoras en el hígado, órgano en el que se 
sintetiza mayoritariamente la TTR. 
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5. CONCLUSION 
 
La novedad y relevancia del presente trabajo radica en haber 
logrado los siguientes objetivos: 
 
- la obtención y caracterización de una familia de 
poliglutamatos (homopolímero, dibloque, tribloque) mediante la 
optimización de los procesos de (i) polimerizacíon vía ROP-NCA a 
través de una nueva metodología (Mw elevados y pdi bajas) y (ii) 
desprotección del grupo protector bencilo (evitando subproductos de 
degradación). Esta metodología ha dado lugar a la generación de un 
Spin-Off (Polypeptide Therapeutic Solutions S.L.); 
 
- diseño y obtención de portadores poliméricos para el 
cruce de la barrera hematoencéfalica para su aplicación en 
enfermedades neurodegenerativas mediante la unión de un ligando 
director contra el receptor transferrina; 
 
- síntesis, caracterización y evaluación biológica de los 
primeros conjugados polímero-fármaco para el tratamiento de PAF. 
Estos conjugados puden considerarse como ‘Fármacos Huérfanos’ ya 
que no se dispone de tratamiento actual para esta enfermedad. 
 
En la presente tesis se han empleado gran variedad de técnicas 
interdisciplinares: síntesis química, biología celular y modelos 
animales, abarcando así una extensa variedad de metodología 
aprendida. Finalmente cabe destacar la novedad y aplicabilidad del 
área de estudio y su importancia en el campo, avalada por los premios 
conseguidos, las dos patentes presentadas (una de ellas dando lugar a 
una Spin Off)  y a los artículos en revistas internacionales que se 
esperan publicar en revistas de alto índice de impacto en los próximos 
meses. 
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APPENDIX II. TABLE OF COMPOUNDS. CHEMICAL STRUCTURES AND 
NOMENCLATURE 
CHEMICAL STRUCTURE NAME (ABB.) REF 
 
H-L-Glu(OBzl)-OH, 
Glu(Bz)NCA 
1 
 
γ-Benzyl-L-
Glutamate N-
Carboxyanhydride 
(NCA monomer) 
2 
 
Poly-γ-benzyl 
glutamate 
(nBu-PGAn, 
PBLGn) 
3 
 
Poly-L-glutamic 
acid 
(nBu-PGAn) 
4 
 
Diblock (DBn) 
(nBu-PGAn--b-
PEGp-4TP, PGAn-
b-PEGp) 
5 
 
Poly(ethylene 
glycol)-co-poly(γ-
benzyl L-
glutamate) 
(protected DBn, 
PEGm-b-PBLGn) 
6 
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Diblock (DBn) 
(PEGm-b-PGAn) 
7 
 
Triblock (TBn) 
(PEGm-b-PGAn-b-
PEGpOMe) 
8 
 
Triblock (TBn) 
(PEGm-b-PGAn-b-
PEGp-4TP) 
9 
 
Poly-γ-benzyl 
glutamate 
(neo-PGAn, 
PBLGn) 
10 
 
Poly-L-glutamic 
acid 
(neo-PGAn) 
11 
 
4-pyridyl 
disulfide-
poly(ethylene 
glycol)-carboxyl 
4TP-SS-PEG-
COOH 
12 
 
4-pyridyl 
disulfide-
poly(ethylene 
glycol)-
succinimide 
4TP-SS-PEG-NHS 
13 
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Tetrafluoroboran 
neopentylammon
ium salt 
(nBuBF4) 
14 
 
Tetrafluoroboran 
n-
Butylammonium 
salt 
(neoBF4) 
15 
 
Tetrafluoroboran 
PEGammonium 
salt 
(PEGBF4) 
16 
 
TBn-Rho (x%) 17 
 
PGAn-OG (x%) 
PGAn : R1=nBu / 
neo, R2=H 
18 
DBn-OG (x%) 
DBn : R1=nBu / 
neo, R2=PEGp-4TP 
DBn : R1=mPEGm , 
R2=PEGp-4TP 
19 
TBn-(OG)x 
TBO (x%) 
TBn : R1=mPEGm,     
R2= PEGp-4TP 
20 
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PGAn-(alkyne)x 21 
 
PGAn-Cy5.5 (x%) 
R1=nBu / neo 
22 
 
TBn- Fmoc 
diamine (x%) 
 
23 
 
TBn-diamine (x%) 24 
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TB-diamine-DTPA 
(x%) 
25 
 
TB-diamine-
DTPA/Gd (x%) 
26 
 
 
TBn-Tyramine 
(x%) 
27 
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PGAn-DOTAtBu 
(x%) 
PGAn : R1=nBu / 
neo 
 
28 
DBn-DOTAtBu 
(x%) 
DBn : R1=mPEGm 
 
 
29 
 
PGAn-DOTA (x%) 
PGAn : R1=nBu / 
neo 
 
30 
DBn-DOTA (x%) 
DBn : R1=mPEGm 
 
 
31 
 
(TBn-(OG)x)q-Tf 32 
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(TB)q-Tf 33 
 
 
DB-Cy55 34 
 
 
Tf-DB-Cy5.5 35 
 
 
 
TB-DTPA/Gd-
mAbOX26 
36 
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PGAn-
(DOTAtBu)x-
(4TP)z 
PGAn : R1=nBu / 
neo 
 
37 
DBn-(DOTAtBu)x-
(4TP)z 
DBn : R1=mPEGm 
 
38 
 
 
 
PGAn-(DOTA)x-
(4TP)z 
PGAn : R1=nBu / 
neo 
 
39 
DBn-(DOTA)x-
(4TP)z 
DBn : R1=mPEGm 
 
 
40 
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PGAn-(DOTA)x-
(SS-Cys-
Angiopep2)z 
R1=nBu / neo 
 
41 
DBn-(DOTA)x-(SS-
Cys-Angiopep2)z 
R1=mPEGm 
 
 
42 
 
 
PGAn-
(DOTAtBu)x-
(BOC-diamine)z 
PGAn : R1=nBu / 
neo 
43 
DBn-(DOTAtBu)x-
(BOC-diamine)z 
DBn : R1=mPEGm 
44 
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46  
PGAn-(DOTA)x-
(diamine)z 
PGAn : R1=nBu / 
neo 
45 
DBn-(DOTA)x-
(diamine)z 
DBn : R1=mPEGm 
 
 
46 
DBn-(DOTA)x-
(cPEP)z 
DBn : R1=mPEGm 
 
48 
 
9-amino 
Doxycycline 
DOXY-NH2 
49 
 
PGA-COO-Doxy 50 
 
PGA-CONH-Doxy 51 
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PGA-CONH-AA-
Doxy 
(R= Gly-Gly, 
R = Leu-Gly) 
52 
 
Bz-Leu-Gly-Doxy 53 
 
Leu-Gly-Doxy 54 
 
Bz-Gly-Gly-Doxy 55 
 
Gly-Gly-Doxy 56 
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RAGE peptide—Gly PEP1 57 
RAGE peptide-Gly-Cys PEP2 58 
 
Succinimide-PEG-
succinimide 
NHS-PEG-NHS 
59 
 
PEG-(PEP1)2 
C2P1 
60 
 
mPEG-PEP1 
C1P1 
61 
 
4TP-SS-PEG-SS-
4TP 
62 
 
PEG-PEP2 
C1P2 
63 
 
PEG-(PEP2)2 
C2P2 
64 
 
Doxy-PGA-DOTA 65 
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Doxy-PGA-Cy5.5. 66 
 
PEP1-PEG-Cy5.5 67 
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APPENDIX III. GENERAL METHODS AND PROTOCOLS. 
1. TECHNIQUES FOR DRUG TRACKING, DRUG LOADING 
DETERMINATION AND LINKAGE STABILITY. 
 
Polymer conjugate characterisation always entails 
development of techniques which enable drug detection in order to 
determine parameters such as total and free dug loading, kinetics of 
drug release or polymer-drug linker stability, etc. Most of the bioactive 
molecules are easily detected by their absorption in UV region or their 
fluorescent properties.  
 
Reverse phase HPLC and LCMS are the most commonly used 
techniques for the identification and quantitative determination of the 
drug in physiological fluids and in vitro media. 
 
High performance liquid chromatography, HPLC  
 
Main characteristic of chromatography is its ability to separate 
substances from each other due to their different distribution 
between a mobile and a stationary phase [1]. Among the compendium 
of techniques using this principle, high performance liquid 
chromatography (HPLC) is the most important analytical technique 
used during the various steps of drug development and 
manufacturing. Methodology bases stems from separation, 
identification and quantification  of the compounds present in a 
solution.  
A high pressure pump is required to force the mobile phase 
(liquid) through the column (stationary phase, solid) at typical flow 
rates of 0.5-2mL/min. Once sample is injected, it goes through the 
column and, depending on the stationary phase, components are 
eluted. Then, they are detected by systems e.g. UV and/or 
fluorescence measurement devices, among others (see section of 
LCMS in appendix III). Detector examines the flow of liquid form the 
column and a chromatogram with peaks corresponding to the 
different components is shown.  
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Reversed phase (RP) has been the stationary phase used 
herein. This separation mode is based on the solvophobicity of the 
analytes and their thermodynamic partitioning between the mobile 
and stationary phases. The stationary phase is typically made of 
spherical silica beads with C18 alkyl chains covalently bound to the 
surface, a hydrophobic matrix which is largely based on their polarity. 
Basically, molecules are bound to the hydrophobic matrix in an 
aqueous buffer (polar) and eluted from the matrix using a gradient of 
organic solvent (non-polar). The elution process can be either isocratic, 
i.e. performed with a constant solvent composition, or gradient based, 
i.e. the solvent polarity is increased with time. If the analyte and the 
stationary phase are similar in chemical structure, intermolecular 
forces will favour the association. They will move more slowly through 
the column. 
 
In this project, apart from the analytical HPLC for 
characterisation purposes, a preparative HPLC has been also used for 
purification of the synthesised peptides. Only difference lies on the 
column size for injection of higher amount of sample, and the collector 
device placed after the detector to recover the purified sample. 
 
Mass spectroscopy (MS) and liquid chromatography-mass 
spectroscopy (LCMS) 
 
As stated in section (a), alternatively HPLC can be also 
connected with other detectors such as a mass spectrometry (MS). 
Combination of both techniques is named LCMS, which provides high 
sensitivity and selectivity detection approach and potential 
identification of compounds in a mixture.  
 
Briefly, MS provides structural data by measuring the weight 
of individual molecules in a sample. First, molecules are transformed 
into gas phase ions  and these ionized compounds generate charged 
molecules or molecule fragments that are measured by their mass-to-
charge ratios [2]. 
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A MS instrument IS constituted by an ion source, a mass 
analyser and a detector. Vaporisation of the sample can be done by 
atmospheric pressure chemical ionisation (APCI) or electrospray 
ionization (ESI). Both are soft ionisation techniques that result in 
protonated or deprotonated molecules with low or no fragmentation. 
In this study, ESI mode was employed where sample molecules ionise 
in solution before they reach the source. On entering the evacuated 
source, they begin a desolvation process. There are two modes of 
detection: positive and negative ions. For a given compound M, the 
protonated [M+H]+ ion, sodium and potassium adducts are commonly 
observed in detection of positive ions. 
The mass analyser sorts the ions by their masses by means of 
electromagnetic fields [3]. In the LCMS utilised, a Single Quadrupole 
was used while there was a TOF (time of flight) for the MS device. 
Quadrupole mass analysers are four parallel metal rods where two of 
them have a direct current potential (U) applied while the others are 
linked to an alternating radio-frequency (rf) potential (V). The 
quadrupole acts as an m/z filter and by scanning values of U, V and rf 
the spectrum of m/z values can be passed to an ion detector. The TOF 
mass analyser is based on the time of flight of the ion through a drift 
tube. A direct relationship is observed between the m/z value and the 
time of flight. 
 
LCMS applications comprise drug development, 
pharmacokinetic studies of pharmaceuticals and many investigations 
in bioanalysis.  In this thesis, LCMS studies has been performed to 
detect free drug in the PGA-X-Doxy conjugates as well as to study if 
drug was released along the in vitro assays.  LCMS system used was 
composed by an UPLC (ultra performance light chromatography ), 
which retains the practicality and principles of HPLC while increasing 
the overall attributes of speed, sensitivity and resolution [4]. In UPLC 
the particle size in the stationary phase is decreased and consequently 
the flow rate of the mobile phase can be increased to attain faster 
separations and improve the resolution.  
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In addition, MS analysis has been carried out to identify the 
synthesised peptides and their PEGylated conjugates as well as 
monitoring their stability under different conditions. Doxy derivative 
was also characterised by this methodology. 
 
Fast protein liquid chromatography, FPLC 
 
As HPLC, FPLC is a liquid chromatography method base in the 
same principles explained (appendix III) and only it only differs in the 
use of a lower pressure (3-4MPa), although flow rates are relatively 
high (from 1 to 5mL/min) [5]. FPLC is generally applied to protein 
purification and allows purification scale up. FPLC columns design 
varies from ion exchange, gel filtration (size exclusion), hydrophobic 
interaction and affinity chromatography.   
 
In the present thesis, FPLC column characteristics had been 
extrapolated for separating polymers conjugated to protein or 
peptides from the non-conjugated polymer or the free 
protein/peptide. In the case of RAGE pep conjugates, the cation 
exchange column was used. This resin is designed for the purification 
of large biomolecules such as PEG modified proteins. PEG is neutral 
and its conjugates exhibit lower average surface charge. Furthermore, 
PEGylation changes size of the protein. Both facts, larger size and 
lower charge contribute to separate reagents and products of the 
conjugation. By increasing the ionic force in the mobile phase, PEG, 
with one or two peptide molecules attached flow out of the column at 
different retention times.    
 
Conformation in solution studies. DLS and SANS. 
 
a) Dynamic Light Scattering, DLS  
 
DLS is one form of spectroscopy, also namely Photon 
Correlation Spectroscopy (PCS). It is a useful non-invasive technique 
with well-established principles for determining size and size 
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distribution of molecules and particles in solution, typically in the 
submicron region [6].  It can be applied to a wide range of chemical 
engineering topics from simple macromolecule size measurements to 
critical phenomena and even monitoring aggregation kinetics.  
 
When light contact the particles, a speckle pattern consisted of 
areas of bright light and dark areas appear. This is explained by the 
constructive (bright patch) or destructive (dark zone) interference by 
the surrounding particles with the scattered light. If in addition, 
particles are moving in a gas or liquid phase as defined by the 
Brownian motion, the constructive and destructive phase addition of 
the scattered light will cause the bright and dark areas to grow and 
diminish the intensity, i.e. the intensity appears to fluctuate. DLS 
measures the rate of intensity fluctuation and then uses this to 
calculate the size of the particles. 
Relationship between the particle size and its velocity due to Brownian 
motion is defined in the Stokes-Einstein equation (equation 1) [7]. The 
hydrodynamic radius, Rh, is determined from the translational 
diffusion coefficient, D (in m2s-1). The radius measured in DLS is a value 
referred to how a particle diffuses within a fluid, therefore a 
“hydrodynamic” radius and it corresponds to a sphere that has the 
same translational diffusion coefficient as the particle.  D depends not 
only on particle size but also on other factors as its surface structure or 
the ionic strength of the medium. 
 
Sample preparation for DLS measurement either by filtration 
or centrifugation is a critical step to remove dust and artefacts from 
the solution. In our experiments, once conjugates were in solution 
they were filtered previous lyophilisation and then resuspended in 
known volumes of filtered solvent. Samples were measured, then 
filtered (0.02μm filters) and measured again. 
 
In this study, DLS reported the size distribution of the PEGylated 
peptides as well as the PGA-X-Doxy conjugates. In a different scenario 
(chapter V.), DLS was useful to determine size reduction of the fibrillar 
TTR once the protein was incubated with the PGA-X-Doxy conjugates. 
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b) Small angle neutron scattering, SANS 
 
SANS uses neutron scattering at small scattering angles to 
elucidate the structure in solution of compounds at length scales from 
1 to 1000Å. This non-invasive methodology does not require use of 
chemical modification such as fluorescence labelling that could 
themselves affect the solution conformation  In the subject that 
concerns us, this advanced technique helps to better understand the 
global and local structure of polymer drug conjugates in solution [8-
10], owning the capability of elucidates the influence of drug type or 
loading on the solution conformation. For the analysis, physiological 
conditions can be reproduced (temperature, pH, ionic strength). 
 
Our purpose in SANS analysis was based on the identification 
of possible differences in solution conformation of the doxy 
conjugates depending on their drug loading. 
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2. PROTOCOLS 
 
Bradford Protein Concentration Assay 
 
Background 
The Bradford protein assay is one of several simple methods 
commonly used to determine the total protein concentration of a 
sample [12] . The method is based on the proportional binding of the 
dye Coomassie to proteins. Within the linear range of the assay (~5-25 
mcg/mL), the more protein present, the more Coomassie binds. 
Furthermore, the assay is colorimetric; as the protein concentration 
increases, the colour of the test sample becomes darker. Coomassie 
absorbs at 595 nm. This dye appears to bind most readily to arginyl 
and lysyl residues of proteins (not to the free amino acids). This 
specificity can lead to variation in the response of the assay to 
different proteins, which is the main disadvantage of the method.  
The protein concentration of a test sample is determined by 
comparison to that of a series of protein standards known to 
reproducibly exhibit a linear absorbance profile in this assay. Although 
different protein standards can be used, we have chosen the most 
widely used protein as our standard - Bovine Serum Albumin (BSA).  
There is no interference from cations nor from carbohydrates such as 
sucrose. However, detergents such as sodium dodecyl sulfate and 
triton x-100 can interfere with the assay, as well as strongly alkaline 
solutions. 
 
Protocol 
Solutions needed to perfom the test were: 
- Bovine Serum Albumine (BSA) solution. Stock: 2mg/mL (To be 
prepared with PBS 0.1M). 
- Bradford solution from Bio Rad Protein Assay. Keep in dark at 
4°C.  
- PBS 0.1M 
The samples and stocks were maintained at 4°C during the 
experiment. For the calibration curve dilutions, 6 eppendorf tubes 
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were prepared and numbered as indicated in the table below. PBS 
amount required was placed in each eppendorf. Then, 100µL of the 
BSA stock was added in the tube 6.  For the tube 5, the quantity 
required (70µL) was taken from the tube number 6. For the tube 4, 
71.4µL were taken from the tube 5. For the tube 3, 50µL were taken 
from the tube4. Same protocol was followed until tube 2. 
 
Tube 
number 
Conc. BSA Vol. PBS Vol. BSA 
(mg/mL) (μL) (μL) 
1 0 100 0 
2 0.25 50 50 
3 0.5 50 50 
4 1 28.6 71.4 
5 1.4 30 70 
6 2 0 100 
The samples were vortexed for 2 or 3 seconds and centrifuged 
(10000rpm, 4°C 12 min) and supernatants were placed into new 
epperdorfs. Samples were diluted with PBS to several concentrations 
to avoid possible saturation in measurements (1:10, 1:2, 1:3,…). Final 
volume of each sample was 20µL. 
In a 96 well plate, 10µL sample or BSA were placed and then 
mixture with 200µL of the Bradford reagent. Plate was incubated at RT 
for 5min in the dark and subsequently, absorbance at 595nm using a 
UV-visible spectrophotometer was measured. Protein amount was 
determined using the calibration curve of BSA. 
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SDS-PAGE gel analysis of polymer-protein/peptide conjugates 
 
Background 
To determine either protein covalent conjugation to the 
polymeric carriers (i.e. TB-S-S-Tf, DB-S-S-Tf, etc) or complete 
purification from the non-conjugated protein, SDS-PAGE (Sodium 
Dodecyl Sulphate Polyacrilamide Gel Electrophoresis) technique was 
exploited, extensively reviewed elsewhere [13-15].  
 
SDS-PAGE is based on molecule separation through their 
differences on size, shape or isoelectric point.  The gel is a cross linked 
polymer matrix used to act as a support and promote the separation 
of the compounds.  
 
Samples under evaluation are first denatured at high 
temperature exposure and afterwards negatively charged their 
mixture with an anionic detergent such as SDS, which denatures 
secondary and non-disulfide-linked tertiary structures and applies a 
negative charge to each protein in proportion to its mass.  This loading 
buffer also contains a tracking dye, bromophenol blue, that is 
intercalated in presence of determined amino acids, allowing 
visualization of the protein. Once acrylamide gel is ready, samples 
mixed with a loading buffer are loaded in the wells of the gel and the 
transference process starts.  It is applied an electric current to the gel 
which promotes protein migration through the matrix to the anode. As 
a pattern, a molecular weight marker is also run with the samples, 
making possible to evaluate the molecular weight of our samples and 
therefore helping to protein identification. 
 
Protocol 
Briefly, acrylamide gel assembly was performed as follows. 
Percentage of acrylamide was adapted depending on the desired band 
of MW. For Tf conjugates, 6% was used. 
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Samples and standards must be loaded in the gel at the same 
protein concentration, i.e. sample (a) with a concentration of protein = 
20ug/µL. In 1.5mL eppendorfs, sample mixtures were prepared 
(sample + LB). Then, samples were heated for 7min at 95°C. 
Afterwards, samples were loaded into the gel. 
 
Reagents recipes: 
 
LAMELY BUFFER (LB5X):0.25M TRIS pH=6.8, 30% sacarose, 10%SDS, 
0.5%bromophenol blue, 0.5M DTT. In the present work, tested 
samples presented disulphide bonds between the protein and the 
polymeric carrier. Therefore denaturing conditions with a LB without 
DTT were studied in parallel to the DTT original one. 
 
RUNNING BUFFER 10X: for 1L of final volume, 144g/L glycine and 
30.27g/L TRIS base were dissolved under strong agitation. Afterwards, 
buffer was autoclaved and store for further use. 
RUNNING BUFFER 1X: 100mL of buffer 10X were diluted in 895mL of 
ddH2O and 5mL of SDS 20% were added. After well mixing, solution 
was used. 
 
GEL: Gel construction is divided in two steps due its two different 
parts. First, the resolving buffer that is on the bottom part of the gel. It 
is made of 5.79mL H2O, 2.5mL TRIS buffer pH=8.8 1.5M, 1.5mL 
AA/Bis40%,0.1mL SDS 10%, 0.1mL APS 10% and 0.01mL TEMED. 
Mixture should be performed in this order and polymerisation starts 
immediately. Secondly, the staking buffer which is composed by of 
2.42mL H2O, 1mL TRIS buffer pH=6.8 0.5M ,0.5mL AA/Bis 40%, 0.04mL 
SDS 10%, 0.04mL APS10% and 0.004mL TEMED, which follows the 
same pattern. 
 
Protocol 
Two glass plates (outer and inner) were assembled into the 
casting frame, which was fitted into the casting stand. System was 
tested to not have any leakage and the mixture of resolving buffer was 
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added, followed by 50µL of butanol. 10-15min later, polymerisation 
had occurred and butanol was removed. Then, stacking buffer was 
added and immediately, the adequate plastic comb was placed. Once 
polimerisation finished, the plastic comb was removed and the two 
glasses with the gel were placed into the clamping frame and 
electrode assembly. After that, it was introduced in the 
electrophoresis box filled with running buffer 1X. The denaturalized 
samples mixted with the loading buffer were carefully loaded into the 
wells of the gel in a known order, as well as a molecular weight 
standard. Gel was run with constant current (90 V) 10min and after 
current was increased until 150V until it was observed the desired MW 
in the standard well. 
 
Once the electrophoresis was finished, device was 
disconnected and dismounted. Gel was carefully detached from the 
glasses and buffer was removed with ddH2O washes. For gel stainining, 
coomasie blue solution was incubated for 1h with the gel under 
constant agitation. For remove excess of stain and observe only sports 
belonging to the protein, gel was then incubated with a strong destain 
solution (10% HAcOH, 30% MeOH). Gel was photographed and 
analysed with Gel DocXR software. 
 
Western Blot 
The western blot (WB) or immunoblot is an analytical 
technique used to detect specific proteins in a given sample (i.e. from 
a tissue homogenate, cellular extract, polymer-protein conjugate 
solution, etc).  By means of gel electrophoresis, first proteins are 
separated by the length of the polypeptide (denaturing conditions). In 
a second step, the proteins are then transferred from the gel to a 
membrane (typically nitrocellulose or PVDF), where they are detected 
through incubation with antibodies specific to the target protein. 
 
In the present work, WB was useful to determine BBB crossing 
of TB-Tf. Brain homogenates were analysed by this technique for 
human Tf presence in rat brains after i.v. administration of TB-Tf. 
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Methodology 
Gel electrophoresis has been already detailed in section 
IV.3.2.2.1. For WB analysis, Coomasie blue staining is not performed. 
After all sample containing was perfectly visualised by electrophoresis, 
they were transferred to a membrane. This procedure is named 
electroblotting. The transference uses the same bases than SDS-PAGE 
technique although WB applies electric current in transversal direction 
instead in vertical, promoting protein migration out of the gel to the 
membrane. After complete migration to the membrane support, 
effectiveness is checked by its staining with coomasie or Ponceaus S 
dyes. Ponceau S is more common due to its higher sensitivity and, as it 
is water soluble facilitates stain removal. Afterwards, membrane is 
blocked. This step prevents non-specific binding by placing the 
membrane in a solution of BSA or non-fat dry milk (NFDM), with 
Tween 20. This protein in solution binds the membrane in all the 
places where there were no protein transferred from the gel, helping 
to reduce the noise in the WB result and eliminating positive false 
results. 
After blocking the membrane, a incubation with a primary 
antibody is carried out. This antibody has to recognize only the protein 
of interest and bind it. Once incubation has been performed, 
membrane is rinsed and exposed to the secondary antibody which will 
bind the primary Ab. This second Ab is directly related with the animal 
specie which produced the first one, i.e. an anti-mouse secondary Ab 
will bind only any mouse-sourced primary antibody. Furthermore, 
secondary Ab bears biotin or an enzyme as alkaline phosphatase or 
horseradish peroxidase (HRP) with the aim of showing an enhanced 
signal to recognize the primary Ab. HRP-linked secondary Ab is the 
most exploited methodology where after the addition of 
quimioluminiscent agent (a substrate called luminal), a reaction occurs 
producing a luminescent signal proportional to the initial amount of 
the protein of interest. To capture that signal, the membrane is placed 
below a sensitive photographic film which captures the final image of 
the antibodies bound to the blot. Band densities of the different lanes 
can be directly compared providing information of the relative 
abundance of the protein of interest. 
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Reagents preparation 
TRANSFER BUFFER: for 1L of final volume, 6g of TRIS BASE, 3.1g of 
boric acid were dissolved under agitation in 1L of ddH2O.  
BLOCKING BUFFER: 5g of non-fat dry milk were dissolved in 100mL of 
0.05% Tween20. 
 
Protocol 
The PVDF membrane Thermo Scientific 0.45 µm (9x7cm) was 
placed in methanol for 1min for its activation. After quick drying, it 
was dropped in a box with transfer buffer. “sandwich” device was 
mounted following the order: a sponge on top of the black cassette 
(negative), three whatman paper (10x7cm), acrylamide gel, 
membrane, three whatman paper (10x7cm) (at this point air bubbles 
were removed), other sponge and finally the “sandwich” was closed 
(positive pole). Device was collocated inside the transfer box and 
electroblotting started at 4100mA for 2h at 4°C. The protein 
transference occur from the negative to the positive pole, e.g. from 
the gel to the membrane. A magnetic stirring bar was placed inside the 
box to allow agitation of the buffer. 
 
Once the transference was finished, membrane was stained 
with Ponceau S for 5min under constant agitation. The proteins of 
interest were observed and after the membrane was washed with 
0.025% PBS Tween 20 to remove the dye. 
 
Afterwards, membrane blocking was performed by introducing 
it in blocking buffer in agitation during 1h at RT. Primary antibody used 
was transferrin (12A6), a mouse monoclonal antibody raised against 
transferrin of human origin. Ab was diluted in the blocking buffer 
1:5000 and incubated 16h at 4ºC. Then, membrane was washed per 
duplicate with 0.05% PBS/Tween 20 for 10min. Incubation with a 
secondary Ab anti-mouse was performed for 2h at RT and again 
membrane washed with the same procedure.  
 
[APPENDIX III.] 
[583] 
Membrane was incubated 1min with ECL and then, cover 
immediately with a transparent film/cling wrap and then, exposed to 
X-ray film in the dark and revealed. Exposition time was optimised in 
order to be able to observe the desired signals.  
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